

Library Declaration Form



University of Otago Library

Author's full name and year of birth: Simon Thomas Kelly,
(for cataloguing purposes) 24 February 1992

Title of thesis: A Bioinformatics Approach to Synthetic Lethal Interactions in Breast Cancer with Gene Expression Data

Degree: Doctor of Philosophy

Department: Department of Biochemistry

Permanent Address: 710 Cumberland Street, Dunedin, NZ

I agree that this thesis may be consulted for research and study purposes and that reasonable quotation may be made from it, provided that proper acknowledgement of its use is made.

I consent to this thesis being copied in part or in whole for

- i) a library
- ii) an individual

at the discretion of the University of Otago.

Signature:

Date:

A Bioinformatics Approach to
Synthetic Lethal Interactions in
Breast Cancer with Gene
Expression Data

S. Thomas Kelly

a thesis submitted for the degree of
Doctor of Philosophy
at the University of Otago, Dunedin,
New Zealand.

31 March 2017

Abstract

Background

Synthetic lethal interactions are re-emerging in genetics research in the genomics era driven by potential applications in precision medicine against cancers. This approach aims to exploit functional redundancy at the genetic level against mutations in cancers for developing specific treatments against them, including loss of function events in tumour suppressors. Of particular interest is the targeting loss of function of E-cadherin, encoded by *CDH1*, a tumour suppressor gene involved in Breast and Stomach cancers. Experimental screens have been used to identify candidate synthetic lethal interactions and here bioinformatics analysis used to augment the triage drug target triage process. Furthermore the pathway composition of synthetic lethal candidates and the effect of pathway structure on their detection in genomics data.

Approach

A computational statistics methodology, the Synthetic Lethal Prediction Tool (SLIPT) has been developed to detect synthetic lethal interactions in gene expression datasets. The methodology has been demonstrated on Breast and Stomach cancer datasets from The Cancer Genome Atlas (TCGA) database, testing for interactions with *CDH1*. Various analyses have been applied to further elucidate these candidates, including differential gene expression, correlation co-expression, unsupervised clustering, gene set over-representation analysis, singular-value decomposition “metagenes”, and permutation re-sampling analysis. A particular challenge of performing these analyses was to compare SLIPT gene candidates to the results of an experimental synthetic lethal siRNA screen of E-cadherin Telford

et al. (2015) at the pathway level. Graph theory methods including information centrality and shortest paths were applied to the most supported pathways from both the computational and experimental synthetic lethal candidates to test for graph structure among hits from each approach. Simulation and modelling was performed to test the statistical performance of the SLIPT methodology and further applied to datasets with simulated correlation structures, including those derived from known graph stuctures.

Findings

A vast number of genes having expression consistent with being synthetic lethal partners of *CDH1* were detected in both TCGA Breast and Stomach cancer genes. For breast cancers, these genes clustered into several distinct groups, with distinct enriched biological functions and elevated expression in different clinical subclasses such as normal-like, basal, or estrogen receptor negative samples. While the number of genes detected by both computational and experimental approaches were not significant, there was significant pathway composition in the overlapping genes. In particular $G_{\alpha i}$ signalling, cytoplasmic microfibres, and extracelluar fibrin clotting were supported by both approaches even after permutation testing. These findings are consistent with the known roles of E-cadherin in cytoskeletal or cell signalling roles and the proposed downstream targets of GPCR singalling of Telford *et al.* (2015). Many of these and related pathways were replicated in the separate stomach cancer dataset. Furthermore other candidate pathways uniquely supported by the computational predictions included regulation of immune signaling and translational elongation, both unlikely to have been detected with high dose siRNA in an isogenic cell line and these are still candidates for further testing in mouse xenograft models.

A number of approaches were adapted or developed to test whether there was a connection between synthetic lethal candidates in the graph structures of the pathways most supported by prior analyses. Network centrality measures were used to compare the importance or connectivity of genes in the pathway subnetworks but no significant difference was found between synthetic candidates and other genes within the same pathway. Another hypothesis was that computational synthetic lethal candidates would be

downstream of experimental candidates within a pathway but no evidence of directionality between the candidates was detected.

A model of synthetic lethality was developed and was sucessfully implemented to simulate gene expression datasets with known underlying synthetic lethal partners of a query gene. For small numbers of known synthetic lethal partners, the SLIPT methdology performed well respect to reciever operator characteristic curves. As the number of true partners to detect increases, the power to detect them diminishes. Increasing sample sizes, however, was able to mitigate this effect somewhat as expected. This finding was replicated in simulations up to a feasible number of human genes (20,000) with more true negatives and correlations structures. The SLIPT methdology performs similarly across these conditions and performs better than Pearson's correlation (for co-expression) or the χ^2 -test without a directional criterion. However, correlation structure of the dataset does impact on synthetic lethal predictions, genes correlated with (or in a pathway structure near to) true synthetic lethal partners having elevated test statistic values over other true negatives. A quadratic (second order polynomial) least squares linear regression methodology has been developed as a comparable alternative with the added benefit of conditioning against known partners (or strongest candidates prior analyses).

Thus my thesis has developed, evaluated and refined a bioinformatics approach to discovery of synthetic lethal genes solely from gene expression data.

Research Contributions During Candidature

Publications Under Peer-Review

Kelly, S. T. and Spencer, H. G. (2017) Population-Genetics Models of Sex-Limited Genomic Imprinting. *Theoretical Population Biology* **115**:35-44 doi:10.1016/j.tpb.2017.03.004

Kelly, S. T., Single, A. B., Telford, B. J., Beetham, H. G., Godwin, T. D., Chen, A., Black, M., A., and Guilford, P. J. (2017) Towards HDGC chemoprevention: vulnerabilities in E-cadherin-negative cells identified by genomic interrogation of isogenic cell lines and whole tumors. Submitted to *Cancer Prevention Research*.

Kelly, S. T., Chen, A., Guilford, P. J., and Black, M. A. (2017) Synthetic lethal interaction prediction of target pathways in E-cadherin deficient breast cancers. Submitted to *BMC Genomics*.

Community Blog Posts

Black, M. A., Kelly, S. T., and Cadzow, M. Posted on the *Software Carpentry* website 2016 July 4th: “Software Carpentry workshop at the University of Otago, New Zealand” <https://software-carpentry.org/blog/2016/07/otago-workshop.html>

Kelly, S. T., Black, M., A., Bae, S., Hayek, W., and Pawlik, A. Posted on the *Software Carpentry* website 2016 September 28th: “Software Carpentry Workshop Attendance: a New Zealand Perspective” <https://software-carpentry.org/blog/2016/09/attendance-nz.html>

Software Packages

Several software packages in the R language have been released on GitHub while preparing this thesis. Please see the appropriate GitHub repository for more information on installing and running these packages, on the following account: <https://github.com/TomKellyGenetics>

slipt is the Synthetic Lethal interaction Prediction Tool, released to accompany the synthetic lethal publication above. **slipt-app** contains an application developed in the R **shiny** environment as part of a related project.

Several plotting functions were customised for the Figures in this thesis (and the above publications), notably `heatmap.2x` and `vioplotx` have been prepared largely for use during this project but are also documented and available to other R users. These are enhancements to the CRAN `gplots` and `vioplot` packages respectively and are intended be user-friendly for those familiar with `heatmap.2` or `vioplot` and `boxplot` (base R) functions. These are backwards compatible with these functions, taking similar inputs as demonstrated in the appropriate vignettes.

The use of iGraph (the R `igraph` package) operations of graph-network structure in the analysis and simulations of pathways involved several original or customised functions to manipulate or plot `igraph` objects and adjacency matrices. These can be install separately from their respective repositories of with the metapackage: `igraph.extensions`. `plot.igraph` enables plotting graph networks with customised inhibitor arrow and node colours. `info.centrality` enables the calculation of additional node and network centrality metrics not available in the `igraph` package. `pathway.structure.permutation` enables testing of related states or node groups in a network by directionality of shortest paths. The `graphsim` package has been set up to simulate a multi-variate normal gene expression dataset with `mvtnorm` while deriving the correlation structure, Σ , from a graph structure. Note that these require various packages for graph theory, statistics and matrix operations and these will be installed as dependencies.

Conference Participation

eResearch 2017 (Queenstown) Speaker February 20th-22nd “Detecting Synthetic Lethality from Cancer Gene Expression: A PhD project on genetic interactions with CDH1 inactivation in TCGA data”

RIKEN Division of Genomic Technologies (Yokohama, Japan) Seminar 2016 October 20th; National Institute of Genetics (Mishima, Japan) Seminar 2016 October 21st; Tokyo University Institute of Medical Science (Shirokanedai Campus, Japan) Seminar 2016 October 24th; Sokendai Graduate University (Hayama, Japan) Seminar 2016 October 25th “Analysis of Synthetic Lethal Pathways in Breast Cancer: A PhD project on genetic interactions with CDH1 inactivation in TCGA data”

Next Generation Sequencing Asia 2016 (Singapore) Poster October 11th-12th “Bioinformatic Investigations of Synthetic Lethal Interactions with E-cadherin in Breast Cancer” (Supported by the University of Otago Division of Health Sciences; Maurice and Phyllis Paykel Trust)

eResearch 2016 (Queenstown, New Zealand) Speaker February 9th-11th “Sifting the Needles in the Haystack: Permutation Resampling Biological Pathways in Cancer Genomic Interaction Data” (Supported by REANNZ)

Genetics Otago Symposium 2016 (Dunedin, New Zealand) Student Speaker March 7th-8th “A Bioinformatics approach to Genetic Interactions: Synthetic Lethal Pathways with E-cadherin in Breast Cancer Genomics Data”

Research Bazaar 2015 (Melbourne, Australia) February 16th-18th “My digital research toolkit” (Supported by the New Zealand eScience Infrastructure)

QMB Cancer Drugs Satellite 2014 (Queenstown, New Zealand) Poster August 24th-25th; Otago School of Medical Sciences 2015 (Dunedin, New Zealand) Poster Postgraduate Symposium April 28th-29th Bioinformatics Prioritisation of Synthetic Lethal Targets for Drug Activity Against E-Cadherin Deficient Cancers

DunDead: Zombie Science and Popular Culture Festival 2014 (Dunedin, New Zealand) Ignite Speaker August 16th-17th “Hidden in Plain Sight - The Genetics of Zombies”

eResearch 2014 (Waikato University, Hamilton, New Zealand) Ignite Speaker June 30th-July 2nd “Bioinformatic analysis of synthetic lethal genetic interactions in breast cancer” (Supported by Google)

Acknowledgements

I thank my supervisors A/Prof. Mik Black and Prof. Parry Guilford for their support and guidance throughout this my postgraduate studies. It has been a great experience, I look forward to seeing what your research groups produce in the future, may this not be the end.

I am also thankful for the guidance and mentorship of Prof. Hamish Spencer for career advice throughout my studies and time in his research group.

I am also grateful to the past and current members of these research groups, and my peers at the laboratory benches and computers across campus. The peer support, comraderie, and guidance to newer students has been an incredible part of my time at Otago and has made my thesis studies not just easier but possible at all. The postgraduate community is very special here and have truly made some lifelong friends from all over the world, you are talented researchers and amazing people. May we meet again some day. Wherever you may end up, there's always time to catch up and I'd be delighted to host some visits while working abroad.

I cannot thank my friends, flatmates and family enough for their patience and support during such as massive, challenging, and (I'm sure you've heard too many times) stressful undertaking during both my PhD and the study leading up to it. There are too many of you to name everyone here without leaving someone out, so thank you all for everything you've done, both the good times and the tough. Thank you for pretending to understand when I try to discuss complex math at the wrong moment. Thank you for checking my writing or slides, even if I should have given you more time. Thank for your time when all I really needed was a chat over a walk or a pint and a moment to think clearly.

I must also thank various organisations supported this research project:

- This thesis was supported by the Postgraduate Tassell Scholarship in Cancer Research, a University of Otago Doctoral Scholarship.
- The New Zealand eScience Infrastructure (NeSI) provided access to the Intel Pan high-performance computing cluster, support, and training to use it effectively. Various aspects of this thesis would not have been possible without access to such a resource.
- The Health Research Council (HRC) of New Zealand provided funding for experimental research in the Cancer Genetics Laboratory. Again some aspects of this project would not have been possible without access to the data and findings funded by this grant.
- The Allan Wilson Centre and Otago School of Biomedical Sciences provided funding for summer research placements which was a valuable opportunity to gain experience and training used in this thesis project.

I thank the following organisations for support towards presenting findings in this thesis at conference and seminars:

- Google (towards eResearch 2014 conference, Hamilton)
- NeSI (towards Software Carpentry training and Research Bazaar 2015, Melbourne)
- REANNZ, NZGL, and NeSI (towards eResearch 2016 conference, Queenstown)
- Otago Division of Health Sciences, Department of Biochemistry, Oxford Global, and Maurice and Phyllis Paykel Trust (towards NGS Asia 2016, Singapore)
- RIKEN Division of Genomics Technologies and the Okinawa Institute of Science and Technology (for hosting seminars in Japan)

Thanks most of all to my fianceé, Dr Yui Kawagishi, you've been an inspiration. Thank you for your support, help, and encouragement, even from afar times, it has always made a difference. It's been incredible to see you flourish in your career and I look forward to joining you again soon. May the next Chapter of our adventures involve a bit less Skype across timezones.

Contents

Glossary	xix
Glossary	xx
Acronyms	xxi
Acronyms	xxii
1 Introduction	1
1.1 Cancer Research in the Post-Genomic Era	1
1.1.1 Cancer as a Global Health Concern	2
1.1.1.1 Genetics and Molecular Biology in Cancers	3
1.1.2 The Human Genome Revolution	5
1.1.2.1 The First Human Genome Sequence	6
1.1.2.2 Impact of Genomics	6
1.1.3 Technologies to Enable Genetics Research	7
1.1.3.1 DNA Sequencing and Genotyping Technologies	7
1.1.3.2 Microarrays and Quantitative Technologies	7
1.1.3.3 Massively Parallel “Next Generation” Sequencing	8
1.1.3.3.1 Molecular Profiling with Genomics Technology .	10
1.1.3.3.2 Sequencing Technologies	10
1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis .	11
1.1.4 Follow-up Large-Scale Genomics Projects	12
1.1.5 Cancer Genomes	13
1.1.5.1 The Cancer Genome Atlas Project	14
1.1.5.1.1 Findings from Cancer Genomes	14
1.1.5.1.2 Genomic Comparisons Across Cancer Tissues .	16
1.1.5.1.3 Cancer Genomic Data Resources	17
1.1.6 Genomic Cancer Medicine	17
1.1.6.1 Cancer Genes and Driver Mutations	18
1.1.6.2 Personalised or Precision Cancer Medicine	18
1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine	19
1.1.6.3 Targeted Therapeutics and Pharmacogenomics	20
1.1.6.3.1 Targeting Oncogenic Driver Mutations	20
1.1.6.4 Systems and Network Biology	21
1.1.6.4.1 Network Medicine, and Polypharmacology	23
1.2 A Synthetic Lethal Approach to Cancer Medicine	24
1.2.1 Synthetic Lethal Genetic Interactions	25

1.2.2	Synthetic Lethal Concepts in Genetics	25
1.2.3	Studies of Synthetic Lethality	26
1.2.3.1	Synthetic Lethal Pathways and Networks	27
1.2.3.1.1	Evolution of Synthetic Lethality	28
1.2.4	Synthetic Lethal Concepts in Cancer	28
1.2.5	Clinical Impact of Synthetic Lethality in Cancer	30
1.2.6	High-throughput Screening for Synthetic Lethality	32
1.2.6.1	Synthetic Lethal Screens	33
1.2.7	Computational Prediction of Synthetic Lethality	36
1.2.7.1	Bioinformatics Approaches to Genetic Interactions	36
1.2.7.2	Comparative Genomics	37
1.2.7.3	Analysis and Modelling of Protein Data	40
1.2.7.4	Differential Gene Expression	42
1.2.7.5	Data Mining and Machine Learning	43
1.2.7.6	Bimodality	46
1.2.7.7	Rationale for Further Development	47
1.3	E-cadherin as a Synthetic Lethal Target	47
1.3.1	The <i>CDH1</i> gene and it's Biological Functions	47
1.3.1.1	Cytoskeleton	48
1.3.1.2	Extracellular and Tumour Micro-Environment	48
1.3.1.3	Cell-Cell Adhesion and Signalling	48
1.3.2	<i>CDH1</i> as a Tumour (and Invasion) Suppressor	49
1.3.2.1	Breast Cancers and Invasion	49
1.3.3	Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer .	49
1.3.4	Somatic Mutations	51
1.3.4.1	Mutation Rate	51
1.3.4.2	Co-occurring Mutations	51
1.3.5	Models of <i>CDH1</i> loss in cell lines	52
1.4	Summary and Research Direction of Thesis	53
2	Methods and Resources	57
2.1	Bioinformatics Resources for Genomics Research	57
2.1.1	Public Data and Software Packages	57
2.1.1.1	Cancer Genome Atlas Data	58
2.1.1.2	Reactome and Annotation Data	59
2.2	Data Handling	60
2.2.1	Normalisation	60
2.2.2	Sample Triage	60
2.2.3	Metagenes and the Singular Value Decomposition	62
2.2.3.1	Candidate Triage and Integration with Screen Data .	62
2.3	Techniques	63
2.3.1	Statistical Procedures and Tests	63
2.3.2	Gene Set Over-representation Analysis	64
2.3.3	Clustering	65
2.3.4	Heatmap	65
2.3.5	Modeling and Simulations	65

2.3.5.1	Receiver Operating Characteristic (Performance)	66
2.3.6	Resampling Analysis	67
2.4	Pathway Structure Methods	68
2.4.1	Network and Graph Analysis	68
2.4.2	Sourcing Graph Structure Data	69
2.4.3	Constructing Pathway Subgraphs	69
2.4.4	Network Analysis Metrics	69
2.5	Implementation	70
2.5.1	Computational Resources and Linux Utilities	70
2.5.2	R Language and Packages	72
2.5.3	High Performance and Parallel Computing	74
3	Methods Developed During Thesis	76
3.1	A Synthetic Lethal Detection Methodology	76
3.2	Synthetic Lethal Simulation and Modelling	79
3.2.1	A Model of Synthetic Lethality in Expression Data	79
3.2.2	Simulation Procedure	83
3.3	Detecting Simulated Synthetic Lethal Partners	86
3.3.1	Binomial Simulation of Synthetic lethality	86
3.3.2	Multivariate Normal Simulation of Synthetic lethality	88
3.3.2.1	Multivariate Normal Simulation with Correlated Genes	91
3.3.2.2	Specificity with Query-Correlated Pathways	98
3.3.2.2.1	Importance of Directional Testing	98
3.4	Graph Structure Methods	100
3.4.1	Upstream and Downstream Gene Detection	100
3.4.1.1	Permutation Analysis for Statistical Significance	101
3.4.1.2	Ranking Based on Biological Context	102
3.4.2	Simulating Gene Expression from Graph Structures	103
3.5	Customised Functions and Packages Developed	107
3.5.1	Synthetic Lethal Interaction Prediction Tool	107
3.5.2	Data Visualisation	108
3.5.3	Extensions to the iGraph Package	110
3.5.3.1	Sampling Simulated Data from Graph Structures	110
3.5.3.2	Plotting Directed Graph Structures	110
3.5.3.3	Computing Information Centrality	111
3.5.3.4	Testing Pathway Structure with Permutation Testing .	111
3.5.3.5	Metapackage to Install iGraph Functions	112
4	Synthetic Lethal Analysis of Gene Expression Data	113
4.1	Synthetic lethal genes in breast cancer	114
4.1.1	Synthetic lethal pathways in breast cancer	116
4.1.2	Expression profiles of synthetic lethal partners	117
4.1.2.1	Subgroup pathway analysis	120
4.2	Comparison of synthetic lethal gene candidates	123
4.2.1	Comparison with siRNA screen candidates	123
4.2.1.1	Comparison with correlation	124

4.2.1.2	Comparison with viability	125
4.2.1.3	Comparison with secondary screen siRNA screen candidates	129
4.2.1.4	Comparison of screen at pathway level	129
4.2.1.4.1	Resampling of genes for pathway enrichment	131
4.3	Metagene Analysis	137
4.3.1	Pathway expression	137
4.3.2	Somatic mutation	140
4.3.3	Mutation locus	141
4.3.4	Synthetic lethal metagenes	143
4.4	Replication in stomach cancer	145
4.4.1	Synthetic Lethal Genes and Pathways	145
4.4.2	Synthetic Lethal Expression Profiles	147
4.4.3	Comparison to Primary Screen	149
4.4.3.1	Resampling Analysis	150
4.4.4	Metagene Analysis	150
4.5	Global Synthetic Lethality	151
4.5.1	Hub Genes	152
4.5.2	Hub Pathways	154
4.6	Replication in cell line encyclopaedia	155
4.7	Discussion	157
4.7.1	Strengths of the SLIPT Methodology	157
4.7.2	Syntheic Lethal Pathways for E-cadherin	158
4.7.3	Replication and Validation	160
4.7.3.1	Integration with siRNA Screening	160
4.7.3.2	Replication across Tissues and Cell lines	161
4.8	Summary	162
5	Synthetic Lethal Pathway Structure	165
5.1	Reactome Network structure and Information Centrality as a measure of gene essentiality	166
5.2	Synthetic lethal genes in synthetic lethal pathways	167
5.3	Centrality and connectivity of synthetic lethal genes	167
5.4	Upstream or downstream synthetic lethal candidates	167
5.5	Hierachical approach	167
5.6	Discussion	167
5.7	Conclusion	167
6	Simulation and Modeling of Synthetic Lethal Pathways	168
6.1	Simulations and Modelling Synthetic Lethality in Expression Data	171
6.2	Simulations over simple graph structures	172
6.2.1	Performance	172
6.2.2	Synthetic lethality across graph stuctures	172
6.2.3	Performance with inhibition links	172
6.2.4	Performance with 20,000 genes	172
6.3	Simulations over pathway-based graphs	172

6.4	Comparing methods	172
6.4.1	SLIPT and Chi-Squared	172
6.4.1.1	Correlated query genes	172
6.4.2	Correlation	172
6.4.3	Bimodality with BiSEp	172
7	Discussion	173
7.1	Significance	175
7.2	Future Directions	176
7.3	Conclusion	177
8	Conclusion	179
References		180
A	Sample Quality	205
A.1	Sample Correlation	205
A.2	Replicate Samples in TCGA Breast	208
B	Software Used for Thesis	212
C	Secondary Screen Data	221
D	Mutation Analysis in Breast Cancer	223
D.1	Synthetic Lethal Genes and Pathways	223
D.2	Synthetic Lethal Expression Profiles	226
D.3	Comparison to Primary Screen	229
D.3.1	Resampling Analysis	231
D.4	Compare SLIPT genes	233
D.5	Metagene Analysis	235
D.6	Mutation Variation	236
D.6.1	Mutation Frequency	236
D.6.2	PI3K Mutation Expression	237
E	Metagene Expression Profiles	240
F	Stomach Expression Analysis	246
F.1	Synthetic Lethal Genes and Pathways	246
F.2	Comparison to Primary Screen	249
F.2.1	Resampling Analysis	251
F.3	Metagene Analysis	253
G	Stomach Mutation Analysis	254
G.1	Synthetic Lethal Genes and Pathways	254
G.2	Synthetic Lethal Expression Profiles	257
G.3	Comparison to Primary Screen	260
G.3.1	Resampling Analysis	262

G.4	Metagene Analysis	264
H	Global Synthetic Lethality in Stomach Cancer	265
H.1	Hub Genes	267
H.2	Hub Pathways	268
I	Replication in cell line encyclopaedia	269
J	Synthetic Lethal Genes in Pathways	274

List of Tables

1.1	Methods for Predicting Genetic Interactions	37
1.2	Methods for Predicting Synthetic Lethality in Cancer	38
1.3	Methods used by Wu <i>et al.</i> (2014)	39
2.1	Excluded Samples by Batch and Clinical Characteristics	62
2.2	Computers used during Thesis	71
2.3	Linux Utilities and Applications used during Thesis	71
2.4	R Installations used during Thesis	72
2.5	R Packages used during Thesis	72
2.6	R Packages Developed during Thesis	74
4.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from Synthetic Lethal Interaction Prediction Tool (SLIPT)	115
4.2	Pathways for <i>CDH1</i> partners from SLIPT	117
4.3	Pathway composition for clusters of <i>CDH1</i> partners from SLIPT	121
4.4	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screening	130
4.5	Pathways for <i>CDH1</i> partners from SLIPT	134
4.6	Pathways for <i>CDH1</i> partners from SLIPT and siRNA primary screen	135
4.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT	144
4.8	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer	146
4.9	Query synthetic lethal genes with the most SLIPT partners	153
4.10	Pathways for genes with the most SLIPT partners	154
4.11	Pathways for <i>CDH1</i> partners from SLIPT in CCLE	155
4.12	Pathways for <i>CDH1</i> partners from SLIPT in breast CCLE	157
B.1	R Packages used during Thesis	212
C.1	Comparing SLIPT genes against Secondary siRNA Screen in breast cancer	221
C.2	Comparing mtSLIPT genes against Secondary siRNA Screen in breast cancer	222
C.3	Comparing SLIPT genes against Secondary siRNA Screen in stomach cancer	222
D.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT	224
D.2	Pathways for <i>CDH1</i> partners from mtSLIPT	225
D.3	Pathway composition for clusters of <i>CDH1</i> partners from mtSLIPT	228
D.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA	230

D.5	Pathways for <i>CDH1</i> partners from mtSLIPT	231
D.6	Pathways for <i>CDH1</i> partners from mtSLIPT and siRNA primary screen	232
D.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT	235
F.1	Synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stomach cancer	247
F.2	Pathway composition for clusters of <i>CDH1</i> partners in stomach SLIPT	248
F.3	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screening	250
F.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer	251
F.5	Pathways for <i>CDH1</i> partners from SLIPT in stomach and siRNA screen	252
F.6	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT in stomach cancer	253
G.1	Synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT in stomach cancer	255
G.2	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	256
G.3	Pathway composition for clusters of <i>CDH1</i> partners in stomach mtSLIPT	259
G.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA	261
G.5	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	262
G.6	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach and siRNA screen	263
G.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT in stomach cancer	264
H.1	Query synthetic lethal genes with the most SLIPT partners	267
H.2	Pathways for genes with the most SLIPT partners	268
I.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in CCLE	270
I.2	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in breast CCLE	271
I.3	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stomach CCLE	272
I.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach CCLE	273
I.5	Pathways for <i>CDH1</i> partners from SLIPT in breast and stomach CCLE	273

List of Figures

1.1	Synthetic genetic interactions	26
1.2	Synthetic lethality in cancer	29
2.1	Read count density	61
2.2	Read count sample mean	61
3.1	Framework for synthetic lethal prediction	77
3.2	Synthetic lethal prediction adapted for mutation	78
3.3	A model of synthetic lethal gene expression	80
3.4	Modeling synthetic lethal gene expression	81
3.5	Synthetic lethality with multiple genes	82
3.6	Simulating gene function	84
3.7	Simulating synthetic lethal gene function	84
3.8	Simulating synthetic lethal gene expression	85
3.9	Performance of binomial simulations	87
3.10	Comparison of statistical performance	87
3.11	Performance of multivariate normal simulations	89
3.12	Simulating expression with correlated gene blocks	92
3.13	Simulating expression with correlated gene blocks	93
3.14	Synthetic lethal prediction across simulations	94
3.15	Performance with correlations	95
3.16	Comparison of statistical performance with correlation structure	96
3.17	Performance with query correlations	97
3.18	Statistical evaluation of directional criteria	98
3.19	Performance of directional criteria	99
3.20	Simulated graph structures	103
3.21	Simulating expression from a graph structure	105
3.22	Simulating expression from graph structure with inhibitions	106
3.23	Demonstration of violin plots with custom features	109
3.24	Demonstration of annotated heatmap	109
3.25	Simulating graph structures	111
4.1	Synthetic lethal expression profiles of analysed samples	119
4.2	Comparison of SLIPT to short interfering ribonucleic acid (siRNA)	123
4.3	Compare SLIPT and siRNA genes with correlation	124
4.4	Compare SLIPT and siRNA genes with correlation	124
4.5	Compare SLIPT and siRNA genes with siRNA viability	126

4.6	Compare SLIPT and siRNA genes with viability	126
4.7	Compare SLIPT and siRNA genes with siRNA viability	128
4.8	Resampled intersection of SLIPT and siRNA candidates	132
4.9	Pathway metagene expression profiles	138
4.10	Somatic mutation against PI3K metagene	140
4.11	Somatic mutation locus against expression	142
4.12	Synthetic lethal expression profiles of stomach samples	148
4.13	Synthetic lethal partners across query genes	152
A.1	Correlation profiles of removed samples	206
A.2	Correlation analysis and sample removal	207
A.3	Replicate excluded samples	208
A.4	Replicate samples with all remaining	209
A.5	Replicate samples with some excluded	210
A.5	Replicate samples with some excluded	211
D.1	Synthetic lethal expression profiles of analysed samples	227
D.2	Comparison of mtSLIPT to siRNA	229
D.3	Compare mtSLIPT and siRNA genes with correlation	233
D.4	Compare mtSLIPT and siRNA genes with correlation	233
D.5	Compare mtSLIPT and siRNA genes with siRNA viability	234
D.6	Somatic mutation locus	236
D.7	Somatic mutation against PIK3CA metagene	237
D.8	Somatic mutation against PI3K protein	238
D.9	Somatic mutation against AKT protein	239
E.1	Pathway metagene expression profiles	241
E.2	Expression profiles for constituent genes of PI3K	242
E.3	Expression profiles for p53 related genes	243
E.4	Expression profiles for estrogen receptor related genes	244
E.5	Expression profiles for BRCA related genes	245
F.1	Comparison of SLIPT in stomach to siRNA	249
G.1	Synthetic lethal expression profiles of stomach samples	258
G.2	Comparison of mtSLIPT in stomach to siRNA	260
H.1	Synthetic lethal partners across query genes	266

Glossary

bioinformatics	Statistical or computational approaches to biological data or research tools.
bisulfite-Seq	Methylome data from sequencing bisulfite treated DNA.
CAGE-Seq	Transcriptome data from cap analysis of gene expression.
E-cadherin	Epithelial cadherin (calcium-dependent adhesion), a cell-adhesion protein encoded by the tumour suppressor gene <i>CDH1</i> .
epigenome	An analysis of epigenetic modifications of all genes in the genome.
exome	An approach or technology designed to generate or use data from all genes in the genome.
genomics	An approach or technology designed to generate or use data from all genes in the genome.
metabolome	An analysis of all the metabolites and enzymes in the cell.
metagenomics	An analysis of all the genes and genomes in a community.
microRNA	Short RNA molecules generally regarded to regulate gene expression by binding to mRNA.
omics	A rationale for applying molecular studies across all of the genes in the genome or biomolecules in the cell.
Pan cancer	Study or analysis of cancers across tissue of origin.
pleiotropy	A gene which has multiple biological functions.

proteome	An analysis of all the proteins expressed from the genome.
RNA-Seq	Transcriptome data from sequencing RNA.
Sanger	A dideoxy chain termination method for DNA sequencing (named after Fred Sanger).
synthetic lethal	Genetic interactions where inactivation of multiple genes is inviable (or deleterious) when they are viable if inactivated separately.
transcriptome	An analysis of all the genes expressed in the genome.

Acronyms

AUROC	Area under the receiver operating characteristic (curve).
BiSEp	Bimodal Subsetting Expression.
CCLE	Cancer Cell Line Encyclopaedia.
cDNA	Complementary deoxyribonucleic acid (from mRNA).
ChIP-Seq	Chromatin immunoprecipitation sequencing.
COSMIC	Catalogue Of Somatic Mutations In Cancer.
DAISY	Data mining synthetic lethal identification pipeline.
DDBJ	DNA Data Bank of Japan.
DNA	Deoxyribonucleic acid.
EMBL	European Molecular Biology Laboratory.
EMT	Epithelial-mesenchymal transition.
ENA	The European Nucleotide Archive.
GEO	Gene Expression Omnibus.
GO	Gene Ontology.
HDAC	Histone deacetylase.
HDGC	Heredity diffuse gastric cancer.
HLRCC	Heredity leiomyomatosis and renal cell carcinoma.
ICGC	International Cancer Genome Consortium.
InDel	Insertion or deletion (in DNA sequence).
JAK	Janus kinase.
lncRNA	Long non-coding ribonucleic acid.

miRNA	microRNA.
mRNA	Messenger ribonucleic acid.
NCBI	National Center for Biotechnology Information (in the USA).
NCI	National Cancer Institute (in the USA).
NGS	Next-generation sequencing.
NHGRI	National Human Genome Research Institute (in the USA).
NIG	National Institute of Genetics (in Japan).
NIH	National Institutes of Health (in the USA).
PCR	Polymerase chain reaction.
PI3K	Phosphoinositide 3-kinase.
qPCR	Quantitative (real-time) polymerase chain reaction.
RFLP	Restriction fragment length polymorphism.
RNA	Ribonucleic acid.
RNAi	Ribonucleic acid interference.
RRBS	Reduced representation bisulfite sequencing.
SGI	synthetic genetic interaction.
siRNA	Short interfering ribonucleic acid.
SLIPT	Synthetic lethal interaction prediction tool.
SNP	Single nucleotide polymorphism.
TCGA	The Cancer Genome Atlas (genomics project).

Chapter 1

Introduction

The thesis presents research into genetic interactions based on genomics data and bioinformatics approaches. This Chapter introduces the recent developments in genomics and bioinformatics, particularly in their application to cancer research. Synthetic lethal interactions are a long standing area of research in genetics in both model organisms and cancer biology. Various reasons why these interactions are of interest in fundamental and translational biology will be outlined but first these and similar interactions will be defined. A bioinformatics approach to synthetic lethal interactions enables much wider exploration of the inter-connected nature of genes and proteins within a cancer cell than previous candidate-based approaches. An alternative approach is experimental screening which will be presented and contrasted with bioinformatics approaches in more detail. An emerging application of synthetic lethality is the design of treatments with specificity against loss of function mutations in tumour suppressor genes. E-cadherin (encoded by *CDH1*) is a prime example of this which will be the focus of the analysis in this thesis and as such the role of this gene in cellular and cancer biology will be briefly reviewed.

1.1 Cancer Research in the Post-Genomic Era

Genomics technologies have the potential to vastly impact upon various areas including health and cancer medicine. Considering the progress in recent genomics research, this technology and the findings from it have considerable potential for significant impacts in the clinic and wider applications of genetics either directly or by enabling more focused genetics research on candidates selected from genomics or bioinformatics analysis. The completion of the draft Human Genome (Lander *et al.*, 2001) marks a major accomplishment in genetics research and raises new challenges to utilise this

genomic scale information effectively. Technologies in this area have rapidly developed since completion of the human genome project and many global large-scale projects have expanded upon the human genome, to populations (1000 Genomes, 2010), to cancers (Dickson, 1999; Zhang *et al.*, 2011), and to deeper functional understanding (Kawai *et al.*, 2001; ENCODE, 2004). However, impact on the clinic has been slower than initially anticipated following the completion of the “draft” genome with genomics technologies yet to become widely adopted in healthcare and oncology. Here we outline the genomics technologies and bioinformatics approaches which have led to availability of genomics data and techniques used in this thesis and potential for applications in cancer research or the clinic in the future.

1.1.1 Cancer as a Global Health Concern

Cancer is a class of diseases involving malignant cellular growth, invasion of tissues, and spread to other organs. While there are also environmental factors, most cancers occur more frequently with age and family history. Accordingly, genetics has become widely acknowledged as having an important role in cancer risk (in addition to environmental factors). Cancers arise from dysregulated cellular growth or differentiation from stem cells. These can occur through genetic mutations or alterations in gene regulation or expression.

Cancers are a major global health concern, being the second leading cause of death globally (WHO, 2017), with an estimated annual incidence of 14.1 million cases and annual mortality of 8.2 million people (Ferlay *et al.*, 2015). Breast and stomach cancers are among the 5 most frequent cancers globally, with breast cancer affecting women more than other cancer tissue types. Breast cancer has an estimated annual incidence of 1.6 million cases and mortality of 520 thousand people. Stomach cancer has an estimated annual incidence of 950 thousand cases and a mortality of 723 thousand people. Cancer is also a major health concern here in New Zealand, with 19.1 thousand people (including 2.5 thousand cases of breast cancer and 370 cases of stomach cancer) diagnosed annually (Hanna, 2003), among the highest incidence (age-standardised per capita) of cancer in the world (Ferlay *et al.*, 2015).

While the genetic contribution to cancer risk and many of the molecular changes occurring in cancers are widely acknowledged (ASCO, 2017; Cancer Research UK, 2017; Cancer Society of NZ, 2017), the majority of these findings have yet to impact on clinical practice. Diagnostics are traditionally based on pathological examination of tissue samples where histological staining for cell type, biomolecules and biomarkers continue

to be widely used, although genetic and biochemical markers are being adopted for some cancer types. In general, the current standard of care includes surgery, radiation, and cytotoxic chemotherapy, depending on whether the cancer is localised or has become systemic (via metastasis) and spread to other organ systems. These approaches can be effective against certain cancers, particularly in early stage cancer or in patients with particular subtypes (such as acute myeloid leukaemia) which respond well to modern treatment regimens. Thus early diagnosis is important to patient survival and quality of life. National screening programs (which prioritise patients with a high risk of cancer) therefore aim to diagnose cancers early and subtypes more accurately. Therefore identification of patients with genetic variants or family histories (for inclusion in national databases) for high risk of particular cancers is an important health issue, particularly where effective interventions exist if these cancers are diagnosed early. Thus high risk individuals being regularly monitored for some cancers are sometimes offered preventative surgery or treatment for pre-cancerous tissue (Guilford *et al.*, 2010; Scheuer *et al.*, 2002).

Chemotherapy is a last-resort treatment for many advanced stage (systemic) cancers which is designed to inhibit the growth and spread of cancer throughout the body by targeting rapidly growing cells. However, this approach often has severe adverse effects, a narrow therapeutic window, and is not suitable for chemopreventative application in many cases (Kaelin, Jr, 2009). Since surveillance preventative surgery (removing the tissue at risk of cancer) is not completely effective at preventing cancers and may impact on quality of life, depending on the cancer tissue types they are at risk of, alternative treatment strategies based on molecular biology and other fields are being investigated. These alternatives include immunological, endocrine, and targeted therapeutics, with a particular interest in treatments with specificity against cancer cells and wider applications (i.e., tolerable effective doses in applications as a chemopreventative or against advanced stage cancers).

1.1.1.1 Genetics and Molecular Biology in Cancers

Cancers involve dysregulation of genes with both somatic mutations or regulatory disruptions which accumulate during a patient's lifetime and germline mutations which predispose individuals to high-risk early onset cancers (American Cancer Society, 2017; Guilford *et al.*, 1998; NCI, 2015). Cancer is widely viewed to be a genetic disease due to these familial cancer syndromes, hereditary risk factors, and the molecular changes occurring in cancers, including numerous cancer genes which have been identified Stratton *et al.* (2009); Vogelstein *et al.* (2013). Cancer genes are generally classified into

two classes: “oncogenes” which are activated in cancers, driving tumour growth and invasion, or “tumour suppressors” which are inactivated in cancers, removing cellular regulation and genomic maintenance functions. The mutations which cause cancers accumulate with age and have been suggested to be inevitably coupled with aging due to the association of cancer incidence with the stem cell divisions in which mutations could occur across tissue types (Tomasetti and Vogelstein, 2015).

Hanahan and Weinberg (2000) identified several key molecular and cellular traits shared across most cancers as a rational approach to the complex changes that occur in cancer initiation and progression due to common molecular machinery underlying all cells. A cancer cell must possess limitless replication potential, modulate growth signals to grow indefinitely, and gain invasive or metastatic capabilities. In addition, cancers must evade apoptosis, the immune system, and sustain angiogenesis and energy metabolism in order to survive (Hanahan and Weinberg, 2000, 2011). In order to achieve this, cancer cells undergo changes to their genomes and the surrounding cells to create a tumour microenvironment. Thus genomic instability has a key role in the survival and proliferation of cancer cells and the progression of further disease, as these malignant characteristics are acquired. Identifying the mechanisms of these acquired traits and the underlying genetic mutation or dysregulation behind them, such as E-cadherin mutation in metastasis or p53 mutation in genomic instability (Hanahan and Weinberg, 2000), will be an important step in understanding and inhibiting cancer with the next generation of genomically-informed treatments.

Molecular biological processes have particular importance in characterising breast cancers. Gene expression and regulatory signals confer cell identity and response to the environment. Therefore gene expression has been investigated with microarray technologies Perou *et al.* (2000), with “intrinsic subtypes” identified characterised by estrogen receptor, *HER2*, and basal, epithelial signalling. The expression profiles were similar across independent samples of the same tumour and between primary and metastatic tumours of the same patient. Thus expression profiles represent the molecular state of a tumour rather than the sample and the molecular configuration of the cells regulation is carried through the cellular lineage of during metastasis preserving the molecular subtype. These molecular intrinsic subtypes “luminal A”, “luminal B”, “*HER2*-enriched”, “basal-like”, and “normal-like” have been replicated across microarray studies (Hu *et al.*, 2006), with their relevance to prognosis (including predicting survival and response to neoadjuvant chemotherapy) demonstrated and a 50-gene subtype predictor from microarray and quantitative PCR (qPCR) analysis has been pro-

vided (Parker *et al.*, 2009; Sørlie *et al.*, 2001). This has been further updated with the “claudin-low” subtype (Herschkowitz *et al.*, 2007) and stimulated further investigations into subtyping of breast cancers by molecular properties. Despite differences in subtyping performed by different research groups and companies, there is widespread agreement that distinguishing luminal, HER2-enriched, and triple negative tumours can be performed with expression profiles and have value in our understanding of cancer progression and prognostic importance for patients Dai *et al.* (2015). High-throughput technologies have the potential to enable such subtyping on a vast scale in discovery of further subtypes in breast cancer or other diseases and in identification of these subtypes along with mutations in routine clinical diagnostic and prognostic testing. The “Pan cancer” approaches by the cancer genome atlas project (as discussed in more detail in Section 1.1.5.1.1) expand on the importance of molecular differences between cancers by examining molecular profiles across cancer tissue types (Weinstein *et al.*, 2013).

Cancer is a major health concern with a well-established genetic contribution, in risk and in the molecular changes occurring during progression (Stratton *et al.*, 2009). Many genes have been discovered to be important in different cancers with molecular differences between cancers, including alterations across the genome, being of clinical importance. As such cancers were among the first samples investigated with genomics following the sequencing of the human genome Dickson (1999) and continue to be the subject of genomics and bioinformatics investigations.

1.1.2 The Human Genome Revolution

The advent of the Human Genome sequence (Lander *et al.*, 2001) has transformed genetics research including the study of health and disease (Lander, 2011; Peltonen and McKusick, 2001). Systematic, unbiased studies across all of the genes in the genome are viable in unprecedented ways. The successful undertaking of such an international scientific megaproject has set an example for numerous initiatives to follow, including many genomics investigations expanding to species, to the functional, or to the population level (Collins *et al.*, 2003). These projects serve as an excellent resource for genetics research globally, particularly for cancers where genomics investigation have been widely applied to different tissues across molecular profiles Bamford *et al.* (2004); Weinstein *et al.* (2013); Zhang *et al.* (2011) . Genome sequencing technologies continue to improve, decrease in price, and become increasingly feasible in a wider range of research and clinical applications.

1.1.2.1 The First Human Genome Sequence

The first human genome is a good example of a large-scale genomics project for it's success as an international collaboration and releasing their data as a resource for the wider scientific community (Collins *et al.*, 2003; Lander *et al.*, 2001). This particular project generated significant public interest due to it being a landmark achievement, the first of it's scale, and some controversial findings. Namely, the number of genes discovered (particularly those specific to vertebrates) was much lower than most estimates for a genome of it's size and the number of repetitious transposon elements was very high. Even the figure of 30–40,000 genes given by the original publication is now regarded to be an overestimate (Ezkurdia *et al.*, 2014; IHGSC, 2004).

Accounting for the “complexity” encoded by the human genome with so few genes has led to investigations into molecular function, expression profiling, and population variation. When announcing the draft genome, Lander *et al.* (2001) conceded that genomic information alone was not sufficient for biological understanding and that many investigations remained to be carried out, with their objective being to share the raw genome data so that it was available for further inquiry rather than interpreting it themselves. While genomics technologies and genomics projects have flourished since then, the need in turn for systematic means of interpreting data of such scale and for the interdisciplinary expertise to do so has only grown.

1.1.2.2 Impact of Genomics

Genomics has stimulated investigations into many of these previously largely explored areas of functional genetics and thus been of immense value in genetics research, attracting high expectations for further applications. Genomics research created widespread anticipation for potential applications in healthcare, agriculture, ecology, conservation, and evolutionary biology despite few of these being realised yet.

Cancer research is an area of particularly high expectations for the clinical impact of genomics in oncology. Genomics technologies have potential applications across cancer diagnostics, prognosis, management, and developing treatment. Cancers often involve genetic mutation or dysregulated gene expression which can be detected in a genome or transcriptome with potential to improve patient care. While direct impact of genomics on the clinic has been limited, compared to initial expectations following the publication of the human genome, diagnostic cancer genes and therapeutic targets identified with genomics research have begun to be introduced in the clinic (Stratton *et al.*, 2009).

1.1.3 Technologies to Enable Genetics Research

1.1.3.1 DNA Sequencing and Genotyping Technologies

Genotyping was once commonly performed on variable regions of the genome with restriction fragment length polymorphism (RFLP) or repetitious microsatellite regions. These exploited sequence variation at target sites of restriction enzymes or measured the length of repetitious regions, using polymerase chain reaction (PCR), restriction enzymes, and gel electrophoresis to measure deoxyribonucleic acid (DNA) genotypes at particular sites. This is laborious and limited to well characterised variable regions of the genome, generally genes or nearby marker regions.

The Sanger (dideoxy) chain termination method (Sanger and Coulson, 1975) enabled DNA sequencing and genotyping at a widespread scale, being less technically difficult than the Maxam-Gilbert sequencing by degradation method (Gilbert and Maxam, 1973; Maxam and Gilbert, 1977), which required more radioactive and toxic reactants. The Sanger methodology has relatively long read length (particularly compared to early versions of more recent technologies), with read lengths of 500–700 base pairs accurately sequenced in most applications, usually following targeted amplification with PCR. Sanger sequencing by gel electrophoresis takes around 6–8 hours and has been further refined with the “capillary” approach to 1–3 hours and requiring less input DNA and reactants. The capillary approach has been scaled up to run in parallel from a 96 well plate, at 166 kilobases per hour. The 96 well parallel capillary method was one of the main innovations which made the first Human Genome Project feasible and was used throughout (Lander *et al.*, 2001). Due to the quality of the Sanger sequence reads and low cost, it is still widely used in smaller scale applications, clinical testing, and to validate the findings of newer approaches.

1.1.3.2 Microarrays and Quantitative Technologies

Real-time or qPCR is another adaptation of genetic technologies to quantitatively study nucleic acids, often reverse transcribed “deoxyribonucleic acid (cDNA)” or messenger “messenger ribonucleic acid (mRNA)” to measure (relative) gene expression or transcript abundance. While numerous quality control measures are required to correctly interpret a qPCR experiment, these have similarly become widely adopted and are still used for smaller scale experiments and as a “gold standard” for measuring gene expression (Adamski *et al.*, 2014). This also represents a shift in the application of qPCR and sequencing technology, where the primary interest is quantifying the amount of input material (by the rate of amplification to a certain level) rather than the qualitative na-

ture of the sequence itself. The more recent technologies of microarrays and RNA-Seq have similarly embraced this application to quantify DNA copy number, ribonucleic acid (RNA) expression, and DNA methylation levels. Due to results of comparable or arguably better quality from these newer technologies (Beck *et al.*, 2016; Git *et al.*, 2010; McCourt *et al.*, 2013; Robin *et al.*, 2016), this “gold standard” status has begun to come under scrutiny.

Microarrays represent a truly high-throughput molecular technique, reducing the cost, time, and labour required to study molecular factors such as genotype, expression, or methylation across many genes, making it feasible to do so over a statistically meaningful number of samples. Microarrays are manufactured with probes which measure binding of particular nucleotide sequences to either quantitatively detect the presence of a sequence such as a single nucleotide polymorphism (SNP) or quantify DNA copy number, gene expression, or DNA CpG methylation. Microarray technologies have popularised “genome scale” studies of genetic variation and expression.

In addition to being more versatile and higher-throughput than PCR based techniques, microarrays are considered cost-effective, particularly when scaled up to a large number of probes. They are also available with established gene panels or customised probes from a number of commercial manufacturers. These remained popular during the introduction of newer technologies due to reliability and relatively lower cost, especially in large-scale projects involving many samples. However, microarrays have issues with signal-to-noise ratio, with both sensitivity to low nucleic acid abundance and “saturation” of probes at high abundance, edge effects, and requiring more starting material than qPCR. Thus qPCR is still used for many small gene panel studies.

1.1.3.3 Massively Parallel “Next Generation” Sequencing

Similar to microarrays, the introduction of massively parallel sequencing technologies have further expanded the availability of high-throughput molecular studies to researchers, with corresponding availability of genomics data from these studies. This “Next-Generation Sequencing” (NGS) expands not only gene expression studies (compared to microarrays) but extends to genome sequencing *de novo* for previously unknown genome and transcriptome sequences at an unprecedented scale. This has been a particularly important technological revolution in genomics, as the cost and time of genome sequencing has dropped dramatically and enabled sequencing projects of far more samples and applications beyond the Human Genome Project. Particularly, when dealing with variants in a species with an existing reference sequence such as humans, where there is a low computational cost of mapping to a reference compared to

a genome assembly. However, the cost of sequencing (RNA-Seq) for gene expression or DNA methylation studies is still considerably higher than a microarray study (limiting feasible sample sizes).

Compared with arrays, NGS studies have additional challenges, particularly regarding large data and compute requirements to handle the raw output data. Compared with the established methods to analyse microarray data, handling NGS data can be more technically difficult. While methods developed for analysing microarray data can be repurposed for sequence analysis in many cases, more bioinformatics expertise is required particularly to handle the raw read data and changing approaches for various developments in sequencing technologies. One of the main computational challenges is the assembly of reads or mapping to a reference genome due to the inherently small reads of most NGS technologies compared to the Sanger methodology. Furthermore, there are fewer software releases and best practices established specifically for RNA-Seq data, thus many analyses are still conducted with customised analysis approaches and command-line tools. Compared to existing graphical tools or pipelines for microarray analysis, this is a more active technology for bioinformatics research where many applications of genomics data have yet to be explored.

However, the methodology itself has challenges with the sample preparation, requiring a relatively high quantity of input material and “contamination” with over abundant ribosomal rRNA taking up the majority of the sequencing if not purified correctly. This abundance of rRNA is a particularly important issue in microarray and RNA experiments in Eukaryotes where it is commonplace to target the mRNA by binding to the poly-A tail (RNA-Seq) or 5' cap (CAGE-Seq). However, this has the potential to exclude miRNA (miRNA) and long non-coding ribonucleic acid (lncRNA) of interest unless the sample is prepared specifically to study these. Similarly capturing a subsection of the genome for exome analysis or reduced representation bisulfite sequencing (RRBS), focuses on sequencing DNA sequences and methylation levels of CpG sites near known genes to reduce cost, noise, and incidental findings.

In many cases, the benefits of NGS technologies over microarrays still outweigh the additional cost. NGS technologies have the advantage of greater potential accuracy and sensitivity than microarrays, depending on the sequencing depth or “coverage”, theoretically sensitive down to the exact number of molecules for each transcript. NGS experiments are regarded as “reproducible” with no need for technical replicates, although these are still performed for a subset of samples in many projects for quality assurance purposes. NGS has a wider dynamic range than microarrays and is able

to detect SNPs, insertions or deletions, and splice variants in addition to quantifying DNA copy number or transcript abundance. NGS scales to all genes and beyond for these molecular applications without having to design new probes as required for a microarray. Thus NGS technologies are not limited to genes with already characterised sequence or functions, do not need to be updated with new probes for each genome annotation release, and do not require a reference genome at all for new species. A “transcriptome” can be assembled *de novo* for an expression study in any organism by sequencing the mRNA extracted from a cell.

1.1.3.3.1 Molecular Profiling with Genomics Technology

NGS is highly adaptable to different applications: DNA sequencing (whole genome or exome), DNA methylation (bisulfite-Seq), RNA-Seq, miRNA, lncRNA, or chromatin immunoprecipitation sequencing (ChIP-Seq). RNA-Seq of the transcriptome is a common adaptation where RNA is reverse transcribed and sequenced from the resulting cDNA. This is utilised to quantify the levels of RNA and identify which regions of DNA are expressed. Similar bisulfite treatment converts cytosine residues to uracil (sequenced as thymidine), sparing methylated cytosine enabling it to be distinguished with bisulfite-Seq for high-throughput detection of the notable epigenetic mark and is a common procedure to generate an epigenome. Subsets of the nucleic acid may be extracted for sequencing such as the coding regions of DNA (for the “exome”), the mRNA 5' cap (CAGE-Seq), mRNA 3' poly-A tail (RNA-Seq), microRNA, or an enriched subset of variable regions for DNA sequencing (“genotyping by sequencing”) and methylation studies (“reduced-representation bisulfite sequencing”). High-throughput gel and mass spectrometry techniques have been applied to proteins and metabolites to generate the proteome and metabolome respectively. These “omics” technologies are applicable across a wide range of biomolecules in a cell and these “molecular profiles” are produced in many experimental laboratories.

1.1.3.3.2 Sequencing Technologies

Illumina sequencing (developed by Solexa and later acquired by Illumina) was released in 2006. It utilises reversible terminating dyes to sequence by synthesis with a lower accuracy (98%) and read lengths of 150–250bp. Illumina more than makes up for relatively short reads (along with improving the read length of the technology) and low accuracy with high-throughput and cost effectiveness, with a Hi-Seq 4000 platform producing up to 10 billion paired-end reads (1500Gbp) in a run of appropriately 3 days,

capable of sequencing 12 human genomes ($30\times$ coverage) or 100 human transcriptomes simultaneously (Illumina, 2017). Illumina has further reduced the cost of sequencing with the economies of scale with the Hi-Seq X 10 claiming to produce a human genome (with $30\times$ coverage) for less than US\$1000, the first platform to achieve this long-standing goal in genomics. The high-throughput of Illumina sequencing also makes deep sequencing for high coverage, high quality consensus reads, and sensitive RNA-Seq experiments feasible. Illumina sequencing now has a dominating market share of the NGS technologies. Their Hi-Seq platforms were used in large-scale genomics projects (such as the cancer genome atlas discussed in Section 1.1.5.1) to generate the sequence data used throughout this thesis.

NGS technologies continue to be refined with Illumina (and competitors) continuing to release refined productions, offer additional genomics-based services, and decreases overhead and operating costs to enable a wider range of research projects. As such RNA-Seq for examining the transcriptome of an organisms and for expression studies in diseases is a growing field of research and expression data will continue to be generated for a range of samples in many healthy and diseased tissues. The technology be also be further improved developments in speed and accuracy (such as Ion Torrent platforms) and towards long reads of single molecules (such as Pacific Biosciences, Oxford Nanopore, and Quantum Biosystems Japan).

Due to such benefits of sequencing over previous technologies (and their continued refinement), this thesis has focused on gene expression data generated by RNA-Seq rather by microarrays. RNA-Seq data is widely available as a resource from large-scale cancer genomics projects and methods to make inferences from RNA-Seq experiments could feasibly be applied to many other studies based on these current (or similar future) technologies.

1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis

Genomics technologies have given rise to data at a scale previously rarely encountered in molecular biology, making inference with conventional techniques difficult. Computational, Mathematical, and Statistical skills are required to handle this data effectively, in addition to biological background to frame and interpret research questions. Drawing upon these disciplines to handle biological data has become the field of “Bioinformatics”, focusing specifically on making inferences from genomics and high-throughput molecular data or developing the tools to do so. This contrasts with the existing fields of “theoretical” or “computational biology” which existed prior to genomics data, focusing on modelling and simulating aspects of biology without necessarily addressing

the genomics data or detecting the phenomena in nature, extending beyond genetics to cell modelling, neuroscience, cancer development, ecology, and evolution.

In practice, many researchers identify with both bioinformatics and computational biology, or draw upon the findings and methods of the other field. This thesis uses many approaches in bioinformatics to biological research questions and established mathematical or bioinformatics resources.

Gene expression analysis is the focus of many bioinformatics research groups, drawing upon statistical approaches to appropriately handle microarray and RNA-Seq data along with making biological inferences from a large number of statistical tests. This presents various challenges from normalising sample data and accounting for batch effects to developing or applying statistical tests tailored to biological hypotheses and testing them at a genome-wide scale, generally across thousands of genes. There are numerous approaches for dealing with these challenges, some of which will be described in Chapter 2.

1.1.4 Follow-up Large-Scale Genomics Projects

A number of projects have attempted to follow up on the human genome project to varying degrees of success. The genomes have since been sequenced for a variety of model organisms, organisms of importance in health, agriculture, metagenomics of microorganisms (microbiome), ecology and conservation. Genomics projects have also been applied functional genetics (Kawai *et al.*, 2001; ENCODE, 2004) and to human populations with an interest variability between individuals and health or disease risk (HapMap, 2003; 1000 Genomes, 2010).

Genomics databases have also focused on facilitating distribution of genomic data generated by researchers, rather than generating it themselves. GenBank hosted by the National Center for Biotechnology Information (NCBI) in the US, the European Nucleotide Archive (ENA) hosted by the European Molecular Biology Laboratory (EMBL), and the DNA Data Bank of Japan (DDBJ) hosted by the National Institute of Genetics (NIG) do so by serving as public repositories of DNA sequence data. Gene Expression Omnibus (GEO) (Clough and Barrett, 2016), arrayExpress (Rustici *et al.*, 2013), and caArray (Heiskanen *et al.*, 2014) serve a similar purpose as a resource for gene expression datasets, originally developed for microarray data but RNA-Seq data is now supported by some platforms. They are repositories for researchers to deposit, share, and access gene expression data, serving as a resource to support ongoing research where larger datasets than would were previously accessible for many

individual laboratories are available (Rung and Brazma, 2013). These resources cover not only DNA sequence across the genome but also molecular profiles of other factors by adapting genomic sequencing or other high throughput technologies for quantifying gene expression or DNA methylation. Sharing the expression datasets generated in a publication is now required by some journals.

Similarly, international projects and consortiums have begun to release data gathered using common agreed upon protocols in laboratories across the world, often hosting public databases of these themselves, publishing their own investigations into the datasets as they are released, or offering basic searches and analytics of the data via a web portal. These databases include many of the genomics projects discussed above and the cancer-specific projects discussed below. In many ways, the quality, consistency, and accessibility of these international projects has become more appealing than accessing smaller studies, particularly for gene expression datasets where the more recent, larger projects have switched from microarray to RNA-Seq technologies. This distinction will also be discussed later.

1.1.5 Cancer Genomes

The importance of genomics technologies in the future of cancer research was noticed, even in the early days of genomics (Dickson, 1999). The Cancer Genome Project (CGP) based at Wellcome Trust Sanger Institute in the UK were among the first to launch investigations into cancer after the publication of the Human Genome, using this genome sequence, consensus across the cancer research literature, and sequencing the genes of cancers themselves. Initially, the Sanger Institute set out to sequence 20 genes across 378 samples while the Human Genome project was still ongoing (Collins and Barker, 2007), optimising sequencing and computation infrastructure for a larger project while doing so. The main aim of the Cancer Genome Project was to discover “cancer genes”, those frequently mutated in cancers by comparing the genes of cancer and normal tissue samples, both “oncogenes” and “tumour suppressors” which are activated and inactivated respectively in cancers. This project is ongoing and the UK continues to be involved in international sequencing initiatives and those focused on particular tissue types.

The Sanger Institute also hosts the Catalogue of Somatic Mutations in Cancer (COSMIC, 2016), a database and website of cancer genes. This launched with 66,634 samples and 10,647 mutations from initial investigations into *BRAF*, *HRAS*, *KRAS*, and *NRAS* (Bamford *et al.*, 2004). It has since expanded to include 1,257,487 samples

with 4,175,8787 gene mutations curated from 23,870 publications, including 29,112 whole genomes (COSMIC, 2016). This database now also identifies cancer genes from DNA copy number, differential gene expression and differential DNA methylation.

1.1.5.1 The Cancer Genome Atlas Project

Based in the US, The Cancer Genome Atlas (TCGA) project was established in 2005, a combined effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) (TCGA, 2017a). They first set out to demonstrate the pilot project on brain (McLendon *et al.*, 2008), ovarian (Bell *et al.*, 2011), and squamous cell lung (Hamerman *et al.*, 2012) cancers. In 2009, the project expanded aiming to analyse 500 samples each for 20-25 tumour tissue types. They have since exceeded that goal, with data available for 33 cancer types including 10 “rare” cancers, a total of over 10,000 samples.

The TCGA projects set out to generate a molecular “profile” of the tumour (and some matched normal tissue) samples: the genotype, somatic mutations, gene expression, DNA copy number, and RNA methylation levels. While these were originally performed largely with microarray technologies, exome and RNA-Seq has been since adopted and performed for many TCGA samples, with whole genomes being performed for some samples. Data which cannot be used to identify the patients (such as somatic mutation, expression, methylation, and various clinical factors) are publicly available.

1.1.5.1.1 Findings from Cancer Genomes

The Cancer Genome Atlas pilot projects (Bell *et al.*, 2011; Hamerman *et al.*, 2012; McLendon *et al.*, 2008) serve to demonstrate the power of applying genomics technologies to cancer research at such a scale. In addition to sequencing the whole genome or a subset (exome), DNA copy number, gene expression, DNA methylation, and somatic mutations were also analysed. The initial projects used microarray technologies for expression and methylation data but these have since been replaced by RNA-Seq for expression. TCGA demonstrated the potential discovery of the molecular basis of cancer by analysing 206 glioblastoma brain cancer samples (McLendon *et al.*, 2008), highlighting the roles of *ERBB2*, *NF1*, *TP53*, and *PIK3R1* mutations, along with altered methylation of *MGMT*, and the core pathways of RTK, p53, and RB signalling in brain cancer. An analysis of 489 serious ovarian cancers (Bell *et al.*, 2011) similarly reported *TP53* mutations specifically over-represented in high grade tumours and reported 133 copy number variants, 168 differentially methylated regions, and recurrently

somatic mutations in 9 genes in low grade tumours including *NF1*, *BRCA1*, *BRCA2*, *RB1*, and *CDK12*. Four transcriptional subtypes of ovarian cancers were identified, alterations in *BRCA1*, *BRCA2*, and *CCL6* had an impact on patient survival, and the homologous recombination, NOTCH and FOXM1 signalling pathways were involved in ovarian cancer growth. The genomics of 178 squamous cell lung cancers (Hamerman *et al.*, 2012) were highly complex, averaging at 360 mutations in coding regions. While no targeted therapies existed for this cancer subtype, 11 recurrently mutated genes were identified including *TP53* and *HLA-A*. The pathways altered in various squamous cell lung cancers were NFE2L2, KEAP1, differentiation genes, PI3K, CDKN2A and RB1. These aberrant genes and pathways represent potential therapeutic targets which could be identified for most samples.

The TCGA breast cancer analysis (TCGA, 2012) consisted of 802 samples with exomes, copy number variants, RPPA protein quantification, and DNA methylation, mRNA, and microRNA arrays with 97 whole genomes sequenced. Four main molecular classes were identified to subtype the samples, despite considerable heterogeneity between samples. Recurrent mutations across more than 10% of samples were identified in *TP53*, *PIK3CA*, and *GATA*. TCGA further suggests subtypes by HER2 and EGFR protein levels. In a further analysis of 817 breast cancer samples including 127 invasive lobular breast and 88 mixed type samples (Ciriello *et al.*, 2015), 3 molecular subtypes of lobular breast cancer were identified. Lobular breast cancer was also characterised by recurrent mutations in *CDH1*, *PTEN*, *TBX2*, and *FOXA1*.

TCGA reported results of colon and rectal cancers in a combined analysis of 267 samples (Muzny *et al.*, 2012), finding no genomic distinction between colorectal cancers. Apart from 16% of hypermutated colorectal cancers, the remaining samples were very similar at the molecular level with 24 significantly recurrently mutated genes identified. These include the expected *APC*, *TP53*, *SMAD4*, *PIK3CA*, and *KRAS* genes. Additionally, novel recurrent mutations were identified in *ARID1A*, *SOX9*, and *FAM123* along with recurrent copy number alterations in *ERBB2* and *IFG2*. Thus the molecular findings of colon and rectal tumours can be applicable across colorectal cancers, including the known characteristics of microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) found in some colorectal tumours.

The TCGA stomach cancer analysis of 295 samples (Bass *et al.*, 2014) identified 4 molecular subtypes of stomach cancers characterised by: the Epstein-Barr virus, MSI, genomics instability, and chromosomal instability. Aberrations in *PD-L1*, *PIK3CA*,

and *JAK2* were also identified in stomach cancers which may present therapeutic targets.

1.1.5.1.2 Genomic Comparisons Across Cancer Tissues

TCGA have identified various genes as recurrent, driver mutations across cancer types which are likely to have a role in driving the proliferation of these cancers and present a molecular target that could be applied across tissue types. These include *TP53* (in brain, lung/head/neck squamous cell, breast, colorectal, uterine, and endometrial cancers), *ERBB2/HER2/NEU* (in brain, breast, colorectal, bladder, and lung cancers), *PIK3CA*, *PIK3R1* (in brain, breast, colorectal, endometrial, bladder, clear cell renal, and lung cancers), *BRCA1/BRCA2* (in breast and ovarian cancers), *NF1* (in brain, ovarian, and skin cancers), *ARID1A* (in colorectal, endometrial, and clear cell renal cancers), *KRAS* (in colorectal, endometrial, and skin cancers), *BRAF* (in colorectal, thyroid, and skin cancers), *EGFR* (in brain, breast, and lung cancers), and *PTEN* (in breast, endometrial, and uterine cancers) (Agrawal *et al.*, 2014; Akbani *et al.*, 2015; Bass *et al.*, 2014; Bell *et al.*, 2011; Burk *et al.*, 2017; Cherniack *et al.*, 2017; Ciriello *et al.*, 2015; Collisson *et al.*, 2014; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Kandoth *et al.*, 2013; Lawrence *et al.*, 2015; McLendon *et al.*, 2008; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014). In addition to disregarding the tissue-based distinction between colon and rectal cancers based on molecular similarity (Muzny *et al.*, 2012), the TCGA project have observed differences within tumour types and proposed molecular subtyping for breast, clear cell renal, papillary renal, stomach, skin, bladder, and prostate cancers (Abeshouse *et al.*, 2015; Akbani *et al.*, 2015; Bass *et al.*, 2014; Ciriello *et al.*, 2015; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Linehan *et al.*, 2016; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014).

The “Pan cancer” project (Hoadley *et al.*, 2014; Weinstein *et al.*, 2013) analysed 3527 samples across 12 tissue types for DNA, RNA, protein, and epigenetic molecular profiles. This project was initiated in 2012 to perform a comprehensive analysis of molecular data across cancer types to identify molecular similarities and differences. Recurrent *TP53* mutations characterised high grade tumours across breast, ovarian, and endometrial cancers. HER2 was identified in brain, endometrial, bladder, and lung cancers, in addition to the known role of HER2 in breast cancers. *BRCA1* and *BRCA2* mutations were also detected across cancers, mainly breast and ovarian cancers as expected. Microsatellite instability characterised both endometrial and colorectal cancers. The Pan cancer project (Hoadley *et al.*, 2014) has identified 11 molecular sub-

types across these tissues, 5 of corresponding to tissue cancer types and the remainder reassigned due to molecular similarities shared across cancer types. Squamous cell lung, head, and neck and a subset bladder cancers were grouped together by molecular similarities, characterized by a high frequency of *TP53* mutations. Conversely, bladder cancers were divided into 3 of these molecular subtypes with distinct profiles. This project further supports the genomic stratification of patients, demonstrated in breast cancer (Parker *et al.*, 2009; Pereira *et al.*, 2016; Perou *et al.*, 2000), which may apply to other cancer types and to molecular characteristics across them targeting recurrent mechanisms of cancer growth and progression (Hanahan and Weinberg, 2000, 2011).

1.1.5.1.3 Cancer Genomic Data Resources

While the findings from the TCGA projects themselves are a considerable contribution to understanding cancer biology within and across tissue types, the main eventual benefit of such projects will be the availability of the data for the research community to analyse further and use to inform future investigations (McLendon *et al.*, 2008; TCGA, 2017a; Weinstein *et al.*, 2013). These serve as a vast resource of common and rare cancer types and are publicly available for further analysis (cBioPortal, 2017; TCGA, 2017a; Zhang *et al.*, 2011). This also applies to the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) project which focuses on breast cancer which also aimed to identify novel molecular subtypes (Curtis *et al.*, 2012). They performed an analysis of 2433 breast cancer samples with long-term clinical data, gene expression, copy number variants, and 173 genes sequenced which identified 40 driver mutations in breast cancer in addition to further support for molecular subtyping to identify patient groups with different clinical outcomes (Pereira *et al.*, 2016).

1.1.6 Genomic Cancer Medicine

There is much anticipation in cancer research for genomics technologies to have a clinical impact in cancer medicine: from diagnosis and prognosis to treatment developments and strategies. These may result either from direct use of genome or RNA-Seq in clinical laboratories or indirectly from biomarkers and treatments developed with research facilitated by genomics. This second strategy is likely to have a more immediate patient benefit due to the cost of genome sequencing, particularly considering adoption in public healthcare systems with a limited budget.

1.1.6.1 Cancer Genes and Driver Mutations

There are two main categories of “cancer genes” (Futreal *et al.*, 2001). Oncogenes are those activated in cancers either by gain of function mutations in proto-oncogenes, amplification of DNA copies, or elevated gene expression. Their normal functions are typically to regulate stem cells or to promote cellular growth and recurrent mutations are typically concentrated to particular gene regions. Conversely, tumour suppressor genes are those inactivated in cancer either by loss of function mutations, deletion of DNA copies, repression of gene expression, or hypermethylation. Their normal functions are typically to regulate cell division, DNA repair, and cell signalling.

Detecting these cancer genes is a major challenge in cancer biology and has been revolutionised by genomic technologies. Recurrent mutations, or DNA copy number variants and differential gene expression or DNA methylation are all indicative of cancer genes (Mattison *et al.*, 2009), which can be detected in genomics data (Pereira *et al.*, 2016; Weinstein *et al.*, 2013). Important “driver” cancer genes (Stratton *et al.*, 2009) are difficult to detect from “passenger” mutations due to patient variation, tumour heterogeneity, and genomic instability. However, many cancer genes have been replicated from previous studies or well supported from genomics data. There remains the challenge of translating the identification of cancer genes to patient benefit with characterisation of variants of unknown significance, which mutation or gene expression markers can be used to monitor tumour progression or treatment response, and design of therapeutic intervention against many molecular targets for which they have yet to be developed or repurposed from other diseases to cancers.

Driver mutations can be identified by whether they co-occur or are mutually exclusive with mutations in other genes in cancers, are recurrently mutated across a significant proportion of samples for a specific tissue type, or if mutations are recurrent across different cancer tissue types (cBioPortal, 2017; Pereira *et al.*, 2016; COSMIC, 2016; Weinstein *et al.*, 2013; Zhang *et al.*, 2011). Approximately 140 driver mutations have been identified, including many novel genes in particular cancers from genomics studies, with 2–8 in typically occurring in each tumour usually affecting cell fate, survival, or genome maintenance (Vogelstein *et al.*, 2013).

1.1.6.2 Personalised or Precision Cancer Medicine

The notion of using a patient’s genome to tailor healthcare to an individual has been appealing since the advent of genomics, popularised with the term “personalised medicine”. This approach was expected to span from preventative lifestyle advice

to effective treatments. Personalised medicine was described in contrast with current strategies of health advice, screening, prognostics, and treatments based on what works well for the majority of the population. Adverse effects of these treatments occur in a significant subpopulation, particularly demographics under-represented in clinical studies.

The importance of genomics is still recognised in translational cancer research. Applications are particularly emphasised in molecular diagnosis, prognosis, and treatments of patients already presenting with cancers in the clinic rather than preventative medicine. This is in part due to the vast number of variants of unknown clinical significance, the ethical issue of reporting on incidental findings, and the regulatory issues direct-to-consumer genetics companies have encountered offering health risk assessment.

More recently the term “genomic medicine” has been preferred to describe the paradigm of treating cancers by their genomic features, particularly grouping patients by the mutation, expression, or DNA methylation profiles of their cancers. Radical proponents advocate for these molecular subtypes to supersede tissue or cell type specific diagnosis of cancers. However, in practice they are often used in combination, with clinical and pathological factors being informative of prognosis and the medical expertise required for treatment. The related term of “precision medicine” also stems from this trend with the rationale to target these molecular subtypes with separate treatment strategies, particularly in developing and applying treatments targeted against a particular mutation specific to cancers. To this end much research in this field is focused on identifying mutations and gene expression signatures amenable to distinguishing cancers, particularly oncogenic driver mutations, and developing treatments against them.

1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine

There is growing support for the use of molecular tools such as mutations or gene expression signatures to diagnose tumour subtypes addition to (or in lieu of) tissue of origin or histology. This is particularly important in breast cancer where analysis of molecular data detected several distinct “intrinsic subtypes” with differences in malignancy and patient outcome which were distinguished by molecular mechanisms rather than tissue or cellular phenotype (Parker *et al.*, 2009; Perou *et al.*, 2000). Conversely, common molecular mechanisms may be shared between cancers across tissue types as discovered by the “Pan cancer” studies, such as those conducted by the TCGA and

International Cancer Genome Consortium (ICGC) projects, which combined molecular profiles across tissue types Weinstein *et al.* (2013). The molecular subtypes could feasibly be included in clinical testing as a panel of biomarkers for diagnostics and prognosis. Such biomarkers also have the potential to monitor drug response or risk of recurrence. This also raises the need for development of treatments that target these molecular subtypes.

1.1.6.3 Targeted Therapeutics and Pharmacogenomics

Targeted therapies with specificity against a molecular target are emerging as precision cancer medicine. Molecular targets can be tested in laboratory conditions with RNA interference or pharmacological agents. Identification of molecular targets is important for developing novel anti-cancer treatments along with validation and drug testing. For oncogenic mutations, the recurrent mutant variant or overexpressed gene is directly inhibited using structure-aided drug design or compound screening. However, oncogenes with high homology to other genes or tumour suppressor genes (where lost in cancers) are not amenable to direct targeting (Kaelin, Jr, 2009).

Despite controversy over their prohibitively high cost (PHARMAC, 2016), targeted therapeutics have been applied as monoclonal antibodies against oncogenes (such as *HER2*) with relative success in clinical trials (Miles, 2001), generating considerable interest in wider application of this approach. Targeted therapeutics have potential to have applications across cancer tissue types, specificity against tumour cells, wide therapeutic windows, and combination therapies (even in advanced disease or as a chemopreventative in high-risk individuals).

1.1.6.3.1 Targeting Oncogenic Driver Mutations

Oncogene targeted therapies have also been developed with some examples of effective clinical application against cancers. However, they have already begun to manifest problems with resistance, recurrence, tissue specificity, and design of inhibitors specific to oncogenic variants rather than proto-oncogene precursors. Targeted anticancer therapeutics can exploit complex interactions to distinguish normal and cancerous cells which may benefit from studies of gene regulation or interaction networks. The unexpected synergy between inhibitors of the oncogenes *BRAF^{V600E}* and *EGFR* in colorectal cancer is an example of such a system Prahallad *et al.* (2012).

Despite successful application of vemurafenib against *BRAF^{V600E}* in melanomas Dienstmann and Tabernero (2011); Ravnan and Matalka (2012), colorectal cancers with

$BRAF^{V600E}$ mutations have poor prognosis and lack drug response. Prahallad *et al.* (2012) used an RNA interference (RNAi) screen and found that $EGFR$ inhibition is synergistic with vemurafenib against $BRAF^{V600E}$ in colon cell lines and xenografts due to feedback activation of $EGFR$. Vemurafenib induced rapid reactivation of MAPK/ERK signalling via $EGFR$ in colorectal cell lines in a tissue-specific manner Corcoran *et al.* (2012) and may be relevant to acquired resistance in melanoma Sun *et al.* (2014). Thus combination therapies against several molecular pathways may be necessary to anticipate acquired resistance Ravnan and Matalka (2012) and targeted therapeutics may be further refined from understanding the pathway structure and functional interactions across cancer cells.

1.1.6.4 Systems and Network Biology

It is also important to consider that driver mutations in oncogenes and tumour suppressor genes do not occur in isolation. The genetic interaction, regulatory and cellular signalling, and metabolic reactions are all inter-related and may each be perturbed by aberrations in gene function occurring in cancers. These relationships can be represented by biological networks by mapping pairs of genes with a particular relationship. Due to the complexity of a cell, these molecular networks are very large consisting of thousands of nodes comprised by genes or proteins.

The properties of large networks were first studied by constructing random networks by randomly linking a fixed number of nodes (Erdős and Rényi, 1959, 1960). Despite the random nature of these networks, properties such as their connectivity were well characterised. The vertex degree (number of partners for each node) of random network follows a Poisson distribution, however this property does not hold in nature, suggesting that natural networks are non-random or not formed in this way Barabási and Oltvai (2004).

This work formed the foundation for studying complex networks (van Steen, 2010), which model features of real world networks not found in Erdős and Rényi's random networks (Erdős and Rényi, 1959, 1960). The small world property, made popular by findings in social networks (Travers and Milgram, 1969), is the remarkably short path lengths between any nodes in a small world network. A small world network is well-connected with a characteristic path length (the average length of shortest paths between all pairs of nodes) proportional to the logarithm of the number of nodes. Watts and Strogatz (1998) developed a model of random rewiring of a regular network to construct random networks with the small world property and a high clustering coefficient. While these properties are more representative of networks occurring in

nature, their model is limited by the degree distribution which converges to a Poisson distribution as it is rewired Barrat and Weigt (2000).

The vertex degree distribution of naturally occurring networks often follows a power law distribution with the majority of nodes having far fewer connections than average and a small subset of highly connected network ‘hubs’ Barabási and Albert (1999). Hubs further differentiate into ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions) Han *et al.* (2004). Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen, 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Barabási and Albert (1999) constructed a network model in an entirely different way to randomly generate scale-free networks which have a power law degree distribution. They constructed random networks by preferential attachment, modelling growth of a network by sequentially adding nodes with links to existing nodes. The scale-free nature of the random networks was ensured by adding new nodes with an increasing probability of attachment to an existing node if it has higher degree. These networks successfully capture the scale-free nature of many real world networks with short characteristic path length and low eccentricity resulting in super small worlds Barabási and Albert (1999). Scale-free networks are limited by a low clustering coefficient and lack of modular structure; however, they have enabled the study of scale-free network topology and served as a basis for modified scale-free models (Dorogovtsev and Mendes, 2003; Holme and Kim, 2002).

Han *et al.* (2004) observed dynamic modularity in biological networks and suggested the network structure may underpin genetic robustness and plasticity. They focus on network hubs which are more likely to be essential genes and define the subgroups of hubs based on correlation of gene expression with protein-protein interaction partners: ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions). Party and date hubs occurred most frequently within and between network modules respectively. Party hubs were considered local regulators, whereas date hubs were considered important to network connectivity as global regulators. This distinction between classes of network hubs was supported by differences in tissue specificity and clinical relevance as a proposed predictor of clinical outcome in breast cancer with an area under the receiver operating

characteristic (AUROC) of 0.784 Taylor *et al.* (2009). However, correlation between expression and protein interactions were not robustly reproduced. The importance of date hubs has been criticised for assuming a bimodal distribution and basing the global importance of data hubs on a small subset Agarwal *et al.* (2010). As an alternative interpretation, (Agarwal *et al.*, 2010) suggest the importance of interactions rather than network hubs as interactions important to the network were between functionally similar proteins. Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Applications of network theory are diverse, including uses in social sciences, engineering, and computer science. Due to their complexity and difficulty of gathering sufficient empirical data, biological applications of network theory are relatively unexplored. High-throughput technologies such as siRNA screens, two-hybrid screens, microarrays and massively parallel sequencing have made generating genome-scale molecular data feasible and enabled analysis of biological networks at the molecular level. Many types of inter-related molecular networks can be constructed and analysed, depending on the biological application. Genetic interaction networks will be the focus of this project because they are relatively unexplored compared to other molecular networks, have potential for applications in drug discovery (particularly cancer treatment), and may lead to better understanding of the role of genetics in cellular function and disease. Genetic interactions are usually studied at a high-throughput scale in simple model organisms such as bacteria, yeasts or the nematode worm; studies in humans, mammals, and non-model organisms (where applications would have the most societal impact) are limited by cost, time and labour constraints. Computational approaches with effective predictive models are the only feasible approach to study the connectivity of a biological network in a complex metazoan cell at the genome-scale.

1.1.6.4.1 Network Medicine, and Polypharmacology

Molecular networks are biological networks consisting of biological molecules including genes, transcripts (with non-coding and microRNAs), or proteins related by known interactions and gene regulatory or metabolic pathways. Targeted therapeutics have had some success for drug discovery, particularly in anticancer applications, including exploiting these molecular networks by designing combination therapies and applying a network pharmacology framework Hopkins (2008). Rational design of drugs selective

to a single target has often failed to deliver clinical efficacy. Many existing effective drugs modulate multiple proteins, having been selected for biological effects or clinical outcome rather than molecular targets. Proponents of network biology and polypharmacology (specific binding to multiple targets) recommend developing drugs with a desired target profile designed for the target topology Barabási and Oltvai (2004); Hopkins (2008). Multi-target treatments aim to achieve a clinical outcome through modulation of molecular networks since the genetic robustness of a cell often compensates for loss of a single molecular target.

While multi-target drugs may be more difficult to design, they are faster to test clinically than drug combinations which are usually required to be tested separately first Hopkins (2008). Synthetic lethal treatments for cancer, drug combinations and multi-target drugs to combat resistance to chemotherapy and antibiotics can be informed by biological networks Barabási and Oltvai (2004); Hopkins (2008). Further optimisation of timing and dosing of drug combinations may increase efficacy of treatments with low efficacy applied separately. Low doses and drug holidays are other counter intuitive approaches which may increase clinical efficacy, reduce adverse effects, and reduce drug resistance (Sun *et al.*, 2014; Tsai *et al.*, 2012).

A molecular map of the interactions and pathways in the mammalian cellular network has the potential to impact upon drug design and clinical practice, particularly in treatment of cancer and infectious disease. Characterisation of the target system and impact of existing treatments, such as *BRAF*^{V600E} and *EGFR* inhibitors, enable wider application of the mechanisms for such interventions exploiting genetic interactions or pathways. This could lead to development of more effective treatment interventions for these systems and prediction of similar molecular systems for development of novel drug targets and combinations.

1.2 A Synthetic Lethal Approach to Cancer Medicine

Synthetic lethality has vast potential to improve cancer medicine by expanding application of targeted therapeutics to include inactivation of tumour suppressors and genes that are difficult to target directly. Synthetic lethal interactions are also studied for gene function and drug mode-of-action in model organisms. This section introduces the concept of synthetic lethality as it was originally conceived and how it has been adopted conceptually in cancer research. Detecting these interactions at scale and interpreting them is the focus of this thesis, hence we start with an overview of the concepts involved, initial work on the interaction, and the rationale for applications to

cancer. Specific investigations into synthetic lethality in cancer, detection by experimental screening, and prediction by computational analysis will then be reviewed.

1.2.1 Synthetic Lethal Genetic Interactions

Genetic interactions are a core concept of molecular biology, discovered among earliest investigations of Mendelian genetics, and receiving revived interest with new technologies and potential applications. Biological epistasis is the effect of an allele at one locus “masking” the phenotype of another locus (Bateson and Mendel, 1909). Statistical epistasis is where there is significant disparity between the observed and expected phenotype of a double mutant, compared to the respective phenotypes of single mutants and the wild-type (Fisher, 1919). Fisher’s definition lends itself to quantitative traits and more broadly encompasses synthetic genetic interactions (synthetic genetic interactions). These have become popular for studies in yeast genetics and cancer drug design (Boone *et al.*, 2007; Kaelin, Jr, 2005).

Synthetic genetic interactions are substantial deviations of growth or viability from the expected null mutant phenotype (of an organism or cell) assuming additive (deleterious) effects of the single mutants. The double mutant does not necessarily have either single mutant phenotype (as shown for cellular growth phenotypes in Figure 1.1). Most SGIs are more viable than either single mutant or less viable than the expected double mutant. Mutations are “synergistic” in negative SGIs with more deviation from the wild-type than expected. Formally, “synthetic sick” (SSL) and “synthetic lethal” (SL) interactions are negative SGIs giving growth inhibition and inviability respectively. Synthetic lethality in cancer research more broadly describes any negative SGI with specific inhibition of a mutant cell, including SSL interactions. Mutations are “alleviating” in positive SGIs with less deviation from the wild-type than expected. For viability, “suppression” and “rescue” are positive SGIs giving at least partial restoration of wild-type growth from single mutants with growth impairment and lethal phenotypes respectively. Negative SGIs were markedly more common than positive SGIs in a number of studies in model systems Boucher and Jenna (2013); Tong *et al.* (2004).

1.2.2 Synthetic Lethal Concepts in Genetics

Synthetic lethal genes are generally regarded to arise due to functional redundancy. Due to the functional level of SGIs, synthetic lethal genes do not need directly interact, nor be expressed in the same cell or at the same developmental stage: serving related functions is sufficient to affect cell (or organism) viability and be relevant to drug-mode-of-action cancer biology. Combined loss of genes performing an essential or




Figure 1.1: Synthetic genetic interactions. Impact of various negative and positive SGIs: negative interactions involve deleterious (sick) or inviable (lethal) phenotypes whereas positive interactions involve restoring viability by masking or suppressing the other mutation or complete rescue of the wildtype phenotype. Figure adapted from (Costanzo *et al.*, 2011) concerning growth viability fitness in yeast.

important function in a cell are therefore deleterious. Synthetic lethal gene pairs are therefore pairwise essential with “induced essentiality”: each synthetic lethal gene becomes essential to the cell upon loss of the other.

Since synthetic lethal gene partners can be affected by extracellular stimuli such as chemicals, essentiality of synthetic lethal genes can be induced by the environment of a cell. An environmental stress condition may inhibit one or the other synthetic lethal gene, such as exposure to chemicals, in which case the synthetic lethal partner gene is “conditionally essential” (Hillenmeyer, 2008). Thus the evolutionary rationale for the abundance of SGIs (compared to the surprisingly low number of essential genes) in a Eukaryotic genome attributed to genetic functional redundancy and network robustness of a cell which are advantageous to survival.

Biological functions are typically performed by a pathway of genes (or their products). Many genes of the same pathway may be functionally interchangeable as synthetic lethal partners of a particular gene since loss of the pathway is deleterious without the synthetic lethal partner gene. Therefore biological pathways can be subject to induced essentiality under loss of a gene and synthetic lethality may occur at pathway level or in a gene regulation network.

1.2.3 Studies of Synthetic Lethality

Genetic high-throughput screens have identified unexpected, functionally informative, and clinically relevant synthetic lethal interactions; including synthetic lethal partners

of genes recurrently mutated in cancer or attributed to familial early-onset cancers. While screening presents an appealing strategy for synthetic lethal discovery, computational approaches are becoming popular as an alternative or complement to experimental methods to overcome inherent bias and limitations of experimental screens. An array of recently developed computational methods (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Tiong *et al.*, 2014; Wang and Simon, 2013; Wappett, 2014) show the need for synthetic lethal discovery in the fundamental genetics and translational cancer research community. However, existing computational methods are not suitable for queries of genomic data for interacting partners of a particular gene: they have been applied pairwise across the genome, do not have software released to apply the methodology, or lack statistical measures of error for further analysis. A robust prediction of gene interactions is an effective and practical approach at a scale of the entire genome for ideal translational applications, analysis of biological systems, and constructing functional gene networks.

1.2.3.1 Synthetic Lethal Pathways and Networks

SGIs are very common in genomes, with $4\times$ more interactions detected with synthetic gene array mating screens than protein-protein interactions yeast-2-hybrid studies (Tong *et al.*, 2004). The SGI network is scale-free with power-law vertex degree distribution and low average shortest path length (3.3) as expected for a complex biological network (Barabási and Oltvai, 2004). Highly connected “hub” genes with the highest number of links (vertex degree) are functionally important with many negative SGI hubs involved in cell cycle regulation and many positive SGI hubs involved in translation (Baryshnikova *et al.*, 2010b; Costanzo *et al.*, 2010). Negative SGIs were far more common than positive SGIs, with synthetic gene loss being more likely to be deleterious to cell than advantageous which indicates than synthetic lethality may be comparably easier to detect than other SGIs.

Essential pathways are highly buffered with $5\times$ more interactions than other SGIs, consistent with strong selection for survival, as found with conditional and partial mutations in essential genes (Davierwala *et al.*, 2005). This SGI network had scale-free topology and rarely shared interactions with the protein-protein interaction network. These networks are related by an “orthogonal” relationship: shared partners in one network tend to be themselves connected directly in the other network. Essential genes were likely to have closely related functions, whereas non-essential networks were relatively more inclined to have SGIs between distinct biological pathways.

1.2.3.1.1 Evolution of Synthetic Lethality

There is poor conservation of specific SGIs between *S. cerevisiae* and *S. pombe* with 29% of the interactions tested in both distantly related species being conserved between them (Dixon *et al.*, 2008). The remaining interactions show high species-specific differences; however, many of the species-specific interactions were still conserved between biological pathways, protein complexes, or protein-protein interaction modules. Similarly, conservation of pathway redundancy was also found between Eukaryotes (*S. cerevisiae*) and prokaryotes (*E. coli*) (Butland *et al.*, 2008). Negative SGIs were more likely to be conserved between biological pathways, whereas positive SGIs were more likely to be conserved within a pathway or protein complex (Roguev *et al.*, 2008).

A modest 5% of interactions were conserved between unicellular (*S. cerevisiae*) and multicellular (*C. elegans*) organisms. However, the nematode SGI network had similar scale-free topology and modularity despite differences in methodology: metazoan RNAi screens are incomplete knockouts whereas screening null mutations is feasible in yeast (Bussey *et al.*, 2006). The nematode SGI screen identified network hubs with important interactions to orthologues of known human disease genes (Lehner *et al.*, 2006). Despite the lack of direct conservation of SGIs between yeasts and nematode worms, genetic redundancy at the gene or pathway level may yet be consistent with an induced essentiality model of SGIs where gene functions are conserved with network restructuring over evolutionary change (Tischler *et al.*, 2008). While nematode models are more closely related to human cells, cancer cells can present growth and viability phenotypes more comparable to yeast models. Therefore findings from both SGA and RNAi models are relevant to understanding cellular network structure and in healthy and cancerous human cells. RNAi has also been applied to human and mouse cancer cells in cell culture and genetic screening experiments. These findings suggest that SGI network “rewiring” is a concern for identifying specific synthetic lethal interactions in cancer and a pathway approach may be more robust in the context of evolution, patient variation, tumour heterogeneity, and disease progression.

1.2.4 Synthetic Lethal Concepts in Cancer

Loss of function occurs in many genes in cancers including tumour suppressors and yet few interventions target such mutations compared to targeted therapies for gain of function mutation in oncogenes (Kaelin, Jr, 2005). Synthetic lethality is a powerful design strategy for therapies selective against loss of gene function with potential for application against a range of genes and diseases (Fece de la Cruz *et al.*, 2015; Kaelin,

Jr, 2009). Since synthetic lethality affects cellular viability by indirect functional relationships between genes, it is suitable for indirectly targeting mutations in cancers. Once synthetic lethal partners of cancer genes are identified, targeted therapeutics can be applied against them. When genes are disrupted in cancers, the induced essentiality of synthetic lethal partners is a vulnerability that may be exploited for anti-cancer therapy. This has the potential to be very specific against cancer cells (with the target mutation) over non-cancer cells (with a functional compensating gene). Analogous to “oncogene addiction”, where cancer cells adapt to particular oncogenic growth signals and become reliant on them to remain viable (Luo *et al.*, 2009; Weinstein, 2000), synthetic lethal partners of inactivated tumour suppressors are required to maintain cancer cell viability and proliferation. As such cancers are subject to “non-oncogene addiction” and are feasible anti-cancer drug targets.




Figure 1.2: Synthetic lethality in cancer. Rationale of exploiting synthetic lethality for specificity against a tumour suppressor gene (e.g., *CDH1*) while other cells are spared under the inhibition of a partner gene.

The synthetic lethal approach to cancer medicine is most amenable to loss of function mutations in tumour suppressor genes, where it would feasibly be effective against any loss of function mutation across the tumour suppressor with a viable synthetic lethal partner gene (as shown in Figure 1.2). However, the approach may also be suitable for cases where cancer cells have mutations where the normal function of the gene

is disrupted such as if it were overexpression (“synthetic dosage lethality”) or if an oncogene interfered with the function of the proto-oncogenic variant such as competitive inhibition. Thus synthetic lethality expands the range of cancer-specific mutations feasible to target with targeted therapeutics to absence of tumour suppressor genes and distinguishing highly homologous oncogenes by functional differences by targeting their synthetic lethal partners.

1.2.5 Clinical Impact of Synthetic Lethality in Cancer

The synthetic lethal interaction of *BRCA1* or *BRCA2* with *PARP1* in breast cancer is an example of how gene interactions are important in cancer, including translation to the clinic. These genetic interactions enable specific targeting of mutations in *BRCA1* or *BRCA2* tumour suppressor genes with PARP inhibitors by inducing synthetic lethality in breast cancer (Farmer *et al.*, 2005). PARP inhibitors are one of the first targeted therapeutics against a tumour suppressor mutation with success in clinical trials.

BRCA1 or *BRCA2* and *PARP1* genes demonstrate the application of the synthetic lethal approach to cancer therapy Ashworth (2008); Kaelin, Jr (2005). *BRCA1* and *BRCA2* are homologous DNA repair genes, widely known as tumour suppressors; mutation carriers have substantially increased risk of breast (risk by age 70 of 57% for *BRCA1* and 59% for *BRCA2*) and ovarian cancers (risk by age 70 of 40% for *BRCA1* and 18% for *BRCA2*) (Chen and Parmigiani, 2007). The *BRCA1* or *BRCA2* genes, which usually repair DNA or destroy the cell if it cannot be repaired, have inactivating somatic mutations in some familial and sporadic cancers. Poly-ADP-ribose polymerase (PARP) genes are tumour suppressor genes involved in base excision DNA repair. Loss of PARP activity results in single-stranded DNA breaks. However, *PARP1*^{-/-} knockout mice are viable and healthy indicating low toxicity from PARP inhibition (Bryant *et al.*, 2005).

Bryant *et al.* (2005) showed that *BRCA2* cells were sensitive to PARP inhibition by siRNA of *PARP1* or drug inhibition (which targets *PARP1* and *PARP2*) using Chinese hamster ovary cells, MCF7 and MDA-MB-231 breast cell lines. This effect was sufficient to kill mouse tumour xenografts and showed high specificity to *BRCA2* deficient cells in culture and xenografts. Farmer *et al.* (2005) replicated these results in embryonic stem cells and showed that *BRCA1* cells were also sensitive to PARP inhibition relative to the wild-type with siRNA and drug experiments in cell culture and drug activity against *BRCA1* or *BRCA2* deficient embryonic stem cell mouse xenografts. They found evidence that PARP inhibition causes DNA lesions, usually

repaired in wild-type cells, which lead to chromosomal instability, cell cycle arrest, and induction of apoptosis in *BRCA1* or *BRCA2* deficient cells. Therefore, the pathways cooperate to repair DNA giving a plausible mechanism for combined loss as an effective anti-cancer treatment.

Thus PARP inhibitors have potential for clinical use against *BRCA1* or *BRCA2* mutations in hereditary and sporadic cancers (Ashworth 2008; Kaelin 2005). PARP inhibition has been found to be effective in cancer patients carrying *BRCA1* or *BRCA2* mutations and some other ovarian cancers, suggesting synthetic lethality between PARP and other DNA repair pathways (Ström and Helleday, 2012). This supports the potential for PARP inhibition as a chemo-preventative alternative to prophylactic surgery for high risk individuals with *BRCA1* or *BRCA2* mutations (Ström and Helleday, 2012). Hormone-based therapy has also been suggested as a chemo-preventative in such high risk individuals and aromatase inhibitors have completed phase I clinical trials for this purpose (Bozovic-Spasojevic 2012). Ström and Helleday (2012) also postulate increased efficacy of PARP inhibitors in the hypoxic DNA-damaging tumour micro-environment.

A PARP inhibitor, olaparib, showed fewer adverse effects than cytotoxic chemotherapy and anti-tumour activity in phase I trials against *BRCA1* or *BRCA2* deficient familial breast, ovarian, and prostate cancers (Fong *et al.*, 2009) and sporadic ovarian cancer (Fong *et al.*, 2010). AstraZeneca has reported phase II trials showing the treatment is effective in *BRCA1* or *BRCA2* deficient breast (Tutt *et al.*, 2010) and ovarian cancers (Audeh *et al.*, 2010) with a favourable therapeutic window and similar toxicity between carriers of *BRCA1* or *BRCA2* mutations and sporadic cases. AstraZeneca announced that olaparib has begun phase III trials for breast and ovarian cancers in 2013. Mixed results in phase II trials in ovarian cancer are behind the delays addressed by retrospective analysis of the cohort subgroup with confirmed mutation of *BRCA1* or *BRCA2* genes in the tumour; unsurprisingly these patients, benefit most from the PARP inhibitor treatment and have increased platinum sensitivity in combination treatment. These PARP inhibitors are FDA approved for some cancers McLachlan *et al.* (2016), are effective against germline and sporadic *BRCA1* or *BRCA2* mutations, and are a potential prevention alternative to prophylactic surgery for high risk mutation carriers Ström and Helleday (2012).

This demonstrates the clinical impact of a well characterised system of synthetic lethality with known cancer risk genes. Synthetic lethality has the benefit of being effective against inactivation of tumour suppressor genes by any means, broader than targeting a particular oncogenic mutation (Kaelin, Jr, 2005). The targeted therapy is

effective in both sporadic and hereditary *BRCA1* or *BRCA2* deficient tumours acting against an oncogenic molecular aberration across several tissues.

1.2.6 High-throughput Screening for Synthetic Lethality

The function of signalling pathways and combinations of interacting genes are important in cancer research but classical genetics approaches have been limited to non-redundant pathways (Fraser, 2004). The emerging RNAi technologies have vastly expanded the potential for studying genetic redundancy in mammalian experimental models including testing experimentally for synthetic lethality (Fraser, 2004). Identifying synthetic lethality is crucial to study gene function, drug mechanisms, and design novel therapies (Lum *et al.*, 2004). Candidate selection of synthetic lethal gene pairs relevant to cancer has shown some success but is limited because interactions are difficult to predict; they can occur between seemingly unrelated pathways in model organisms (Costanzo *et al.*, 2011). While biologically informed hypotheses have had some success in synthetic lethal discovery (Bitler *et al.*, 2015; Bryant *et al.*, 2005; Farmer *et al.*, 2005), interactions occurring indirectly between distinct pathways would be missed (Boone *et al.*, 2007; Costanzo *et al.*, 2011). Scanning the entire genome for interactions against a clinically relevant gene is an emerging strategy being explored with high-throughput screens (Fece de la Cruz *et al.*, 2015) and computational approaches (Boucher and Jenna, 2013; van Steen, 2012).

Experimental screening for synthetic lethality is an appealing strategy for wider discovery of functional interactions *in vivo* despite many potential sources of error which must be considered. The synthetic lethal concept has both genetic and pharmacological screening applications to cancer research. Genetic screens, with RNAi to discover the specific genes involved, inform development of targeted therapies with a known mode of action, anticipated mechanisms of resistance, and biomarkers for treatment response. RNAi is a transient knockdown of gene expression more similar to the effect of drugs than complete gene loss and makes comparison to screens in model organisms difficult (Bussey *et al.*, 2006). The RNAi gene knockdown process has inherent toxicity to some cells, potential off-target effects, and issues with a high false positive rate. Therefore, it is important to validate any candidates in a secondary screen and replicate knockdown experiments with a number of independent shRNAs. Alternative gene knockout procedures have also been proposed for synthetic lethal screening including a genome-wide application of the CRISPR/Cas9/sgRNA genome editing technology (Sander and Joung, 2014), episomal gene transfer (Vargas *et al.*, 2004), or RNAi with lentiviral

transfection for delivery of shRNA (Telford *et al.*, 2015). Genetic screens have potential for quantitative gene disruption experiments to selectively target overexpressed genes in cancer via synthetic dosage lethality. While powerful for understanding fundamental cellular function, analysis of isogenic cell lines is inherently limited by assuming only a single mutation differs between them despite susceptibility to “genetic drift” and cannot account for diverse genetic backgrounds or tumour heterogeneity (Fece de la Cruz *et al.*, 2015). Genetic screens thus identify targets to develop or repurpose targeted therapies for disease but alone will not directly identify a lead compound to develop for the market or clinical translation.

Chemical screens are immediately applicable to the clinic by directly screening for selective lead compounds with suitable pharmacological properties. However chemical screens lack a known mode of action, may affect many targets, and screen a narrow range of genes with existing drugs. With either approach there are many challenges translating candidates into the clinic such as finding targets relevant to a range of patients, validation of targets, accounting for a range of genetic (and epigenetic) contexts or tumour micro-environment, identifying effective synergistic combinations, enhancers of existing radiation or cytotoxic treatments, avoiding inherent or acquired drug resistance, and developing biomarkers for patients which will respond to synthetic lethal treatment, including integrating these into clinical trials and clinical practice. Identifying specific target genes is an effective way to anticipate such challenges, which can be approached with genetic screens, so we will focus on these and computational alternatives. Screening methods have proven a fruitful area of research, despite being costly, laborious, and having many different sources of error. These limitations suggest a need for complementary computational approaches to synthetic lethal discovery.

1.2.6.1 Synthetic Lethal Screens

Overexpression of genes is another suitable application for synthetic lethality since overexpressed genes cannot be distinguished from the wild-type by direct sequence specific targeted therapy. Overexpression of oncogenes, such as *EGFR*, *MYC*, and *PIM1*, has been found to drive many cancers. *PIM1* is a candidate for synthetic lethal drug design in lymphomas and prostate cancers, where it interacts with *MYC* to drive cancer growth. van der Meer *et al.* (2014) performed an RNAi screen for synthetic lethality between *PIM1* overexpression and gene knockdown in RWPE prostate cancer cell lines. *PLK1* gene knockdown and drug inhibition was effective as a specific inhibitor of *PIM1* overexpressing prostate cells in cell culture and mouse tumour xenografts. *PLK1* inhibition reduced *MYC* expression in pre-clinical models, consistent with ex-

pression in human tumours in which *PIM1* and *PLK1* are co-expressed and correlated with tumour grade. Thus RNAi screening was valuable to identify therapeutic targets and biomarkers for patient response as demonstrated with the finding of *PLK1* as a candidate drug target against prostate cancer progression.

Heredity leiomyomatosis and renal cell carcinoma (HLRCC) is a cancer syndrome of predisposition to benign tumours in the uterus and risk of malignant cancer of the kidney attributed to inherited mutations in fumarate hydratase (*FH*). Boettcher *et al.* (2014) performed an RNAi screen on HEK293T renal cells for synthetic lethality with *FH*. They found enrichment of haem metabolism (consistent with the literature) and adenylate cyclase pathways (consistent with cAMP dysregulation in *FH* mutant cells). Synthetic lethality between *FH* mutation and adenylate cyclases was validated with gene knockdown, drug experiments, and replicated across both HEK293T renal cells and VOK262 cells derived from a HLRCC patient, suggesting new potential treatments against the disease.

Similarly, hereditary diffuse gastric cancer (HDGC) is a cancer syndrome of predisposition to early-onset malignant stomach and breast cancers attributed to mutations in E-cadherin (*CDH1*). Telford *et al.* (2015) performed an RNAi screen on MCF10A breast cells for synthetic lethality with *CDH1*. They found enrichment of G-protein coupled receptors (GPCRs) and cytoskeletal gene functions. The results were consistent with a concurrent drug compound screen with a number of candidates validated by lentiviral shRNA gene knockdown and drug testing including inhibitors of Janus kinase, histone deacetylases, phosphoinositide 3-kinase, aurora kinase, and tyrosine kinases. Therefore the synthetic lethal strategy has potential for clinical impact against HDGC, with particular interest in interventions with low adverse effects for chemo-prevention, including repurposing existing approved drugs for activity against *CDH1* deficient cancers.

RNAi screening for synthetic lethality is also useful for functional genetics to understand drug sensitivity. Aarts *et al.* (2015) screened WiDr colorectal cells for synthetic lethality between *WEE1* inhibitor treatment and an RNAi library of 1206 genes with functions known to be amenable to drug treatment or important in cancer such as kinases, phosphatases, tumour suppressors, and DNA repair (a pathway *WEE1* regulates). Screening identified a number of synthetic lethal candidates including genes involved in cell cycle regulation, DNA replication, repair, homologous recombination, and Fanconi anaemia. Synthetic lethality with cell-cycle and DNA repair genes was consistent with the literature and validation in a panel of breast and colorectal cell

lines supported checkpoint kinases, Fanconi anaemia, and homologous recombination as synthetic lethal partners of *WEE1*. These results show that synthetic lethality can be used to improve drug sensitivity as a combination treatment, especially to exploit genomic instability and DNA repair, which are known to be clinically applicable from previous results with *BRCA1* or *BRCA2* genes and PARP inhibitors (Lord *et al.*, 2015). Therefore, *WEE1* inhibitors are an example of treatment which could be repurposed with the synthetic lethal strategy. Similar findings would be valuable to clinicians as a source of biomarkers and novel treatments. While using a panel of cell lines to replicate findings across genetic background is a promising approach to ensure wide clinical application of validated synthetic lethal partners, a computational approach may be more effective as it could account for wider patient variation than scaling up intensive experiments on a wide array of cell lines and could screen beyond limited candidates from an RNAi library.

Chemical genetic screens are also a viable strategy to identify therapeutically relevant synthetic lethal interactions. Bitler *et al.* (2015) investigated *ARID1A* mutations, aberrations in chromatin remodelling known to be common in ovarian cancers, for drug response. Ovarian RMG1 cells were screened for drug response specific to *ARID1A* knockdown cells. They used *ARID1A* gene knockdown for consistent genetic background, with control experiments and 3D cell culture to ensure relevance to drug activity in the tumour micro-environment. Screening a panel of commercially available drugs targeting epigenetic regulators found *ESH2* methyltransferase inhibitors effective and specific against *ARID1A* mutation with validation in a panel of ovarian cell lines. Synthetic lethality between *ARID1A* and *ESH2* was supported by decreases in H3K27me3 epigenetic marks and markers of apoptosis in response to *ESH2* inhibitors. This was mechanistically supported with differential expression of *PIK3IP1* and association of both synthetic lethal genes with the *PIK3IP1* promoter identifying the PI3K-AKT signalling pathway as disrupted when both genes were inhibited.

This successfully demonstrates the importance of synthetic lethality in epigenetic regulators, identifies a therapeutically relevant synthetic lethal interaction, and shows that chemical genetic screens could model drug response and combination therapy in cancer cells. However this approach is limited to finding synthetic lethal interactions between genes with known similar function, which may not be the most suitable for treatment. Further limiting experiments to genes with existing targeted drugs reduces the number of synthetic lethal interactions detected, assumes the specificity of drugs to a particular target, and many of these drugs are not yet clinically available yet anyway,

although they are clinical trials for other diseases or limited to access by patients from a particular countries.

The examples above show that high-throughput screens are an effective approach to discover synthetic lethality in cancer with a wide range of applications. Screens are more comprehensive than hypothesis-driven candidate gene approaches and successfully find known and novel synthetic lethal interactions with potential for rapid clinical application. They have the power to test mode of action of drugs, find unexpected synthetic lethal interactions between pathways, or identify effective treatment strategies without needing a clear mechanism. However, synthetic lethal screens are costly, labour-intensive, error-prone, and biased towards genes with effective RNAi knockdown libraries. Limited genetic background, lethality to wild-type cell during gene knockdown, off-target effects, and difficulty replicating synthetic lethality across different cell lines, tissues, laboratories, or conditions stems from a high false positive rate and a lack of standardised thresholds to identify synthetic lethality in a high-throughput screen. Therefore there is a need for replication, validation, and alternative approaches to identify synthetic lethal candidates. Varied conditions between experimental screens and differences between RNAi and drug screens renders meta-analysis ineffective.

Genome-scale synthetic lethal experiments (across gene pairs) are not feasible, even in model organisms, and they typically focus on specific gene candidates or the partners of a gene of interest (such as importance in health). Therefore a computational approach is more suitable for this task and may further augment experimental screening to replicate screen candidates beyond experimental models.

1.2.7 Computational Prediction of Synthetic Lethality

1.2.7.1 Bioinformatics Approaches to Genetic Interactions

Prediction of gene interaction networks is a feasible alternative to high-throughput screening with biological importance and clinical relevance. There are many existing methods to predict gene networks, as reviewed by van Steen (2012) and Boucher and Jenna (2013) and summarised in Table 1.1. However, many of these methods have limitations including the requirement for existing SGI data, several data inputs, and reliability of gene function annotation. Many of the existing methods also assume conservation of individual interactions between species, which has been found not to hold in yeast studies (Dixon *et al.*, 2008). Tissue specificity is important in gene regulation and gene expression, which are used as predictors of genetic interaction. However, tissue specificity of genetic interactions cannot be explored in yeast studies

and has not been considered in many studies of multicellular model organisms, human networks, or cancers. Similarly, investigation into tissue specificity of protein-protein interactions (PPIs), an important predictor of genetic interactions, is difficult given that high-throughput two-hybrid screens occur out of cellular context for multicellular organisms.

Table 1.1: Methods for Predicting Genetic Interactions

Method	Input Data	Species	Source	Tool Offered
Between Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Within Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Decision Tree	PPI, expression, phenotype	<i>S. cerevisiae</i>	Wong <i>et al.</i> (2004)	2 Hop
Logistic Regression	SGI, PPI, co-expression, phenotype	<i>C. elegans</i>	Zhong and Sternberg (2006)	Gene Orienteer
Network Sampling	SGI, PPI, GO	<i>S. cerevisiae</i>	Le Meur and Gentleman (2008) Le Meur <i>et al.</i> (2014)	SLGI(R)
Random Walk	GO, PPI, expression	<i>S. cerevisiae</i> <i>C. elegans</i>	Chipman and Singh (2009)	
Shared Function	Co-expression, PPI, text mining, phylogeny	<i>C. elegans</i>	Lee <i>et al.</i> (2010b)	WormNet
Logistic Regression	Co-expression, PPI, phenotype	<i>C. elegans</i>	Lee <i>et al.</i> (2010a)	GI Finder
Jaccard Index	GO, SGI, PPI, phenotype	Eukarya	Hoehndorf <i>et al.</i> (2013)	
Machine Learning			Pandey <i>et al.</i> (2010)	MNMC
Machine Learning Meta-Analysis			Wu <i>et al.</i> (2014)	MetaSL
Flux Variability Analysis				
Flux Balance Analysis	Metabolism	<i>E. coli</i> <i>M. pneumoniae</i>	Güell <i>et al.</i> (2014)	
Network Simulation				

There are a number of existing computational methods for predicting synthetic lethal gene pairs in humans with a specific interest in cancer (as summarised in 1.2). While these demonstrate the power and need for predictions of synthetic lethality in human and cancer contexts, limitations of previous methods could be met with a different approach. Existing computational approaches to synthetic lethal prediction are often difficult to interpret, replicate for new genes, or are reliant on data types not available for a wider range of genes to test.

1.2.7.2 Comparative Genomics

A comparative genomics approach by Deshpande *et al.* (2013) used the results of well characterised high-throughput mutation screens in *S. cerevisiae* as candidates for synthetic lethality in humans (Baryshnikova *et al.*, 2010a; Costanzo *et al.*, 2010, 2011; Tong *et al.*, 2001, 2004). Yeast synthetic lethal partners were compared to human orthologues to find cancer relevant synthetic lethal candidate pairs with direct therapeutic potential. Proposed as a complementary approach to siRNA screens, approximately 24,000 of the 116,000 negative SGIs in yeast (Costanzo *et al.*, 2011) were matched to human orthologues, with over 500 involving a cancer gene (Futreal *et al.*, 2004). Under strict

Table 1.2: Methods for Predicting Synthetic Lethality in Cancer

Method	Input Data	Source	Tool Offered
Network Centrality	protein-protein interactions	Kranthi <i>et al.</i> (2013)	
Differential Expression	Expression Mutation	Wang and Simon (2013)	
Comparative Genomics	Yeast synthetic gene interactions	Heiskanen and Aittokallio (2012)	
Chemical-Genomics	Homology		
Comparative Genomics	Yeast synthetic gene interactions Homology	Deshpande <i>et al.</i> (2013)	
Machine Learning		Discussed by Babyak (2004) and Lee and Marcotte (2009)	
Differential Expression	Expression	Tiong <i>et al.</i> (2014)	
Literature Database		Li <i>et al.</i> (2014)	Syn-Lethality
Meta-Analysis	Meta-Analysis	Wu <i>et al.</i> (2014)	MetaSL
Pathway Analysis		Zhang <i>et al.</i> (2015)	
Protein Domains	Homology	Kozlov <i>et al.</i> (2015)	
Data-Mining	Expression	Jerby-Arnon <i>et al.</i> (2014)	
Machine Learning	Somatic mutation and DNA CNV siRNA in cell lines	Ryan <i>et al.</i> (2014) Crunkhorn (2014) Lokody (2014)	DAISY (method)
Genome Evolution	Expression	Lu <i>et al.</i> (2013)	
Hypothesis Test	DNA CNV	Lu <i>et al.</i> (2015)	
Machine Learning	Known SL		
Bimodality	Expression DNA CNV Somatic Mutation	Wappett (2014) Wappett <i>et al.</i> (2016)	BiModal Subsetting ExPression (BiSEp)
Directional Chi-Square	Expression (microarray) Somatic mutation	Kelly, S. T., Guilford, P. J., and Black, M. A. Dissertation (Kelly, 2013) and developed here	SLIPT

criteria of one-to-one orthologues, large effect size and significant interaction in yeast data ($\epsilon < -0.2$, $p < 0.05$), 1,522 interactions were identified with 70 involving cancer genes. Of the 21 gene interactions tested with pairs of siRNA in IMR1 fibroblast cells, 6 exhibited synthetic lethal effects. The two strongest interactions (*SMARCB1* with *PSMA4* and *ASPSCR1* with *PSMC2*) were successfully validated by protein analysis of human cells and replication with tetrad analysis for yeast orthologues.

Another approach to systematic synthetic lethality discovery specific to human cancer (in contrast to the plethora of yeast synthetic lethality data) was to build a database as done by Li *et al.* (2014). In their relational database, called “Syn-lethality”, they have curated both known experimentally discovered synthetic lethal pairs in humans (113 pairs) from the literature and those predicted from synthetic lethality between orthologous genes in *S. cerevisiae* yeast (1114 pairs). This knowledge-based database is the first dedicated to human cancer synthetic lethal interactions and integrates gene function annotation, pathway and molecular mechanism data with experimental and predicted synthetic lethal gene pairs. This combination of data sources is intended to tackle the trade-off between more conclusive synthetic lethal experiments in yeast and more clinically relevant synthetic lethal experiments in human cancer models,

such as RNAi, especially when high-throughput screens are costly and prone to false positives in either system and difficult to replicate across gene backgrounds. This database centralises a wealth of knowledge scattered in the literature including cancer relevant genes (*BRCA1*, *BRCA2*, *PARP1*, *PTEN*, *VHL*, *MYC*, *EGFR*, *MSH2*, *KRAS*, and *TP53*) and is publicly available as a Java App. These included the previously mentioned interactions of *BRCA1* and *BRCA2* with *PARP1* and *TP53* with *WEE1* and *PLK1*. However, the computational methodology was not released, so it is not possible to replicate their results, nor to add to the findings with new datasets, which are limited to 647 human genes. Suggested future directions were promising, such as constructing networks of known synthetic lethality, applying known synthetic lethality to cancer treatment, data mining, replicating the approach for synthetic lethality in model organisms, signalling pathways, and developing a complete global network in human cancer or yeast (both of which are still incomplete with experimental data), some of which has been implemented in “SynLethDB” (Guo *et al.*, 2016).

Table 1.3: Machine Learning Methods used by Wu *et al.* (2014)

Method	Source	Tool Offered
Random Forest	Breiman (2001)	
Random Forest		
J48 (decision tree)		
Bayes (Log Regression)		
Bayes (Network)	Hall <i>et al.</i> (2009)	WEKA
PART (Rule-based)		
RBF Network		
Bagging / Bootstrap		
Classification via Regression		
Support Vector Machine (Linear)	Vapnik (1995)	
Support Vector Machine (RBF – Gaussian)	Joachims (1999)	
Multi-Network Multi-Class (MNMC)	Pandey <i>et al.</i> (2010)	
MetaSL (Meta-Analysis)	Wu <i>et al.</i> (2014)	MetaSL

Machine learning approaches have also been proposed for synthetic lethal discovery (Babyak, 2004; Lee and Marcotte, 2009). Due to concerns that these may be subject to overfitting or noise, Wu *et al.* (2014) developed a meta-analysis method (based on the machine learning methods in Table 1.3) for synthetic lethal gene pairs relevant to developing selective drugs against human cancer, building upon their previous database

(Li *et al.*, 2014). They used training data of 10,885 synthetic lethal interactions from yeast experiments of which 7347 occurred between the 5,504 non-essential genes. Their “metaSL” approach utilises genomic, proteomic and annotation data (including GO terms Ashburner *et al.* (2000), PPI, protein complexes, and biological pathway) with strong statistical performance in yeast data (AUROC of 0.871). The predicted orthologous synthetic lethal partners in human data were not experimentally validated but several would be relevant to cancer such as *EGFR* with *PRKCZ*. They note that computational approaches scale-up across the genome at lower cost than experimental screen and share their most supported interactions online. However, the method is not available for analysis of other genes studied by the cancer research community. While machine learning has great potential as a predictor, the results vary greatly depending on the predictive features selected and it is not clear which threshold should be used to report reliably detected genes. Syn-Lethality (Li *et al.*, 2014) and MetaSL (Wu *et al.*, 2014) demonstrate the value of computational approaches to synthetic lethality but omit many genes of importance in cancer, such as *CDH1*, and there remains a need to enable biological researchers to query such genes in a particular tissue or genetic background.

There is also concern for analyses based on yeast data that many synthetic lethal interactions may not be conserved between species Dixon *et al.* (2009), although interactions between pathways may be more comparable. It is unsurprising that many of the interactions identified were not experimentally validated. There have been many gene duplications in the separate evolutionary histories of humans and yeast which may lead to differences in genetic redundancy. Yeast are not an ideal human cancer model because they do not have tissue specificity, multicellular gene regulation, or orthologues to a number of known cancer genes such as p53. Although these studies have tried to anticipate these issues with stringent criteria such as requiring one-to-one orthologues, there remains the possibility that changes in gene function may affect whether these are solely redundant such as if functions had coevolved without sequence homology. Many genes will also be excluded since they lack homologues in yeast, the corresponding experimental data, or having paralogues in either species. Thus conservation of yeast interactions is not an ideal strategy and analysis of human data directly for comparison with human experimental data will be the focus of this thesis.

1.2.7.3 Analysis and Modelling of Protein Data

Kranthi *et al.* (2013) took a network approach to discovery of synthetic lethal candidate selection applying the concept to “centrality” to a human PPI network involving

interacting partners of known cancer genes. The effect of removing pairs of genes on connectivity of the network was used as a surrogate for viability which is supported by observations that the PPI and synthetic lethal networks are orthogonal in *S. cerevisiae* studies (Tong *et al.*, 2004). They showed that the human cancer protein interaction network (of 1539 proteins and 6471 interactions) exhibits the power law distribution expected of a scale-free synthetic lethal network with high connectivity (average vertex degree of 23.67 and network efficiency of 0.2952). Their top 100 candidate interactions included interactions of the tumour suppressor *TP53* with *BRCA1*, *CDKNA1*, *CDKNA2*, *MET*, and *RB1* which have been detected by prior studies. The gene pairs were often observed to be in the same or a plausible compensatory pathway. Thus the network structure is important in the biological functions of cancers and could be exploited for targeting *TP53* loss of function mutations.

However, their approach was limited to known cancer genes and is not applicable to genes that do not have PPI data. Other nucleotide sequencing data types are more commonly available for cancer studies at a genomic scale. Of further concern is that the results were enriched for p53 synthetic lethal partners which is relevant to many cancer researchers but this genome-wide approach did not detect many other cancer genes due to multiple testing. This enrichment may be due to the known drastic effect of removing p53 itself from the network as a master regulator, cancer driving tumour suppressor gene, and highly connected network “hub”. The focus on cancer genes is useful for translation into therapeutics but does not account for variable genetic backgrounds or effect of protein removal on the whole cellular network.

Focusing on the potential for synthetic lethality to be an effective anti-cancer drug target, Zhang *et al.* (2015) used modelling of signalling pathways to identify synthetic lethal interactions between known drug targets and cancer genes by simulating gene knockdowns. A computational approach was applied to avoid the limitations of experimental RNAi screens such as scale, instability of knockdown, and off-target effects. This ‘hybrid’ method of a data-driven model and known signalling pathways showed potential as a means to predict cell death in single and combination gene knockouts. They used time series protein phosphorylation data (Lee *et al.*, 2012) for 28 signalling proteins and Gene Ontology (GO) (GO) pathways Ashburner *et al.* (2000); Blake *et al.* (2015). This approach successfully detected many known essential genes in the human gene essentiality database, known synthetic lethal partners in the Syn-Lethality database (Li *et al.*, 2014), and predicted novel synthetic lethal gene pairs. The strongest essential genes in single knockdowns were *AKT*, *TP53*, *CHK1*, *S6K1*, and *CYCLIND1*.

Pairwise knockdowns identified 252 candidate synthetic lethal interactions including *TP53* with *CHK1*, *S6K1*, *WEE1*, *CYCLIND1*, and *CASP9*; *AKT* with *WEE1*; and *CDK1* with *CYCLIND1*. These novel results contained many *TP53* and *AKT* synthetic lethal partners, genes known to be important in many cancers, however these also have a severe impact on the signalling pathways in their essentiality analysis of single gene disruptions and large phenotypic changes in cancer. This approach is amenable to detect functionally related pathways and protein complexes across the molecular function, cellular component, and biological process annotations provided by GO. The results were consistent with the experimental results in the literature but the novel synthetic lethal interactions have yet to be validated. While the mathematical reasoning and algorithms are given, the code was not released to replicate the findings or apply the methodology beyond the signalling pathways analysed by Zhang *et al.* (2015). While this is an interesting approach, the analysis of this thesis will focus on gene expression and RNAi data which is available to test a wider range of candidate gene pairs.

1.2.7.4 Differential Gene Expression

Differential gene expression has been explored to predict synthetic lethal pairs in cancer which would be widely applicable due to the availability of public gene expression data for a large number of samples and cancer types. Wang and Simon (2013) found differentially expressed genes (by the t-test, adjusted by FDR) between tumours with or without functional p53 mutations in TCGA (McLendon *et al.*, 2008) and Cancer Cell Line Encyclopaedia (CCLE) (Barretina *et al.*, 2012) RNA-Seq gene expression data as candidate synthetic lethal partner pathways of p53. They identified 2, 8, and 21 candidate synthetic lethal partner genes in 3 microarray datasets from the NCI60 cell lines, 31 partner genes from the CCLE RNA-Seq data, and 50 in TCGA RNA-Seq data. *PLK1* was replicated across 4 of these analyses and 17 other genes were replicated across 2 analyses (including *MTOR*, *PLK4*, *MAST2*, *MAP3K4*, *AURKA*, *BUB1* and 6 CDK genes) with many playing a role in cell cycle regulation. This was supported by a drug sensitivity experiment on the NCI60 cell lines which found that cells which lacked functional p53 were more sensitive to paclitaxel (which targets *PLK1*, *AURKA*, and *BUB1*). This demonstrated the potential of gene expression as a surrogate for gene function and use of public genomic data to predict synthetic lethal gene pairs in cancer. Wang and Simon (2013) advocated for pre-screening of expression profiles to augment future RNAi screens. However, the analyses were limited to kinase genes and focused on currently druggable genes, lacking wider application of synthetic lethal prediction

methodology. This approach may not be feasible or applicable in cancer genes with a lower mutation rate than p53.

Tiong *et al.* (2014) also investigated gene expression as a predictor of synthetic lescale-freethal pairs with colorectal cancer microarrays from a Han Chinese population with a sample size of 70 tumour and 12 normal tissue samples. Simultaneously differentially expression of “tumour dependent” gene pairs (which includes co-expression) between cancer and normal tissue was used to rank 663 candidate synthetic lethal interactions identified in cell line siRNA experiments. Of the top 20 genes, 17 were tested for testing differential expression at the protein level with immunohistochemistry staining and correlation with clinical characteristics, with 11 pairs exhibiting synergistic effects. Some of the predicted synthetic lethal pairs were consistent with the literature (including *TP53* with *S6K1* and partners of *KRAS*, *PTEN*, *BRCA1*, and *BRCA2*) and two novel synthetic lethal interactions (*TP53* with *CSNK1E* and *CTNNB1*) were validated in pre-clinical models. This serves a valuable proof-of-concept for integration of *in silico* approaches to synthetic lethal discovery in cancer demonstrating it’s utility to triage and identify synthetic lethal partners of p53 applicable to colorectal tissues. Although the experimental work was the focus of the paper, these findings show that bioinformatics synthetic lethal candidates can be validated in patient tissue samples (from a non-caucasian population) to find those applicable to colorectal cancers.

1.2.7.5 Data Mining and Machine Learning

Recognising the utility of synthetic lethality to drug inhibition and specificity of anti-cancer treatments, Jerby-Arnon *et al.* (2014) also saw the need for effective prediction of gene essentiality and synthetic lethality to augment experimental studies of SL. They developed the DAData mIning SYnthetic lethal identification pipeline (DAISY), a data-driven approach for genome-wide analysis of synthetic lethality in public cancer genomics data from TCGA and CCLE (Barretina *et al.*, 2012). DAISY is intended to predict the candidate synthetic lethal partners of a query gene such as genes recurrently mutated in cancer.

Jerby-Arnon *et al.* (2014) combined a computational approach to triage candidates with a conventional RNAi screen to validate synthetic lethal partners. They screened a selection of computationally predicted candidates and randomly selected genes with RNAi against *VHL* loss of function mutation in RCC4 renal cell lines. The computational method had a high AUROC of 0.779 and predictions were enriched 4× for validated RNAi hits over randomly selected genes. This approach detected known synthetic lethal pairs such as *BRCA1* or *BRCA2* genes with *PARP1* and *MSH2* with

DHFR. The synthetic lethal candidates identified with both RNAi screening and computational prediction formed an extensive network of 2077 genes with 2816 synthetic lethal interactions and similar network of 3158 genes with 3635 synthetic dosage lethal interactions (for synthetic lethality with over-expression). Each network was scale-free as expected of a biological network and was enriched for known cancer genes, essential genes in mice, and could be harnessed for predicting prognosis and drug response. While demonstrating the feasibility of combining experimental and computational approaches to synthetic lethality in cancer, there remain challenges in predicting synthetic lethal genes, novel drug targets, and translation into the clinic.

The DAISY methodology (Jerby-Arnon *et al.*, 2014) compares the results of analysis of several data types to predict synthetic lethality, namely: DNA copy number and somatic mutation for TCGA patient samples and CCLE cell lines. The cell lines were also analysed with gene expression and gene essentiality (shRNA screening) profiles. Genes were classed as inactivated by copy number deletion, somatic loss of function mutation, or low expression and tested for synthetic lethal gene partners which are either essential in screens or not deleted with copy number variants. Co-expression is also used for synthetic lethality prediction based on studies in yeast (Costanzo *et al.*, 2010; Kelley and Ideker, 2005). Copy number, gene expression and, essentiality analyses are stringently compared by adjusting each for multiple tests with Bonferroni correction and only taking hits which occur in all analyses. This methodology was also adapted for synthetic dosage lethality by testing for partner genes where genes are overactive with high copy number or expression. As discussed above, the predictions performed well and an RNAi screen for the example of *VHL* in renal cancer validated predicted synthetic lethal partners of *VHL* demonstrating the feasibility of combining approaches to synthetic lethal discovery in cancer and using computational predictions to enable more efficient high-throughput screening. DAISY performs well statistically with a AUROC of 0.779 on a set of gene pairs with experimental screen data, although co-expression and shRNA functional examination contributes much less of this than the mutation and copy number analysis (AUROC 0.683 alone). However, this methodology is very stringent, missing potentially valuable synthetic lethal candidates, may not be applicable to genes of interest to other groups and the software for the procedure has not been publicly released for replication.

Although the DAISY procedure performs well and has been well received by the scientific community (Crunkhorn, 2014; Lokody, 2014; Ryan *et al.*, 2014), showing a need for such methodology, there is no indication of adoption of the methodology in the

community yet. The co-expression analysis may not be the most effective way to test gene expression for directional synthetic lethal interactions (where inverse correlation would be expected). In the interests of a large sample size, tissue types were not tested separately despite tissue-specific synthetic lethality being likely since gene function (and by extension expression, isoforms, and clinical characteristics) in cancers may often be tissue-dependent. Some data forms and analyses used, such as gene essentiality, may not be available for all cancers, genes, or tissues, and may not be reproduced.

Lu *et al.* (2015) critique the assumption of co-expression in the DAISY methodology and propose an alternative computational prediction of synthetic lethality based on machine learning methods and a “cancer genome evolution” hypothesis. Using DNA copy number and gene expression data from TCGA patient samples, a cancer genome evolution model assumes that synthetic lethal gene pairs behave in two distinct ways in response to an inactive synthetic lethal partner gene, either a “compensation” pattern where the other synthetic lethal partner is overactive or a “co-loss underrepresentation” pattern where the other synthetic lethal partner is less likely to be lost, since loss of both genes would cause death of the cancer cell. During the genome evolution of cancers, the cell becomes addicted to the remaining synthetic lethal partner due to induced gene essentiality. These patterns would explain why DAISY detects only a small number of synthetic lethal pairs, compared to the large number expected based on model organism studies (Boone *et al.*, 2007), and the disparity between screening and computationally predicted synthetic lethal candidates due to testing different classes of synthetic lethal gene pairs.

Lu *et al.* (2015) compared a genome-wide computational model of genome evolution and gene expression patterns to the experimental data of Vizeacoumar *et al.* (2013) and Laufer *et al.* (2013). This simpler model performing well with an AUROC of 0.751 but was less than DAISY, although it did not rely on data from cell lines which may not represent patient disease. They predict a larger comprehensive list of 591,000 human synthetic lethal partners with a probability score threshold of 0.81, giving a precision of 67% and 14 \times enrichment of synthetic lethal true positives compared to randomly selected gene pairs. Discovery of such a vast number of cancer-relevant synthetic lethal interactions in humans would not be feasible experimentally and is a valuable resource for research and clinical applications. These predictions are not limited by assuming co-expression of synthetic lethal partners or evolutionary conservation with model organisms enabling wider synthetic lethal discovery. However, there remains a lack of basis for an expectation of how many synthetic lethal partners a particular gene

will have, how many pairs there are in the human genome, and whether pathways or correlation structure would influence predicted synthetic lethal partners.

Large scale, computational approaches have yet to determine whether synthetic lethal interactions are tissue-specific since Lu *et al.* (2015) used pan-cancer data for 14136 patients with 31 cancer types. Experimental data used for comparison was a small training dataset specific to colorectal cancer, and based on screens for other phenotypes, which may limit performance of the model or application to other cancers. Proposed expansion of the computational approach to mutation, microRNA, or epigenetic modulation of gene function and tumour micro-environment or heterogeneity suggests that synthetic lethal discovery could be widely applied to the current challenges in cancer genomics. This approach was also based on machine learning methodology and not supported by a software release for the community to develop, contribute to, or reproduce beyond the gene pairs given in the supplementary results.

1.2.7.6 Bimodality

Wappett *et al.* (2016) demonstrate a multi-omic approach to identification of synthetic lethality in cancer with a strategy to detect bimodal patterns in molecular profiles. They released this solution as the BiSEp R package Wappett (2014) which aims to detect subtle bimodal and non-normal patterns in expression data. Since loss of gene function is not consistently genetic, Wappett *et al.* (2016) advocate the use of gene expression (loss of mRNA) and deletion (loss of copy number) data in addition to mutation. The BiSEp procedure was demonstrated on an analysis of 881 cell lines from CCLE (Barretina *et al.*, 2012), 442 cell lines from Catalogue Of Somatic Mutations In Cancer (COSMIC) (Forbes *et al.*, 2015), and RSEM normalised RNA-Seq data for 178 TCGA lung patient samples (Collisson *et al.*, 2014). BiSEp was demonstrated to have significant enrichment of validated tumour suppressor, synthetic lethal gene pairs (detecting 76 experimentally supported gene pairs) and was improved (detecting 420) with expression data rather than relying on detecting loss of gene function by mutation or deletion. They identified interactions with genes relevant to cancer with support in experimental screens including *ERCC4* with *XRCC1*, *BRCA1* with *PARP3*, and *SMARCA1* with *SMARCA4*.

Wappett *et al.* (2016) demonstrated that analysis of genomics data, particularly expression data, is relevant to augment the identification of synthetic lethal interactions with screening experiments. They further show that this is applicable in both genetically homogeneous cell lines and heterogeneous cell population from patient samples. This approach is limited however to genes which exhibit bimodal expression patterns

which do not commonly occur, particularly in normalised gene expression data, and other approaches may need to be considered for gene such as *CDH1* which were not identified by BiSEp.

1.2.7.7 Rationale for Further Development

Many of the approaches discussed here aimed to identify the strongest synthetic lethal pairs across the yeast or human genomes (Deshpande *et al.*, 2013; Lu *et al.*, 2015; Wappett *et al.*, 2016; Wu *et al.*, 2014), which may not be an ideal strategy to identify interactions in particular functions or relevance to particular cancers. These demonstrate a need for computational approaches to prioritise candidate gene pairs for validation but this thesis will focus on the interactions with *CDH1* with particular importance in breast and stomach cancers, although these partners may be applicable in other cancers. As such, this thesis presents a query-based method, amenable to identification of candidate partners for a selected gene of functional or translational importance such as *CDH1*.

1.3 E-cadherin as a Synthetic Lethal Target

E-cadherin is a transmembrane protein (encoded by *CDH1*) with several characterised functions in the cytoskeleton and cell-to-cell signalling. Here we outline the key known functions of E-cadherin and it's importance in cancer biology. *CDH1* is a tumour suppressor gene, with loss of function occurring in both familial (germline mutations) and sporadic (somatic mutations) cancers. As such, *CDH1* inactivation is a prime example of a genetic event that could be targeted by synthetic lethality for anti-cancer treatments. Most notably this includes patients at risk of developing hereditary breast and stomach cancers for which conventional surgical or cytotoxic chemotherapy is not ideal (due to impact of quality of life) and who have a known genetic aberration in their familial syndromic cancers. Effective treatments against *CDH1* inactivation would also benefit patients with sporadic diffuse gastric cancers since they often present with symptoms at a late stage.

1.3.1 The *CDH1* gene and it's Biological Functions

The tumour suppressor gene *CDH1* is implicated in hereditary and sporadic lobular breast cancers (Berx *et al.*, 1996; Berx and van Roy, 2009; De Leeuw *et al.*, 1997; Masciari *et al.*, 2007; Semb and Christofori, 1998; Vos *et al.*, 1997). The *CDH1* gene encodes the E-cadherin protein and is normally expressed in epithelial tissues, where it has also been identified as an invasion suppressor and loss of *CDH1* function has

been implicated in breast cancer progression and metastasis (Becker *et al.*, 1994; Berx *et al.*, 1995; Christofori and Semb, 1999).

1.3.1.1 Cytoskeleton

The primary function of *CDH1* is cell-cell adhesion forming the adherens junction, maintaining the cytoskeleton and mediating molecular signals between cells. The function of the adherens complex is particularly important for cell structure and regulation because it interacts with cytoskeletal actins and microtubules. The cytoskeletal role of E-cadherin maintains healthy cellular viability and growth in epithelial tissues including cellular polarity. E-cadherin is not essential to cellular viability but loss in epithelial cells does lead to defects in cytoskeletal structure and proliferation. In addition to a central role in the adherens complex, E-cadherin is involved in many other cellular functions and thus *CDH1* is regarded as a highly pleiotropic gene.

1.3.1.2 Extracellular and Tumour Micro-Environment

As a transmembrane signalling protein E-cadherin also interacts with the extracellular environment and other cells, most notably forming tight junctions between cells. These junctions serve to both regulate movement of ion signals between cells and separate membrane proteins on the apical and basal surfaces of a cell, maintaining cell polarity. Thus E-cadherin is an important regulator of epithelial tissues by intercellular communication. It also has important roles in the extracellular matrix, including fibrin clot formation. The role of intercellular interactions and the tissue micro-environment are important themes in cancer research, being a potential mechanism for cancer progression and malignancy in addition to its potential for specifically targeting tumour cells.

1.3.1.3 Cell-Cell Adhesion and Signalling

The signals mediated by tight junctions are also passed on to intracellular signalling pathways and thus E-cadherin also has a role in maintaining cellular function and growth. One such example is the regulation of β -catenin which interacts with both the actin cytoskeleton and acts as a transcription factor via the WNT pathway. Similarly, the Hippo and PI3K/AKT pathways are implicated in being mediated by E-cadherin, having roles in promoting cell survival, proliferation, and repressing apoptosis. E-cadherin shares several downstream pathways with signalling pathways such as integrins and thus indirectly interacts with them, particularly since feedback loops may occur in such pathways. Conversely, the multifaceted roles of E-cadherin have been

shown with differing overexpression in ovarian cells promoting tumour growth, while it maintains healthy cellular functions in other cells.

1.3.2 *CDH1* as a Tumour (and Invasion) Suppressor

E-cadherin has key roles in maintaining cellular structure and regulating growth, consistent with *CDH1* being a tumour suppressor gene. Loss of *CDH1* in epithelial tissues leads to disrupted cell polarity, differentiation, and migration. E-cadherin loss has been identified as a recurrent driver tumour suppressor mutation in sporadic cancers of many tissues including breast, stomach, lung, colon, and pancreas tissue.

1.3.2.1 Breast Cancers and Invasion

E-cadherin loss in breast cancers has been shown to cause increased proliferation, lymph node invasion, and metastasis with poor cell-cell contact. Thus *CDH1* gene has also been implicated as an invasion suppressor, with a key role in the epithelial-mesenchymal transition (EMT), an established mechanism of cancer progression (Hanahan and Weinberg, 2011). The epithelial-mesenchymal transition is important during development and wound healing but such changes in cellular differentiation also occur in cancers. If *CDH1* is inactivated by mutation or DNA methylation (Berx *et al.*, 1996; Guilford, 1999; Machado *et al.*, 2001), it is likely that EMT will drive growth of E-cadherin deficient cancers (Berx and van Roy, 2009; Graziano *et al.*, 2003; Polyak and Weinberg, 2009). While loss of E-cadherin is not sufficient to cause EMT or tumourigenesis, it is an important step in this mechanism of tumour progression and a potential therapeutic intervention may therefore also impede cancer progression and have activity against advanced stage cancers.

1.3.3 Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer

CDH1 loss of function mutations also causes familial cancers, including diffuse gastric cancer and lobular breast cancer (Graziano *et al.*, 2003; Guilford *et al.*, 2010, 1999; Oliveira *et al.*, 2009). Individuals carrying a null mutation in *CDH1* have a syndromic predisposition to early-onset these cancers, known as hereditary diffuse gastric cancer (HDGC) (Guilford *et al.*, 1998). Due to the loss of an allele, these individuals are prone to carcinogenic lesion in the breast and stomach when the other allele is inactivated, occurring much more frequently and thus younger than in individuals without a second functional allele of *CDH1*. The loss of the second allele is most often hypermethylation suppressing expression rather than mutation, although loss of heterozygosity may also

occur. Therefore HDGC is an autosomal dominant cancer syndrome with incomplete penetrance. The “lifetime” (until age 80 years) risk for mutation carriers of diffuse gastric cancer is 70% in males and 56% in females. In addition, the lifetime risk of lobular breast cancer is 42% in female mutation carriers.

HDGC affects less than 1 in a million people globally (Ferlay *et al.*, 2015) and less than 1% of gastric cancers. However, HDGC is documented to affect several hundred families globally. E-cadherin mutations in the germline is implicated in 1-3% of gastric cancers presenting with a family history, varying between high and low incidence populations. E-cadherin is also mutated in 13% of sporadic gastric cancers.

While diagnostic testing for *CDH1* genotype has enabled more effective management of HDGC and improved patient outcomes, there are still limited options for clinical interventions (Guilford *et al.*, 2010). Individuals with a family history of HDGC are recommended to be tested for *CDH1* mutations in late adolescence and are offered prophylactic stomach surgery before the risk of developing cancers increases with age. Another option is annual endoscopic screening to diagnose early stage stomach cancers with surgical intervention once they are detected (Oliveira *et al.*, 2013). However, these early stage cancers are difficult to detect and may be missed in regular screening. Thus patients carrying *CDH1* mutations either have surgical interventions with a significant impact on quality of life and risk of complications or remain at risk of developing advanced stage stomach cancers. Due to the lower mortality rate due to stomach cancers, there is increasing concerns among these HDGC families on the elevated risk of lobular breast cancers for women later in life.

The current clinical management of HDGC still has significant risks for patients and therefore a greater understanding of the molecular and cellular function of *CDH1* is important for its role in these cancers. Such studies may lead to alternative treatment strategies such as pharmacological treatments with specificity against *CDH1* null cells, once they lose the second allele. While a loss of gene function cannot be targeted directly, designing a treatment with specificity against *CDH1* may also have activity in sporadic cancers in a range of epithelial cancers. Thus an effective treatment against *CDH1* mutant cancers would potentially have significant therapeutic and preventative applications in a large number of patients.

1.3.4 Somatic Mutations

1.3.4.1 Mutation Rate

Estimates for the prevalence of *CDH1* somatic mutations in sporadic cancers varies. The Cancer Gene Census (Futreal *et al.*, 2004; Pleasance *et al.*, 2010) detected 994 distinct mutations in 10,143 tumour samples (at a rate of 7.52%), COSMIC (2016) detected 632 distinct mutations in 43,865 tumour samples (at a rate of 1.71%), and detected mutations in 13.2% of 53 of the NCI60 cancer cell lines. While there is no consensus on the prevalence of *CDH1* mutations, the vast variability of mutations is consistent with it's role as a tumour suppressor and it has been found to be recurrently mutated in a wide range of cancers of epithelial tissues.

COSMIC (2016) reports *CDH1* mutations in 40 cancer tissue types including stomach (11.40% in 1342 samples), breast (10.29% in 3343 samples), large colon (2.87%), skin (2.83%), endometrial (2.81%), and bladder (1.9%) cancer. ICGC (2017) reports *CDH1* mutations in 29 cancer tissue types including skin (23.41% in 598 samples), breast (14.50% in 1696 samples), ovary (13.98% in 93 samples), and stomach (11.41% in 289 samples) cancer samples. *CDH1* mutations are reported at similar rates in breast and stomach cancer in other cancer genomics projects and studies across distinct populations. cBioPortal (2017) reports *CDH1* mutation prevalence in stomach cancer at 16.7% (Kakiuchi *et al.*, 2014, 30 samples), 15% (Wang *et al.*, 2014, 100 samples), 14.1% (Chen *et al.*, 2015, 78 samples), and 9.4% (TCGA, 2017b, 393 samples). cBioPortal (2017) also reports *CDH1* mutation prevalence in breast cancer at 12.7% (TCGA, 2017b, 963 samples) and 10.8% (Curtis *et al.*, 2012; Pereira *et al.*, 2016, 2051 samples). The rare plasmacytoid bladder cancer subtype also has a high prevalence of *CDH1* mutations in COSMIC (2016) at a rate of 81.8% (N=33). These demonstrate that *CDH1* is important in many cancers and targeting *CDH1* may be widely applied against sporadic cancers in addition to hereditary cancers. However, some of these studies have focused on disease subgroups (such as lobular subtype or estrogen receptor negative breast cancers) with poor patient outcomes which may have inflated the prevalence of *CDH1* mutations which are more common in some of these subtypes.

1.3.4.2 Co-occurring Mutations

Another concern is that *CDH1* mutations may co-occur with other known cancer driver genes such as highly prevalent tumour suppressor gene *TP53* or the proto-oncogene *PIK3CA*. cBioPortal (2017) reports the prevalence of the mutations in these genes at 10% for *CDH1*, 49% for *TP53*, 22% for *PIK3CA* in stomach cancer (TCGA, 2017b, 393

samples). There is no evidence of significant co-occurring mutations between *CDH1* and *PIK3CA* (mutex $p = 0.231$) but there is evidence for significant mutually exclusive mutations for *CDH1* (mutex $p = 0.002$) and *PIK3CA* (mutex $p = 0.004$) with *TP53*. cBioPortal (2017) also reports the prevalence of the mutations in these genes at 13% for *CDH1*, 32% for *TP53*, 36% for *PIK3CA* in breast cancer (TCGA, 2017b, 963 samples). There is evidence of significant co-occurring mutations with *CDH1* and *PIK3CA* (mutex $p < 0.0001$) and evidence for significant mutually exclusive mutations for *CDH1* (mutex $p = 0.003$) and *PIK3CA* (mutex $p = 0.032$) with *TP53*.

These cancer driver mutations have distinct molecular features, leading to disease progression in distinct ways which is a concern for drug resistance when several mutations may accumulate, particularly for sporadic cancers where this is common. Targeting *CDH1* specifically is most suitable for hereditary cancers and combination therapies may be required for sporadic cancers. However, *CDH1* and *TP53* mutant cancers appear to be distinct pathways of tumour progression so the high impact of *TP53* mutation on cancer cells need not be considered for the purposes of studying *CDH1*.

1.3.5 Models of *CDH1* loss in cell lines

Previous work our research group has published used a model of homozygous *CDH1*^{-/-} null mutation in non-malignant MCF10A breast cells to show that loss of *CDH1* alone was not sufficient to induce EMT with compensatory changes in the expression of other cell adhesion genes occurring (Chen *et al.*, 2014). However, *CDH1* deficient cells did manifest changes in morphology, migration, and weaker cell adhesion (Chen *et al.*, 2014).

This *CDH1*^{-/-} MCF10A model has been used in a genome-wide screen of 18,120 genes using siRNA and a complementary drug screen using 4,057 compounds to identify synthetic lethal partners to E-cadherin (Telford *et al.*, 2015). One of the strongest candidate pathways identified by Telford *et al.* (2015) were the GPCR signalling cascades, which were highly enriched by GO analysis of the candidate synthetic lethal partners the primary siRNA screen. This was supported by validation with Pertussis toxin, known to target G_{αi} signalling (Clark, 2004), as were various candidate cytoskeletal pathways by inhibition of Janus kinase (JAK) and aurora kinase. The drug screen also produced candidates in histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) which were supported by validation and time course experiments.

1.4 Summary and Research Direction of Thesis

Genomics technologies and the data available from them have immense potential for understanding of genetics and improving healthcare, including identification of genes altered in cancer for molecular diagnosis, prognostic biomarkers, and therapeutic targets. This has been demonstrated with the identification of cancer genes in many cancers, distinguishing tumour subtypes by expression profiles, and the development of targeted therapies against oncogenes (such as *BRAF* and tumour suppressors (such as *BRCA1*). Synthetic lethality is an important genetic interaction to study fundamental cellular functions and exploit them for biomarkers and cancer treatment. They present a means to target loss of function mutations and genetic dysregulation in tumour suppressor genes by identifying interacting partners with redundant or compensating molecular functions.

CDH1 (encoding E-cadherin) is an example of a tumour suppressor gene implicated in sporadic breast and stomach cancers. Germline mutations in *CDH1* are also found in many patients with familial early onset cancers (HDGC). Discovery of synthetic lethal partners would contribute to an understanding on the molecular mechanisms driving the growth of *CDH1* deficient tumours and identification of potential therapeutic targets or chemopreventative agents for management of HDGC. The clinical potential of the synthetic lethal approach has been demonstrated with the application of olaparib against *BRCA1* and *BRCA2* mutations Lord *et al.* (2015) but there remains the need to systematically identify synthetic lethal partner genes for other tumour suppressors such as *CDH1*. A synthetic lethal screen has been conducted on breast cell lines Telford *et al.* (2015) but computational approaches to identification of synthetic lethal partners of *CDH1* remains to be done.

While there are a wide range of experimental and computational approaches to synthetic lethal discovery, many are limited to particular applications, prone to false positives, inconsistent across independent approaches, or enriched for particular genes of interest. Therefore synthetic lethal interactions are difficult to replicate or apply in the clinic. Computational approaches to synthetic lethality are not widely adopted by the cancer research community and experimental approaches cannot be combined to study synthetic lethality at a genome-wide scale. However, these show interest in synthetic lethal discovery in the community and the need for robust predictions of synthetic lethal interactions in cancer and human tissues.

Effective screening, prediction, and analysis of synthetic lethal interactions are a crucial part of developing next generation anti-cancer strategies. Therefore, we propose developing a computational statistical procedure to identify synthetic lethal interactions and construct gene networks. This will enable the development of personalised medicine targeted to particular molecular aberrations. Genetic tests and genomics have the potential to revolutionise cancer screening, diagnosis, and prognostics; targeted therapeutics, similarly, have applications in prevention and therapy of sporadic or hereditary cancers with known molecular properties.

To address the concerns raised by recent computational approaches to synthetic lethal discovery in cancer (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Wappett *et al.*, 2016), I present similar analysis using solely gene expression data which is widely available for a large number of samples in many different cancers. This uses a statistical methodology the SLIPT developed for this purpose. To further determine the limitations and implications of synthetic lethal predictions, modelling and simulation was performed upon the statistical behaviour of synthetic lethal gene pairs in genomics data. Comparison of synthetic lethal gene candidates from public data analysis and experimental candidates, pathway analysis, and networks structure will also be presented to investigate the relationships between synthetic lethal candidates. Release of R codes used for simulation, prediction, and analysis will enable adoption of the methodology in the cancer research community and comparison to existing methods.

My thesis aims to develop such predictions for synthetic lethal partner genes with a focus on the example of E-cadherin to compare to the findings of Telford *et al.* (2015), develop of network approaches for pathway structure, and simulate gene expression on pathway structure with the following bioinformatics and computational biology investigations:

- Developed a query-based synthetic lethal detection methodology (SLIPT) for use on gene expression data
- Adapt this methodology to utilise somatic mutation for query genes or candidate pathway metagenes
- Apply Synthetic lethal prediction to public breast cancer genomics data from TCGA (TCGA, 2012)
- Identify over-represented biological pathways using Reactome (Croft *et al.*, 2014) among synthetic lethal candidate partner genes

- Compare these at the gene and pathway level to experimental screen data in breast cell lines from Telford *et al.* (2015)
- Replicate these analyses in stomach cancer genomics data from TCGA (Bass *et al.*, 2014)
- Determine whether synthetic lethal candidates have importance in biological networks of candidate partner pathways
- Determine whether there are relationships within biological network structures between experimental and predicted gene candidate partners
- Develop a statistical model of synthetic lethal gene expression
- Simulate gene expression with synthetic lethal genes and pathway structures
- Evaluate the effects of modification to the SLIPT procedure on it's statistical performance
- Compare the statistical performance of the SLIPT procedure to alternative statistical methods
- Release a synthetic lethal prediction methodology (SLIPT) to the research community for wider application

Thesis Aims

- To develop a statistical approach to detect synthetic lethal gene pairs in cancer from expression data
- To apply this methodology to public cancer gene expression data against *CDH1* and analyse pathway structure with comparisons to experimental screen data
- To construct a statistical model of synthetic lethality in multivariate normal expression data
- To develop a simulation pipeline of expression with pathway structure on a high-performance computing cluster
- To examine the statistical performance of the methodology with simulated expression including pathways and compare it to other approaches
- To release the synthetic lethal detection methodology and pathway simulation procedure as R software packages

Chapter 2

Methods and Resources

In this Chapter, I will outline the various existing resources and methods utilised throughout this project. This includes public data repositories, stable and development releases of software packages (mostly for the R programming environment), and implementation of bioinformatics methods and statistical concepts with Shell or R scripts developed for this purpose. Methods and packages developed specifically for this project will be covered in more detail along with preliminary data to demonstrate and support their use in Chapter 3.

2.1 Bioinformatics Resources for Genomics Research

2.1.1 Public Data and Software Packages

Various bioinformatics resources, such as databases and methods, have become integral parts of genetics and genomics research. Reference genomes, genotyped variants, gene expression, and epigenetics profiles are among the most commonly used resources. Gene expression data in particular is widely available from many microarray and RNA-Seq studies, from repositories such as Gene Expression Omnibus (GEO) (Clough and Barrett, 2016), caArray (Heiskanen *et al.*, 2014), and ArrayExpress (Rustici *et al.*, 2013). Such profiles are excellent resources to examine the changes of gene expression occurring in cancers and the variation between samples. These microarray initiatives have set a precedent for data sharing, data mining, and the wider benefits of publicly available data for enabling the scientific community to further utilise the data rather than a single research group or consortium (Rung and Brazma, 2013). The practice of integrating findings from publicly available genomics data with the research questions and experimental results of individual research groups has carried over into RNA-Seq

datasets including the large-scale cancer genomics projects (Zhang *et al.*, 2011). This thesis is one such example of an investigation enabled by this wider movement and tools developed in various disciplines to generate, process, and disseminate genomic-scale data.

Along with databases, it is also becoming common practice for bioinformatics researchers to release their code as open-source or provide a software package to enable replication of the findings or further applications of the methods (Stajich and Lapp, 2006). This is part of a wider movement in software and data analysis with many tools to facilitate such work being released for use in Linux or the R programming environment (R Core Team, 2016). In addition to the R packages hosted on CRAN (CRAN, 2017), the Bioconductor repositories (Gentleman *et al.*, 2004) also contain many packages specifically for applications in bioinformatics, and the GitHub site hosts many packages in various stages of development and early release. Packages from these various sources have been used throughout this project and cited where-ever possible. Several R packages have been developed during this thesis project and either publicly released on GitHub or prepared to accompany a publication.

2.1.1.1 Cancer Genome Atlas Data

Molecular profile data from normal and tumour samples was downloaded from publicly available sources, using the TCGA (TCGA, 2012) and the International Cancer Genome Consortium (ICGC) web portals (Zhang *et al.*, 2011). These include gene expression (RNA-Seq), somatic mutations, and anonymous clinical data. These versions downloaded were on the 6th of August 2015 (Release 19) and the 2nd of May 2016 (Release 20) for breast and stomach cancer respectively via the ICGC data portal (<https://dcc.icgc.org/>).

Performing a genomic alignment remains a challenge in bioinformatics and methods to do so may yet be improved (Chen and Tompa, 2010). However, the statistical and biological aspects of bioinformatics are the focus of this thesis, comparing alignment methods is outside the scope of these investigations. The TCGA project (TCGA, 2012) used widely adopted tools: “Bowtie” for alignment (Langmead *et al.*, 2009), “mapsplice” to detect splice sites (Wang *et al.*, 2010), and the Reads Per Kilobase per Million mapped reads (RPKM) approach to qualify reads per transcript as a measure of gene expression (Mortazavi *et al.*, 2008). These are widely acceptable tools for processing RNA-Seq data which were used to produce the raw counts of mapped reads (tier 1) and normalised expression data (tier 3) publicly available from TCGA.

Raw count and RSEM normalised TCGA expression data from Illumina RNA-Seq protocols were available from 1,177 breast samples (113 normal, 1,057 primary tumour, and 7 metastases) for 20,501 genes. TCGA breast somatic mutation data for 981 samples (976 primary tumours and 5 metastases) across 25,836 genes were available including 969 samples (964 primary tumours and 5 metastases) with corresponding RNA-Seq expression data and 19,166 genes mapped from Ensembl identifiers to gene symbols, of which 16,156 had corresponding gene expression information. Unless otherwise stated, the raw counts were used for further processing rather than the RSEM normalised data (provided by TCGA tier 3). For the purposes of this analysis somatic mutations were reported if they were detected to non-synonymous substitutions, frameshifts, or truncations (by premature stop codons) which would likely disrupt the wild-type gene function. Normalised protein expression was used (as provided by TCGA tier 3), generated from reverse phase protein arrays (RPPA) for 142 antibodies targeting 115 genes for 298 TCGA breast samples.

Raw count TCGA expression data (TCGA tier 1) from Illumina RNA-Seq was also available for 450 stomach samples (35 normal, 415 primary tumour) for 20,501 genes. TCGA stomach mutation data was also available for 289 samples across 25807 genes, corresponding to 19436 genes with expression data. Normalised protein expression (RPPA) data was also sourced (from TCGA tier 3) for 201 antibodies targeting 158 genes for 357 stomach samples.

Cell line data was downloaded from the CCLE on the 7th of November 2014 (Barretina *et al.*, 2012; CCLE, 2014). This includes expression data (generated by Affymetrix U133 Plus 2.0 arrays) for 1037 cell lines across 19544 genes (last updated on the 18th of October 2012), DNA copy number, somatic mutation, drug response, and sample information. Samples include 59 breast cell lines and 38 stomach cell lines.

2.1.1.2 Reactome and Annotation Data

Unless otherwise specified, pathway analysis was performed for human pathway annotation from the Reactome database (version 52) with pathway gene sets derived from the `reactome.db` R package. Entrez identifiers were mapped to gene symbols or aliases to match to TCGA expression and mutation data using the `org.Hs.eg.db` R package. Further pathway analysis used breast cancer gene signatures from Gatza and colleagues (Gatza *et al.*, 2011; Gatza *et al.*, 2014). These gene symbols were matched to the relevant dataset and used to construct a matrix of category membership using the `safe` R package (Barry, 2016).

2.2 Data Handling

2.2.1 Normalisation

Apart from the PAM50 subtyping procedure (Parker *et al.*, 2009), which required RSEM normalised data (J.S. Parker personal communication), the analysis of the RNA-Seq data presented here was based on raw read count data. Raw read counts were log-scaled; samples removed for consistency (based on a Euclidean distance correlation matrix as described in Section 2.2.2); and the final dataset was TMM normalised (Robinson and Oshlack, 2010) then processed using the `voom` function (Law *et al.*, 2014) in the `limma` R package (Ritchie *et al.*, 2015). Protein expression data generated from RPPA was normalised to dilution curves using the `SuperCurve` R package (Ju *et al.*, 2015; Neeley *et al.*, 2009).

The microarray expression data sourced from the CCLE was used as provided, using the Robust Multi-array Average (RMA) and normalized by quantile normalization.

2.2.2 Sample Triage

The TCGA breast RNA-Seq data were assessed for batch effects using a correlation matrix of the log-transformed raw counts for which a heatmap (Euclidean distance, complete linkage) is shown in Figure A.2. While no major batch effects were detectable between the samples, 9 samples were excluded due to poor correlation with the remaining samples, as detailed in Table 2.1. These samples showed unusual density plots compared to the rest of the dataset, and exhibited low mean read count in Figures 2.1 and 2.2. A heatmap showing key clinical properties of these excluded samples and their correlation with the remainder of the samples is shown in Figure A.1, and a full correlation heatmap (Figure A.2) shows these samples as relatively poorly correlated outliers in the bottom rows and left columns. In addition to the clustering analysis (in Appendix A.1), replicate tumour samples were also examined for sample quality in Appendix A.2. After removal of these samples, the TCGA dataset used for analysis consisted of the remaining 1168 samples (from 1040 patients): 1049 tumour samples, 112 normal tissue for matched samples, and 7 metastases.

Similarly, a correlation matrix of log-transformed raw counts was used to evaluate sample quality for TCGA stomach RNASeq. A tumour sample (patient 4294) was removed due to similar quality concerns leaving a final dataset for 449 samples (from 417 patients): 414 tumour samples and 35 normal tissue samples.




Figure 2.1: **Read count density.** Sample density plots of raw counts on log-scale and voom normalised showing samples removed due to quality concerns.




Figure 2.2: **Read count sample mean.** Boxplots of sample means for raw counts on log-scale and voom normalised show removed tumour samples with low mean read count.

Table 2.1: Excluded Samples by Batch and Clinical Characteristics.

Tissue Source	Type	Batch	Plate	Patient	Samples	p53	Subtype	Treatment (History)	Clinical Subtypes (Stage)			
A7 Christiana	Tumour	47	A227	A0DB	1 of 3	NA	Luminal A	Mastectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	96	A220	A13D	1 of 3	Wildtype	Luminal A	Mastectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	96	A227	A13E	1 of 3	NA	Basal	Lumpectomy	(no)	ER-	Ductal	(2)
A7 Christiana	Tumour	142	A277	A26E	1 of 3	NA	Basal	Lumpectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	47	A277	A0DC	1 of 2	NA	Luminal A	Mastectomy	(yes)	ER+	Lobular	(3)
A7 Christiana	Tumour	142	A220	A26I	1 of 2	Mutant	Basal	Lumpectomy	(yes)	ER-	Ductal	(2)
AC Intl Genomics	Tumour	177	A18M	A2QH	2 of 2	Mutant	Basal	Radical Mastectomy	(no)	ER-	Metaplastic	(2)
AC Intl Genomics	Tumour	177	A220	A2QH	2 of 2	Mutant	Basal	Radical Mastectomy	(no)	ER-	Metaplastic	(2)
GI ABS IUPUI	Normal	177	A16F	A2C8	1 of 1	NA	Luminal A	Radical Mastectomy and Neoadjuvant	(no)	ER+	Ductal	(2)

2.2.3 Metagenes and the Singular Value Decomposition

A “metagene” offers a consistent signal of pathway (expression) activation or inactivation by dimension reduction of a matrix, avoiding negatively correlated genes averaging out the signal of a mean-based centroid (Huang *et al.*, 2003). Constructing these pathway metagenes used gene sets for Reactome and Gatzka signatures (Gatzka *et al.*, 2011, 2014) as specified above (see Section 2.1.1.2). The singular-value decomposition was performed ($X = U^T DV$ where X is the data matrix of the gene set with genes \times samples) and the leading eigenvector (first column of V) corresponding to the largest singular value was used as a metagene for the pathway gene set. To ensure consistent directionality of metagene signals, the median of the gene set in each sample was calculated and correlated against the metagene with the (arbitrary) metagene sign adjusted as needed to conform with the majority of the gene set (i.e., positive correlation between metagene and the median-based centroid). To ensure that genes and pathways were weighted equally, metagenes were derived from a z-transformed dataset of gene expression and samples were scaled (by fractional ranking) for each metagene so that they were comparable on a $[0, 1]$ scale.

2.2.3.1 Candidate Triage and Integration with Screen Data

Candidate triage in combination with the experimental data was intended to integrate findings of the SLIPT analysis with an ongoing experiment project (Chen *et al.*, 2014; Telford *et al.*, 2015). The first procedure to compare the SLIPT gene candidates for *CDH1* with an siRNA experimental screen (Telford *et al.*, 2015) was a direct comparison of the overlapping candidates, presented in a Venn diagram and tested with the χ^2 test. Since these candidates modestly overlapped at the gene level (even when excluding genes not contained in both datasets), further gene set over-representation analysis was performed for pathways specific to each detection approach and the intersection of the two.

The pathway composition of the intersection was further verified by a permutation resampling analysis (as described in Section 2.3.6): the same number of genes detected by SLIPT were sampled randomly from the universe of genes tested by both approaches. These samplings were performed over 1 million iterations and the pathway over-representation was compared for each of the 1,652 reactome pathways. These over-representation scores (χ^2) were compared the observed over-representation in the intersection of the SLIPT candidates, with the proportion of resamplings with higher χ^2 values used for empirical p-values of pathway composition. The χ^2 test was used as an appropriation of Fisher's exact test on a hypergeometric distribution for resampling to computationally scale pathway over-representation tests across iterations. Pathways for which no resamplings were occurred as high as the observed were reported as $p < 10^{-6}$. These empirical p-values were adjusted for multiple comparisons (FDR). Intersection size was not assumed to be constant across resamplings so similarly with the proportion of resamplings with higher or lower intersection size were used to evaluate significance of enrichment or depletion respectively (of siRNA candidate among SLIPT candidate genes).

2.3 Techniques

Various statistical, computational, and bioinformatics techniques were performed throughout this thesis. This section describes these techniques and gives the parameters used unless otherwise specified. Where relevant, the R package implementation which provided the technique will be acknowledged.

2.3.1 Statistical Procedures and Tests

As described in sections 2.3.4 and 2.2.3, the z-transform has been used to generate z-scores in various analyses in this thesis. Each row of dataset (x) is transformed into a scores (z) using the mean (μ) and standard deviation (σ) of the data such that:

$$z = \frac{x - \mu(x)}{\sigma(x)}$$

This generates data where each row (gene) has a mean of 0 and standard deviation of 1. Where plotted as a heatmap, any data more than 3 standard deviations above or below the mean is plotted as 3 or -3 respectively.

Empirical Bayes differential expression analysis was performed using the `limma` R package (Ritchie *et al.*, 2015). Where specified, the Fisher's exact test, χ^2 test, and correlation were used to measure associations between variables (as implemented in

the `stats` R package (R Core Team, 2016)). Unless otherwise specified, Pearson’s correlation was used for correlation analyses (r) and coefficient of determination (R^2). Where these comparisons are discussed in more detail, Fisher’s exact test and χ^2 tests are supported by a table or Venn diagram, rendered with the `limma` R package (Ritchie *et al.*, 2015). In some analyses, correlation is further supported by a scatter plot and a line of best fit derived by least squares linear regression.

The `t.test` function (R Core Team, 2016) has also been used to implement the t-test to compare pairs of data. Where relevant, an analysis of variance (ANOVA) has been performed to report significance of multivariate predictors of outcomes, or least squares linear regression performed for the adjusted coefficient of determination (R^2) and F-statistic p-value to evaluate the fit of the predictor variables. For some analyses these are supported by boxplot or violinplot visualisation (rendered in R).

Multiple comparisons are adjusted by the Benjamini-Hochberg procedure to control the false discovery rate (FDR) unless otherwise specified (Benjamini and Hochberg, 1995). This procedure adjusts p-values to achieve an average of the proportion of false-positives among significant tests below a threshold, α . The more stringent Holm-Bonferroni (Holm) procedure (Holm, 1979) was also applied in some cases to adjust for multiple comparisons and control the family-wise error rate which adjusts p-values so that the probability that any one of the tests is a false-positive (type-1 error) below a threshold, α .

2.3.2 Gene Set Over-representation Analysis

Gene set enrichment over-representation was performed to test whether there is an enrichment of a gene set (such as a biological pathway) among a group of input genes. Such input genes may be predicted synthetic lethal candidates or a subset defined by clustering (in Section 2.3.3) or comparison with experimental candidates (see Section 2.2.3.1). Initially, these tests were performed using the GeneSetDB web tool (Araki *et al.*, 2012) hosted by the University of Auckland on the Reactome pathways (Croft *et al.*, 2014). Since the GeneSetDB tool used an older version of Reactome (version 40), it was difficult to directly compare with the results of other analysis (see sections 2.2.3.1 and 2.3.6) performed on version 52 (as described in Section 2.1.1.2). Thus an implementation of the hypergeometric test in R (R Core Team, 2016) was used to test for over-representation against Reactome (version 52) pathways. Pathways containing less than 10 genes or more than 500 (as performed in GeneSetDB by Araki *et al.*, 2012) were excluded before adjusting for multiple comparisons.

2.3.3 Clustering

Clustering analysis when performed uses unsupervised hierarchical clustering with complete linkage (distance calculated from the furthest possible pairing). For correlation matrices or multivariate normal parameters (e.g., Σ), the distance metric used was Euclidean distance. For empirical or simulated gene and pathway expression data correlation distance was used, calculated by $distance = 1 - cor(t(x))$ where cor is Pearson's correlation and $t(x)$ is the transpose of the expression matrix.

2.3.4 Heatmap

Standardised z-scores of the data were used to plot heatmaps on an appropriate scale. Raw (log-scale) read counts or voom normalised counts per gene (as specified) were plotted as normalised z-scores on a $[-3, +3]$ blue-red scale. Similarly, correlations were plotted on a $[-1, +1]$ blue-red scale. These heatmaps were performed using the linkage and distance specified for the clustering performed in Section 2.3.3. The `gplots` R package (Warnes *et al.*, 2015) was used to generate many of the heatmaps throughout this thesis, along with a customised heatmap function (released as `heatmap.2x`). Where clearly specified, data have been split into subsets with clustering performed separately on each subset with these plotted alongside each other.

2.3.5 Modeling and Simulations

Statistical modeling and simulations have been used to test various synthetic lethal detection procedures on simulated data. This involves constructing a statistical model of how synthetic lethality would appear in (continuous normally distributed) gene expression data. Where presented (in Section 3.2.1), the assumptions of the model are stated clearly. The model allows sampling from a multivariate normal distribution (using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)) to generate simulated data with known underlying synthetic lethal partners (detailed in Section 3.2.2). We can test whether statistical procedures, including those developed in this thesis (presented in Section 3.1), are capable of detecting them upon this simulated data. This multivariate normal simulation procedure also enables the inclusion of correlation structure which is either given as correlated blocks of genes or derived from pathway structures (as detailed in Section 3.4.2).

If this multivariate normal distribution was sampled once and the procedure to add known synthetic lethal partners was performed, it generates a simulated dataset. Performing this simulation procedure and testing with a synthetic lethal detection

procedure iteratively, these simulations can be used to assess the statistical performance of the detection procedure. The number of iterations (`Reps`) will be given for each simulation result. Typically, these are performed 1000 or 10,000 times depending on computational feasibility of doing so on larger datasets.

Several measures of statistical performance were used to assess the simulations. The following measures used the final classification of the detection procedure, statistical significance for χ^2 , significance and directional criteria met for SLIPT (see Section 3.1), and an arbitrary threshold: < -0.2 and $> +0.2$ for negative correlation and correlation respectively. Sensitivity (or “true positive rate”) was measured as the proportion of known synthetic lethal partners predicted to be synthetic lethal. Specificity (or “true negative rate”) was measured as the proportion of known non-synthetic lethal partners predicted not to be synthetic lethal. The “false discovery rate” (also used in adjusting for multiple comparisons) was measured here as the proportion of known non-synthetic lethal partners out of all putative partners predicted by the detection procedure. Statistical “accuracy” is the proportion of true predictions for a detection procedure, which is both the correctly predicted known synthetic lethal partners and correctly negative known non-synthetic lethal partners.

2.3.5.1 Receiver Operating Characteristic (Performance)

A more general procedure to measure the statistical performance of a simulation is the Receiver Operating Characteristic (ROC) curve which does not assume a threshold for classification of synthetic lethality but demonstrates the trade-off of sensitivity and specificity (Akobeng, 2007; Fawcett, 2006; Zweig and Campbell, 1993). These curves (implemented with the `ROCR` R package (Sing *et al.*, 2005)) plot the True Positive Rate (sensitivity) against the False Positive Rate (1–specificity) as the prediction threshold is varied. An ideal detection method will have a true positive rate of 1 and a false positive rate of 0, hence the Area Under the ROC curve (AUC or AUROC) is a measure of statistical performance for a detection procedure accounting for this trade-off. AUROC values are typically range from 0.5 the value expected by random chance to 1 for an optimal detection method, however it is possible for an AUROC below 0.5 for a poor detection method that performs worse than random chance. In cancer biology, an AUROC of approximately 0.8 is a predictive biomarker suitable for publication (Hajian-Tilaki, 2013) but predictors with lower AUROC values may still be informative depending on the context. In this thesis, the AUROC values varies widely across simulation parameters and a primarily used for comparisons across these parameters, although they can also be used to refine thresholds for optimal classification.

2.3.6 Resampling Analysis

Resampling analyses (e.g., “permutation” analysis) are used to statistically test the significance of an observation without assuming the underlying distribution of expected test statistics Collingridge (2013). Instead these are derived from randomly shuffling test statistics or randomly sampling predicted candidates. For the purposes of this thesis, this involved randomly sampling genes from those tested to be analysed as putative synthetic lethal candidates. This was performed both for testing the significance of pathway composition in the intersection with experimental gene candidates (Section 2.2.3.1) and for assessing the significance of pathway structure among synthetic lethal candidates (Section 3.4.1.1).

These were analysed to compare the observed synthetic lethal genes against values derived from randomly sampling the same number of genes as observed by synthetic lethal from among the genes tested. Sampling iteratively across many resampling procedures, these resampling-based values form a null distribution that would be observed if the null hypothesis were true. Thus the proportion of resampling-based values across these iterations that are greater than or equal to that observed, forms an empirically derived p-value to test significance.

Resampling was performed for comparison (in Section 2.2.3.1) with fixed experimental screen candidates (Telford *et al.*, 2015) both resampling the number of genes overlapping with the screen candidates and test statistics for pathway enrichment. Resampling analysis was also applied to shortest paths and network metrics (in Section 3.4.1.1) to test significance of directional relationships between synthetic lethal candidate genes within pathway structures.

The number of iterations determines the accuracy of these p-values. For pathway composition (in Section 2.2.3.1), a million iterations were performed using high performance computing (as detailed in Section 2.5.3) to provide sufficient accuracy after adjusting for multiple comparisons across pathways. For the purposes of network analysis (in Section 3.4.1.1), a thousand iterations were sufficient to reject the null hypothesis for the majority of pathways tested before adjusting for multiple comparisons, and thus further iterations were not performed.

2.4 Pathway Structure Methods

2.4.1 Network and Graph Analysis

Networks are important in considering the structure of relationships in molecular biology, including gene regulation, kinase cellular signaling, and metabolic pathways (Barabási and Oltvai, 2004). Network theory is an interdisciplinary field which combines the approaches of computer science with the metrics and fundamental principles of graph theory, an area of pure mathematics dealing with relationships between sets of discrete elements. The vast amounts of molecular and cellular data from high-throughput technologies have enabled the application of network-based and genome-wide bioinformatics analysis to examine the complexity of a cell at the molecular level and understand aberrations in cancer. This thesis uses various metrics and analysis procedures developed in Graph and Network theory to analyse graph structure of biological pathways. Where feasible, these have been implemented using the `igraph` R package with such procedures described below (Csardi and Nepusz, 2006). Custom R functions to perform more complex analysis and visualisation of iGraph data objects will be described later.

Graph theory is a branch of pure mathematics which deals with the properties of sets of discrete objects (referred to as a ‘node’ or ‘vertex’) with some pairs are joined (by a ‘link’ or an ‘edge’). While a seemingly reductionist abstraction to mathematically study relationships, graph theory serves has applications in a wide range of studies including life sciences. Network theory is the sub-discipline of graph theory which deals with networks which has become popular due to the vast potential for applications of networks (van Steen, 2010).

Applications vary depending on the situation modelled, particularly in how the edges between vertices are defined, whether they are directed or weighted, and whether multiple redundant edges between a pair of vertices (referred to as ‘parallel edges’) or edges connecting a vertex to itself (referred to as ‘loops’) are permitted in the model. Networks are defined such that the edges represent a relationship between the vertices and may be directed, weighted, or contain parallel edges or loops depending on the application (van Steen, 2010). Unless otherwise stated, graph structures and networks in thesis will be unweighted and have no parallel edges or loops. Where a directional relationship is known or modelled, it will be represented with a directed edge in a directed graph.

2.4.2 Sourcing Graph Structure Data

Pathway Commons interaction data was sourced using the paxtools-4.3.0 Java application on October 6th 2015 (Cerami *et al.*, 2011; Demir *et al.*, 2013). This utility was used to source ‘sif’ format interaction data into R (R Core Team, 2016), from which the human Reactome (version 52) dataset of interactions was imported (Croft *et al.*, 2014), matching those used for pathway enrichment analysis. These interactions were used to construct an adjacency matrix for the Reactome network and subnetworks corresponding to each relevant biological pathway.

2.4.3 Constructing Pathway Subgraphs

Subgraphs for each relevant pathway were constructed by matching the nodes in the complete Reactome network to the pathway gene sets (as derived in Section 2.1.1.2). A subgraph with adjacent nodes was constructed by adding nodes which have an edge with a gene in the pathway gene set. The pathways these adjacent nodes belong to were added to form a “meta-pathway” to account for the possibility for nodes within the pathway being linked by the surrounding graph structure.

2.4.4 Network Analysis Metrics

The existing network analysis measures applied in this thesis (as described below) used an implementation in the `igraph` R package where it was available (Csardi and Nepusz, 2006). Otherwise, custom features were developed for analysis of iGraph objects in R and released as `igraph.extensions` (as described in Section 3.5.3).

Vertex degree is the number of edges a node has and is a fundamental measure of the importance and connectivity of a network (van Steen, 2010). More connected nodes, such as network hubs, will have a higher vertex degree relative to other nodes. For the purposes of this thesis, vertex degree ignored edge direction with loops (edges with itself) and double edges to the same node excluded.

A fundamental concept in network analysis is a “shortest path”, that is the shortest route via edges between any two particular nodes in a network. These are computed by Dijkstra’s algorithm (Dijkstra, 1959) in the `igraph` R package (Csardi and Nepusz, 2006). Where applicable paths will only use directed edges in a particular direction. Shortest paths are a useful measure of how close nodes are in a network. This is used to compute information centrality, and for further analysis of pathway structure (as described in Section 3.4.1).

Network centrality is an alternative measure of the importance or influence of a node to the graph structure (Borgatti, 2005). Various strategies are used to derive centrality, typically based on how connected the node is or the impact of node removal on the connectivity of the network. One of the most notable is the “PageRank” algorithm, a refinement of eigenvector centrality based on the eigenvectors of the adjacency matrix (Brin and Page, 1998). This is implemented in the `igraph` R package (Csardi and Nepusz, 2006).

Another network centrality measure that has been previously applied to biological protein interaction networks (Kranthi *et al.*, 2013) is the “information centrality”. The information centrality of a node is the relative impact on efficiency (transmission of information via shortest paths) of the network when the node is removed. That is the centrality (C) (Kranthi *et al.*, 2013) for node n in graph G is defined as:

$$C_n = \frac{E(G) - E(G')}{E(G)}$$

where G' is the subgraph with the node removed and E is the efficiency (Latora and Marchiori, 2001) derived from shortest paths (d_{ij} between nodes i and j) as:

$$E(G) = \frac{2}{N(N-1)} \sum_{i < j \in G} \frac{1}{d_{ij}}$$

The efficiency of the network can be derived from shortest paths implemented in the `igraph` R package and the iterative network centrality computation of each node has been released as an R package (`info.centrality`) and included in the `igraph.extensions` package.

2.5 Implementation

2.5.1 Computational Resources and Linux Utilities

Several computers were used to process and store data during this thesis (as summarised in Table 2.2), running different versions of Linux operating systems, including a personal laptop computer, laboratory desktop machine, departmental server, and the New Zealand eScience Infrastructure Intel Pan high-performance computing cluster (a supercomputer based at the University of Auckland). Each of these systems support a 64-bit architecture. Current workflows on local machines use Elementary OS (based on the Ubuntu versions given in Table 2.2) and interacting with these via ZSH shell. However, Ubuntu OS and the Bourne Again SHell (bash) were used at the inception of this project and bash is continues to be used for running scripts. Various Linux applications

and command-line utilities were used on these machines (as summarised in Table 2.3). As such, the workflows developed in this project should be backwards-compatible with Ubuntu Linux (and other derivatives). The majority of novel methodology and implementations were performed in R which is a cross-platform language, packages developed in R will be available for users of Linux, Mac, and Windows machines.

Table 2.2: Computers used during Thesis

	Viao Laptop	Lab Machine	Biochem Server	NeSI Pan Cluster
Operating System (OS)	Elementary OS Freya 0.3.2	Elementary OS Loki 0.4	Red Hat Enterprise Maipo 7.2	Cent OS Final 6.4
	Ubuntu LTS Trusty 14.04	Ubuntu LTS Xenial 16.04		
Upstream OS	3.19.0-65-generic	4.4.0-36-generic	3.10.0-327.36.2.el7.x86_64	2.6.32-504.16.2.el6.x86_64
	Shell: bash 4.3.11(1)	4.3.46(1)	4.2.46(1)	4.2.1(1)
Linux Kernel	Shell: zsh 5.0.2	5.1.1	5.0.2	5.2

Table 2.3: Linux Utilities and Applications used during Thesis

	Viao Laptop	Lab Machine	Biochem Server	NeSI Pan Cluster
OS	Elementary OS	Elementary OS	Red Hat Enterprise	Cent OS
	Freya 0.3.2	Loki 0.4	Maipo 7.2	Final 6.4
	Linux Kernel	3.19.0-65-generic	4.4.0-36-generic	3.10.0-327.36.2.el7.x86_64
Scripting	Shell: bash 4.3.11(1)	4.3.46(1)	4.2.46(1)	4.2.1(1)
	Shell: zsh 5.0.2	5.1.1	5.0.2	5.2
Programming	Python	2.7.6	2.7.12	2.7.5
	Java	1.8.0_101	9-ea	1.8.0_101
	C++	4.8.4	5.4.0	4.8.5
Text Editor	nano	2.2.6	2.5.3	2.3.1
	kile (\LaTeX)	2.1.3	2.1.3	
Version Control	git	1.9.1	2.11.0	1.7.1
Shell Utilities	sed	4.4.2	4.4.2	4.4.2
	grep	2.16-1	2.25-1	2.20
	nohup	8.21	8.25	8.22
Typesetting	T _E X	3.1415926	3.14159265	
	TeXLive (\LaTeX)	2013	2015	
	PDFT _E X	2.5-1	2.6	
	pandoc	1.12.2.1	1.16.0.2	
Remote Computing	slurm scheduler			16.05.6
	OpenSSH	7.2p2	7.2p2	5.3p1
	OpenSSL	1.0.2g	1.0.2g	1.0.01e-fips
	rsync	3.1.0p31	3.1.1p31	3.0.9p30
	Globus Online Transfer			3.1
	Cisco AnyConnect VPN		3.1.05170	
Image Processing	Inkscape	0.48.4	0.91	
	GIMP	2.8.10	2.8.16	
	ImageMagick	6.7.7.10-6		

2.5.2 R Language and Packages

The R programming language has been used for the majority of this thesis. Current R installations across the machines used are given in Table 2.4. Local machines currently run the latest version of the R (at the time of writing) and remote machines run the versions and modules as managed by the system administrator.

Various scripts and packages in this thesis were developed or run in previous versions of RStudio and R but these run without error in the current version of R (and the older versions on remote machines). The R packages which were used throughout this thesis (as detailed in Table 2.5 with versions specified) were installed from the Comprehensive R Archive Network (CRAN, 2017), Bioconductor (Gentleman *et al.*, 2004, version 3.4; BiocInstaller 1.24.0), or GitHub. These packages were not updated when they would change the functionality of scripts or functions in packages, in particular imported data from annotation packages (used to define gene sets) have been saved as local files to continue using stable versions of these pathway data (across machines).

This is a summary of the key packages which (in addition to their dependencies) have been used throughout this project. Where a package implementation has been central to the methods applied, they are described in more detail in the relevant section. A full table of packages used in this thesis can be found in Appendix B (Table B.1). The R packages developed during this thesis are given in Table 2.6 with the relevant sections describing their implementation and use where appropriate, in addition to further details on these functions in Section 3.5.

Table 2.4: R Installations used during Thesis

	Viao Laptop OS	Lab Machine Elementary OS Freya 0.3.2	Biochem Server Elementary OS Loki 0.4	NeSI Pan Cluster Red Hat Enterprise Maipo 7.2
Programming	R	3.3.2	3.3.2	3.3.1
Development	RStudio	1.0.136	1.0.136	1.0.136 (server)

Table 2.5: R Packages used during Thesis

Package	Version Used	Built	Repository
colorspace	1.3-2	3.3.1	CRAN
curl	2.3	3.3.1	CRAN
data.table	1.9.6	3.3.1	CRAN
dendextend	1.4.0	3.3.2	CRAN

DBI	0.5-1	3.3.1	CRAN
devtools	1.12.0	3.3.1	CRAN
dplyr	0.5.0	3.3.1	CRAN
ggplot2	2.2.1	3.3.1	CRAN
git2r	0.18.0	3.3.1	CRAN
gplots	3.0.1	3.3.1	CRAN
gtools	3.5.0	3.3.1	CRAN
igraph	1.0.1	3.3.1	CRAN
matrixcalc	1.0-3	3.3.1	CRAN
mclust	5.2.2	3.3.1	CRAN
mvtnorm	1.0-6	3.3.1	CRAN
org.Hs.eg.db	3.1.2	3.1.2	Bioconductor
openssl	0.9.6	3.3.1	CRAN
plyr	1.8.4	3.3.1	CRAN
purrr	0.2.2	3.3.1	CRAN
reactome.db	1.52.1	3.2.1	Bioconductor
RColorBrewer	1.1-2	3.3.1	CRAN
Rcpp	0.12.9	3.3.1	CRAN
ROCR	1.0-7	3.3.1	CRAN
roxygen2	6.0.1	3.3.2	CRAN
shiny	1.0.0	3.3.1	CRAN
snow	0.4-2	3.3.1	CRAN
testthat	1.0.2	3.3.2	CRAN
tidyR	0.6.1	3.3.2	CRAN
tidyverse	1.1.1	3.3.2	GitHub (hadley)
sm	2.2-5.4	3.3.1	CRAN
Unicode	9.0.0-1	3.3.2	CRAN
vioplot	0.2	3.3.1	CRAN
viridis	0.3.4	3.3.2	CRAN
xml2	1.1.1	3.3.2	CRAN
xtable	1.8-2	3.3.1	CRAN
zoo	1.7-14	3.3.1	CRAN
graphics	3.3.2	3.3.2	base
grDevices	3.3.2	3.3.2	base
cluster	2.0.5	3.3.1	base

graphics	3.3.2	3.3.2	base
grDevices	3.3.2	3.3.2	base
Matrix	1.2-8	3.3.1	base
stats	3.3.2	3.3.2	base

Table 2.6: R Packages Developed during Thesis

	Package Name	Description and GitHub Repository	Section
visualisation	<code>slipt</code>	Synthetic lethal detection by SLIPT (to accompany publication) https://github.com/TomKellyGenetics/slipt	3.1
	<code>vioplotx</code>	Customised violin plots (based on <code>vioplot</code>) https://github.com/TomKellyGenetics/vioplotx	
	<code>heatmap.2x</code>	Customised heatmaps (based on <code>gplots</code>) https://github.com/TomKellyGenetics/heatmap.2x	2.3.4
igraph.extensions	<code>igraph.extensions</code>	Meta-package to install the follow iGraph functions https://github.com/TomKellyGenetics/igraph.extensions	3.5.3
	<code>plot.igraph</code>	Custom plotting of directed graphs https://github.com/TomKellyGenetics/plot.igraph	2.4.4
	<code>info.centrality</code>	Computing information centrality from network efficiency https://github.com/TomKellyGenetics/info.centrality	3.4.2
	<code>pathway.structure.permutation</code>	Testing pathway structure with resampling analysis https://github.com/TomKellyGenetics/pathway.structure.permutation	3.4.1.1
	<code>graphsim</code>	Generating simulated expression from graph structures https://github.com/TomKellyGenetics/graphsim	3.4.2

2.5.3 High Performance and Parallel Computing

Another enabling technology for bioinformatics is parallel computing, performing independent operations in separate cores: this “multithreading” is widely used to increase the time to compute results. Bioinformatics is particularly amenable to this since performing multiple iterations of a simulation or testing separate genes is often “embarrassingly parallel”, being completely independent of the results of each other. As such parallel computing is offered by many high-performance “supercomputers” including national research infrastructure.

The New Zealand eScience Infrastructure (NeSI) is a computating resource providing the Intel Pan cluster hosted by the University of Auckland (NeSI, 2017). The Pan cluster used throughout this thesis project to optimise and perform computations which would have otherwise been infeasible in the timeframe of thesis. Such technological developments and infrastructure initiatives have enabled bioinformatics research including this project. High performance computing on the Pan cluster was used extensively in this project including for resampling analysis (in sections 2.3.6 and 3.4.1.1), calculating information centrality (in Section 2.4.4), and in simulations (in sections 2.3.5, 3.2, and 3.4.2)

Scripts and data were transferred between the Pan cluster and University of Otago computing resources by `rsync` or the Globus file transfer service (Globus, 2017). R scripts (R Core Team, 2016) were run in parallel with the “simple network of work-stations” `snow` R package Tierney *et al.* (2015). This utilised the “message passing interface” (Yu, 2002) when it was feasible with memory requirements to run in parallel across multiple compute nodes, otherwise SOCKS was used to access multiple cores within an instance of R and pass input data to them. R jobs were submitted to queue for available resources and run on the Pan cluster via the Slurm (Simple Linux Utility for Resource Management) workload manager (Slurm, 2017). When running R scripts across many parameters or for memory-intensive jobs, Slurm array job submission and independent submission of different parameters via shell commands with arguments passed to R. In some cases, this submission was automated across a range of parameters with Bash scripts.

Chapter 3

Methods Developed During Thesis

In this Chapter, I will outline the rationale and development of various methods used throughout this thesis to examine synthetic lethality in gene expression data, graph structures, models and simulations. First by describing the Synthetic Lethal Interaction Prediction Tool (SLIPT), a bioinformatics approach to triage of synthetic lethal candidate genes. This is considered one of the main research outputs of the thesis, which is supported by comparisons to an experimental screen from a related project and performance on simulated data. These supporting data will be covered in further Chapters but preliminary data to support the use and design of SLIPT are provided alongside description of the method. This includes the construction of a statistical model of synthetic lethality in (continuous multivariate Gaussian) gene expression data, which enables testing SLIPT upon simulated data with known synthetic lethal partners. Another key component of the simulation pipeline used later is the generation of simulated data from a known graph structure or simulated biological pathway. The development of this simulation procedure and other statistical treatment of graph and network structures will also be covered. Various R packages have been developed to support this project, most notably the `slipt` package to implement the SLIPT methodology. The additional R packages for handling graph structures, simulations, and custom plotting features will also be described as research outputs of this thesis, methods applied throughout, and contributions to the open-source software community that made this project feasible.

3.1 A Synthetic Lethal Detection Methodology

The SLIPT methodology identifies gene expression patterns consistent with synthetic lethal interactions between a query gene and a panel of candidate interacting partners.

Gene expression is called low, medium, or high by separating samples into tertiles (3-quantiles) for each gene. Genes with insufficient expression across all samples were excluded by requiring that the first tertile of raw counts is above zero. Then a χ^2 test is performed between the query gene and each candidate partner, with the p-values for the χ^2 test being corrected for multiple testing using false discovery rate (FDR) error control to reduce false positives for large candidate gene panels (Benjamini and Hochberg, 1995). Significance was called only if FDR adjusted p-values were below the threshold $p < 0.05$. A synthetic lethal interaction is predicted (as shown in Figure 3.1) when (i) the χ^2 test is significant; (ii) observed low-query, low-candidate samples are less frequent than expected; and (iii) observed low-query, high-candidate and high-query, low-candidate samples are more frequent than expected.

The synthetic lethal prediction procedure has also been adapted to utilise somatic mutation data for the query gene. This is intended to utilise a query gene known to be recurrently mutated in the disease (and dataset), with the majority of mutations

		Candidate Gene		
		Low	Medium	High
Query Gene (e.g. <i>CDH1</i>)	Low	Observed less than expected		Observed more than expected
	Medium			
	High	Observed more than expected		

Figure 3.1: Framework for synthetic lethal prediction. SLIPT was designed to identify candidate interacting genes from gene expression data using the χ^2 test against a query gene. Samples are sorted into low, medium, and high expression quantiles for each gene to test for a directional shift. A sample being low in both genes of a synthetic lethal pair is unlikely, since loss of both genes will be deleterious, and is expected to be statistically under-represented in a gene expression dataset. We expect a corresponding (symmetric) increase in frequency of sample with low-high gene pairs. Synthetic lethal candidate (exprSL) partners of a gene are identified by running this procedure on all possible partner genes, selecting those with an FDR-adjusted χ^2 p-value of $p < 0.05$, and meeting the directional criteria. Since synthetic lethal genes are partners of each other commutatively, the symmetric direction criteria are all required such that synthetic lethal genes will be predicted to be partners of each other.

		Candidate Gene		
		Low	Medium	High
Query Gene (e.g. <i>CDH1</i>)	Mutation	Observed less than expected		Observed more than expected
	Wild-type	Observed more than expected		

Figure 3.2: Synthetic lethal prediction adapted for mutation. SLIPT was also adapted to identify candidate interacting genes using (somatic) mutation data of the query gene in the χ^2 test. Samples are sorted into low, medium, and high expression quantiles for each candidate gene and tested for a directional shift against mutation status of the query gene. A sample having low expression or mutation for the synthetic lethal pair is expected to be unlikely with a corresponding increase in frequency of sample with mutant-high or wild-type-low gene pairs. Synthetic lethal candidate (mtSL) partners of a gene are identified by running this procedure on all possible partner genes, selecting those with an FDR-adjusted χ^2 p-value of $p < 0.05$, and meeting the directional criteria.

inactivating gene function (such as null or frameshift mutations). A synthetic lethal interaction is predicted (as shown in Figure 3.2) when (i) the χ^2 test is significant; (ii) observed mutant-query, low-candidate samples are less frequent than expected; and (iii) observed mutant-query, high-candidate and wild-type-query, low-candidate samples are more frequent than expected. Unless otherwise specified, computationally predicted synthetic lethal gene candidates from SLIPT used expression data (exprSL) for both genes (as shown in Figure 3.1) rather than mutation data (mtSL) for the query gene (as shown in Figure 3.2).

The SLIPT methodology is amenable for use on expression data including pathway metagenes (as generated in Section 2.2.3). The suitability of the SLIPT methodology to application on public gene expression data will further be supported by simulation results in Section 3.3 and Chapter 6, including comparison to other statistical methods. SLIPT results for *CDH1* will also compare experimental screen results in a breast cell line (Telford *et al.*, 2015), primary screen results are discussed in Section 4.2 and secondary (validation) screen results are presented in Appendix C.

3.2 Synthetic Lethal Simulation and Modelling

A statistical model of Synthetic Lethality was developed to generate simulated data to test the SLIPT procedure. This section will describe the synthetic lethal model and the simulation procedure for generating gene expression data with known synthetic lethal partners. Some preliminary results to support usage of the SLIPT methodology throughout this thesis will be presented here. The simulation procedure will be applied in more depth in Chapter 6, including in combination with simulations from graph structures.

3.2.1 A Model of Synthetic Lethality in Expression Data

A conceptual model of synthetic lethality was constructed (see Figure 3.3), which will be used to build a statistical model of synthetic lethal gene expression from which to simulate expression data to on which test SLIPT and various potential synthetic lethal prediction methods. In the model, synthetic lethality arises between genes with related functions as a cell death phenotype when these functions are removed.

This model suggests that synthetic lethality is detectable in measures of gene inactivation across a sample population, namely mutation, DNA copy number, DNA methylation, and suppression of expression. While any of these mechanisms of gene inactivation could lead to synthetic lethality, expression data is readily available and changes in these alternative mechanisms are likely to impact on the amount of expressed (functional) RNA or protein detectable. There are several ways that functional relationships between genes could manifest in expression data, including coexpression, mutual exclusivity and directional shifts. Co-expression is overly simplistic and has previously performed poorly as a predictor of synthetic lethality (Jerby-Arnon *et al.*, 2014), although this will still be tested with correlation measures in later simulations. Here the alternative hypothesis is that synthetic lethality will lead to a detectable directional shift in the number of samples exhibiting low or high expression of either gene. This model does not preclude mutual exclusivity (Wappett *et al.*, 2016), compensating expression or co-loss under-representation (Lu *et al.*, 2015) as previously postulated to occur between synthetic lethal genes.

The first condition of the synthetic lethal model is that if there are only two synthetic lethal genes (e.g., *CDH1* and one SL partner), then they will not both be non-functional in the same sample (in an ideal model). Gene function is thus determined for each sample in a model of synthetic lethal with the proportion of samples with a functional or non-functional gene being arbitrary. Whether a gene is functional can




Figure 3.3: A model of synthetic lethal gene expression. A conceptual model of synthetic lethal interactions between a Query gene and partner gene (G_X). Genes that are synthetic lethal may not both be non-functional in the same sample without another gene compensating for the loss of function. This is most likely to be detectable as low gene expression, whether they are lost by mutation, deletion, DNA methylation, or suppressing regulatory signals. This could manifest as coexpression, mutual exclusivity, or directional shifts in sample frequency. Thus the alternative hypothesis (H_A) is that synthetic lethal genes will have a reduced frequency of co-loss samples while the null hypothesis (H_0) is that non-synthetic lethal gene pairs would show no such relationship, even if they may be correlated for other means such as pathway relationships. In this model synthetic lethal genes may compensate for the loss of each other but this is not assumed, only that loss of both is unfavourable to cell viability and probability of detecting samples with combined gene loss.





Figure 3.4: Modeling synthetic lethal gene expression. When modeling synthetic lethal interactions between a Query gene with partner genes (G_X and G_Y) above, cellular viability requires that at least of genes is not inactivated. Expression below a threshold is used as a model of loss of function, where genes are regarded as non-functional for the purposes of modelling synthetic lethality. Tumour suppressor genes with loss of function also have cancer specific phenotypes (although these thresholds are not necessarily the same). Expression is modeled by a normally (Gaussian) distributed continuous data such as (log-scale) data from RNA (microarray or RNA-Seq), protein, or pathway metagenes. This rationale generalises for several genes on a multivariate normal distribution.

similarly be modelled by an arbitrary threshold of continuous and normally distributed gene expression data to define gene function (as shown in Figure 3.4). For the purposes of modeling synthetic lethality in breast cancer expression data, a threshold of the 30th percentile of the expression levels was used because approximately 30% of samples analysed had *CDH1* inactivation. This was generalised for a model of the proportion of samples inactivated for each gene. In this ideal case, no samples lowly expressing both of these genes are expected to be observed. While this is not observed, that is to be expected as it is unlikely that only 2 genes will have an exclusive synthetic lethal partnership. The threshold of the 0.3 quantile was used in simulations derived from this model throughout this thesis.

A synthetic lethal pair of genes is unlikely to act in isolation, therefore higher-order synthetic lethal interactions (i.e., 3 or more genes) must be considered in the model as shown in Figure 3.5. Even when testing pairwise interactions, modelling higher level interactions that may interfere is important. If there are additional synthetic lethal partners, there are two possibilities for adding these: 1) that they are independent partners of the query genes interacting pairwise (and not with each other) or 2) that



an addition partner gene interacts with both of the synthetic lethal genes already in the system and any of the three (or more) are required to be functional for the cell to survive.

The signal (in terms of gene expression data) will be weaker for this latter case and this model has the more stringent assumption that all synthetic lethal partner genes interact with each other: that only one of these must be expressed to satisfy the model of synthetic lethality. In this model any of the synthetic lethal genes in a higher-order interaction is able to provide the missing function of the others, allowing for higher-level synthetic lethal partners to compensate for loss a synthetic lethal gene pair. While samples expressing low levels of the synthetic lethal gene pairs will be under-represented, they may not be completely absent from the dataset due to these higher-level interactions.


In the example of 3 synthetic lethal genes 3.5, only one of genes involved in the higher-order synthetic lethal interaction is required for cell viability. For synthetic lethal pairs, only a subset of these samples will be inviable (i.e., removed from simulated data), leading to an under-representation.

In practice, samples are not removed from a simulated dataset, rather the expression and function of the query gene is generated across samples separately from the pool of potential partner genes. The query gene data is matched to simulated samples (as shown in Figure 3.7), satisfying the synthetic lethal condition with the procedure described in Section 3.2.2. This is performed to maintain a comparable samples size across simulations and the preserve the assumed (multivariate) normal distribution of the data.

3.2.2 Simulation Procedure

Simulations were developed to simulate normal distributions of expression data and define function with a threshold cut-off. This is the reverse to the procedure of SLIPT to predict synthetic lethal partners (although the threshold is assumed to be unknown when testing upon simulated data). While gene function is used as an intermediary step in modelling synthetic lethal genes in expression data, the normal distribution is sampled for simulated data to represent normalised empirical gene expression data for which SLIPT (and other methods) will be applicable.


Sampling a distribution for expression profiles has the added advantage of being amenable to simulating correlation structures with the multivariate normal distribution (using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)). The



(a) Simulated expression matrix

(b) Corresponding gene function calls

Figure 3.6: **Simulating gene function.** A simulated dataset with samples (columns) and genes A–H (rows) is transformed from a continuous (coloured blue–red) scale to a discrete matrix of gene function (black for functional levels and grey for non-functional).




(a) Simulated gene function with SL genes

(b) Query gene added with SL condition

Figure 3.7: **Simulating synthetic lethal gene function.** In a discrete simulated gene function dataset (shaded for functional levels and pale otherwise) with samples (columns) and genes (rows), genes A and I are SL partners of a “Query” gene. A partner is selected (highlighted in green) randomly in each sample for simulating synthetic lethality, then ordered such that the query gene or an SL partner are functional in each sample.

parameter Σ is a covariance matrix defines the correlation structure between simulated genes being sampled. With a diagonal of one, this Σ matrix simulates genes with a standard deviation of one and the covariance parameters between them are the correlations between each gene. In Figure 3.6, an example of such a simulated multivariate normal dataset is shown with the functional threshold applied.

Once we have generated a simulated dataset, the samples are compared by gene function (as derived from a functional threshold). Known underlying synthetic lethal partners are selected within the dataset and a query gene is generated by sampling from the normal distribution. These are matched (as shown for 2 synthetic lethal partners in Figure 3.7) such that the synthetic lethal condition is met: that at least one of the synthetic partner genes and the query gene are functional in any particular cell. The samples are ordered by functional data (without assuming correlation of underlying expression values) with the query gene in one direction and the remaining dataset ordered by the selected synthetic lethal partner.



This results a simulated dataset where samples with non-functional query gene have at least one functional partner gene. Similarly, the query gene is functional in all samples where all of the synthetic lethal partner genes are non-functional. Therefore a

dataset has been generated with known synthetic lethal partners (see Figure 3.8) by as few assumptions about the relationships between the each synthetic lethal pair as possible (and allowing compensating functions from higher-order interactions). This has been designed to have the most stringent (least detectable) synthetic lethal relationships where higher-order interactions are possible for the purposes of testing pairwise detection procedures such as SLIPT.

3.3 Detecting Simulated Synthetic Lethal Partners

The synthetic lethal detection methodology (SLIPT), as described in Section 3.1, was tested on simulated data with known synthetic lethal partners, generated using the procedure described in Section 3.2.2. This section will present basic simulations to demonstrate the methodology and support it's use throughout this thesis. These will be performed with sampling from basic statistical distributions as described, including multivariate normal distribution with correlated blocks of genes, with the Σ matrix show in the plots where relevant. A more complex multivariate normal sampling procedure based on pathway graph structures, as described in section 3.4.2, will be applied in Chapter 6.

3.3.1 Binomial Simulation of Synthetic lethality

A previous version of the synthetic lethal simulation procedure (described in Section 3.2.2), used gene function sampled directly from a binomial distribution using the binomial probability of observing functional gene levels ($p = 0.3$) in one observation ($n = 1$) for each samples:

$$X \sim \text{Bin}(n, p)$$

Once a query gene consistent with synthetic lethality has been added, these functional levels were passed directly into SLIPT as “low” and “high” categories.

The simulation procedure was performed with 20,000 total genes (as feasible in the human genome and expression datasets) with a variable number of true synthetic lethal partners and sample sizes of 500, 1000, 2000, and 5000. Each ROC curve was derived from the results of 10,000 replicate simulations. The statistical performance (as shown in Figure 3.9) of such an approach based on the χ^2 p-value declines towards random predictions (an AUROC of 0.5) with an increasing number of underlying true synthetic lethal partners to detect. However, increased sample size mitigates this decline to some extent, as expected with a statistical predictor, particularly for moderate numbers of synthetic lethal partners.




Figure 3.9: Performance of binomial simulations. Gene function was simulated by binomial sampling and tested for synthetic lethal genes. Statistical performance declines with additional known synthetic partners but this is mitigated by increased sample sizes.




Figure 3.10: Comparison of statistical performance. Binomial simulation of synthetic lethality (in colour) is compared (in greyscale) to multivariate normal simulations (detailed below) which consistently outperforms binomial simulation across parameters.

Simulations based on a simple binomial model of synthetic lethality are limited but form a basis for building a more complex model including expression and correlation structures. While this does not represent the data that SLIPT will be applied to, binomial simulations do demonstrate that SLIPT is able to distinguish small numbers of synthetic lethal partners in a simplistic simulated system with behaviour expected with respect to sample size. This supported further development of the synthetic lethal model and simulation pipeline (as described in Section 3.2) using the multivariate normal distribution.

The multivariate normal simulation procedure is more representative of the (normalised) expression data SLIPT is intended for and enables the prediction procedure to be tested without changes to the methodology (presented in more detail in Section 3.3.2). Sampling continuous expression values from a normal distribution allows the expression threshold for gene function to differ from the categorical “low” and “high” expression binning performed by SLIPT (as discussed in Section 3.2.1) which represents that the SLIPT procedure does not assume a known threshold for expression but rather uses expression as an estimate of gene function. This functionality can be included in the multivariate normal simulation without compromising the statistical performance of the SLIPT, rather the performance estimates (shown in Figure 3.10) were a marked improvement over the binomial simulation procedure across simulation parameters in an equivalent simulation (without correlation structure). This improvement may be due to binomial model defining the synthetic lethal condition in a way that, while ensuring at least one synthetic lethal partner is active in query deficient samples, disrupts the number of samples with functional synthetic lethal genes compared to other genes affecting the expected sample proportions of χ^2 test.


3.3.2 Multivariate Normal Simulation of Synthetic lethality

The multivariate normal simulation procedure was initially performed using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016) (as described in Section 3.2) without correlation structure.

Expression is sampled from multivariate normal distribution with a mean ($\mu = 0$), standard deviation ($\sigma = 1$), and no correlation between genes ($r = 0$):


$$X \sim N(\bar{\mu}, \Sigma)$$

Once a query gene consistent with synthetic lethality has been added, the simulated expression values are tested by SLIPT exactly as described in Section 3.1.



(a) Statistical evaluation

(b) Receiver operating characteristic



(c) Statistical performance

Figure 3.11: Performance of multivariate normal simulations. Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (without correlation structure). Performance of SLIPT declines for more synthetic partners but this is mitigated by increased sample sizes (in darker colours). This generally occurs as the sensitivity decreases for a greater number of true positives to detect, leading to a trade off in accuracy as seen in a trough for false discovery rate and the ROC curves.

As shown in Figure 3.11(a), the statistical accuracy of SLIPT as a binary classifier is considerably high across simulations of a full human dataset of 20,000 genes. However, with the χ^2 p-value as a threshold for prediction, this is largely to desirable specificity: the majority of non-SL genes are distinguished from the few underlying synthetic lethal genes. In this regard, the SLIPT methodology generally performs better with larger datasets with more expected negatives and thus the results of simulations of smaller numbers of genes (such as the graph structures analysed in Chapter 6) can be applied to larger datasets where they are expected to perform comparably or better with a lower false negative rate. Accordingly, key results will be supported by replication with larger numbers of non-SL genes added to the simulations.

However, with higher numbers of synthetic lethal genes to detect, the sensitivity (in Figure 3.11(a)) of SLIPT as a binary classifier of synthetic lethality declines, although this is somewhat mitigated by higher sample sizes (shown in darker colours). Thus the minority of true synthetic lethal partners are more difficult to distinguish when there are more of them (and a weaker expression signal from each). While a reasonable reduction of the false discovery rate can be achieved for moderate numbers of underlying synthetic lethal partners, we can not be sure how many partners are expected to be detected in analyses of expression data. However this simulation procedure is amenable to assessing the performance of SLIPT across simulation parameters, graph structures and comparisons to other approaches (presented in more detail in Chapter 6).

Not all of the genes detected by SLIPT will be true synthetic lethals but these will be among the strongest candidates and it performs better with fewer underlying synthetic lethals to detect. This supports a focus on pathway analyses, in particular detecting pathways for further investigation. Since individually gene candidates are not necessarily gene synthetic lethal themselves, pathway over-representation analysis will be performed to detect functional groups recurrently detected by SLIPT as these detection of functionally related genes further support their role in synthetic lethal relationships in addition to being biologically informative. Alternatively, pathway meta-genes will reduce the number of underlying synthetic lethals to identify synthetic lethal pathways. Both of these approaches will be applied in Chapter 4 to identify and replicate synthetic pathways of *CDH1*. Pathways are also more likely to replicate across experimental models as demonstrated by Dixon *et al.* (2008).

The receiver operating characteristic curves (in Figure 3.11(b)) demonstrate that SLIPT is subject to near equal trade-off between sensitivity and specificity across threshold values. The lower sensitivity and higher specificity with a binary classification

(in Figure 3.11(a)) stems from stringent testing by SLIPT with (FDR) p-values adjusted for multiple tests. The area under these curves is also used to compare statistical performance (in Figure 3.11(c)), with declining performance across increased underlying synthetic lethal partners and increased performance with sample size in multivariate normal simulations.

3.3.2.1 Multivariate Normal Simulation with Correlated Genes

Correlation structures can be added to the simulation procedure (as discussed in Section 3.2), starting with simple correlated blocks of genes as the Σ parameter depicted in Figure 3.12(a). These correlated blocks represent genes with correlated expression such as that expected by coregulation or biological pathways. Figure 3.12 gives an example of 4 synthetic lethal genes (out of 100), each with 5 correlated genes that are not themselves synthetic lethal partners of the query gene. This serves to test whether synthetic lethal genes are distinguishable from correlated partners. This Σ matrix produces a similar correlation structure (Figure 3.12(b)) in the resulting expression profiles (Figure 3.12(c)) where apart from correlated blocks of genes ($r = 0.8$), the remaining genes have only slight variations due to random sampling. The structure of the dataset, particularly between synthetic lethal genes and the query, is shown at the gene expression (Figure 3.12(c)) and function (Figure 3.12(d)). These are ordered by the SLIPT results and the synthetic lethal genes are ranked high, with the majority of them being distinguishable from highly correlated genes.

The use of correlation structures generalises to larger datasets, such as 1000 genes shown in Figure 3.13. Synthetic lethal genes are highly ranked by SLIPT and still largely distinguishable from correlated genes. As previously discussed in Section 3.3.2, these synthetic lethal genes are still detectable among a larger number of true negatives and the SLIPT methodology performs better on such datasets.

These plots (Figures 3.12 and 3.13) also show similar correlated blocks with a non-synthetic lethal gene (true negative) and the query gene (which is not synthetic lethal with itself). Neither of these should be synthetic lethal (or detected to be) but they may impact upon the performance of the model, particularly the specificity as correlated negative genes may be distinguishable from true synthetic lethals. The non-synthetic lethal correlated block has no impact on synthetic lethal detection but the impact of query correlated genes will be discussed in Section 3.3.2.2 and Chapter 6.

These simulations (on 100 genes) were repeated to examine the variation between detection on different samples and varying the number of underlying synthetic lethal partners, in simulated gene expression data with correlations structure. A small number




Figure 3.12: Simulating expression with correlated gene blocks. A Σ matrix (a) is used to generate a multivariate normal distribution with 100 genes in correlated blocks of genes (correlated by 0.8) with a comparable structure (b) to the input Σ , as shown by correlation on a red–green scale. The annotation bars for genes give the χ^2 (in blue if the direction of SLIPT is met or red otherwise) and the gene category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL). The simulated gene expression (c) and function (d) generated are ordered by χ^2 showing the functional structure of synthetic lethal genes and that they are among the strongest SLIPT results.





Figure 3.13: Simulating expression with correlated gene blocks. Using the (a) Σ matrix, sampling from a multivariate normal distribution with of 1000 genes produced (b) correlated blocks of genes (correlated by 0.8) on a red-green scale. The simulated gene expression (c) and function (d) generated are ordered by χ^2 and SLIPT direction show that synthetic lethal genes are among the strongest SLIPT results with high specificity against many potential false positives. These are annotated for χ^2 (on a red-green scale) and category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL) for each gene.




(a) Gene category in simulations (b) Corresponding χ^2 values

Figure 3.14: Synthetic lethal prediction across simulations. The gene category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL) ordered by χ^2 signed by the SLIPT directional condition is shown across simulations. For each of 1–10 SL partners, 10 simulations demonstrate that the increasing numbers of SL partners become harder detect. The χ^2 values show a clear threshold for SL and correlated genes when there are fewer of them, distinguishable from correlated genes in this case.


(10 for each) simulations are shown in Figure 3.14 to demonstrate the variation between replicate simulations, with iterative sampling from the same multivariate normal distribution. These simulations show synthetic lethal genes are not only highly ranked by SLIPT when there are few of them but also that they are fairly consistent across replicate simulations. Whereas they become less consistent for increasing numbers of true synthetic lethal partners to detect and thus more difficult to distinguish from other genes, particularly those correlated with them. Similarly, the χ^2 values show a marked stepwise increase with clear thresholds for SL and correlated genes in simple simulations, whereas these become less evident for higher numbers of SL partners.

Whether the synthetic lethal genes detected in simple simulations (in Figure 3.14) are robustly detectable across greater number of simulations, in addition to further comparisons, was tested with a supporting ROC analysis. These results (in Figure 3.15) are very similar to simulations without correlation structure, with SLIPT as a binary classifier having a poor sensitivity with increasing numbers of synthetic lethal partners



(a) Statistical evaluation

(b) Receiver operating characteristic



(c) Statistical performance

Figure 3.15: Performance with correlations. Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (with correlation structure). Performance of SLIPT declines for more synthetic partners but this is mitigated by increased sample sizes (darker colours). This generally occurs as the sensitivity decreases for a greater number of true positives to detect, leading to a trade off in accuracy as seen in a trough for false discovery rate and the ROC curves.





Figure 3.16: Comparison of statistical performance with correlation structure.
Multivariate simulation of synthetic lethality with correlation structure (in colour) has comparable performance to simulation without correlations (in greyscale) with known synthetic partners across parameters.

to detect but high specificity in a total of 20,000 genes with the vast majority being true negatives. This is reflected in a similar decline in statistical performance for increasing numbers of synthetic lethal partners and a compensating increase in performance with higher sample size. Overall, the statistical performance is very similar to simulations without correlation structure (as shown in Figure 3.16).


Thus SLIPT is robust across correlation structures and applicable to real gene expression data where pathway structures and correlations are a consideration. These correlation structures are not intended to model specific biological pathways or represent them, rather they serve to test the impact of correlation structure on the performance of SLIPT with an extreme example of closely correlated ($r = 0.8$) gene blocks. More complex correlation structures, such as genes positively correlated with the query gene and derived from pathway graph structures (as described in 3.4.2) will be examined below (in Section 3.3.2.2) and in Chapter 6 respectively.

In particular, genes correlated with true synthetic lethal genes have little impact on the performance of SLIPT detection: synthetic lethal genes are as distinguishable from true negative genes as without correlated genes. Synthetic lethal correlated genes will not interfere with the detection of true synthetic lethals, although they may be ranked next below them and be biologically informative with related gene functions.



(a) Statistical evaluation

(b) Receiver operating characteristic



(c) Statistical performance

Figure 3.17: Performance with query correlations. Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (with correlation structure including correlated genes with non-SL and query genes). As before, performance of SLIPT declines for more synthetic partners and is mitigated by increased sample sizes (darker colours) but the sensitivity remains higher for a greater number of true positives with corresponding improvements in ROC curves.

3.3.2.2 Specificity with Query-Correlated Pathways

Another consideration for correlation structures is positively correlated genes with the query that are not synthetic lethal. As described in Section 3.3.2.1, 5 highly correlated ($r = 0.8$) with the query gene were added. These simulations perform similarly to before (in Figure 3.17) with a higher specificity and a lower false discovery rate being feasible (as shown in 3.17(a)).

3.3.2.2.1 Importance of Directional Testing

It is important to notice here that the directional criteria of the SLIPT procedure is enhancing its performance, particularly in distinguishing positively correlated true negatives. The multivariate normal simulation results, with 20,000 genes including all of the correlation structures discussed (SL, non-SL, and query correlated genes), are compared here for SLIPT with and without (χ^2) directional testing. There is a marked improvement in statistical performance with directional criteria, particularly with increased sensitivity and lower false discovery rate (as shown in Figure 3.18).






Figure 3.18: **Statistical evaluation of directional criteria.** A simulated multivariate normal dataset of 20,000 genes with correlation structures was tested by SLIPT with the directional condition and the equivalent χ^2 test without. SLIPT exhibited a consistently higher sensitivity and lower false discovery rate.



(a) χ^2 testing without direction

(b) SLIPT with directional criteria



(c) Statistical performance

Figure 3.19: **Performance with directional criteria.** A simulated multivariate normal dataset of 20,000 genes with correlation structures was tested by SLIPT with the directional condition and the equivalent χ^2 test without. SLIPT has higher performance across simulation parameters, clearly differing from random (grey diagonal) in ROC curves up to 100 SL genes (b). The performance (c) of SLIPT (in greyscale) was consistently higher than the χ^2 test (in color).

This is encouraging for the application of SLIPT to empirical expression datasets as positively correlated genes are likely to occur and the directional condition robustly improves the performance of SLIPT across simulation parameters. Without assuming the underlying number of synthetic lethal genes, SLIPT will perform better than the χ^2 test alone at detecting them. This is further supported irrespective of significance threshold for the χ^2 test by the ROC analysis in Figure 3.19. The directional SLIPT methodology outperforms the ordinary χ^2 test at detecting synthetic lethal partners with some predictive power (above random and AUROC of 0.5) even up to 100 synthetic lethal genes.

Together these simulation results support the application of the SLIPT methodology as it has been performed throughout Chapter 4 and 5. However, the methodology and simulation procedure will explored in more detail in Chapter 6, with the inclusion of graph structures and comparison to other synthetic lethal detection approaches.

3.4 Graph Structure Methods

Graph structures have been used in several ways in this project with novel approaches to analysis and simulations. Procedures were developed for statistical and network analysis of gene states in pathway structures. Specifically, the relationships between siRNA and SLIPT genes were tested within biological pathways in Chapter 5. These graph structures were also used in Chapter 6 for the simulation of synthetic lethality to derive correlation structure between simulated gene expression profiles in manner that resembles biological pathways.

3.4.1 Upstream and Downstream Gene Detection

Comparison of experimental and computational candidate synthetic lethal partner genes within pathway structures arose from the hypothesis that these sets of genes were related by pathway structure. Due to differences in how these candidates were generated, it should not be expected that they detect the identical genes within the candidate biological pathways, rather they may be related by being upstream or downstream of each other.

Using the Reactome version 52 data (Croft *et al.*, 2014) as described in Section 2.4.2, genes identified by each synthetic lethal discovery approach were mapped to the graph structure for the candidate pathways identified in Chapter 4 (with subgraphs defined as described in Section 2.4.3). To test whether siRNA candidate genes were upstream of SLIPT candidate genes, shortest paths were traced between each potential pair of

these genes in a directed network. The number of genes where the siRNA candidate was upstream were scored “up” and where the siRNA candidate was downstream were scored “down”. This procedure enabled counting the total number of shortest paths which supported siRNA genes being upstream or downstream of the SLIPT genes and measuring the difference between these to determine if there is an imbalance in a particular direction. While this difference is indicative of the number of paths between the gene candidate groups in either direction, alone it is not sufficient to statistically support structure or relationships between siRNA and SLIPT genes. However, it may be combined with a permutation resampling procedure (as described in Section 3.4.1.1) to test for directional relationships in either direction.

The original version of this procedure excluded gene detected by both approaches since they would count in both directions. Upon further consideration, the intersection genes were restored to being accounted for by the shortest paths counts since they may count unequally to being upstream or downstream of each gene set if there are unequal numbers above or below them in the pathway structure.

3.4.1.1 Permutation Analysis for Statistical Significance

A permutation procedure was developed to randomly assign members of the pathway to siRNA and/or SLIPT groups, with the same number of each candidate partner gene set as observed in the pathway. These permuted genes are measured for pathway structure between the permuted gene groups as performed for the observed candidates (as performed in Section 3.4.1). A distribution of pathway structure relationships expected by chance is generated by permuting iteratively over these pathways. This null distribution can be compared to the observed counts of relationships (in either direction), which yields a permutation p-value as the proportion of permutations in which had value or greater or more extreme magnitude than the observed value.

The null hypothesis is that there is no relationship between these gene groups that would not have occurred had the genes been selected at random. Thus we can test both the alternate hypothesis that the siRNA genes were upstream of the SLIPT genes or that they are downstream of them.

The permutation procedure does not assume the underlying distribution of the data under the null hypothesis and accounts for the total number of nodes, edges, siRNA, and SLIPT genes in each pathway network structure. The intersection size of the siRNA and SLIPT genes was originally not accounted for under the shortest path counts procedure that excluded them. A refined version of this procedure ensured that

the number of intersecting genes was equal to the number observed to test for pathway structure without changing the intersection size, the subject of prior analyses.

3.4.1.2 Ranking Based on Biological Context

An alternative approach to pathway structure was performed based on the biological context that genes at the upstream and downstream ends of a pathway perform different functions, such as a kinase signalling cascade receiving signals from external stimuli and passes these on ribosomes or the nucleus. The genes were ranked to determine if genes of either candidate group (or those with stronger support for either group) performed upstream or downstream functions disproportionately.

A network-based approach was used to determine the pathway ranking of genes in a computationally rational way when applied to different biological pathways with a directed graph structure, G (without loops). The diameter of the network (i.e., the length of longest possible shortest path between the most distant genes) was used to identify a gene (z) at the downstream end of the pathway (at the end of a diameter spanning shortest path), assigned a rank of:

$$\text{rank}(z) = 1 + \text{diameter}(G)$$

Having identified the downstream end of the pathway, genes upstream (e.g., gene i) of this are assigned a rank by the length of their shortest path to this gene, z .

$$\text{rank}(i) = \text{rank}(z) - d_{iz}$$

The remaining unassigned genes (e.g., gene j) gain the rank of the length of the shortest path downstream from the nearest assigned gene if possible.

$$\text{rank}(j) = \text{rank}(i) + d_{ij}$$


This process may be performed iteratively to fill in pathway ranking but it was not necessary to perform further iterations for the candidate synthetic lethal pathways investigated (amenable to this procedure) which exhibited clear directional structure and the small world property (with a low diameter). Thus genes in a pathway graph structure were assigned integer valued rankings upstream to downstream by this procedure:

$$\text{rank} \in \{1, 2, 3, \dots, 1 + \text{diameter}(G)\}$$

This ranking of pathway directionality can be used for comparison with measures of the number of genes of each candidate group and the support for being synthetic lethal partners with either approach.

3.4.2 Simulating Gene Expression from Graph Structures

A further refinement of the simulation procedure generated expression data with correlation structure, derived from a known graph structure. This enables modelling of synthetic lethal partners within a biological pathway and the investigation of impact of pathway structure on synthetic lethal prediction. A simulated pathway is first constructed as a graph structure, with the `igraph` R package Csardi and Nepusz (2006), with the added annotation of the state of the edges (i.e, whether they activate or inhibit downstream pathway members). This simulation procedure was intended for biological pathway members with correlated gene expression (higher than the background of genes in other pathways) but it may also be applicable to modelling protein levels (in a kinase regulation cascade) or substrates and products (in a metabolic pathway).




First, the graph structure is constructed for simulated data to be generated from (by sampling from a multivariate normal distribution using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)). Throughout this section, the simulation procedure will be demonstrated with the relatively simple constructed graph structure shown in Figure 3.20. This graph structure visualisation was specifically developed for (directed) iGraph objects in R and has been released in the `plot.igraph` package and

`igraph.extensions` library (see Table 2.6 and Section 3.5.3). The `plot_directed` function allows customisation of plot parameters for each node or edge and mixed (directed) edge types for indicating activation or inhibition. These inhibition links (which often occur in biological pathways) are demonstrated in Figure 3.20(b).


The simulation procedure is designed to use such graph structures to inform development of a “Sigma” variance-covariance matrix (Σ) for sampling from a multivariate normal distribution (using the `mvtnorm` R package). Given a graph structure (or adjacency matrix), such as Figure 3.21(a), a relation matrix is calculated based on distance such that nearer nodes are given higher weight than farther nodes. For the purposes of this thesis a geometrically decreasing (relative) distance weighting is used, with each more distant node being related by $1/2$ compared to the next nearest as shown in Figure 3.21(b). However, an arithmetically decreasing (absolute) distance weighting is also available in the `graphsim` R package release of this procedure.

A Σ matrix is derived from this distance weighting matrix, creating a matrix (with a diagonal of 1) where each node has a variance and standard deviation of 1. Thus covariances between adjacent nodes are assigned by a correlation parameter and the remaining matrix based on weighting these correlations with by the distance matrix (or the nearest “positive definite” matrix). For the purposes of this thesis, the correlation parameter is 0.8 unless otherwise specified (as used for the example in Figure 3.21(c)). This Σ matrix is used to sample from a multivariate normal distribution with each gene having a mean of 0, standard deviation 1, and covariance within the range [0, 1] such that they are correlations. This procedure generates a simulated (continuous normally distributed) expression profile for each node (as shown in Figure 3.21(e)) with corresponding correlation structure (Figure 3.21(d)). The simulated correlation structure closely resembles the expected correlation structure (Sigma in 3.21(c)) even for the relatively modest sample size ($N = 100$) illustrated in 3.21. Once a simulated gene expression dataset has been generated (as in Figure 3.21(e)), then a discrete matrix of gene function can be constructed with a functional threshold quantile to simulate functional relationships of synthetic lethality (as shown in Figure 3.4). For the purposes of this thesis, this threshold is the 0.3 quantile (as discussed in Section 3.2.1) which generates functional discrete matrices such as those used for synthetic lethal simulation in Section 3.2.2 (as shown Figure 3.21(f))


The simulation procedure (depicted in Figure 3.21) is amenable to pathways containing inhibition links (as shown in Figure 3.22) with several refinements. With the inhibition links (as shown in Figure 3.22(a)), distances are calculated in the same




(a) Activating pathway structure




(b) Distance matrix




(c) Sigma, Σ (expected correlation)



(d) Simulated correlation structure




(e) Simulated expression data




(f) Simulated gene function calls


Figure 3.21: **Simulating expression from a graph structure.** An example graph structure is used to derive a correlation structure from the relative distances between nodes and simulate continuous gene expression with sampling from the multivariate normal distribution.




(a) Pathway structure with inhibition




(b) Distance matrix




(c) Sigma, Σ (expected correlation)



(d) Simulated correlation structure



(e) Simulated expression data



(f) Simulated gene function calls

Figure 3.22: **Simulating expression from graph structure with inhibitions.** An example graph structure is used to derive a correlation structure from the relative distances between nodes and simulate continuous gene expression with sampling from the multivariate normal distribution.

manner as before (Figure 3.22(b)) with inhibitions accounted for by iteratively multiplying downstream nodes by -1 to form blocks of negative correlations (as shown in Figures 3.22(c) and 3.22(d)). As before, a multivariate normal distribution with these negative correlations can be sampled to generate simulated data (as shown in Figures 3.22(e) and 3.22(f)).

These simulated datasets are amenable to simulating synthetic lethal partners of a query gene within a graph network. The query gene is assumed to be separate from the graph network pathway and is added to the dataset using the procedure in Section 3.2.2. Thus we can simulate known synthetic lethal partner genes within a synthetic lethal partner pathway structure.

3.5 Customised Functions and Packages Developed

[Move to Appendix?]

Various R packages have been developed throughout this thesis using `devtools` (Wickham and Chang, 2016) and `roxygen` (Wickham *et al.*, 2017) to enable reproducibility of customised analysis and visualisation. Many of these have the added benefit of the functions being documented, demonstrated in example vignettes, and released on GitHub to enable the research community to access utilise them in their own analysis. These are summarised in Table 2.6, along with the corresponding urls for their GitHub repository which contains a README file with instructions for installation with the `devtools` R package (Wickham and Chang, 2016) and links to the relevant vignette(s) where available.

3.5.1 Synthetic Lethal Interaction Prediction Tool

The statistical methodology for detection of synthetic lethality in gene expression data (SLIPT) is one of the main novel procedures developed in this thesis, as described in Section 3.1. The `slipt` R package has been prepared for release to accompany a publication demonstrating the applications of the methodology for identifying candidate interacting genes and pathways with *CDH1* in breast cancer (TCGA, 2012).

SLIPT is amenable to analysis of any effectively continuous measure of gene activity (e.g., microarray, RNA-Seq, protein abundance, or pathway metagenes). Executing `slipt` is straightforward: the `prep_data_for_SL` function scores samples as “low”, “medium”, or “high” for each gene, then the `detect_SL` function tests a given query gene against all potential partners by performing the chi-squared test and directional conditions. This function returns a table summarising the observed and expected sam-

ple numbers used for the directional criteria, the χ^2 values, and corresponding p-values including adjusting for multiple comparisons. The `count_of_SL` and `table_of_SL` functions serve to facilitate summary and extraction of the positive SLIPT hits, respectively, from the table of predictions of synthetic lethal partners.



The SLIPT methodology in this package release has been used in later analyses rather than the corresponding source R code, including use on remote machines and upon simulated data. In particular, the functions in the package facilitate alterations to parameters, such as the proportion of samples called as exhibiting low or high gene activity. This release support reproducibility and enables wider use of SLIPT in future investigations into other disease genes.

3.5.2 Data Visualisation

Customisations to existing data visualisations in R have been developed to present data throughout this thesis. The `vioplotx` and `heatmap.2x` packages are enhancements of the `vioplot` package (Adler, 2005) and `heatmap.2` provided by the `gplots` package (Warnes *et al.*, 2015).

The `vioplotx` package provides an alternative visualisation (of continuous variables against categories) to the more familiar boxplot, showing variability of the data by the width of the plots. As demonstrated in Figure 3.23, the customised version enables separate plotting parameters for each violin with vector inputs for colour, shape, and size of various elements of the median point, central boxplot, borders, and fill colour for the violin. Scaling violin width to adjust violin area and splitting data by a second categorical variable is also enabled. This function is intended to be backwards compatible with the inputs of `vioplot` (applying scalar inputs across all violins) and `boxplot` (by enabling formula inputs as an S3 method). Each of these features is demonstrated with examples in respective vignettes on the package GitHub repository.

The `heatmap.2x` provides extensions for annotation colour bars for both the rows and columns (as shown in Figure 3.24). Multiple bars are enabled on both axes with matrix inputs (rather than single vector for `heatmap.2`) which facilitates additional plotting of gene and sample characteristics for comparison with correlation matrices, expression profiles, or pathway metagenes. Annotation bar inputs correspond to their orientation on the plot, each colour bar is provided as a column for the row annotation on the left of the heatmap and as a row for the column annotation on top of the heatmap. Row and column annotation bars are labelled with the column or row names respectively. Additional parameters enable resizing of these annotation bar labels and



control of reordering columns for if samples are ordered in advance (e.g., ranked by a metagene or split into groups clustered separately). These features were used through this thesis and are provided in a package GitHub repository.

3.5.3 Extensions to the iGraph Package

The following features were developed during this thesis using “iGraph” data objects, building upon the `igraph` package (Csardi and Nepusz, 2006). These have been released as separate packages for each respective procedure and can be installed together as a collection of extensions to the `igraph` package.

3.5.3.1 Sampling Simulated Data from Graph Structures

The `graphsim` package implements the procedure for simulating gene expression from graph structures (as described in Section 3.4.2). By default, this derives a matrix with a geometrically decreasing weighting by distance (by shortest paths) between each pair of nodes with. An absolute decreasing weighting is also available with the option of to derive correlation structures from adjacency matrices or the number of links common partners (i.e., size of the shared “neighbourhood” (Hell, 1976)) between each pair of nodes. Functions to compute these are called directly by passing parameters to them when running the `generate_expression` or `make_sigma_mat` commands. This package enables simulating expression data directly from a graph structure (with the intermediate steps automated) or generating Σ parameters for `mvtnorm` from graph structures or matrices derived from them. These functions support assigning activating or inhibiting to each edge (with a `state` parameter).

3.5.3.2 Plotting Directed Graph Structures

The `plot.igraph` package provides the `plot_directed` function specifically developed for directed graph structures and to plot activating or inhibiting for each edge (as described in Section 3.4.2). As shown in Figure 3.25, this function supports separate plotting parameters for each node, node label, and edge. This includes colours of node fill, border, label text, and edges and size of nodes, edge widths, arrowhead lengths, and font size of labels. The `state` parameter for assigning activating or inhibiting to each edge determines whether edges are depicted with 30° or 90° arrowheads. Colours are assigned separately and so they may be customised. Vectorised parameters are applied across each node or edge, whereas scalar parameters apply the same plotting parameters across them. The default layout function is `layout.fruchterman.reingold` but any layout function supported by `plot` function in `igraph` (Csardi and Nepusz, 2006)

is compatible such as `layout.kamada.kawai` used to implement the Kamada–Kawai algorithm (Kamada and Kawai, 1989) for graph plots throughout this thesis.




Figure 3.25: **Simulating graph structures.** An example graph structure which will be used throughout demonstrating the simulation procedure from graph structures. Here activating links are denoted by blue arrows and inhibiting links by red edges.

3.5.3.3 Computing Information Centrality

The shortest paths of a network are computed by the `igraph` package Csardi and Nepusz (2006) which can be extended to calculate the network efficiency but is not provided by the package itself (as described in Section 2.4.4). The “information centrality” of a vertex is computed as the relative change in the network efficiency when the vertex is removed. Information centrality is calculated iteratively for each node and the sum of information centrality for each vertex is the information centrality for the network. These metrics are provided by the `info.centrality` package.

3.5.3.4 Testing Pathway Structure with Permutation Testing

A network-based procedure developed was used for comparison of siRNA and SLIPT candidate genes in a pathway structure. Such pathway structure relationships were tested by computing the number of shortest paths between two different groups of nodes in either direction within a graph. This pathway relationship metric was implemented in the `pathway.structure.permutation` package with permutation testing (as described in sections 3.4.1 and 3.4.1.1).

3.5.3.5 Metapackage to Install iGraph Functions

These features may be installed together with `igraph.extensions` which can be accessed from a GitHub repository. This meta-package installs `igraph` (Csardi and Nepusz, 2006) and the packages described in Section 3.5.3 including their dependencies for matrix operations and statistical procedures: `Matrix`, `matrixcalc`, and `mvtnorm` (Bates and Maechler, 2016; Genz and Bretz, 2009; Genz *et al.*, 2016; Novomestky, 2012).

Chapter 4

Synthetic Lethal Analysis of Gene Expression Data

Having developed a statistical synthetic lethal detection methodology (SLIPT), it was applied to empirical (publicly available) cancer gene expression datasets in this Chapter. The analysis largely focuses findings from the TCGA breast cancer data (TCGA, 2012) which covers a range of clinical subtypes and is more closely modelled by siRNA data (Telford *et al.*, 2015) generated from screening experiments conducted in MCF10A breast cells. Although stomach cancer data will also be considered to replicate findings in an independent dataset and for it's relevance to syndromic hereditary diffuse gastric cancer. The TCGA data also has the advantages of other clinical and molecular profiles (e.g., somatic mutation and DNA copy number) for many of the same samples, in addition to a considerable sample size for RNASeq expression data, treated with a rigorous procedure to minimise batch effects. Some findings will be replicated in the Cancer Cell Line Encyclopaedia (CCLE) (Barretina *et al.*, 2012) which may be more comparable to the cell line experiments.

Synthetic lethal candidate partners for *CDH1* will be described at both the gene and pathway level. SLIPT gene candidates will be analysed by cluster analysis for common expression profiles across samples and relationships with clinical factors and mutations in key breast cancer genes. These genes will also be compared to the gene candidates from a primary and secondary (validation) screens conducted by Telford *et al.* (2015) on isogenic cell lines. For comparison, an alternative SLIPT methodology which uses mutation data for *CDH1* against expression of candidate partners will also be presented which may better represent the null mutations in HDGC patients and the experiment cell model (Chen *et al.*, 2014). Pathways will be analysed by

over-representation analysis (with resampling for comparisons with siRNA data) and supported by a metagene analysis of pathway gene signatures. The pathway metagene expression profiles will be used to replicate known relationships between clinical and molecular characteristics for breast cancer and to demonstrate application of SLIPT directly on metagenes to detect synthetic lethal pathways.

Together these results will demonstrate the wide range of applications for SLIPT analysis and examine the synthetic lethal partners of *CDH1* in breast and stomach cancer. These synthetic lethal genes and pathways will be described in both context of the functional implications of novel synthetic lethal relationships and as potential actionable targets against *CDH1* deficient tumours, in addition to replication of established functions of E-cadherin. In particular, the focus of these analysis will be in comparisons with experimental screening data to explore the potential for SLIPT to augment such triage of candidate partners and support further experimental investigations. The key synthetic lethal partner pathways for *CDH1*, supported by both approaches, will be examined in more detail at the gene and pathway structure level in Chapter 5.

Some of the findings presented in this Chapter have also been included in manuscripts submitted for publication (Kelly *et al.*, 2017a,b) and may bear similarity to them, although the results in this thesis have been edited to cohesively fit with additional findings (including consistent data versions). These findings are the result of investigations conducted throughout this thesis project and only these contributions to the articles are included in this Chapter, not that conducted by co-authors.

4.1 Synthetic lethal genes in breast cancer

The SLIPT methodology (as described in Section 3.1) was applied to the normalised TCGA breast cancer gene expression dataset ($n = 1168$). As shown in Table 4.1, the most significant genes had strong evidence of expression-based association with *CDH1* (high χ^2 values) with fewer samples exhibiting low expression of both genes than expected statistically. Eukaryotic translation gene were among the highest gene candidates, including initiation factors, elongation factors, and ribosomal proteins. These are clearly necessary for cancer cells to grow and proliferate, with sustained gene expression needed to maintain growth signaling pathways and resist apoptosis or immune factors translation may be subject to non-oncogene addiction for *CDH1*-deficient cells.

While these are among the strongest synthetic lethal candidates, translational genes are crucial to the viability of healthy cells and dosing for a selective synthetic lethal effect against these may be difficult compared to other biological functions which may also be supported among the SLIPT candidate genes. Furthermore, few known biological functions of *CDH1* were among the strongest SL candidates so the remaining candidate genes may also be informative since they are likely to contain these expected functions in addition to novel relationships for *CDH1*. Thus further pathway level analyses were also conducted to examine biological functions over-represented among synthetic candidate genes and identify synthetic lethal pathways.

Table 4.1: Candidate synthetic lethal gene partners of *CDH1* from SLIPT

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>TRIP10</i>	62	130	162	5.65×10^{-34}	1.84×10^{-31}
<i>EEF1B2</i>	56	130	158	3.10×10^{-33}	9.45×10^{-31}
<i>GBGT1</i>	61	131	156	1.08×10^{-32}	3.14×10^{-30}
<i>ELN</i>	81	130	149	3.46×10^{-31}	8.82×10^{-29}
<i>TSPAN4</i>	78	130	146	1.63×10^{-30}	3.79×10^{-28}
<i>GLIPR2</i>	72	130	146	1.68×10^{-30}	3.86×10^{-28}
<i>RPS20</i>	73	131	145	1.89×10^{-30}	4.28×10^{-28}
<i>RPS27A</i>	80	130	143	5.53×10^{-30}	1.18×10^{-27}
<i>EEF1A1P9</i>	63	130	141	1.91×10^{-29}	3.74×10^{-27}
<i>C1R</i>	73	130	141	2.05×10^{-29}	3.97×10^{-27}
<i>LYL1</i>	73	130	140	2.99×10^{-29}	5.74×10^{-27}
<i>RPLP2</i>	71	130	139	4.88×10^{-29}	9.07×10^{-27}
<i>C10orf10</i>	73	130	138	6.72×10^{-29}	1.20×10^{-26}
<i>DULLARD</i>	74	131	138	9.29×10^{-29}	1.61×10^{-26}
<i>PPM1F</i>	64	130	136	1.61×10^{-28}	2.65×10^{-26}
<i>OBFC2A</i>	69	130	136	2.49×10^{-28}	3.93×10^{-26}
<i>RPL11</i>	70	130	136	2.56×10^{-28}	3.97×10^{-26}
<i>RPL18A</i>	70	130	135	3.08×10^{-28}	4.70×10^{-26}
<i>MFNG</i>	76	131	133	7.73×10^{-28}	1.12×10^{-25}
<i>RPS17</i>	77	131	133	8.94×10^{-28}	1.29×10^{-25}
<i>MGAT1</i>	73	130	132	1.44×10^{-27}	2.03×10^{-25}
<i>RPS12</i>	72	130	128	8.57×10^{-27}	1.12×10^{-24}
<i>C10orf54</i>	73	130	127	1.37×10^{-26}	1.75×10^{-24}
<i>LOC286367</i>	72	130	126	2.20×10^{-26}	2.70×10^{-24}
<i>GMFG</i>	70	130	126	2.20×10^{-26}	2.70×10^{-24}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

The modified mtSLIPT methodology (as described in Section 3.1) was also applied to the normalised TCGA breast cancer gene expression dataset, against somatic loss of function mutations in *CDH1*. As shown in Table D.1, the most significant genes also had strong evidence of expression associated with *CDH1* mutations (high χ^2 values) with fewer samples exhibiting both low expression and mutations of each gene than expected statistically. Although, these were not strongly supported as the expression analysis (in Table 4.1) nor were as many genes detected. This is unsurprising due to the lower sample size with matching somatic mutation data and the lower frequency of *CDH1* mutations compared to low expression by $1/3$ quantiles.

The mtSLIPT candidates had more genes involved in cell and gene regulation, particularly DNA and RNA binding factors. The strongest candidates also include microtubule (*KIF12*), microfibril (*MFAP4*), and cell adhesion (*TENC1*) genes consistent with the established cytoskeletal role of *CDH1*. The elastin gene (*ELN*) was notably strongly supported by both expression and mutation SLIPT analysis of *CDH1* supporting interactions with extracellular proteins and the tumour microenvironment.

4.1.1 Synthetic lethal pathways in breast cancer

Translational pathways were strongly over-represented in SLIPT partners, as shown in Table 4.2. These include ribosomal subunits, initiation, peptide elongation, and termination. Regulatory processes involving mRNA including 3' untranslated region (UTR) binding, L13a-mediated translational silencing, and nonsense-mediated decay were also implicated. These are consistent with protein translation being subject to “non-oncogene addiction” (Luo *et al.*, 2009), as a core process that is dysregulated to sustain cancer proliferation and survival (Gao and Roux, 2015).

Immune pathways, including the adaptive immune system and responses to infectious diseases were also strongly implicated as synthetic lethal with loss of E-cadherin. This is consistent with the alterations of immune response being a hallmark of cancer Hanahan and Weinberg (2000), since evading the immune system is necessary for cancer survival. Either of these systems are potential means to target *CDH1* deficient cells, although these were not detected in an isolated cell line experimental screen (Telford *et al.*, 2015) and the differences between findings in patient data will be described in more detail in Section 4.2.1.4.

It is also notable that the pathways over-represented in SLIPT candidate genes have strongly significant over-representation of Reactome pathways from the hypergeometric test (as described in Section 2.3.2). Even after adjusting stringently for multiple tests,

Table 4.2: Pathways for *CDH1* partners from SLIPT

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	81	1.3×10^{-207}
Peptide chain elongation	83	78	5.6×10^{-201}
Eukaryotic Translation Termination	83	77	1.2×10^{-196}
Viral mRNA Translation	81	76	1.2×10^{-196}
Formation of a pool of free 40S subunits	93	81	3.7×10^{-194}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	77	5.3×10^{-187}
L13a-mediated translational silencing of Ceruloplasmin expression	103	82	9.6×10^{-183}
3' -UTR-mediated translational regulation	103	82	9.6×10^{-183}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	82	1.9×10^{-181}
Nonsense-Mediated Decay	103	80	6.2×10^{-176}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	103	80	6.2×10^{-176}
Adaptive Immune System	412	167	6.5×10^{-174}
Eukaryotic Translation Initiation	111	82	5.7×10^{-173}
Cap-dependent Translation Initiation	111	82	5.7×10^{-173}
SRP-dependent cotranslational protein targeting to membrane	104	79	2.0×10^{-171}
Translation	141	91	6.1×10^{-170}
Infectious disease	347	146	1.6×10^{-166}
Influenza Infection	117	81	1.9×10^{-163}
Influenza Viral RNA Transcription and Replication	108	77	1.9×10^{-160}
Influenza Life Cycle	112	77	2.5×10^{-156}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

biologically related pathways give consensus support to these pathways. These pathways are further supported by testing for synthetic lethality against *CDH1* mutations (mtSLIPT) with many of these pathways also among the most strongly supported in this analysis (shown in Table D.2). This analysis more closely represents the null *CDH1* mutations in HDGC (Guilford *et al.*, 1998) and the experimental MCF10A cell model (Chen *et al.*, 2014). Although it still supports translational and immune pathways not detected in the isolated experimental system, G-protein-coupled receptors (GPCRs) were also among the most strongly supported pathways, supporting the experimental findings of Telford *et al.* (2015) for these intracellular signalling pathways already being targeted for other diseases.


4.1.2 Expression profiles of synthetic lethal partners

Due to the sheer number of gene candidates and to examine their expression patterns, investigations proceeded into correlation structure and pathway over-representation. This serves to explore the functional similarity of the synthetic lethal partners of *CDH1*, with the eventual aim to assess their utility as drug targets. As shown in Figure 4.1 (which clusters *CDH1* lowly expressing samples separately), there were several large

clusters of genes among the expression profiles of the *CDH1* synthetic lethal candidate partners. The clustering suggests co-regulation of genes or pathway correlation between partner gene candidates. A number of candidates from an experimental RNAi screen study performed by Telford *et al.* (2015) were also identified by this approach. In addition, we identified novel gene candidates, which had little effect on viability in isogenic cell line experiments.

In these expression profiles, a gene with a moderate or high signal across samples exhibiting low *CDH1* expression would represent a potential drug target. However, it appears that several molecular subtypes of cancer have elevation of different clusters of synthetic lethal candidates in samples with low *CDH1*. This clustering suggests that different targets or combinations could be effective in different patients suggesting potential utility for stratification. In particular, estrogen receptor negative, basal subtype, and “normal-like” samples Dai *et al.* (2015); Eroles *et al.* (2012); Parker *et al.* (2009) have elevation of genes specific to particular clusters which is indicative of some synthetic lethal interactions being specific to a particular molecular subtype or genetic background. Thus synthetic lethal drug therapy against these subtypes may be ineffective if it were designed against genes in another cluster.

A similar correlation structure was observed among the candidates tested against *CDH1* mutation (mtSLIPT), as shown in Figure D.1. This clustering analysis similarly identified several major clusters of putative synthetic lethal partner genes. Although in this case many partner genes had consistently high expression across most of the (predominantly lobular subtype) *CDH1* breast cancer samples. However, a major exception to this in the *CDH1* expression analysis were the normal samples which were excluded from the mutation data (as they were not tested for tumour-specific genotypes). This supports synthetic lethal interventions being more applicable to *CDH1* mutant tumours and genotyping tumours for loss of function will be essential for clinical application. There was still considerable correlation structure, particularly among *CDH1* wildtype samples, sufficient to distinguish gene clusters. In contrast to the expression analysis the (predominantly ductal *CDH1* wildtype) basal subtype and estrogen receptor negative samples have depleted expression among most candidate synthetic lethal partners. This is consistent with synthetic lethal interventions only being effective in lobular estrogen receptor positive breast cancers in which they are a more common, as recurrent (driver) mutation. However, the remaining samples are still informative for synthetic lethal analysis (by SLIPT) as it requires highly expressing *CDH1* samples for comparison.



The *CDH1* mutant samples (in Figure 4.1) were predominantly among the *CDH1* lowly expressing samples and distributed throughout *CDH1* samples with clustering analysis. Thus the molecular profiles of *CDH1* low samples are indistinguishable from *CDH1* mutant samples with the exception of normal samples (that do not have somatic mutation data as it is inferred from comparison to them to tumour-specific genotypes). Conversely, many of the *CDH1* mutant samples (in Figure D.1) had among the lowest *CDH1* expression and some of the synthetic lethal partners were also highly expressed in lowly expressing *CDH1* wildtype samples, despite these not being considered as “inactivated” by mtSLIPT analysis.

Together these results support the use for low *CDH1* expression as a strategy for detecting *CDH1* inactivation. This has the benefit of increasing sample size (including samples such as normal tissue which do not have somatic mutation data available) and increasing the expected number of mutually inactive (low-low) samples for the directional criteria of (mt)SLIPT which enabling it to better distinguish significant deviations below this (as discussed in Section 6.4). This also circumvents the assumption that all (detected) mutations are inactivating (although synonymous mutations were excluded from the analysis), which may not be the case for several highly expressing *CDH1* mutant samples that do not cluster together in Figures 4.1 or D.1. One of these exhibits among the lowest expression for many predicted synthetic lethal partners and would not be vulnerable to inactivation of these genes. As such correctly genotyping inactivating mutations will be essential in clinical practice for synthetic lethal targeting tumour suppressor genes, particularly for other genes such as *TP53* where oncogenic and tumour suppressor mutations (with different molecular consequences) are both common in cancers. Using expression as a measure of gene expression also avoids the assumptions that mutations are somatic rather than germline and that gene inactivation is by detectable mutations rather than other mechanisms such as epigenetic changes which is supported by many lowly expressing *CDH1* wildtype samples clustering with similar profiles to mutant samples.

4.1.2.1 Subgroup pathway analysis

Synthetic lethal gene candidates for *CDH1* from SLIPT performed on RNA-Seq expression data were also used for pathway over-representation analyses (as described in Section 2.3.2). The correlation structure in the expression of candidates synthetic lethal genes in *CDH1* low tumours (lowest 1/3rd quantile of expression) was examined for distinct biological pathways in subgroups of genes elevated in different clusters of samples. These genes were highly expressed in different samples with their clinical fac-

Table 4.3: Pathway composition for clusters of *CDH1* partners from SLIPT

Pathways Over-represented in Cluster 1	Pathway Size	Cluster Genes	p-value (FDR)
Collagen formation	67	10	4.0×10^{-11}
Extracellular matrix organisation	238	21	1.8×10^{-9}
Collagen biosynthesis and modifying enzymes	56	8	1.8×10^{-9}
Uptake and actions of bacterial toxins	22	5	9.5×10^{-9}
Elastic fibre formation	37	6	1.9×10^{-8}
Muscle contraction	62	7	2.4×10^{-7}
Fatty acid, triacylglycerol, and ketone body metabolism	117	10	4.9×10^{-7}
XBP1(S) activates chaperone genes	51	6	6.6×10^{-7}
IRE1alpha activates chaperones	54	6	1.2×10^{-6}
Neurotoxicity of clostridium toxins	10	3	1.3×10^{-6}
Retrograde neurotrophin signalling	10	3	1.3×10^{-6}
Assembly of collagen fibrils and other multimeric structures	40	5	1.9×10^{-6}
Collagen degradation	58	6	2.0×10^{-6}
Arachidonic acid metabolism	41	5	2.1×10^{-6}
Synthesis of PA	26	4	3.0×10^{-6}
Signaling by NOTCH	80	7	3.3×10^{-6}
Signalling to RAS	27	4	3.7×10^{-6}
Integrin cell surface interactions	82	7	4.2×10^{-6}
Smooth Muscle Contraction	28	4	4.4×10^{-6}
ECM proteoglycans	66	6	6.3×10^{-6}
Pathways Over-represented in Cluster 2	Pathway Size	Cluster Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	75	1.1×10^{-181}
Viral mRNA Translation	81	72	9.8×10^{-179}
Peptide chain elongation	83	72	1.9×10^{-175}
Eukaryotic Translation Termination	83	72	1.9×10^{-175}
Formation of a pool of free 40S subunits	93	75	1.9×10^{-171}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	72	9.9×10^{-168}
L13a-mediated translational silencing of Ceruloplasmin expression	103	75	3.0×10^{-159}
3' -UTR-mediated translational regulation	103	75	3.0×10^{-159}
Nonsense-Mediated Decay	103	75	3.0×10^{-159}
Nonsense-Mediated Decay enhanced by the Exon Junction Complex	103	75	3.0×10^{-159}
SRP-dependent cotranslational protein targeting to membrane	104	75	3.2×10^{-158}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	75	3.2×10^{-158}
Eukaryotic Translation Initiation	111	75	4.5×10^{-151}
Cap-dependent Translation Initiation	111	75	4.5×10^{-151}
Influenza Infection	117	75	1.4×10^{-145}
Influenza Viral RNA Transcription and Replication	108	72	5.7×10^{-145}
Translation	141	81	8.0×10^{-143}
Influenza Life Cycle	112	72	2.3×10^{-141}
Infectious disease	347	103	2.2×10^{-95}
Formation of the ternary complex, and subsequently, the 43S complex	47	33	6.8×10^{-80}
Pathways Over-represented in Cluster 3	Pathway Size	Cluster Genes	p-value (FDR)
Adaptive Immune System	412	90	6.1×10^{-61}
Chemokine receptors bind chemokines	52	27	6.7×10^{-56}
Generation of second messenger molecules	29	21	6.5×10^{-55}
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	64	29	6.5×10^{-55}
TCR signalling	62	27	8.9×10^{-51}
Peptide ligand-binding receptors	161	40	1.5×10^{-45}
Translocation of ZAP-70 to Immunological synapse	16	14	3.1×10^{-43}
Costimulation by the CD28 family	51	22	4.0×10^{-43}
PD-1 signalling	21	15	4.0×10^{-41}
Class A/I (Rhodopsin-like receptors)	258	50	6.7×10^{-41}
Phosphorylation of CD3 and TCR zeta chains	18	14	1.3×10^{-40}
Interferon gamma signalling	74	24	5.0×10^{-39}
GPCR ligand binding	326	57	1.8×10^{-38}
Cytokine Signaling in Immune system	268	48	8.9×10^{-37}
Downstream TCR signalling	45	18	1.8×10^{-35}
G _{αi} signalling events	167	33	2.2×10^{-33}
Cell surface interactions at the vascular wall	99	21	1.3×10^{-26}
Interferon Signalling	164	28	1.7×10^{-26}
Extracellular matrix organisation	238	35	2.7×10^{-25}
Antigen activates B Cell Receptor leading to generation of second messengers	32	12	7.2×10^{-25}
Pathways Over-represented in Cluster 4	Pathway Size	Cluster Genes	p-value (FDR)
Extracellular matrix organisation	238	48	8.0×10^{-41}
Class A/I (Rhodopsin-like receptors)	258	47	2.8×10^{-36}
GPCR ligand binding	326	54	2.1×10^{-34}
G _{αi} signalling events	83	22	1.4×10^{-31}
GPCR downstream signalling	472	68	1.1×10^{-29}
Haemostasis	423	61	3.3×10^{-29}
Platelet activation, signalling and aggregation	180	31	7.1×10^{-28}
Binding and Uptake of Ligands by Scavenger Receptors	40	14	9.9×10^{-27}
RA biosynthesis pathway	22	11	2.5×10^{-26}
Response to elevated platelet cytosolic Ca ²⁺	82	19	3.0×10^{-26}
Developmental Biology	420	57	3.5×10^{-26}
G _{αi} signalling events	167	28	7.3×10^{-26}
Platelet degranulation	77	18	1.6×10^{-25}
Gastrin-CREB signalling pathway via PKC and MAPK	171	28	2.5×10^{-25}
Muscle contraction	62	16	4.7×10^{-25}
G _{αq} signalling events	150	25	3.2×10^{-24}
Retinoid metabolism and transport	34	12	5.0×10^{-24}
Phase 1 - Functionalisation of compounds	67	16	6.5×10^{-24}
Signalling by Retinoic Acid	42	13	6.7×10^{-24}
Degradation of the extracellular matrix	102	19	1.4×10^{-22}

tors including estrogen receptor status and intrinsic (PAM50) subtype (Parker *et al.*, 2009) shown in Figure 4.1.

As shown by the most over-represented pathways in Table 4.3, each correlated cluster of candidate synthetic lethal partners of *CDH1* contains functionally different genes. Cluster 1 contains genes with less evidence of over-represented pathways than other clusters, corresponding to less correlation between genes within the cluster, and to it being a relatively small group. While there is some indication that collagen biosynthesis, microfibril elastic fibres, extracellular matrix, and metabolic pathways may be over-represented in Cluster 1, these results are mainly based on small pathways containing few synthetic lethal genes. Genes in Cluster 2 exhibited low expression in normal tissue samples compared to tumour samples (see Figure 4.1) and show compelling evidence of over-representation of post-transcriptional gene regulation and protein translation processes. Similarly, Cluster 3 has over-representation of immune signalling pathways (including chemokines, secondary messenger, and TCR signaling) and downstream intracellular signalling cascades such as G protein coupled receptor (GPCR) and G_{αi} signalling events. While pathway over-representation was weaker among genes in Cluster 4, they contained intracellular signalling pathways and were highly expressed in normal samples (in contrast to Cluster 2). Cluster 4 also involved extracellular factors and stimuli such as extracellular matrix, platelet activation, ligand receptors, and retinoic acid signalling.

Based on these results, potential synthetic lethal partners of *CDH1* include processes known to be dysregulated in cancer, such as translational, cytoskeletal, and immune processes. Intracellular signalling cascades such as the GPCRs and extracellular stimuli for these pathways were also implicated in potential synthetic lethality with *CDH1*.

Similar translational, cytoskeletal, and immune processes were identified among SLIPT partners with respect to *CDH1* mutation, shown in Table D.3. While GPCR signalling was replicated in mtSLIPT analysis, there was also stronger over-representation for NOTCH, ERBB2, and PI3K/AKT signalling in mutation analysis consistent with these signals being important for proliferation of *CDH1* deficient tumours. The GPCR and PI3K/AKT pathways are of particular interest as pathways with oncogenic mutations that can be targeted and downstream effects on translation (a strongly supported process across analyses). Extracellular matrix pathways (such as elastic fibre formation) were also supported across analyses (in Tables 4.3 and D.3) consistent with the

established cell-cell signalling role of *CDH1* and the importance of the tumour microenvironment for cancer proliferation.

4.2 Comparison of synthetic lethal gene candidates

4.2.1 Comparison with siRNA screen candidates

Gene candidates were compared between computational (SLIPT in TCGA breast cancer data) and experimental (the primary siRNA screen performed by Telford *et al.* (2015)) approaches in Figure 4.2. The number of genes detected by both methods did not produce a significant overlap but these may be difficult to compare due to vast differences between the detection methods. There were similar issues comparison of mtSLIPT genes tested against *CDH1* mutations (in Figure G.2), despite excluded genes not tested by both methods in either test. However, these intersecting genes may still be functionally informative or amenable to drug triage as they were replicated across both methods and pathway over-representation differed between the sections of the Venn diagram (see Figure 4.2).




Figure 4.2: **Comparison of SLIPT to siRNA.** Testing the overlap of gene candidates for E-cadherin synthetic lethal partners between computational (SLIPT) and experimental screening (siRNA) approaches. The χ^2 test suggests that the overlap is no more than would be expected by chance ($p = 0.281$).

4.2.1.1 Comparison with correlation




Figure 4.3: Compare SLIPT and siRNA genes with correlation. The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared against Pearson's correlation of gene expression with *CDH1*. Genes detected by SLIPT or siRNA are coloured according to the legend.




Figure 4.4: Compare SLIPT and siRNA genes with correlation. Genes detected as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression analysis and experimental screening (with siRNA) were compared against Pearson's correlation of gene expression with *CDH1*. There were no differences in correlation between gene groups detected by either approach.

Another potential means to triage drug target candidates is correlation of expression profiles with *CDH1*. Correlation with *CDH1* was compared to SLIPT and siRNA results in Figure 4.3. The genes not detected by SLIPT (including siRNA candidates) included genes with high (insignificant) SLIPT p-values. As expected, these genes were distributed around a correlation of zero and genes with higher correlation with *CDH1* (either direction) had more significant SLIPT p-values, although there were exceptions to this trend and larger positive correlations were negative correlations.

The majority of SLIPT candidates appeared to have negative correlations and moreso for those genes detected by both approaches, although these were typically weak correlations and are unlikely to be sufficient to detect such genes on their own. This is supported by simulation results in Section 6.4.

There were not strong positive correlations with *CDH1* among siRNA candidates, consistent with previous findings that co-expression is not predictive of synthetic lethality (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015). Negative correlation may not be indicative of synthetic lethality either as many siRNA candidates also had positive correlations. The SLIPT methodology has shown to detect genes with both positive and negative correlations, although it does appear to preferentially detect negatively correlated genes to some extent. These findings were replicated with the mtSLIPT approach against *CDH1* mutation (in Figure D.3), although the range of the χ^2 p-values differ due to lower sample size for mutation analysis.

However, the apparent tendency for genes detected by SLIPT or siRNA to have negative correlations with *CDH1* expression may be due to the smaller number of genes in these groups. The distribution of *CDH1* correlations does not differ across these gene groups (as shown by Figures 4.4 and D.4). Therefore further triage of gene candidates by correlation is not suitable, nor is use of correlation itself to predict synthetic lethal partners in the first place.

4.2.1.2 Comparison with viability

A similar comparison of SLIPT results was made with the viability ratio (of *CDH1* mutant to wildtype) in the primary siRNA screen performed by Telford *et al.* (2015). The significance and viability thresholds used for SLIPT and siRNA detection of synthetic lethal candidate partners of *CDH1* are clear in Figure 4.5. However note that not all of the genes below these thresholds are necessarily selected to be candidate partners as additional criteria were used in each case: directional criteria as for SLIPT (see Section 3.1) and minimum wildtype viability for siRNA (Telford *et al.*, 2015).




Figure 4.5: Compare SLIPT and siRNA genes with siRNA viability. The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. Genes detected by SLIPT or siRNA are coloured according to the legend.




Figure 4.6: Compare SLIPT and siRNA genes with viability. The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared (on a log-scale) against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. Genes detected by SLIPT or siRNA are coloured according to the legend with a grey line for $p = 0.05$.

There does not appear to be a clear relationship between SLIPT and siRNA candidates. Many genes not detected by both approaches were numerous in Figures 4.2 and D.2. These genes detected by either are not necessarily near the thresholds for the other. In this respect the SLIPT approach with patient data and cell line experiments are independent means to identify synthetic lethal candidates. While genes detected by both approaches were not necessarily more strongly supported by either, the genes with a viability closer to 1 (no synthetic lethal effect) in siRNA included those with more significant SLIPT p-values whereas more extreme viability ratios tended to be less significant (as shown by a logarithmic plot in Figure 4.6). Although it should be noted that genes with more moderate viability ratios were more common and SLIPT was capable (despite adjusting for multiple testing) of detecting significant genes with extreme viability ratios, particularly those considerably lower than 1.

However, there was not support for SLIPT candidates or those detected by both approaches having considerably different viability ratios (as shown in Figures 4.7 and D.5). The difference between the gene groups stems largely from the viability thresholds used by Telford *et al.* (2015) to detect synthetic lethal candidates in the primary screen, rather than more extreme viability ratios for genes identified by SLIPT.




Figure 4.7: Compare SLIPT and siRNA genes with siRNA viability. Genes detected as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression analysis and experimental screening (with siRNA) were compared against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. There were clear no differences in viability between genes detected by SLIPT and those not with the differences being primarily due to viability thresholds being used to detect synthetic lethality by Telford *et al.* (2015).

4.2.1.3 Comparison with secondary screen siRNA screen candidates

However, it should be noted that genes with a lower viability ratio were not necessarily the strongest supported by experimental screening. The primary screen (with 4 pooled siRNAs) has been used for the majority of comparisons in this thesis because the genome-wide panel of target genes screened enables a large number of genes to be compared with SLIPT results from gene expression and somatic mutation analysis. A secondary screen was also performed by Telford *et al.* (2015) on the isogenic MCF10A breast cell lines to individually validate the siRNAs separately, with the strongest candidates being those exhibiting synthetic lethal viability ratios replicated across independently targeting siRNAs. This was performed for the top 500 candidates (with the lowest viability ratio) from the primary screen and the 482 of these genes also tested by SLIPT in breast cancer (and the 486 genes tested by SLIPT in stomach cancer).

The secondary screen results are given in Appendix C which show that SLIPT candidate genes are more significantly ($p = 7.49 \times 10^{-3}$ by Fisher's exact test) more likely to be validated in the secondary screen and are thus informative of more robust partner genes, in addition to providing support that these interactions are consistent with expression profiles from heterogeneous patient samples across genetic backgrounds. While the individual genes detected by either approach do not necessarily match (and are potentially false-positives), the biological functions important in *CDH1* deficient cancers and potential mechanisms for specific targeting of them can be further supported by pathway analysis of the gene detected by either method. The genes detected by both approaches may therefore be more informative at the pathway level, where it is unlikely for a pathway to be consistently detected by chance. As the SLIPT candidates differ from the siRNA candidates (and are more likely to be validated), they can provide additional mechanisms by which *CDH1* deficient cancers proliferate and vulnerabilities that may be exploited against them by using the synthetic lethal pathways.

4.2.1.4 Comparison of screen at pathway level

These pathway over-representation analyses (performed as described in Section 2.3.2) correspond to genes separated into SLIPT or siRNA screen candidates unique to either method or detected by both (Table 4.4). The SLIPT-specific gene candidates were involved most strongly with translational and immune regulatory pathways, although extracellular matrix pathways were also supported. These pathways were largely consistent with those identified in Table 4.2 and in the clustering analysis (Table 4.3). The

Table 4.4: Pathway composition for *CDH1* partners from SLIPT and siRNA screening

Predicted only by SLIPT (4025 genes)	Pathway Size	Genes Identified	p-value (FDR)
Eukaryotic Translation Elongation	80	75	1.5×10^{-182}
Peptide chain elongation	77	72	2.9×10^{-176}
Viral mRNA Translation	75	70	4.9×10^{-172}
Eukaryotic Translation Termination	76	70	5.9×10^{-170}
Formation of a pool of free 40S subunits	87	74	9.5×10^{-166}
Nonsense Mediated Decay independent of the Exon Junction Complex	81	70	1.2×10^{-160}
L13a-mediated translational silencing of Ceruloplasmin expression	97	75	3.8×10^{-155}
3' -UTR-mediated translational regulation	97	75	3.8×10^{-155}
GTP hydrolysis and joining of the 60S ribosomal subunit	98	75	6.0×10^{-154}
Nonsense-Mediated Decay	96	73	5.2×10^{-150}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	96	73	5.2×10^{-150}
SRP-dependent cotranslational protein targeting to membrane	97	73	7.8×10^{-149}
Eukaryotic Translation Initiation	105	75	4.7×10^{-146}
Cap-dependent Translation Initiation	105	75	4.7×10^{-146}
Translation	133	83	4.0×10^{-142}
Influenza Viral RNA Transcription and Replication	102	71	2.9×10^{-137}
Influenza Infection	111	74	3.7×10^{-137}
Influenza Life Cycle	106	71	2.3×10^{-133}
Infectious disease	326	125	4.2×10^{-120}
Extracellular matrix organisation	189	77	5.4×10^{-95}

Detected only by siRNA screen (1599 genes)	Pathway Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)	282	44	1.3×10^{-27}
GPCR ligand binding	363	52	5.8×10^{-26}
G _{αq} signalling events	159	26	6.7×10^{-23}
Gastrin-CREB signalling pathway via PKC and MAPK	180	27	2.0×10^{-21}
G _{αi} signalling events	184	27	5.3×10^{-21}
Downstream signal transduction	146	23	7.6×10^{-21}
Signalling by PDGF	172	25	4.0×10^{-20}
Peptide ligand-binding receptors	175	25	8.5×10^{-20}
Signalling by ERBB2	146	22	1.3×10^{-19}
DAP12 interactions	159	23	2.6×10^{-19}
DAP12 signalling	149	22	2.7×10^{-19}
Organelle biogenesis and maintenance	264	33	5.5×10^{-19}
Signalling by NGF	266	33	8.2×10^{-19}
Downstream signalling of activated FGFR1	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR2	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR3	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR4	134	20	1.1×10^{-18}
Signalling by FGFR	146	21	1.3×10^{-18}
Signalling by FGFR1	146	21	1.3×10^{-18}
Signalling by FGFR2	146	21	1.3×10^{-18}

Intersection of SLIPT and siRNA screen (604 genes)	Pathway Size	Genes Identified	p-value (FDR)
Visual phototransduction	54	9	6.9×10^{-10}
G _{αs} signalling events	48	7	1.6×10^{-7}
Retinoid metabolism and transport	24	5	1.7×10^{-7}
Acyl chain remodelling of PS	10	3	6.5×10^{-6}
Transcriptional regulation of white adipocyte differentiation	51	6	6.5×10^{-6}
Chemokine receptors bind chemokines	22	4	6.5×10^{-6}
Signalling by NOTCH4	11	3	6.9×10^{-6}
Defective EXT2 causes exostoses 2	11	3	6.9×10^{-6}
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	11	3	6.9×10^{-6}
Platelet activation, signalling and aggregation	146	12	6.9×10^{-6}
Phase 1 - Functionalisation of compounds	41	5	1.3×10^{-5}
Amine ligand-binding receptors	13	3	1.7×10^{-5}
Acyl chain remodelling of PE	14	3	2.4×10^{-5}
Signalling by GPCR	300	23	2.4×10^{-5}
Molecules associated with elastic fibres	29	4	2.6×10^{-5}
DAP12 interactions	128	10	2.6×10^{-5}
Cytochrome P ₄₅₀ - arranged by substrate type	30	4	3.2×10^{-5}
GPCR ligand binding	147	11	3.8×10^{-5}
Acyl chain remodelling of PC	16	3	4.0×10^{-5}
Response to elevated platelet cytosolic Ca ²⁺	66	6	4.2×10^{-5}

genes detected only by the siRNA screen had over-representation of cell signalling pathways, including many containing genes known to be involved in cancer (e.g., MAPK, PDGF, ERBB2, and FGFR), with the detection of Class A GPCRs supporting the independent analyses by Telford *et al.* Telford *et al.* (2015). The intersection of computational and experimental synthetic lethal partners of *CDH1* has stronger evidence for over-representation of GPCR pathways and more specific subclasses, such as visual phototransduction ($p = 6.9 \times 10^{-10}$) and $G_{\alpha s}$ signalling events ($p = 1.7 \times 10^{-7}$), than other signalling pathways.

The pathway analysis for mtSLIPT against *CDH1* mutations (in Table D.4) had concordant results for both mtSLIPT-specific and siRNA-specific pathways. While the specific pathway composition of the intersection of these analyses differed from SLIPT against low *CDH1* expression, signalling pathways including GPCRs, NOTCH, EERB2, PDGF, and SCF-KIT. These findings indicate the signalling pathways are among the most suitable vulnerability to exploit in targeting *CDH1* deficient tumours as they can be detected in both a patient cohort (with TCGA expression data) and tested in a laboratory system. However, it is possible that the isolated experimental system is set up to preferentially detect kinase singalling pathways (which are amenable to pharmacological inhibition and translation to the clinic) and the other pathways identified by SLIPT may still be informative of the role of *CDH1* loss of function in cancers or mechanisms by which further gene loss leads to specific inviability.

4.2.1.4.1 Resampling of genes for pathway enrichment

Comparing genes between experimental screen candidates and prediction from TCGA expression data has been less consistent than pathways. Although this is not unexpected since synthetic lethal pathways more robustly conserved (Dixon *et al.*, 2008) and the computational approach using patient samples from complex tumour microenvironment has considerably different strengths to an experimental screen (Telford *et al.*, 2015) based on genetically homogenous cell line models in an isolated laboratory environment. For instance, it is unlikely for immune signaling to be detected in an isolated cell culture system.

The overlap between synthetic lethal from bioinformatics SLIPT predictions and siRNA screening has raised other questions including whether the pathways over-represented would be expected by chance. This of particular concern since the siRNA candidate genes themselves are highly over-represented for particular pathways (such as GPCRs) so selecting any intersect with them would be enriched for these pathways.




Figure 4.8: Resampled intersection of SLIPT and siRNA candidates. Resampling analysis of intersect size from genes detected by SLIPT and siRNA screening approaches over 1 million replicates. The proportion of expected intersection sizes for random samples below or above the observed intersection size respectively, lacking significant over-representation or depletion of siRNA screen candidates within the SLIPT predictions for *CDH1*.

Another pathway approach is to test whether pathways are over-represented in randomly sampled genes, comparing many “resamplings” or “permutations” of these genes to the enrichment statistics observed for these pathways in the SLIPT candidates and their intersection with the siRNA hits shows whether we detect these pathways more than we expect by chance (as described in Section 2.3.6).

Of particular concern are the over-represented pathways in genes detected by both methods. Pathway over-representation alone does not detect whether SLIPT predicted genes or siRNA candidates are enriched within each other. This resampling analysis therefore detects whether over-represented pathways were detected by SLIPT independently of their over-representation among siRNA candidates (without assuming an underlying test statistic distribution).

A resampling approach is also applicable to testing whether the number of genes detected by each approach significantly intersected. As shown in Figure 4.8, resampling did not find evidence of significant depletion or over-representation for experimental synthetic lethal candidates in the computationally predicted synthetic lethal partners of *CDH1* and the overlap may be observed by chance. This is consistent with previous

findings (see Figure 4.2) and does not preclude pathway relationships being supported by resampling.

A permutation analysis was performed to resample the genes tested by both approaches to investigate whether the observed pathway over-representation could have occurred in a randomly selected sample of genes from the experimental candidates, that is, whether the pathway predictions from SLIPT could be expected by chance (as described in sections 2.2.3.1 and 2.3.6). While the number of siRNA candidate genes detected by SLIPT was not statistically significant ($p = 0.281$), this may be due to the vastly different limitations of the approaches and the correlation structure of gene expression not being independent (as assumed for multiple testing procedures). The intersection may still be functionally relevant to *CDH1*-deficient cancers, such as the pathway data in Table 4.4. The resampling analysis for pathways was compared to the pathway over-representation for SLIPT predicted synthetic lethal partners in Table 4.5. Similarly, the pathway resampling for intersection between SLIPT predictions and experimental screen candidates was compared to pathway over-representation in Table 4.6 for intersection with siRNA data.

The pathway resampling approach for SLIPT-specific gene candidates (Table 4.5) replicates the gene set over-representation analysis for all SLIPT genes, detecting evidence of synthetic lethal pathways for *CDH1* in translational, immune, and cell signalling pathways including G_{αi} signalling, GPCR downstream signalling, and chemokine receptor binding. While the immune and signal transduction pathways were not significantly over-represented in the resampling analysis, the results for the two approaches were largely consistent for translation and post-transcriptional gene regulation, supporting gene set over-representation of the SLIPT-specific pathways in Table 4.5. In particular, some of the most significantly over-represented pathways had higher observed χ^2 values than any of the 1 million random permutations. Similar pathways were also replicated by permutation analysis for mtSLIPT candidate partners against *CDH1* mutation (shown in Table D.5). This shows that many of the pathways detected specifically by SLIPT are replicated by permutation procedures and that the permutation approach is capable of detecting many of the most strongly over-represented pathways.

The permutation approach was then also applied to the intersection between computational and experimental candidates. Where the permutation analysis is testing for consistent detection of pathways independent of their pre-existing status as exper-

Table 4.5: Pathways for *CDH1* partners from SLIPT

Reactome Pathway	Over-representation	Permutation
Eukaryotic Translation Elongation	1.3×10^{-207}	$< 1.241 \times 10^{-5}$
Peptide chain elongation	5.6×10^{-201}	$< 1.241 \times 10^{-5}$
Viral mRNA Translation	1.2×10^{-196}	$< 1.241 \times 10^{-5}$
Eukaryotic Translation Termination	1.2×10^{-196}	$< 1.241 \times 10^{-5}$
Formation of a pool of free 40S subunits	3.7×10^{-194}	$< 1.241 \times 10^{-5}$
Nonsense Mediated Decay independent of the Exon Junction Complex	5.3×10^{-187}	$< 1.241 \times 10^{-5}$
L13a-mediated translational silencing of Ceruloplasmin expression	9.6×10^{-183}	$< 1.241 \times 10^{-5}$
3' -UTR-mediated translational regulation	9.6×10^{-183}	$< 1.241 \times 10^{-5}$
GTP hydrolysis and joining of the 60S ribosomal subunit	1.9×10^{-181}	$< 1.241 \times 10^{-5}$
Nonsense-Mediated Decay	6.2×10^{-176}	$< 1.241 \times 10^{-5}$
Nonsense Mediated Decay enhanced by the Exon Junction Complex	6.2×10^{-176}	$< 1.241 \times 10^{-5}$
Adaptive Immune System	6.5×10^{-174}	0.15753
Eukaryotic Translation Initiation	5.7×10^{-173}	$< 1.241 \times 10^{-5}$
Cap-dependent Translation Initiation	5.7×10^{-173}	$< 1.241 \times 10^{-5}$
SRP-dependent cotranslational protein targeting to membrane	2.0×10^{-171}	$< 1.241 \times 10^{-5}$
Translation	6.1×10^{-170}	$< 1.241 \times 10^{-5}$
Infectious disease	1.6×10^{-166}	0.23231
Influenza Infection	1.9×10^{-163}	$< 1.241 \times 10^{-5}$
Influenza Viral RNA Transcription and Replication	1.9×10^{-160}	$< 1.241 \times 10^{-5}$
Influenza Life Cycle	2.5×10^{-156}	$< 1.241 \times 10^{-5}$
<i>Extracellular matrix organisation</i>	1.1×10^{-152}	0.071761
GPCR ligand binding	1.1×10^{-143}	0.55801
Class A/1 (Rhodopsin-like receptors)	1.5×10^{-142}	0.58901
<i>GPCR downstream signalling</i>	7.6×10^{-140}	0.098357
Haemostasis	1.9×10^{-134}	0.27059
Developmental Biology	2.0×10^{-123}	0.52737
Metabolism of lipids and lipoproteins	3.3×10^{-120}	0.724
Cytokine Signalling in Immune system	2.6×10^{-119}	0.39661
Peptide ligand-binding receptors	3.7×10^{-109}	0.61102
G_{αs} signalling events	8.9×10^{-100}	$< 1.241 \times 10^{-5}$

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italicics (FDR < 0.1).

imental candidates. The pathway results for these candidate partners (in Table 4.6) differed between over-representation and resampling analyses.

Namely, many of the over-represented pathways were not significant in the resampling analysis, including visual phototransduction and retinoic acid signalling, although pathways involving defective *EXT1* or *EXT2* genes approach significance after FDR adjustment for multiple tests. Of the highest over-represented pathways in the intersection, only G_{αs} signalling events were supported by both over-representation and resampling analyses. Other pathways supported by both analyses were cytoplasmic elastic fibre formation, associated HS-GAG protein modification pathways, energy metabolism, and the fibrin clotting cascade.

Many of the pathways supported in the intersection by permutation analysis were also replicated in the mtSLIPT analysis of partners tested with *CDH1* mutation (in Table D.6), including G_{αs}, elastic fibres, HS-GAG, and energy metabolism. While there were differences between the pathways Identified by over-representation analysis,

Table 4.6: Pathways for *CDH1* partners from SLIPT and siRNA primary screen

Reactome Pathway	Over-representation	Permutation
Visual phototransduction	6.9×10^{-10}	0.91116
G_{as} signalling events	1.6×10^{-7}	0.012988
Retinoid metabolism and transport	1.7×10^{-7}	0.20487
Transcriptional regulation of white adipocyte differentiation	6.5×10^{-6}	0.38197
Acylic chain remodelling of PS	6.5×10^{-6}	0.58485
Chemokine receptors bind chemokines	6.5×10^{-6}	0.97255
<i>Defective EXT2 causes exostoses 2</i>	6.9×10^{-6}	0.056437
<i>Defective EXT1 causes exostoses 1, TRPS2 and CHDS</i>	6.9×10^{-6}	0.056437
Signalling by NOTCH4	6.9×10^{-6}	0.15497
Platelet activation, signalling and aggregation	6.9×10^{-6}	0.53358
Phase 1 - Functionalisation of compounds	1.3×10^{-5}	0.24836
Amine ligand-binding receptors	1.7×10^{-5}	0.3195
Acylic chain remodelling of PE	2.4×10^{-5}	0.7307
Signalling by GPCR	2.4×10^{-5}	0.9939
Molecules associated with elastic fibres	2.6×10^{-5}	0.0072929
DAP12 interactions	2.6×10^{-5}	0.78273
Cytochrome P ₄₅₀ - arranged by substrate type	3.2×10^{-5}	0.87019
GPCR ligand binding	3.8×10^{-5}	0.99417
Acylic chain remodelling of PC	4.0×10^{-5}	0.65415
Response to elevated platelet cytosolic Ca ²⁺	4.2×10^{-5}	0.55461
<i>Arachidonic acid metabolism</i>	4.4×10^{-5}	0.060298
Defective B4GALT7 causes EDS, progeroid type	4.9×10^{-5}	0.15497
Defective B3GAT3 causes JDSSDHD	4.9×10^{-5}	0.15497
Elastic fibre formation	4.9×10^{-5}	0.0019227
HS-GAG degradation	6.2×10^{-5}	0.017747
Bile acid and bile salt metabolism	6.2×10^{-5}	0.15497
Netrin-1 signalling	7.1×10^{-5}	0.95056
Integration of energy metabolism	7.1×10^{-5}	0.0019287
DAP12 signalling	7.9×10^{-5}	0.67835
GPCR downstream signalling	8.1×10^{-5}	0.88678
Diseases associated with glycosaminoglycan metabolism	8.7×10^{-5}	0.017747
Diseases of glycosylation	8.7×10^{-5}	0.017747
Signalling by Retinoic Acid	8.7×10^{-5}	0.13592
Signalling by Leptin	8.7×10^{-5}	0.15497
Signalling by SCF-KIT	8.7×10^{-5}	0.73399
Opioid Signalling	8.7×10^{-5}	0.99417
Signalling by NOTCH	0.0001	0.26453
Platelet homeostasis	0.0001	0.55912
Signalling by NOTCH1	0.00011	0.13797
Class B/2 (Secretin family receptors)	0.00011	0.4659
Diseases of Immune System	0.00013	0.15497
Diseases associated with the TLR signalling cascade	0.00013	0.15497
A tetrasaccharide linker sequence is required for GAG synthesis	0.00013	0.33566
Nuclear Receptor transcription pathway	0.00016	0.22735
Formation of Fibrin Clot (Clotting Cascade)	0.00016	0.0054639
Syndecan interactions	0.00016	0.3974
Class A/1 (Rhodopsin-like receptors)	0.00016	0.99454
HS-GAG biosynthesis	0.0002	0.37199
Platelet degranulation	0.0002	0.39003
EPH-ephrin mediated repulsion of cells	0.00021	0.6193

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

those replicated by permutation were highly concordant supported the combined use of these pathways approaches to identify synthetic lethal gene functions and targets.

While this indicates that $G_{\alpha s}$ and GPCR class A/1 signalling events were significantly detected by both approaches, GPCR signalling pathways overall were not. It is likely that GPCRs were primarily over-represented in the intersection with the experimental candidates due to strong over-representation of these pathways in experimental candidates, rather than detection by SLIPT, which may be driven by these more specific constituent pathways.

However, several pathways, including some immune functions and neurotransmitters, were supported by the resampling analysis (in Tables 4.6 and D.6) when the initial pathway over-representation test was not significant. These functions appear to have been detected by both approaches more than expected by chance but must be interpreted with caution since they were still not common enough to be detected in pathway over-representation analysis.

Therefore computational and experimental approaches to synthetic lethal screening for *CDH1* lead to a broader functional characterisation and many candidate partners, when combined, despite different strengths and limitations. Compared to candidate gene approaches, experimental genome-wide screens are an appealing unbiased strategy for identifying synthetic lethal interactions. Since these screens are costly, laborious, and subject to genetic background, computational analysis can augment candidate triage to either reduce the initial panel of screened genes or prioritise validation.

GPCR pathways were detected among both computational and experimental synthetic lethal candidates, with more support in the experimental screen (Table 4.6). The homogeneous cell line model may be more likely to detect particular pathways. For instance, SLIPT identified immune pathways, not expected to be detected in isolated cell culture. GPCR signalling was supported in experimental models Telford *et al.* (2015) with some of these pathways replicated in varied genetic backgrounds of patient samples. These pathways require further investigation such as identification of more specific pathways, higher order interactions, and modes of resistance.

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-representation (Table 4.4) and supported by resampling analysis (Table 4.6), despite a modest intersection of genes between them (Figure 4.2). Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represented due to small effect sizes, thus both tests are required

for a candidate pathway. The pathways detected by both over-representation and resampling are the strongest candidates for further investigation, such as $G_{\alpha s}$ signalling, a strong candidate in prior analyses with a role in the regulation of translation in cancer Gao and Roux (2015), another function supported by SLIPT analysis.


The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of *CDH1*. This diversity is consistent with the wide ranging role of *CDH1* in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. These distinct synthetic lethal gene clusters and pathways may further lead to the elucidation of drug resistance mechanisms.

4.3 Metagene Analysis

Metagenes serve as a consistent signal of pathway activity. The direction of metagenes is generally arbitrary but care has been taken to ensure that these occur in a direction which reflect overall activation of the pathway (as described in Section 2.2.3). This will be supported by examining the pathway expression of gene signatures in breast cancer to ensure they behave as expected in TCGA expression data. These metagenes were also compared to somatic mutation to show the limitations of mutation as a measure of gene activity. Having established that metagenes generated with this procedure reflect gene activity, these were then applied to the Reactome pathways for synthetic lethal analysis of pathways directly to provide an alternative approach to identifying synthetic lethal pathways with *CDH1*.

4.3.1 Pathway expression

Pathway metagenes (generated as described in Section 2.2.3) for gene signatures of key processes in breast cancer (Gatza *et al.*, 2011) were used to check that metagenes were generated in the correct direction to indicate pathway activation. These gene signatures were plotting in Figure 4.9 for comparison with clinical factors and somatic mutations. The “intrinsic subtype” was computed by performing the PAM50 procedure Parker *et al.* (2009) for RNASeq data which was highly concordant with the subtypes provided by UCSC for TCGA samples previously analysed by microarrays (TCGA, 2012). Somatic mutations were reported for recurrently mutated genes in breast cancer, as reported by TCGA (TCGA, 2012), related genes, and those previously discussed to be important in hereditary breast cancers (*BRCA1*, *BRCA2*, and *CDH1*).



These gene signatures reflect intrinsic subtypes as expected. In particular, the estrogen and progesterone receptor signatures are low in the ER– and PR– basal subtype tumours. These tumours also had the highest frequency of *TP53* mutations and a corresponding reduction of p53 metagene activity, as expected for loss of a tumour suppressor. The luminal A and luminal B tumour subtypes are the most similar, which is reflected in these metagenes signatures, although they are distinguishable molecular subtypes as shown by elevated PI3K, AKT, RAS, asn -catenin signalling in luminal B tumours. Although, these pathways were also elevated in Basal and HER2-enriched subtypes and lowly expressed in the “normal-like” subtype (which contained the normal samples). These intrinsic subtype specific gene signature profiles were further supported with metagenes for an extended set of signatures (Gatza *et al.*, 2014), as shown in Figure E.1.

TP53 mutations were the most frequent and more common in basal subtype. Similarly, *GATA3* mutations were more common in luminal subtype tumours. PI3K mutations were more frequent across breast tumours, although these were less common in the basal subtype despite an elevated metagene (this discrepancy will be discussed further in Section 4.3.2). *CDH1* mutations similarly occurred across molecular subtypes with the exception of the basal subtype (as observed in gene expression with Figure 4.1). *CDH1* low samples occurred in all subtypes but were predominantly lobular subtype. Apart from these genes, mutations did not show clear specificity to a particular subtype and the variation between samples reflects the range of molecular cascades that can result in tumours with similar molecular profiles, supporting the use of expression for cancer diagnostics and identification of molecular targets.

The direction of the metagenes were also consistent with the clinical characteristics and formed a consensus of gene activity as shown in Figures E.2–E.5. In each of the examples for gene signatures for PI3K (Figure E.2), p53 (Figure E.3), estrogen receptor (Figure E.4), and BRCA (Figure E.5) genes (Gatza *et al.*, 2011, 2014), the expression of the majority of the genes were highly concordant with the metagene, being either positively or negatively correlated. These were generally consistent with established clinical and molecular subtypes of breast cancer and the recurrent mutations shown. However, the *PIK3CA* and *PIK3R1* mutant samples did not necessarily have elevated PI3K pathway metagene activity (as shown in Figure E.2).




Figure 4.10: **Somatic mutation against PI3K metagene.** Mutations in *PIK3CA*, *PIK3R1*, *CDH1*, and *TP53* were examined in TCGA breast cancer for their effect on the PI3K (Gatza *et al.*, 2011) pathway metagene. The tumour suppressors *CDH1* and *TP53* showed an increase and decrease in the metagene respectively, whereas *PIK3CA* and *PIK3R1* mutations had little effect on the metagene levels.

4.3.2 Somatic mutation

It should be noted that metagenes, while consistent with the consensus of constituent expressed genes, were not necessarily reflecting the somatic mutation status. The PI3K (Gatza *et al.*, 2011) metagene levels in particular, were not statistically sig-

nificant in between mutant and wildtype *PIK3CA* samples (shown in Figure 4.10). Although the PI3K metagene differed across *CDH1* and *TP53* mutations, remarkably in opposite directions considering that PI3K is an oncogenic growth pathway and these are both most frequently tumour suppressors inactivated in cancers. This shows that *CDH1* and *TP53* deficient tumours have distinct molecular growth pathways and that synthetic lethal inactivations against *CDH1* inactivation may not be applicable to other cancers with driver mutations such as *TP53*, although these were kept in the analysis for comparison. These differences may be related to these mutations being more frequent in tumours with difference clinical characteristics (as observed in Section 4.3.1). Thus mutations do not necessarily have corresponding changes in pathway expression, particularly for oncogenes which may change in function rather than being upregulated.

While the more specific *PIK3CA* (Gatza *et al.*, 2014) metagene showed significant differences with *PIK3CA* and *PIK3R1* mutations (as shown in Figure D.7), this metagene replicated stronger differences for *CDH1* and *TP53*. These differences were less pronounced in the protein levels of p110 α (enocded by *PIK3CA*) and the downstream AKT gene (shown in Figures D.8 and D.9 respectively). Although this may be due to this regulatory cascade (kinases) being transmitted as a change in protein state (phosphorylation) rather than changes in expression levels. Another consideration is that mutations at different loci have different effects on protein function, particularly for oncogenes.

4.3.3 Mutation locus

The gene locus distribution of *PIK3CA* and it's receptor *PIK3R1* were consistent with oncogenic and tumour suppressor mutations, as shown in Figure D.6. *PIK3CA* is an has recurrent mutations in 2 hotspots, centered around the E545K and H1047R (shown in Figure D.6(a)), as expected for an oncogene. This contrasts with the tumour suppressors, *PIK3R1*, and *CDH1* (shown in Figures D.6(b) and D.6(c) respectively), which have low frequency inactivating mutations spread across them. A notable exception is *TP53* (shown in Figure D.6(d)) which displays both inactivating mutations throughout and recurrent (oncogenic) mutations at high frequency, consistent with the complex role of *TP53* in cancer biology which is outside of the scope of this thesis and shown for comparison.

These differences in gene locus may explain why mutations do not necessarily have corresponding changes in gene or metagene expression. Specifically, the recurrent




Figure 4.11: Somatic mutation locus against expression. The recurrent E545K and H1047R oncogene mutations in *PIK3CA* were examined in TCGA breast cancer to show the effect of mutation locus on gene, pathway, and protein expression. While neither of these mutations had an impact of *PIK3CA* mRNA expression, E545K had specifically lower PI3K (Gatza *et al.*, 2011) metagene levels and both mutations had higher *PIK3R1* mRNA expression. However, these differences were not reflected in the protein expression levels.

E545K and H1047R oncogene mutations in *PIK3CA* did not affect *PIK3CA* mRNA expression but E545K had specifically lower PI3K (Gatza *et al.*, 2011) metagene levels. Both mutations had higher *PIK3R1* mRNA expression but these differences differences were not reflected in the protein expression levels of p110 α protein (encoded by *PIK3CA*), it's downstream target AKT, E-cadherin (encoded by *CDH1*), or p53 (as shown in Figure 4.11).

While the complex effects of mutation in oncogenes such as *PIK3CA* are not necessarily detected in a pathway metagene, these do capture the consensus of pathway gene expression and account for other potential means of pathway activation. Thus metagenes are sufficient as a measure of gene activity for the purposes of synthetic lethal detection with SLIPT. This approach is more applicable to tumour suppressor genes with a relationship between gene expression and activity (rather than activation at the protein level) but this is not a major concern since synthetic lethality is more clinically relevant for targeting tumour suppressor mutations than oncogenes.

4.3.4 Synthetic lethal metagenes

Pathway metagenes for Reactome pathways (generated as described in Section 2.2.3) were also used for testing synthetic lethal partner pathways with *CDH1* by SLIPT. Since the metagenes have are higher when the pathway as a whole is activated, they are amenable to SLIPT analysis using low metagene levels for inactivated pathways. These synthetic lethal metagenes differed to the over-represented pathways among synthetic lethal gene candidates. However, there were some similarities to previous findings, as shown in Tables 4.7. In particular, translational pathways were replicated as observed in Table 4.2. While the specific pathways differ, immune pathways (such as NF- κ B) were also supported by metagene synthetic lethal analysis.

Signalling pathways were more strongly supported by mtSLIPT analysis of metagene pathway expression against *CDH1* mutation, as shown in Table D.7. Although these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include G α z, insulin-related growth factor (IGF), GABA receptor, G α s, S6K1 and various toxin responses mediated by GPCRs. Metabolic processes including processing of carbohydrates and fatty acids were also implicated across these analyses.

The metagene analyses differ more between expression and *CDH1* mutation than previous analyses, with more specific signalling pathways identified in the mutation analysis. This supports the usage of a complete null mutant model in experimental

Table 4.7: Candidate synthetic lethal metagenes against *CDH1* from SLIPT

Pathway	ID	Observed	Expected	χ^2 value	p-value	p-value (FDR)
Glycogen storage diseases	3229121	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Myoclonic epilepsy of Lafora	3785653	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Diseases of carbohydrate metabolism	5663084	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Arachidonic acid metabolism	2142753	81	130	157	8.13×10^{-33}	1.49×10^{-30}
Translation initiation complex formation	72649	70	130	152	7.08×10^{-32}	1.17×10^{-29}
Synthesis of 5-eicosatetraenoic acids	2142688	68	130	151	1.25×10^{-31}	1.88×10^{-29}
SRP-dependent cotranslational protein targeting to membrane	1799339	69	130	150	2.01×10^{-31}	2.76×10^{-29}
L13a-mediated translational silencing of Ceruloplasmin expression	156827	72	130	148	5.91×10^{-31}	6.44×10^{-29}
3' -UTR-mediated translational regulation	157279	72	130	148	5.91×10^{-31}	6.44×10^{-29}
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	72662	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Formation of the ternary complex, and subsequently, the 43S complex	72695	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Ribosomal scanning and start codon recognition	72702	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Eukaryotic Translation Elongation	156842	72	130	146	1.19×10^{-30}	9.28×10^{-29}
Nonsense Mediated Decay independent of the Exon Junction Complex	975956	71	130	146	1.24×10^{-30}	9.28×10^{-29}
Viral mRNA Translation	192823	70	130	146	1.51×10^{-30}	1.04×10^{-28}
Eukaryotic Translation Termination	72764	70	130	146	1.51×10^{-30}	1.04×10^{-28}
NF- κ B is activated and signals survival	209560	71	130	145	1.90×10^{-30}	1.19×10^{-28}
Peptide chain elongation	156902	72	130	145	1.91×10^{-30}	1.19×10^{-28}
Influenza Life Cycle	168255	70	130	145	1.95×10^{-30}	1.19×10^{-28}
Formation of a pool of free 40S subunits	72689	73	130	145	2.01×10^{-30}	1.19×10^{-28}
Nonsense-Mediated Decay	927802	71	130	145	2.44×10^{-30}	1.34×10^{-28}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	975957	71	130	145	2.44×10^{-30}	1.34×10^{-28}
GTP hydrolysis and joining of the 60S ribosomal subunit	72706	72	130	145	2.58×10^{-30}	1.37×10^{-28}
Influenza Viral RNA Transcription and Replication	168273	72	130	144	4.01×10^{-30}	2.07×10^{-28}
Signaling by NOTCH1 HD Domain Mutants in Cancer	2691230	79	130	143	5.99×10^{-30}	2.82×10^{-28}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

testing for synthetic lethality of signalling pathways against *CDH1* inactivation rather than a knockdown in expression. However, low expression of partners has been used in either case to be applicable to dose-dependent pharmacological inhibition and across genes where mutations have different functional consequences, including variants of unknown significance.

These results show an independent pathway approach to detecting synthetic lethal gene functions interacting with *CDH1*. Synthetic lethal metagenes, replicates support for these pathways independent of pathway size (as genes are weighted equally). The synthetic lethal analysis against low *CDH1* expression support prior findings in translational and immune pathways even if they were not able to detected in an experimental screen (Telford *et al.*, 2015). Together these findings support the role of *CDH1* loss in cancer disrupting cell signalling with wider effects on protein translation and metabolism necessary for the proliferation of cancer cells. This is consistent with the GPCR pathways such as *Gαs* signalling being supported by SLIPT gene candidates and the experimental primary siRNA screen, as shown by resampling in Section 4.2.1.4.1.

4.4 Replication in stomach cancer

The synthetic lethal analysis of genes and pathways (previously described for TCGA breast cancer data) was replicated in TCGA stomach cancer. The accompanying data for SLIPT and mtSLIPT analyses against *CDH1* expression and mutation are in Appendices F and G respectively.

The experimental screen (Telford *et al.*, 2015) was conducted in MCF10A breast cells so it may not be as comparable to stomach cancer. Nevertheless, *CDH1* is also important in stomach cancer biology as a driver tumour suppressor gene and as a germline mutation in many cases of hereditary diffuse gastric cancer.

While the sample size was lower for TCGA stomach cancer (particularly for mutations), these results serve to support the findings in breast cancer in an independent patient cohort and tissue samples. The molecular profiling, including RNA-Seq expression, were performed by TCGA using the sample procedures as for breast cancer and the findings reported here were performed used data analysis techniques identical to those presented previously. These procedures should ensure as close comparison as feasible across cancer types for those relevant to HDGC and recurrent *CDH1* mutations.

4.4.1 Synthetic Lethal Genes and Pathways

The strongest SLIPT genes for stomach cancer (shown in Table F.1) did not necessarily directly correspond to those observed in breast cancer (shown in Table 4.1). However, several gene functions were replicated in stomach cancer. Cell membrane genes including *EMP3*, *GYPC*, *LGALS1*, *PRR24*, and *FUNCD2* were among the strongest SL candidates. Similarly, cell signalling genes including *PLEKHO1*, *RARRES2*, *VEGFB*, *HSPB2*, and *CREM* were detected in stomach cancers. It is notable that several of these genes (*EMP3*, *PLEKHO1*, and *FUNCD2*) have a known role in cancer. Together these genes support the roles of *CDH1* in cell membrane and signalling functions (of epithelial tissues) which are perturbed in both breast and stomach cancers.

The strongest mtSLIPT genes tested against *CDH1* mutatoin for stomach cancer (shown in Table G.1) supported similar gene functions. Membrane and cell-adhesion genes including *KFBP6*, *THY1*, *CLELC2B*, *NISCH*, *TSPAN1*, and *KCTD12* and signalling genes including *ZEB2*, *CCND2*, *NEURL1B*, *KFBP6*, and *OGN* were detected. Similarly, these include cancer genes such as *VIM*, *ZEB2*, *BCL2*, *THY1*, and *RUNX1T1*. The mtSLIPT procedure also replicated several of the strongest candidates in breast cancer (shown in Table D.1) such as *NRIP2* and *NISCH*.

Together, these gene candidates indicate widespread functions of *CDH1* and strongly detectable synthetic lethality with many genes from a strategy that can be applied across cancer types. More specifically, the signalling genes included GPCR signalling genes (such as *GNG11*, *GNAI1*, *DZIP1*, *PTGFR*, and *KCTD12*), a growth signalling pathway which was one of the most supported synthetic lethal pathways in breast cancer analysis, the experimental screen (Telford *et al.*, 2015), and has many actionable drug targets which have been applied to other diseases.

These findings were further supported by the pathways over-represented in SLIPT candidates from TCGA stomach cancer (shown in Table 4.8) which were replicated the translational and immune pathways observed in TCGA breast cancer (shown in Table 4.2). Further support for GPCR signalling pathways including the class A/1 receptors. The extracellular matrix was also detected at the pathway level in stomach cancer SLIPT candidates and replicated in mtSLIPT analysis for *CDH1* mutation (shown in Table G.2), including elastic fibres, glycosylation, collagen, and integrin cell-surface interactions. Thus there was strong evidence for the role of extracellular matrix pathways and the tumour microenvironment in *CDH1* deficient stomach cancers, in addition to cell signalling and translation pathways important in tumour growth across breast and stomach cancer.

Table 4.8: Pathways for *CDH1* partners from SLIPT in stomach cancer

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Extracellular matrix organization	241	104	7.5×10^{-140}
Hemostasis	445	138	1.8×10^{-121}
Developmental Biology	432	125	9.2×10^{-107}
Axon guidance	289	94	1.5×10^{-102}
Eukaryotic Translation Termination	84	49	1.9×10^{-99}
GPCR ligand binding	373	108	3.8×10^{-99}
Viral mRNA Translation	82	48	3.3×10^{-98}
Formation of a pool of free 40S subunits	94	51	3.3×10^{-98}
Eukaryotic Translation Elongation	87	49	1.6×10^{-97}
Peptide chain elongation	84	48	7.2×10^{-97}
Class A/1 (Rhodopsin-like receptors)	289	90	2.7×10^{-96}
Nonsense Mediated Decay independent of the Exon Junction Complex	89	49	3.0×10^{-96}
Infectious disease	349	100	2.6×10^{-94}
GTP hydrolysis and joining of the 60S ribosomal subunit	105	52	3.4×10^{-94}
L13a-mediated translational silencing of Ceruloplasmin expression	104	51	2.8×10^{-92}
3' -UTR-mediated translational regulation	104	51	2.8×10^{-92}
Neuronal System	272	84	8.4×10^{-92}
SRP-dependent cotranslational protein targeting to membrane	105	51	9.5×10^{-92}
Eukaryotic Translation Initiation	112	52	2.0×10^{-90}
Cap-dependent Translation Initiation	112	52	2.0×10^{-90}


Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

4.4.2 Synthetic Lethal Expression Profiles

The expression profiles of candidate synthetic lethal partners detected by SLIPT and mtSLIPT in stomach cancer were plotted against clinical characteristics as described in section for breast cancer data in Section 4.1.2 (shown in Figures 4.12 and G.1 respectively). As expected the majority of *CDH1* mutant samples had low expression of *CDH1* and were the diffuse type of stomach cancer.

The SLIPT partners of *CDH1* exhibited similar clustering in stomach cancer to breast cancer, replicating the diverse roles of elevated partner genes in different clinical samples. Specifically (in Figure 4.12), the diffuse type stomach cancers had higher expression of the candidate synthetic lethal partners (where *CDH1* has a role as a driver mutation), despite an unbiased clustering. This is consistent with compensating expression of synthetic lethal partners under loss of *CDH1*, as suggested by Lu *et al.* (2015). The pathway composition of gene clusters for stomach cancer (shown in Table F.2) was also highly concordant with breast cancer findings (shown in Table 4.3). These included replicated of translation (Cluster 1), immune functions (Cluster 2), Gαs signalling (Cluster 3), and further support for the roles of GPCRs and the extracellular matrix (Cluster 4) in the synthetic lethal partners and functions of *CDH1*, replicated across stomach and breast cancers. Clusters 1 and 4, which had particularly high expression of SLIPT candidate partner genes in the diffuse subtype, also had the most significant over-representation of pathways.

There was less variation between the expression profiles of mtSLIPT partners of *CDH1* in stomach cancer, although clusters were still detectable (as shown in Figure G.1). While the genes and pathways detected was less significant (due to lower sample size), the composition of clusters was further indicative for the roles of extracellular matrix (including elastic fibres), immune functions, and the cell signalling.



4.4.3 Comparison to Primary Screen

The number of genes detected by both SLIPT in TCGA stomach cancer data and siRNA in breast cell lines (shown in Figure F.1) was also not a significant overlap (as observed for breast cancer in Figure 4.2). This was particularly the case of mtSLIPT against *CDH1* mutation in stomach cancer which detected very few genes (as shown in Figure G.2) due to low sample size and mutation frequency.

This smaller overlap can also be attributed to the tissue-specific differences between the stomach cancers and the breast cells used for the experimental model (Chen *et al.*, 2014). Nevertheless, many genes were detected across SLIPT in stomach cancers and the experimental screen (Telford *et al.*, 2015) and the pathways detected were consistent with prior observations in breast cancer. Despite differences in the specific genes detected, the functions of *CDH1* were conserved across epithelial cancers in different tissues and synthetic lethal inhibition of interacting pathways may be effective against molecular targets such as *CDH1* inactivation across tissue types.

However, the pathway composition of SLIPT-specific genes and those replicated with the siRNA primary screen (Telford *et al.*, 2015) were highly concordant between the pathways identified by SLIPT in TCGA stomach cancer (shown in Table F.3) and pathways previously identified in TCGA breast cancer (shown in Table 4.4). In both cases, translation and immune pathways were highly over-represented in SLIPT-specific genes, which we would not expect to be detected by siRNA screening in cell lines, as discussed in Section 4.2.1.4. In addition, the extracellular matrix was supported by in stomach cancer. While the pathways identified by specifically by SLIPT in stomach cancer or siRNA screening were similar to those observed for breast cancer (in Table 4.4), the pathways over-represented in the intersection for stomach cancer SLIPT candidates and the siRNA primary screen (Telford *et al.*, 2015) also had a clear over-representation of signalling pathways, although they differed from those observed in breast cancer SLIPT candidates. GPCR signalling was supported in genes detected in both TCGA stomach cancer and screening, including $G\alpha_q$, $G\alpha_s$, serotonin receptors, and class A signalling (shown in more detail in Table F.5). In addition MAPK and NOTCH signalling pathways were detected. These replicate the findings in breast cancer and show consistent detection of signalling pathways in stomach cancer despite less genes being detected by SLIPT and patient samples differing from the tissue in which the experiments were conducted.

Similarly, the SLIPT-specific gene candidates against *CDH1* mutation (shown in Table G.4) replicated pathways observed in breast cancer (shown in Table D.4), despite

a lower number of genes detected. In particular, the extracellular matrix and elastic fibres were over-represented. While the number of genes overlapping with the siRNA was too low to be amenable to pathway analysis, there is further indication that members of these genes replicated across mutation SLIPT analyses include cell-membrane, elastic fibre, and GPCR signalling genes.

4.4.3.1 Resampling Analysis

Similarly, resampling for SLIPT specific candidates (shown in Tables F.4 and G.5) replicated many of the most highly over-represented pathways in stomach cancer. These include translational, immune, GPCR signalling, and elastic fibres, consistent with previous analyses in breast cancer (shown in Tables 4.5 and D.5).

While fewer pathways were supported by resampling for the intersection of SLIPT and experimental screen (Telford *et al.*, 2015) candidate partners in stomach cancer than breast cancer, many of those detected (shown in Table F.5) replicate those detected in breast cancer (shown in Tables 4.6 and D.6). The pathways detected by both permutation and over-representation were more likely to be replicated across stomach and breast cancer than those detected by over-representation alone, supporting the use of this procedure to detect synthetic lethal pathways applicable across cancer types. These include $G\alpha_s$ signalling and elastic fibre formation as discussed for breast cancer (in Section 4.2.1.4.1)

While many pathways were detected by resampling for mtSLIPT against *CDH1* mutation in stomach cancer (shown in Table G.6), there were not enough genes detected by both mtSLIPT and the siRNA primary screen to determine over-represented pathways. Therefore this may be due to small numbers of genes which does not constitute support for pathway composition. However, this under-powered analysis does not preclude the replicated synthetic lethal pathways detected across SLIPT expression analyses in TCGA breast and stomach cancer data with an accompanying siRNA primary screen (Telford *et al.*, 2015). Rather this further supports the use of SLIPT to test against low expression of query genes as measure of gene inactivation to avoid this issue, despite mutation (which often produces similar results) being more indicative of complete gene inactivation.

4.4.4 Metagene Analysis

Metagene analysis (as conducted in Section 4.3.4) was also performed for TCGA stomach cancer expression data, using Reactome pathways. These results (as shown in Table F.6) provided further support for signalling and extracellular processes as synthetic

lethal pathways across stomach and breast cancer. Namely, cell-cell communication, VEGF signalling, and various GPCR pathways were detected.

Signalling and immune pathways were also supported by mtSLIPT analysis of meta-gene pathway expression against *CDH1* mutation, as shown in Table G.7. Although these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include prostacyclin, SCF-KIT, ERK, MAPK, NGF, VEGF, and PI3K/AKT. The innate immune response, the inflammasome, and integrin signaling were also implicated to be synthetic lethal with *CDH1* mutations. Cell surface interactions, cholesterol biosynthesis, and platelet homeostasis also support the role of extracellular processes in proliferation of *CDH1* deficient cancers and interactions of *CDH1* with the extracellular environment that was not tested in the cell line experimental screen.

4.5 Global Synthetic Lethality

Global levels of synthetic lethality were analysed to address concerns raised by the high numbers of synthetic lethal candidates for *CDH1*. The SLIPT procedure (as described in Section 3.1) was performed with each possible query gene from the TCGA breast cancer RNA-Seq dataset. Due to the computational demands of this procedure, it was performed on the New Zealand eScience Infrastructure Intel Pan supercomputer (as described in Section 2.5.3).

The observed number of SLIPT appears to be typical for most genes in the TCGA breast RNA- Seq dataset as shown in Figure 4.13. This figure was actually lower than the majority (95%) of genes tested, although *CDH1* was ranked higher for a similar in SLIPT analysis of TCGA stomach cancer data, shown in Figure H.1. The differences in sample size make these analyses difficult to compare but (in either case), the number of partners detected for *CDH1* is not unexpected, even when adjust for multiple comparisons across candidate partners.

The number of detected candidates reported here is higher than in Figures 4.2 and F.1 because these excluded genes not tested by the siRNA primary screen (Telford *et al.*, 2015) for comparison with it. For an statistically rigorous measure of global synthetic lethality, multiple comparison procedures would need to be performed for all pairs of genes tested. However, only partner genes for each query SLIPT analysis were performed for the purposes of comparing the number of partners predicted with those observed for *CDH1* throughout this thesis.




Figure 4.13: **Synthetic lethal partners across query genes.** Global synthetic lethal pairs were examined across the genome in TCGA breast expression data by applying SLIPT across query genes. The high number of predicted partners for *CDH1* was typical for a human gene and lower than many other genes.

4.5.1 Hub Genes

The genes with the most synthetic lethal interactions by this SLIPT analysis are the “hub” genes of a synthetic lethal network. These genes with the highest number of candidate partners detected by SLIPT in TCGA breast cancer expression data are summarised in Table 4.9. These include several genes involved in cellular signalling such as *TGFBR2*, *PDGFRA*, *FAM126A*, *KCTD12*, *MAML2*, and *CAV1*. Gene regulation including chromatin, DNA, and RNA bindings genes were also observed as hub genes such as *CELF2*, *PLAGL1*, *TSHZ2*, *FOXO1*, and *SVEP1*. Genes involved in the cellular membrane such as *ANXA1* and *FAM171A1* were also observed in addition to genes specifically implicated in cell adhesion and tight junctions such as *TNS1*, *BOC*, *AMOTL1*, *FAT4*, and *EPB41L2*.

Table 4.9: Query synthetic lethal genes with the most SLIPT partners

Gene	Direction	raw p-value	p-value (FDR)	SLIPT raw p-value	SLIPT (FDR)
<i>TGFBR2</i>	8134	17982	17973	8007	8006
<i>A2M</i>	8571	17605	17583	8345	8339
<i>TNS1</i>	8019	17949	17934	7874	7873
<i>PROS1</i>	8539	17668	17642	8317	8310
<i>ANXA1</i>	9085	17330	17302	8689	8682
<i>CELF2</i>	8665	17406	17368	8370	8355
<i>BOC</i>	8694	17371	17348	8384	8381
<i>PLAGL1</i>	8792	17361	17327	8448	8436
<i>PDGFRA</i>	8296	17650	17621	8095	8087
<i>FAM171A1</i>	8874	17560	17533	8567	8562
<i>FAM126A</i>	8510	17383	17356	8184	8178
<i>TSHZ2</i>	7942	17983	17976	7787	7786
<i>KCTD12</i>	8366	17651	17621	8115	8108
<i>MAML2</i>	8336	17537	17503	8069	8061
<i>FOXO1</i>	8027	17753	17737	7840	7836
<i>AMOTL1</i>	8425	17388	17347	8147	8139
<i>FAT4</i>	8111	17750	17732	7925	7919
<i>CAV1</i>	8645	17491	17464	8342	8331
<i>SVEP1</i>	7945	17859	17842	7791	7784
<i>EPB41L2</i>	8415	17327	17296	8097	8092

Genes with the most candidate SL partners SLIPT in TCGA breast expression data with the number of partner genes predicted by direction criteria and χ^2 testing separately and combined as a SLIPT analysis.

Where specified, the p-values for the χ^2 test were adjusted for multiple tests (FDR).

Genes involved in adhesion and tight junctions were also hub genes in stomach cancer (shown in Table H.1) such as *HEG1*, *FAT4*, *NFASC*, *LAMA4*, *LAMC1*, *TNS1*, and *AMOTL1*. These also included cytoskeletal genes such as *ANK2*, *TTC28*, and *MACF1*. Cancer genes were also among hub genes across breast and stomach cancer such as *BOC*, *FAT4*, and *MRVI1*.

It is therefore unsurprising that signalling and regulatory genes have been detected throughout this thesis. Not only are they suitable targets for anti-cancer therapy, they are also highly interacting genes themselves and so it is plausible that their interactions would be detectable by SLIPT. This is consistent with the established role of aberrant signalling and gene regulation in proliferation and survival of tumours and the importance of these pathways in development with highly redundant functions across many genes under complex regulation. These are also highly amenable to detection by SLIPT analysis of expression data since their functions are dynamically regulated with corresponding changes in expression.

Cytoskeletal, membrane bound, and extracellular matrix genes are also among highly interacting synthetic lethal hubs, including focal adhesion, tight junctions, microtubules, and fibronectin. These support the use of synthetic lethal interactions to

target *CDH1*, as a tumour suppressor gene involved in these functions. Cellular structure and cell-cell interactions are thus important functions with highly redundant genes for which there are many feasible synthetic lethal interactions by which to understand regulation of cellular functions. These functions may also be exploited as vulnerabilities in cancer as they are frequently disrupted in cancers, including HDGC where loss of *CDH1* is a driver of cancer proliferation and malignancy.

4.5.2 Hub Pathways

Pathways over-represented among TCGA breast cancer hub genes (as shown in Table 4.10) particularly support the importance of signalling pathways, such as the PI3K/AKT pathway, as synthetic lethal hubs. The highly redundant natures of cell-cell interaction and the extracellular matrix functions was also further supported.

Table 4.10: Pathways for genes with the most SLIPT partners

Pathways Over-represented	Pathway Size	SL Genes	p-value	p-value (FDR)
Constitutive Signaling by Aberrant PI3K in Cancer	56	10	8.4×10^{-16}	8.7×10^{-13}
PI3K/AKT Signaling in Cancer	78	11	2.1×10^{-14}	1.1×10^{-11}
Role of LAT2/NTAL/LAB on calcium mobilization	96	12	7.7×10^{-14}	2.2×10^{-11}
Complement cascade	33	7	1.2×10^{-13}	2.2×10^{-11}
Cell surface interactions at the vascular wall	99	12	1.6×10^{-13}	2.2×10^{-11}
PI3K events in ERBB4 signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PIP3 activates AKT signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PI3K events in ERBB2 signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR1	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR2	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR3	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR4	87	11	2.6×10^{-13}	2.2×10^{-11}
Extracellular matrix organization	238	22	4.7×10^{-13}	3.6×10^{-11}
Muscle contraction	62	9	4.9×10^{-13}	3.6×10^{-11}
PI3K/AKT activation	90	11	5.5×10^{-13}	3.8×10^{-11}
GAB1 signalosome	91	11	7.1×10^{-13}	4.6×10^{-11}
Smooth Muscle Contraction	28	6	2.4×10^{-12}	1.5×10^{-10}
Response to elevated platelet cytosolic Ca ²⁺	82	10	2.6×10^{-12}	1.5×10^{-10}
Signaling by SCF-KIT	126	13	3.0×10^{-12}	1.6×10^{-10}
Signaling by FGFR	143	14	5.0×10^{-12}	2.2×10^{-10}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in the top 500 “hub” genes with the most candidate synthetic lethal partners by SLIPT analysis of TCGA breast expression data

Pathway over-representation for synthetic lethal hub genes was replicated in TCGA stomach cancer expression data. However, these pathways differ considerably from breast cancer, as shown in Table H.2. Cell-cell interactions and extracellular matrix pathways, including elastic fibres, were also among the hub genes for stomach cancer.

The signalling pathways differ as expected in a different tissue type, although BMP and PAK signalling were detected as hub gene functions.

4.6 Replication in cell line encyclopaedia

As breast cancer cell lines are the experimental system in which many cancer genetics and drug targets are investigated, these were analysed in addition to patient samples from TCGA. The cancer cell line encyclopaedia (CCLE) is a resource for genomics profiles across a range of cell lines. These have also been used to generate synthetic lethal candidates for comparison to those in experimental screen and predictions from TCGA expression data.

Table 4.11: Pathways for *CDH1* partners from SLIPT in CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Cell Cycle	442	207	1.2×10^{-215}
Cell Cycle, Mitotic	365	180	2.9×10^{-209}
Signaling by Rho GTPases	311	136	9.4×10^{-156}
M Phase	212	104	8.8×10^{-145}
Infectious disease	289	123	1.3×10^{-142}
RHO GTPase Effectors	207	98	5.3×10^{-135}
HIV Infection	200	94	2×10^{-130}
Separation of Sister Chromatids	140	77	5.6×10^{-128}
Organelle biogenesis and maintenance	258	107	1.4×10^{-127}
Chromatin modifying enzymes	181	87	4.7×10^{-126}
Chromatin organization	181	87	4.7×10^{-126}
Mitotic Metaphase and Anaphase	149	78	1.2×10^{-124}
Mitotic Anaphase	148	77	6.3×10^{-123}
Developmental Biology	421	142	1.6×10^{-121}
RHO GTPases Activate Formins	94	60	5.3×10^{-118}
Mitotic Prometaphase	93	59	5.4×10^{-116}
Hemostasis	421	138	7.2×10^{-116}
Adaptive Immune System	397	132	3.2×10^{-115}
Assembly of the primary cilium	143	72	2.4×10^{-114}
Transcription	133	68	6.2×10^{-111}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

The cancer cell line encyclopaedia provides further support for synthetic lethal genes and pathways that may be applicable across cell types and reproducible in experimental systems. In contrast to the homogeneous pooled cell samples of patients, the cell lines provide a genetically homogeneous cell population in which to examine molecular functions and as a preclinical model of cancerous disease. The complete set of 1037 cell lines was tested for synthetic lethality across tissues, in addition to the 59 breast cell lines and 38 stomach cell lines being tested separately for partners of *CDH1*. Synthetic lethal genes were detected by SLIPT (as described in Section 3.1) and over-represented synthetic lethal Reactome pathways (as described in Section 2.3.2).

Synthetic lethal gene candidates were detectable by SLIPT across each of these sample sets of cells lines (as shown in Tables I.1–I.3). Although these were most highly significant across the samples in the CCLE expression dataset (as shown in Table I.1) and included genes detected in prior analyses such as *VIM*, *ZEB2*, *EMP3*. Pathways were also highly over-represented among synthetic lethal candidates for the full CCLE dataset (as shown in Table 4.11) including Rho GTPase (GPCRs), immune, and gene regulation (chromatin and transcription). This is unexpected since immune pathways would not be expected to be detectable in isolated cell lines, although this could be attributed to cytokine and integrin signalling occurring the cancer cells in addition to interactions with immune cells in the tumour microenvironment (which could not be distinguished in patient samples). Cell cycle and mitosis were among the highest synthetic lethal pathways across cell lines supporting *CDH1* deficient cells having aberrant cell signalling and consequences for proliferation such as cancer cells. However, cell cycle genes were not as strongly supported in TCGA patient samples or the siRNA screen (Telford *et al.*, 2015) and they may not be applicable to epithelial tissues such as breast or stomach cancer or amenable to selective inhibition in experimental models.

Synthetic lethal pathways specific to SLIPT candidates from breast cell lines (as shown in Table 4.12) were more consistent with previous observations, particularly the established role of E-cadherin in cell junctions and the Adherens complex. Although the number of SLIPT candidate genes detected in stomach cell lines was insufficient to replicate the findings in breast cell lines to TCGA patient samples. However, SLIPT candidates across breast and stomach CCLE cell lines were over-represented (as shown in Table I.5) for similar pathways to breast cell lines with additional support for extracellular matrix pathways including elastic fibres which were replicated with resampling across breast and stomach TCGA analyses and the primary siRNA screen Telford *et al.* (2015).

Table 4.12: Pathways for *CDH1* partners from SLIPT in breast CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Cell junction organization	71	5	0.006
Adherens junctions interactions	29	3	0.006
Dermatan sulfate biosynthesis	11	2	0.006
Non-integrin membrane-ECM interactions	52	4	0.006
Regulation of pyruvate dehydrogenase (PDH) complex	12	2	0.0069
Cell-extracellular matrix interactions	17	2	0.021
Pyruvate metabolism	17	2	0.021
Cell-cell junction organization	46	3	0.039
Synthesis of substrates in N-glycan biosynthesis	50	3	0.057
Detoxification of Reactive Oxygen Species	26	2	0.082
Keratan sulfate biosynthesis	28	2	0.092
Laminin interactions	28	2	0.092
Cell-Cell communication	118	5	0.12
Keratan sulfate/keratin metabolism	32	2	0.12
Opioid Signalling	63	3	0.12
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide) and transfer to a nascent protein	63	3	0.12
Intraflagellar transport	34	2	0.14
Signaling by Retinoic Acid	36	2	0.16
Pyruvate metabolism and Citric Acid (TCA) cycle	36	2	0.16
Nef mediated downregulation of MHC class I complex cell surface expression	10	1	0.22

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

4.7 Discussion

4.7.1 Strengths of the SLIPT Methodology

Synthetic lethal discovery with SLIPT used established statistical procedures identify putative partner genes from gene expression data. Such use of the χ^2 -value is amenable to pathway or permutation analyses and could feasibly be applied to other disease gene or pair-wise across the genome. Although genome-wide approaches were unable to find informative candidate genes for E-cadherin Lu *et al.* (2015). Synthetic lethal discovery in cancer has focused on genes with severe cellular mutant phenotypes, such as essential genes or the oncogenes *TP53* and *AKT* Lu *et al.* (2015); Tiong *et al.* (2014); Wang and Simon (2013), with other cancer genes, such as *CDH1*, requiring more focused investigations. Prior computational approaches for synthetic lethal discovery, in cancer, vary widely (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Tiong *et al.*, 2014; Wappett *et al.*, 2016). There is no consensus for which for the approach is more appropriate and they are difficult to compare as they either do not have a released code implementation or do not make predictions solely from normalised expression data.

However, the query-based approach demonstrated by SLIPT analysis is suitable for wider application on expression data and augmenting experimental studies such as high-throughput screens. This approach has identified biologically plausible synthetic lethal pathways for *CDH1*, triaged candidates from experimental screening (Telford *et al.*, 2015), and replicates genes and pathways across breast and stomach cancers datasets. In addition, SLIPT avoids critical assumptions underlying the design of some prior approaches such as coexpression of synthetic candidates or that they will have known (annotated) similarities in function.

The DAISY methodology Jerby-Arnon *et al.* (2014), which took a similar query-based approach with the tumour suppressor *VHL*, has been critiqued for being too stringent Lu *et al.* (2015) which impedes pathway analysis. Since functional redundancy does not require genes to be expressed at the same time, the SLIPT approach does not assume co-expression of synthetic lethal genes which may enrich for synthetic lethal genes in established coregulated pathways. Rather, the interpretation of synthetic lethality for SLIPT was similar to other computational methods based on ‘co-loss under-representation’, ‘compensation’, or ‘simultaneous differential expression’ Lu *et al.* (2015); Tiong *et al.* (2014); Wang and Simon (2013).

Genomics analyses are prone to false-positives and require statistical caution, particularly where working with gene-pairs scale up the number of multiple tests drastically, at the expense of statistical power. Experimental screens for synthetic lethality are also error-prone, especially with false-positives, raising the need for understanding the expected behaviour and number of functional relationships and genetic interactions in the genome, or in discovery of synthetic lethal partners of a particular query gene. Thus analyses throughout this thesis have focused on querying for partners of a particular gene of interest. Statistical modelling and simulations (in Section 3.3 and Chapter 6) will further support the design decisions underlying SLIPT analysis and its strengths over other approaches.

4.7.2 Synthetic Lethal Pathways for E-cadherin

As specific genes were difficult to replicate across experiments, gene expression profiles for synthetic lethal partners must be more complex than originally expected to directly compensate for loss of query gene or completely lack (or clearly under-representation) mutual loss (Jerby-Arnon *et al.*, 2014; Kelly, 2013; Lu *et al.*, 2015). The predicted synthetic lethal partners of *CDH1* (with FDR correction) were investigated with gene expression profiles and clinical variables to find relationships in gene expression, gene

function, and clinical characteristics. The large number of hits indicate that synthetic lethal detection is error-prone and identifying genes relevant for clinical application will be difficult without a supporting biological pathway rationale. As such, investigations into the genes identified by SLIPT, correlation structure between them, and those which were validated by experimental screening (Telford *et al.*, 2015) focused on the pathway level throughout this Chapter. Similarly, comparisons across analyses were largely made at the pathway level, including comparisons between expression and mutation, breast and stomach TCGA datasets, and patient sample data with cell line expression profiles.

Potential synthetic lethal partners of *CDH1* identified by SLIPT had many distinct functions, with each gene cluster highly expressed in different patient subgroups (Figure 4.1). The expression profiles of the SL partners of *CDH1* predicted from the TCGA breast cancer RNA-Seq data (expected to have compensating high or stable expression) and their corresponding functional enrichment found subgroups of genes with functional organisation particularly among *CDH1* low breast tumours. Ductal breast cancers show higher expression of synthetic lethal partners suggesting treatment would be more effective in this tumour subtype. However, there is consistently low expression of SL partners in estrogen receptor negative tumours, although this is independent of tumour stage and consistent with poor prognosis in these patients and could inform other treatment strategies or prevent ineffective treatment further impacting quality of life in these patients. These results suggest that synthetic lethal partner expression varies between patients; that these different tumour classes would react differently to the same treatment; that treatment of different pathways and combinations in different patients is the most effective approach to target genes compensating for *CDH1* gene loss; and the expression of synthetic partners could be a clinically important biomarker.

The pathways that synthetic lethal partners of *CDH1* identified by SLIPT were involved in a diverse range of biological functions and differed to those detected experimentally. This discrepancy may be accounted for by gene expression analyses detecting both synthetic lethal partners (as screened for experimentally Telford *et al.* (2015)) and their downstream targets (not detected by siRNA), capturing the wider pathways and mechanisms involved in synthetic lethality with *CDH1* inactivation. In particular, GPCR phosphorylation cascades (which regulates gene expression and translation in cancers Gao and Roux (2015)) were predicted to be synthetic lethal with *CDH1*. The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of *CDH1*. The most consistently supported pathways

include elastic fibres in the extracellular matrix, GPCR signalling, and translation presenting vulnerabilities for *CDH1* deficient cancer cells from extracellular stimuli to the core growth mechanisms of a cell.

This diversity in synthetic lethal functions is consistent with the wide ranging role of *CDH1* in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. Identification of distinct synthetic lethal gene clusters may further lead to the elucidation of drug resistance mechanisms. While these pathways are indicative of the main functions of E-cadherin and synthetic lethal partners, it remains to identify the genes within these pathways that are the most actionable or supported across SLIPT analysis in patient samples and detected by experiments in preclinical models (Chen *et al.*, 2014; Telford *et al.*, 2015). The specific genes within key pathways will be discussed in Chapter 5, along with further investigations into their relation to pathway structure. While these are important clinical implications, the synthetic lethal predictions lack enough confidence for direct translation into pre-clinical models or clinical applications leading to a need for statistical modelling and simulation of synthetic lethality in genomics expression data.

These synthetic lethal pathways have potential clinical implications, particularly those supported in pre-clinical models and in patient expression data. However, further validation of gene candidates will be necessary to ensure that these are able to be reproduced in further pre-clinical studies, they are applicable to tumours *in vivo*, and that effective inhibitory agents can be repurposed or designed against them.

4.7.3 Replication and Validation

4.7.3.1 Integration with siRNA Screening

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-representation (Table 4.4) and supported by resampling analysis (Table 4.6), despite a modest intersection of genes between them (Figure 4.2). Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represented due to small effect sizes, thus both tests are required for a candidate pathway.

The pathways detected by both over-representation and resampling are the strongest candidates for further investigation and the pathway structure analyses in Chapter 5

will focus on these pathways detected by both over-representation and resampling. Particularly, those replicated across datasets or with pathway metagenes. In addition to GPCR pathways detected across these analyses, the PI3K cascade will also be investigated in Chapter 5, this signalling pathway is a well characterised mediator between GPCR receptors and regulation of translation (Gao and Roux, 2015) (both detected throughout this Chapter) and exhibited unexpected behaviour with pathway the metagenes (in section 4.3). This pathway is activated by protein Phosphorylation states and thus inactivation may not be detectable with expression.

However, the SLIPT approach was shown to be predictive of which siRNA primary screen candidate partners of *CDH1* were validated in a secondary screen (as shown in Appendix C). These results further support SLIPT for identifying robust synthetic lethal candidates which can be validated and as a triage approach for interpreting screening experiments.

4.7.3.2 Replication across Tissues and Cell lines

Furthermore, synthetic lethal partners identified by SLIPT were replicated across breast and stomach cancer. These were particularly concordant at the pathway level, as expected between tissues since synthetic lethal pathways have higher conservation between species (Dixon *et al.*, 2008). These findings support gene functions conserved across *CDH1* deficient cancers in breast and stomach tissues, presenting vulnerabilities that could be applied against molecular targets in both cancers. In addition, these analyses serve as a replication across independent patient cohorts from breast and stomach cancers, decreasing the likelihood of the synthetic lethal pathways detected being false positives or artifacts of either dataset.

Synthetic lethal pathways were also replicated across expression analyses of TCGA patient samples in heterogeneous tumours and homogeneous cell line isolates. This further supports that the subset of synthetic lethal functions detectable in experimental models (Chen *et al.*, 2014; Telford *et al.*, 2015) would be applicable to tumours of patients with *CDH1* deficient cancers.

There are many gene functions replicated across breast cancer gene expression analyses. Many of these were also replicated with mutation analysis and with stomach cancer or cell line expression data. These pathways were more consistent across replication analyses than previous investigations with TCGA microarray data Kelly (2013).

4.8 Summary

We have developed a simple, interpretable, computational approach to predict synthetic lethal partners from genomics data. The analyses focus on gene expression data as it is widely available for applications in other cancers and other disease genes, particularly those with malignant loss of function.

This approach has been applied to robustly detect synthetic lethal pathways for the E-cadherin (*CDH1*) in TCGA breast cancer molecular profiles with comparisons to experimental screening (Telford *et al.*, 2015) in cell lines, and replication in TCGA stomach cancer molecular profiles and across cell types in the cancer cell line encyclopaedia. The pathway replicated across several analyses included extracellular matrix pathways (such as elastic fibres formation), cell signalling (including GPCRs), and core gene regulation and translation processes crucial for the growth and proliferation of cancer cells. These pathways show evidence of non-oncogene addiction for *CDH1* deficient cells and present vulnerabilities which may be exploited for specific treatment against *CDH1* mutations in HCGC and sporadic cancers. There was also support for synthetic lethal pathways with *CDH1* in cell adhesion and cytoskeletal processes to which *CDH1* belongs, supporting the finding that synthetic lethality occurs within biological pathways (Boone *et al.*, 2007; Kelley and Ideker, 2005).

While translational and immune pathways detected by SLIPT were not supported by primary siRNA screening (Telford *et al.*, 2015), these were replicated across various analyses. Due to the differences between an experimental cell line model (Barretina *et al.*, 2012; Chen *et al.*, 2014; Fece de la Cruz *et al.*, 2015) and patient molecular profiles (Bass *et al.*, 2014; TCGA, 2012), these would not be expected to be completely concordant. Furthermore, many pathways are difficult to test in an isolated experimental system. Nevertheless, many of the genes and pathways detected by SLIPT are suitable to inform further investigations and triage of therapeutic targets against *CDH1* deficient tumours in combination with experimental screening.

A characteristic of gene interaction networks is a scale-free topology leading to highly interacting hub genes, these represent important genes in a functional network. Cell surface interactions, the extracellular matrix, and cell signalling (particularly PI3K/AKT signalling) were also found to be synthetic lethal hubs with more interactions detected than other genes. This indicates that these pathways are functionally important to survival of cancer cells since they are subject to high functional redundancy, despite frequent disruptions in cancer. These pathways being involved in

a disproportionate number of synthetic lethal interactions is also consistent with their detection for *CDH1*.

Thus synthetic lethal pathways have been identified using TCGA patient molecular profiles, CCLE cancer cell line expression data, and experimental screening results. Some of these were robustly replicated across these datasets and against *CDH1* mutation or expression analysis. However, there remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost. While the genes identified between these analyses were less concordant the results of the TCGA breast cancer analysis will be used to test pathway structure relationships and further examine the synthetic lethal genes detected in the following Chapter.

Aims

- Pathway Structure of Candidate Synthetic Lethal Genes for *CDH1* from TCGA breast data
- Comparisons to Experimental siRNA Screen Candidates
- Replication of Pathways across in TCGA Stomach data

Summary

- We have developed a Synthetic Lethal detection method that generates a high number of synthetic lethal candidates
- Pathways in cell signalling, extracellular matrix, and cytoskeletal functions were supported with experimental candidates and the known functions of E-cadherin
- Several candidate pathways were supported by mutation analysis and replicated across breast and stomach cancer
- Translation and immune functions were uniquely detected by the computational approach which may be explained by differences between patient samples and cell line models
- There remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost

Chapter 5

Synthetic Lethal Pathway Structure

Aims

- Synthetic Lethal Genes within a Biological Pathway Structure
- Importance and Connectivity of Synthetic Lethal Genes within Pathway Networks
- Upstream and Downstream Relationships between SLIPT and siRNA Candidates

Summary

- Synthetic Lethal genes were explored within a graph structures for key pathways identified previously
- In some cases these graph structures appeared to have relationships between synthetic lethal genes
- However, no existing network metrics of importance and connectivity with the networks were elevated significantly for Synthetic Lethal genes
- Nor was there significant evidence of upstream and downstream relationships between SLIPT and siRNA Candidates in a shortest path permutation analysis

Having identified key pathways implicated in synthetic lethal genetic interactions with *CDH1*, these were investigated for the underlying synthetic lethal genes within them and their relationships to pathway structure in Reactome pathways. This chapter will focus on the pathway structure of biological pathways detected across analyses in Chapter 4. The synthetic lethal genes considered here are candidates those detected by SLIPT (as described in Section ??) in TCGA breast cancer expression and mutation data (TCGA, 2012) in comparison to the candidate gene partners from the siRNA screening in breast cell lines (Telford *et al.*, 2015).

5.1 Synthetic lethal genes in synthetic lethal pathways

5.2 Centrality and connectivity of synthetic lethal genes




Figure 5.1: **Synthetic Lethality and Vertex Degree.** Synthetic Lethality and Vertex Degree




Figure 5.2: Synthetic Lethality and Centrality. Synthetic Lethality and Information Centrality (log-scale).




Figure 5.3: Synthetic Lethality and PageRank. Synthetic Lethality and PageRank.




Figure 5.4: **Structure of Synthetic Lethality Resampling.** Structure of Synthetic Lethality Resampling.

5.3 Upstream or downstream synthetic lethal candidates

pathway	Graph:		States:		Observed:				Permutation p-value:	
	nodes	edges	exprSL	siRNA	up	down	up-down	up/down	up abs	down abs
PI3K Cascade	138	1495	38	25	122	128	-6	0.953125	0.5326	0.4606
PI3K/AKT Signaling in Cancer	275	12882	98	44	779	679	100	1.147275405	0.3255	0.6734
G _{αi} Signaling	292	22003	95	58	836	1546	-710	0.5407503234	0.9971	0.0029
GPCR downstream	1270	142071	312	160	9755	9261	494	1.0533419717	0.3692	0.6305
Elastic fibre formation	42	175	24	7	1	2	-1	0.5	0.5461	0.3865
Extracellular matrix	299	3677	127	29	547	455	92	1.2021978022	0.3351	0.6636
Formation of Fibrin	52	243	18	5	12	17	-5	0.7058823529	0.6198	0.3564
Nonsense-Mediated Decay	103	102	74	2	0	74	-74	0	1	0
3' -UTR-mediated translational regulation	107	2860	77	1	0	0	0	NaN	0.4902	0.5027
Eukaryotic Translation Elongation	92	3746	76	0	0	0	0	NaN	0.4943	0.4933

Sampling only within target pathway

Number of siRNA+SLIPT matched to observed

siRNA+SLIPT kept for up/down evaluation

5.4 Hierachical approach

5.5 Discussion

5.6 Conclusion




Figure 5.5: **Structure of PI3K Ranking.** Structure of PI3K Ranking.




Figure 5.6: **Structure of Synthetic Lethality in PI3K.** Structure of Synthetic Lethality in PI3K.

Chapter 6

Simulation and Modeling of Synthetic Lethal Pathways

Aims

- A Model of Synthetic Lethal Genes in Gene Expression Data
- Simulations of Known Synthetic Lethal Genes within Pathway Networks
- Comparison of SLIPT to Alternative Approaches

Summary

- We have designed a straight-forward rational query-based synthetic lethal detection method with the example of application to *CDH1* in cancer gene expression
- We have developed a simulation pipeline to generate continuous gene expression with pathway structure including a procedure to simulate synthetic lethality
- Our simulation procedure is robust across pathway structures and has desirable performance compared to other statistical techniques

Synthetic lethality (SL) is the death of a cell or organism with the combined loss of two non-essential genes. This phenomenon was originally used to study genetic interactions and functional redundancy in models organisms (Boone et al. 2007). While synthetic lethal experiments have been performed in *Drosophila melanogaster* (Dobzhansky 1946), *Caenorhabditis elegans* (Lehner et al. 2006), *Escherichia coli* (Butland et al. 2008), *Schizosaccharomyces pombe* (Roguev et al. 2007), and various mammalian cell lines (Kaelin 2005), the most extensive synthetic lethal screens have been performed with the synthetic gene array (SGA) technique in *Saccharomyces cerevisiae* (Boone et al. 2007; Costanzo et al. 2011; Tong et al. 2004).

Originally defined by double mutants, a range of mechanisms for gene inactivation of synthetic lethal partners can induce cell death including RNA interference and drug treatment where it is sometimes called induced essentiality or non-oncogene addiction in cancer research (Fece de la Cruz et al. 2015). Cellular viability is the main means to measure synthetic lethal effects experimentally because it is quantified and measured consistently (as shown in Figure 1), whereas qualitative measures of impaired organism viability are ambiguous and less relevant to yeast or cancer research.

The cancer genetics laboratory are currently working on developing a synthetic lethal approach to target the tumour suppressor gene CDH1 which has been found to cause predispose early-onset breast and stomach cancers in mutation carriers, including families of New Zealand Māori (Berx et al. 1995; Guilford et al. 1998). These families are currently closely monitored and offered drastic preventative surgery. If it were developed, a drug selective against CDH1 mutant tumours would serve not only as a chemopreventative alternative for these families but also benefit the wider community as a treatment for sporadic cases of CDH1 mutant cancer. To augment experimental work on CDH1 with isogenic cell lines (Telford et al. 2015), a computational methodology is explored here to exploit public cancer genomic databases.

Microarray and massively-parallel sequencing technologies are driving a revolution in molecular biological research, particularly with regard to cancer where the premise of genomic medicine is rapidly becoming feasible with the use of genomics to identify cancer genes, diagnose patients with actionable mutations, and use gene expression as a prognostic marker. Genomic data could also be used to identify novel drug targets and synthetic lethal partners of known cancer genes in particular. The Cancer Genome Atlas database (TCGA) and the overarching International Cancer Genome Consortium (ICGC) provide a valuable public cancer genome data resource because they support many different data types for the same samples, for many different cancer types, and

for high sample sizes (Cancer Genome Atlas Research Network 2014; Cancer Genome Atlas Research Network et al. 2013; International Cancer Genome Consortium 2014). They host data of patient clinical factors, gene expression, somatic mutation, DNA copy number, and DNA methylation which could all serve to predict synthetic lethality from frequency of mutually exclusive gene inactivation and its impact on patient survival. A number of other databases are given in the Table 6 which may be used to explore gene function, drug target feasibility, or replicate analyses but TCGA and ICGC datasets will be the focus of this project.

There is a growing need for a robust approach to cost-effective prediction of candidate synthetic lethal interaction, particularly in cancer research. Exploiting existing public genomic databases is an ideal way to utilise existing resources with suitable sample sizes, data types, and different limitations to those of laboratory experiments. A number of computation approaches to synthetic lethality have been developed but many of these rely on data not available to cancer researchers, methods that are difficult to replicate, over-fitted to a particular dataset, having mixed validation results, or do not have a software tool accessible to the research community. These methodologies are reviewed in detail in the accompanying literature review. They will still be considered to develop an improved synthetic lethal interaction prediction tool (SLIPT).

A bioinformatics approach has distinct limitations to experimental methods and would work well combined with genetic screen data and conventional molecular biology laboratory validation techniques to answer biological research questions. Compared with an experimental screen, a bioinformatics approach has the benefits of reduced costs, with the potential for automation, scaling up, and replication of the same gene across populations and cell types. Analysis of public genomic data accounts for real tumour variation showing detection with tumour heterogeneity and genomic instability. Compared with a cell line or xenograft experimental model we are limited by difficulties in establishing validity of a novel method, lack of mechanism, or potential for testing drug activity in the same system. However, computational methods may further miss useful therapeutic candidates from variable genetic background and be limited by the population sampled. This research builds on previous work in an Honours project and similar approaches in the literature (Jerby-Arnon et al. 2014; Kelly 2013; Lu et al. 2015).

6.1 Simulations and Modelling Synthetic Lethality in Expression Data

Synthetic lethality was modelled for effects on expression levels and whether these are detectable in known interacting and non-interacting genes in simulated data. These were conducted for expression data but the nature of these simulations would be relevant to how synthetic lethality would manifest in other factors, particularly DNA copy number variation and DNA methylation. These simulations were discussed at length in the previous meeting and showed that synthetic lethality was detectable with our approach in simple cases. While it was less effective, the methods were able to detect synthetic lethal genes in expression data with correlation structure (generated with the multi-variate normal distribution) and were distinguishable from correlated genes. Therefore the strongest (most significant) synthetic lethal genes are more likely to be true synthetic lethal partners and a high number of hits are expected from correlated genes and co-regulated pathways.

The power of the method to detect interactions depleted with increasing multiple tests, interactions, and cryptic (third party) interacting partners. Increased sample size counteracted these effects as expected. This led the idea that pathways would be more suitable as the focus of this project. Biological pathways led to fewer multiple tests, more relevant to understanding cancer biology, and are often drug targets in practice.

6.2 Simulations over simple graph structures

6.2.1 Performance

6.2.2 Synthetic lethality across graph stuctures

6.2.3 Performance with inhibition links

6.2.4 Performance with 20,000 genes

6.3 Simulations over pathway-based graphs

6.4 Comparing methods

6.4.1 SLIPT and Chi-Squared

6.4.1.1 Correlated query genes

6.4.2 Correlation

6.4.3 Bimodality with BiSEp

Chapter 7

Discussion

Aims

- To develop a statistical approach to detect synthetic lethal gene pairs in cancer from expression data
- To apply this methodology to public cancer gene expression data against *CDH1* and analyse pathway structure with comparisons to experimental screen data
- To construct a statistical model of synthetic lethality in multivariate normal expression data
- To develop a simulation pipeline of expression with pathway structure on a high-performance computing cluster
- To examine the statistical performance of the methodology with simulated expression including pathways and compare it to other approaches
- To release the synthetic lethal detection methodology and pathway simulation procedure as R software packages

Summary

- We have developed a Synthetic Lethal detection method that generates a high number of synthetic lethal candidates

- Pathways in cell signalling, extracellular matrix, and cytoskeletal functions were supported with experimental candidates and the known functions of E-cadherin
- Several candidate pathways were supported by mutation analysis and replicated across breast and stomach cancer
- Translation and immune functions were uniquely detected by the computational approach which may be explained by differences between patient samples and cell line models
- There remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost
- Synthetic Lethal genes were explored within a graph structures for key pathways identified previously
- In some cases these graph structures appeared to have relationships between synthetic lethal genes
- However, no existing network metrics of importance and connectivity with the networks were elevated significantly for Synthetic Lethal genes
- Nor was there significant evidence of upstream and downstream relationships between SLIPT and siRNA Candidates in a shortest path permutation analysis
- We have designed a straight-forward rational query-based synthetic lethal detection method with the example of application to *CDH1* in cancer gene expression
- We have developed a simulation pipeline to generate continuous gene expression with pathway structure including a procedure to simulate synthetic lethality
- Our simulation procedure is robust across pathway structures and has desirable performance compared to other statistical techniques

7.1 Significance

Development of an effective synthetic lethal discovery tool for bioinformatics analysis has a wide range of applications in genetics research including functional genomics, medical and agricultural applications. Of particular interest is a complementary approach to discovery of synthetic lethal drug targets for cancer therapy to aid the cancer research community which currently relies on cell line and mouse models for screening and validation experiments (Fece de la Cruz et al. 2015). The potential for synthetic lethal drug design against cancer mutations including gene loss or overexpression could lead to a revolution in cancer therapy and chemoprevention with personalised treatment of cancers and high risk individuals. Examples of the synthetic lethal strategy to cancer treatment have been shown to be clinically effective with many large-scale RNAi screens underway to discover more cancer gene function and drug targets for similar application.

However, there are limitations to both experimental screens and computational approaches, both known to be prone to false-positives. Modelling and simulation of synthetic lethal discovery in genomic data has been explored to address these concerns and ensure the validity of candidate synthetic lethal interactions, particularly given the recent emergence of a number of conflicting synthetic lethal screening and prediction approaches. Exploring synthetic lethality in simulated data will ensure the optimal performance of our prediction method with comparison to the distribution of test statistic distribution in empirical gene expression data, informed selection of thresholds for prediction, and estimated error rates. The model of gene expression with known synthetic lethal genes is limited by the assumption that it represents the distribution of gene expression when it may not. Having shown synthetic lethality is detectable in simple models and added correlation structure, the model still needs to be developed to better represent real data. However, the behaviour of synthetic lethal genes and effects of parameters explored so far remains important to inform future model design and interpretation of empirical data analysis. The synthetic lethal discovery strategy could be adapted to any form of gene inactivation or disruption such as changes to gene expression, regulation, epigenetics, DNA sequence, or copy number which could plausibly induce cell death due to SL interactions. Further applications of synthetic lethal interactions such as analysis of gene networks, tissue specificity, evolutionary conservation, or drug target feasibility are possible with synthetic lethal candidates predicted with confidence on a large scale.

Network analysis enables properties of the network and its connectivity to be measured and compared across datasets (Barabsi & Oltvai 2004). Tissue specificity is an important consideration, largely unexplored with synthetic lethal studies, since it has clinical importance to ensure targeted drug treatments are effective, predict adverse effects in other tissues, determine whether targeted treatments could be repurposed for other cancer types or diseases, and whether drug resistance mechanisms could emerge. Comparison of tissues, populations, and species can all ensure that synthetic lethal predictions are robust, that experimental candidates are clinically relevant, and treatments designed to exploit them would be specific to the disease in large patient cohort (with known biomarkers).

Drug targets must be feasible to have effective anti-cancer interventions designed against them, which raises the need for targets with existing drugs in the clinic, trials, or feasible to development with structural analysis or screening. Druggable targets could be selected by gene functions known to be amendable to drugs, with a structure amenable with development, with conserved specific sites without homology to other genes, or with known approval or developing drugs which could be repurposed from other disease applications.

7.2 Future Directions

Such a bioinformatically-informed synthetic lethal screening and validation strategy could be integrated into existing and future screens for synthetic lethality in cancer.

Possible improvements to the SLIPT method include developing a Bayesian inference method or simulations and modelling to account for pathway structure among synthetic lethal genes. Another extension would be to test for higher order synthetic lethal interactions, where 3 or more genes perform a redundant function.

Further development of the synthetic lethal model and simulation is needed to explore the parameters, ensure relevance to empirical data analysis, and understanding the implications of findings so far. An example of more complex correlation structure is shown in supplementary Figures S1 and S2 with genes correlated to the Query genes (showing need for directional synthetic lethal condition) and correlated with other non-synthetic lethal genes (showing the predictions are robust to other correlation structure). The impact of these modifications on model performance in a large number of genes or simulation replicates is yet to be seen or whether such correlation structure reflects the correlation structure of empirical data (as shown in Figure 3 with the row dendrogram for correlation distance between genes), known biological pathways, or

known synthetic lethal interactions. Correlation between synthetic lethal genes could also be considered.

Comparing the findings of modelling and simulation with public gene expression analysis and experimental screen targets is still needed to identify putative synthetic lethal interactions. This application will be tested with the example of CDH1 as a query gene in breast cancer for follow up to earlier results, relevance to ongoing research in the Cancer genetics Laboratory, and comparison to the experimental screen data of MCF10A cells by Telford et al. (2015). While this methodology is intended to be widely applicable, particularly to other cancer genes and will be made available to the research community (manuscript and code release in preparation).

There are several avenues for further research on synthetic lethality in breast cancer. The main alternative themes are network analysis with a focus on tissue specificity or drug feasibility with an emphasis on pharmacogenomics, biological pathways, and whether candidate targets could be inactivated by compounds with favourable pharmacokinetic properties. Either approach remains within the scope of the project, although each will require adoption of new computational tools, which is important topic for consideration in the meeting and changes to the project direction later in the year.

7.3 Conclusion

Synthetic lethal interactions are important for understanding gene function and development of targeted anti-cancer treatments. Synthetic lethal discovery with experimental screening is error prone and limited by the model systems in which it is performed. A bioinformatics tool to predict synthetic lethal interactions from genomics data would greatly benefit the cancer research community (and wider genetics research community). Several such tools exist, including one we have developed, but they have conflicting design and results are often inconsistent with experimental screen data. Therefore, modelling and simulation of synthetic lethality in gene expression data is needed to ensure the statistical validity of predictions. We have developed a model with correlation structure based on a Multivariate Normal distribution for which simulations detect synthetic lethality with high performance in simple cases and which has the potential to be developed to model complex correlation structure, biological pathways, or patterns observed in empirical gene expression data. The modelling, public data analysis, and experimental screen data approaches will be combined to further examine the example of CDH1 in breast cancer. Analysis of gene networks, tissue specificity,

biological pathways, or drug targets remain options to explore tool development and implications for synthetic lethal cancer research in the future.

Chapter 8

Conclusion

References

- Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J., and Turner, N.C. (2015) Functional genetic screen identifies increased sensitivity to wee1 inhibition in cells with defects in fanconi anemia and hr pathways. *Mol Cancer Ther*, **14**(4): 865–76.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C.D., Annala, M., Aprikian, A., Armenia, J., Arora, A., *et al.* (2015) The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **163**(4): 1011–1025.
- Adamski, M.G., Gumann, P., and Baird, A.E. (2014) A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. *PLoS ONE*, **9**(8): e103917.
- Adler, D. (2005) *vioplot: Violin plot*. R package version 0.2.
- Agarwal, S., Deane, C.M., Porter, M.A., and Jones, N.S. (2010) Revisiting date and party hubs: Novel approaches to role assignment in protein interaction networks. *PLoS Comput Biol*, **6**(6): e1000817.
- Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B., *et al.* (2014) Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **159**(3): 676–690.
- Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., *et al.* (2015) Genomic Classification of Cutaneous Melanoma. *Cell*, **161**(7): 1681–1696.
- Akobeng, A.K. (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Padiatrica*, **96**(5): 644–647.
- American Cancer Society (2017) Genetics and cancer. <https://www.cancer.org/cancer/cancer-causes/genetics.html>. Accessed: 22/03/2017.

American Society for Clinical Oncology (ASCO) (2017) The genetics of cancer. <http://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>. Accessed: 22/03/2017.

Araki, H., Knapp, C., Tsai, P., and Print, C. (2012) GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis. *FEBS Open Bio*, **2**: 76–82.

Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., *et al.* (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*, **25**(1): 25–29.

Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair. *J Clin Oncol*, **26**(22): 3785–90.

Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 245–51.

Babyak, M.A. (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med*, **66**(3): 411–21.

Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., *et al.* (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer*, **91**(2): 355–358.

Barabási, A.L. and Albert, R. (1999) Emergence of scaling in random networks. *Science*, **286**(5439): 509–12.

Barabási, A.L. and Oltvai, Z.N. (2004) Network biology: understanding the cell's functional organization. *Nat Rev Genet*, **5**(2): 101–13.

Barrat, A. and Weigt, M. (2000) On the properties of small-world network models. *The European Physical Journal B - Condensed Matter and Complex Systems*, **13**(3): 547–560.

- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., *et al.* (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**(7391): 603–607.
- Barry, W.T. (2016) *safe: Significance Analysis of Function and Expression*. R package version 3.14.0.
- Baryshnikova, A., Costanzo, M., Dixon, S., Vizeacoumar, F.J., Myers, C.L., Andrews, B., and Boone, C. (2010a) Synthetic genetic array (sga) analysis in *saccharomyces cerevisiae* and *schizosaccharomyces pombe*. *Methods Enzymol*, **470**: 145–79.
- Baryshnikova, A., Costanzo, M., Kim, Y., Ding, H., Koh, J., Toufighi, K., Youn, J.Y., Ou, J., San Luis, B.J., Bandyopadhyay, S., *et al.* (2010b) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat Meth*, **7**(12): 1017–1024.
- Bass, A.J., Thorsson, V., Shmulevich, I., Reynolds, S.M., Miller, M., Bernard, B., Hinoue, T., Laird, P.W., Curtis, C., Shen, H., *et al.* (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **513**(7517): 202–209.
- Bates, D. and Maechler, M. (2016) *Matrix: Sparse and Dense Matrix Classes and Methods*. R package version 1.2-7.1.
- Bateson, W. and Mendel, G. (1909) *Mendel's principles of heredity, by W. Bateson*. University Press, Cambridge [Eng.].
- Beck, T.F., Mullikin, J.C., and Biesecker, L.G. (2016) Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin Chem*, **62**(4): 647–654.
- Becker, K.F., Atkinson, M.J., Reich, U., Becker, I., Nekarda, H., Siewert, J.R., and Hfler, H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Research*, **54**(14): 3845–3852.
- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., *et al.* (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**(7353): 609–615.
- Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*, **57**(1): 289–300.

- Berx, G., Cleton-Jansen, A.M., Nollet, F., de Leeuw, W.J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J*, **14**(24): 6107–15.
- Berx, G., Cleton-Jansen, A.M., Strumane, K., de Leeuw, W.J., Nollet, F., van Roy, F., and Cornelisse, C. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene*, **13**(9): 1919–25.
- Berx, G. and van Roy, F. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb Perspect Biol*, **1**: a003129.
- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., et al. (2015) Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, **21**(3): 231–8.
- Blake, J.A., Christie, K.R., Dolan, M.E., Drabkin, H.J., Hill, D.P., Ni, L., Sitnikov, D., Burgess, S., Buza, T., Gresham, C., et al. (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res*, **43**(Database issue): D1049–1056.
- Boettcher, M., Lawson, A., Ladenburger, V., Fredebohm, J., Wolf, J., Hoheisel, J.D., Frezza, C., and Shlomi, T. (2014) High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. *BMC Genomics*, **15**: 158.
- Boone, C., Bussey, H., and Andrews, B.J. (2007) Exploring genetic interactions and networks with yeast. *Nat Rev Genet*, **8**(6): 437–49.
- Borgatti, S.P. (2005) Centrality and network flow. *Social Networks*, **27**(1): 55 – 71.
- Boucher, B. and Jenna, S. (2013) Genetic interaction networks: better understand to better predict. *Front Genet*, **4**: 290.
- Breiman, L. (2001) Random forests. *Machine Learning*, **45**(1): 5–32.
- Brin, S. and Page, L. (1998) The anatomy of a large-scale hypertextual web search engine. *Computer Networks and ISDN Systems*, **30**(1): 107 – 117.

- Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005) Specific killing of *BRCA2*-deficient tumours with inhibitors of polyadribose polymerase. *Nature*, **434**(7035): 913–7.
- Burk, R.D., Chen, Z., Saller, C., Tarvin, K., Carvalho, A.L., Scapulatempo-Neto, C., Silveira, H.C., Fregnani, J.H., Creighton, C.J., Anderson, M.L., *et al.* (2017) Integrated genomic and molecular characterization of cervical cancer. *Nature*, **543**(7645): 378–384.
- Bussey, H., Andrews, B., and Boone, C. (2006) From worm genetic networks to complex human diseases. *Nat Genet*, **38**(8): 862–3.
- Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., Yang, W., Li, J., Gagarinova, A.G., Pogoutse, O., *et al.* (2008) esga: *E. coli* synthetic genetic array analysis. *Nat Methods*, **5**(9): 789–95.
- Cancer Research UK (2017) Family history and cancer genes. <http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/inherited-cancer-genes-and-increased-cancer-risk/family-history-and-inherited-cancer-genes>. Accessed: 22/03/2017.
- Cancer Cell Line Encyclopedia (CCLE) (2014) Broad-Novartis Cancer Cell Line Encyclopedia. <http://www.broadinstitute.org/ccle>. Accessed: 07/11/2014.
- cBioPortal for Cancer Genomics (cBioPortal) (2017) cBioPortal for Cancer Genomics. <http://www.cbioportal.org/>. Accessed: 26/03/2017.
- Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G.D., and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Res*, **39**(Database issue): D685–690.
- Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., Wiggins, G.A.R., Godwin, T.D., Yap, A.S., and Guilford, P.J. (2014) E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer*, **14**(1): 552.
- Chen, K., Yang, D., Li, X., Sun, B., Song, F., Cao, W., Brat, D.J., Gao, Z., Li, H., Liang, H., *et al.* (2015) Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. *Proc Natl Acad Sci USA*, **112**(4): 1107–1112.

- Chen, S. and Parmigiani, G. (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, **25**(11): 1329–1333.
- Chen, X. and Tompa, M. (2010) Comparative assessment of methods for aligning multiple genome sequences. *Nat Biotechnol*, **28**(6): 567–572.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., *et al.* (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **31**(3): 411–423.
- Chipman, K. and Singh, A. (2009) Predicting genetic interactions with random walks on biological networks. *BMC Bioinformatics*, **10**(1): 17.
- Christofori, G. and Semb, H. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends in Biochemical Sciences*, **24**(2): 73 – 76.
- Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., *et al.* (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **163**(2): 506–519.
- Clark, M.J. (2004) Endogenous Regulator of G Protein Signaling Proteins Suppress G_o-Dependent μ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **310**(1): 215–222.
- Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. *Methods Mol Biol*, **1418**: 93–110.
- Collingridge, D.S. (2013) A primer on quantitized data analysis and permutation testing. *Journal of Mixed Methods Research*, **7**(1): 81–97.
- Collins, F.S. and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. *Sci Am*, **296**(3): 50–57.
- Collins, F.S., Morgan, M., and Patrinos, A. (2003) The Human Genome Project: lessons from large-scale biology. *Science*, **300**(5617): 286–290.
- Collisson, E., Campbell, J., Brooks, A., Berger, A., Lee, W., Chmielecki, J., Beer, D., Cope, L., Creighton, C., Danilova, L., *et al.* (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **511**(7511): 543–550.

- Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Della Pelle, P., Dias-Santagata, D., Hung, K.E., *et al.* (2012) Egfr-mediated reactivation of mapk signaling contributes to insensitivity of *BRAF*-mutant colorectal cancers to raf inhibition with vemurafenib. *Cancer Discovery*, **2**(3): 227–235.
- Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., Ding, H., Koh, J.L., Toufighi, K., Mostafavi, S., *et al.* (2010) The genetic landscape of a cell. *Science*, **327**(5964): 425–31.
- Costanzo, M., Baryshnikova, A., Myers, C.L., Andrews, B., and Boone, C. (2011) Charting the genetic interaction map of a cell. *Curr Opin Biotechnol*, **22**(1): 66–74.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Robertson, A., Chu, A., Beroukhim, R., Cibulskis, K., Signoretti, S., *et al.* (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, **499**(7456): 43–49.
- Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., *et al.* (2014) The Reactome pathway knowledgebase. *Nucleic Acids Res*, **42**(database issue): D472D477.
- Crunkhorn, S. (2014) Cancer: Predicting synthetic lethal interactions. *Nat Rev Drug Discov*, **13**(11): 812.
- Csardi, G. and Nepusz, T. (2006) The igraph software package for complex network research. *InterJournal, Complex Systems*: 1695.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., *et al.* (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **486**(7403): 346–352.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., and Shi, B. (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*, **5**(10): 2929–2943.
- Davierwala, A.P., Haynes, J., Li, Z., Brost, R.L., Robinson, M.D., Yu, L., Mnaimneh, S., Ding, H., Zhu, H., Chen, Y., *et al.* (2005) The synthetic genetic interaction spectrum of essential genes. *Nat Genet*, **37**(10): 1147–1152.

- De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., and Cleton-Jansen, A.M. (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol*, **183**(4): 404–11.
- Demir, E., Babur, O., Rodchenkov, I., Aksoy, B.A., Fukuda, K.I., Gross, B., Sumer, O.S., Bader, G.D., and Sander, C. (2013) Using biological pathway data with Paxtools. *PLoS Comput Biol*, **9**(9): e1003194.
- Deshpande, R., Asiedu, M.K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Pirotowski, J., Shin, S.H., Yoshida, M., Costanzo, M., *et al.* (2013) A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res*, **73**(20): 6128–36.
- Dickson, D. (1999) Wellcome funds cancer database. *Nature*, **401**(6755): 729.
- Dienstmann, R. and Tabernero, J. (2011) *BRAF* as a target for cancer therapy. *Anti-cancer Agents Med Chem*, **11**(3): 285–95.
- Dijkstra, E.W. (1959) A note on two problems in connexion with graphs. *Numerische Mathematik*, **1**(1): 269–271.
- Dixon, S.J., Andrews, B.J., and Boone, C. (2009) Exploring the conservation of synthetic lethal genetic interaction networks. *Commun Integr Biol*, **2**(2): 78–81.
- Dixon, S.J., Fedyshyn, Y., Koh, J.L., Prasad, T.S., Chahwan, C., Chua, G., Toufighi, K., Baryshnikova, A., Hayles, J., Hoe, K.L., *et al.* (2008) Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. *Proc Natl Acad Sci U S A*, **105**(43): 16653–8.
- Dorogovtsev, S.N. and Mendes, J.F. (2003) *Evolution of networks: From biological nets to the Internet and WWW*. Oxford University Press, USA.
- Erdős, P. and Rényi, A. (1959) On random graphs I. *Publ Math Debrecen*, **6**: 290–297.
- Erdős, P. and Rényi, A. (1960) On the evolution of random graphs. In *Publ. Math. Inst. Hung. Acad. Sci*, volume 5, 17–61.
- Eroles, P., Bosch, A., Perez-Fidalgo, J.A., and Lluch, A. (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer Treat Rev*, **38**(6): 698–707.

- Ezkurdia, I., Juan, D., Rodriguez, J.M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., and Tress, M.L. (2014) Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Human Molecular Genetics*, **23**(22): 5866.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., *et al.* (2005) Targeting the dna repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**(7035): 917–21.
- Fawcett, T. (2006) An introduction to ROC analysis. *Pattern Recognition Letters*, **27**(8): 861 – 874. {ROC} Analysis in Pattern Recognition.
- Fece de la Cruz, F., Gapp, B.V., and Nijman, S.M. (2015) Synthetic lethal vulnerabilities of cancer. *Annu Rev Pharmacol Toxicol*, **55**: 513–531.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**(5): E359–386.
- Fisher, R.A. (1919) Xv.the correlation between relatives on the supposition of mendelian inheritance. *Earth and Environmental Science Transactions of the Royal Society of Edinburgh*, **52**(02): 399–433.
- Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., *et al.* (2009) Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, **361**(2): 123–34.
- Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., *et al.* (2010) Poly(adp)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, **28**(15): 2512–9.
- Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., *et al.* (2015) COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res*, **43**(Database issue): D805–811.

- Fraser, A. (2004) Towards full employment: using RNAi to find roles for the redundant. *Oncogene*, **23**(51): 8346–52.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**(3): 177–183.
- Futreal, P.A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and Stratton, M.R. (2001) Cancer and genomics. *Nature*, **409**(6822): 850–852.
- Gao, B. and Roux, P.P. (2015) Translational control by oncogenic signaling pathways. *Biochimica et Biophysica Acta*, **1849**(7): 753–65.
- Gatza, M.L., Kung, H.N., Blackwell, K.L., Dewhirst, M.W., Marks, J.R., and Chi, J.T. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. *Breast Cancer Res*, **13**(3): R62.
- Gatza, M.L., Silva, G.O., Parker, J.S., Fan, C., and Perou, C.M. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet*, **46**(10): 1051–1059.
- Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., *et al.* (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*, **5**(10): R80.
- Genz, A. and Bretz, F. (2009) Computation of multivariate normal and t probabilities. In *Lecture Notes in Statistics*, volume 195. Springer-Verlag, Heidelberg.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2016) *mvtnorm: Multivariate Normal and t Distributions*. R package version 1.0-5. URL.
- Gilbert, W. and Maxam, A. (1973) The nucleotide sequence of the lac operator. *Proceedings of the National Academy of Sciences*, **70**(12): 3581–3584.
- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**(5): 991–1006.

Globus (Globus) (2017) Research data management simplified. <https://www.globus.org/>. Accessed: 25/03/2017.

Graziano, F., Humar, B., and Guilford, P. (2003) The role of the E-cadherin gene (*CDH1*) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Annals of Oncology*, **14**(12): 1705–1713.

Güell, O., Sagus, F., and Serrano, M. (2014) Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. *PLoS Comput Biol*, **10**(5): e1003637.

Guilford, P. (1999) E-cadherin downregulation in cancer: fuel on the fire? *Molecular Medicine Today*, **5**(4): 172 – 177.

Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scouller, R., Miller, A., and Reeve, A.E. (1998) E-cadherin germline mutations in familial gastric cancer. *Nature*, **392**(6674): 402–5.

Guilford, P., Humar, B., and Blair, V. (2010) Hereditary diffuse gastric cancer: translation of *CDH1* germline mutations into clinical practice. *Gastric Cancer*, **13**(1): 1–10.

Guilford, P.J., Hopkins, J.B., Grady, W.M., Markowitz, S.D., Willis, J., Lynch, H., Rajput, A., Wiesner, G.L., Lindor, N.M., Burgart, L.J., *et al.* (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat*, **14**(3): 249–55.

Guo, J., Liu, H., and Zheng, J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. *Nucleic Acids Res*, **44**(D1): D1011–1017.

Hajian-Tilaki, K. (2013) Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*, **4**(2): 627–635.

Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., and Witten, I.H. (2009) The weka data mining software: an update. *SIGKDD Explor Newsl*, **11**(1): 10–18.

Hammerman, P.S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., Gabriel, S., *et al.* (2012) Comprehensive

genomic characterization of squamous cell lung cancers. *Nature*, **489**(7417): 519–525.

Han, J.D.J., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, A.J.M., Cusick, M.E., Roth, F.P., *et al.* (2004) Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature*, **430**(6995): 88–93.

Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell*, **100**(1): 57–70.

Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell*, **144**(5): 646–674.

Hanna, S. (2003) Cancer incidence in new zealand (2003-2007). In D. Forman, D. Bray F Brewster, C. Gombe Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, R. Swaminathan, and J. Ferlay (editors), *Cancer Incidence in Five Continents*, volume X, 902–907. International Agency for Research on Cancer, Lyon, France. Electronic version <http://ci5.iarc.fr> Accessed 22/03/2017.

Heiskanen, M., Bian, X., Swan, D., and Basu, A. (2014) caArray microarray database in the cancer biomedical informatics grid™ (caBIG™). *Cancer Research*, **67**(9 Supplement): 3712–3712.

Heiskanen, M.A. and Aittokallio, T. (2012) Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery*, **2**(3): 263–272.

Hell, P. (1976) Graphs with given neighbourhoods i. problèmes combinatorics at theorie des graphes. *Proc Coll Int CNRS, Orsay*, **260**: 219–223.

Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., *et al.* (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol*, **8**(5): R76.

Hillenmeyer, M.E. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science*, **320**: 362–365.

- Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., *et al.* (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **158**(4): 929–944.
- Hoechndorf, R., Hardy, N.W., Osumi-Sutherland, D., Tweedie, S., Schofield, P.N., and Gkoutos, G.V. (2013) Systematic analysis of experimental phenotype data reveals gene functions. *PLoS ONE*, **8**(4): e60847.
- Holm, S. (1979) A simple sequentially rejective multiple test procedure. *Scandinavian Journal of Statistics*, **6**(2): 65–70.
- Holme, P. and Kim, B.J. (2002) Growing scale-free networks with tunable clustering. *Physical Review E*, **65**(2): 026107.
- Hopkins, A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*, **4**(11): 682–690.
- Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., *et al.* (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, **7**: 96.
- Huang, E., Cheng, S., Dressman, H., Pittman, J., Tsou, M., Horng, C., Bild, A., Iversen, E., Liao, M., Chen, C., *et al.* (2003) Gene expression predictors of breast cancer outcomes. *Lancet*, **361**: 1590–1596.
- Illumina, Inc (Illumina) (2017) Sequencing and array-based solutions for genetic research. <https://www.illumina.com/>. Accessed: 26/03/2017.
- International HapMap 3 Consortium (HapMap) (2003) The International HapMap Project. *Nature*, **426**(6968): 789–796.
- International Human Genome Sequencing Consortium (IHGSC) (2004) Finishing the euchromatic sequence of the human genome. *Nature*, **431**(7011): 931–945.
- Jerby-Arnon, L., Pfetzer, N., Waldman, Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P., *et al.* (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. *Cell*, **158**(5): 1199–1209.

- Joachims, T. (1999) Making large-scale support vector machine learning practical. In S. Bernhard, lkopf, J.C.B. Christopher, and J.S. Alexander (editors), *Advances in kernel methods*, 169–184. MIT Press.
- Ju, Z., Liu, W., Roebuck, P.L., Siwak, D.R., Zhang, N., Lu, Y., Davies, M.A., Akbani, R., Weinstein, J.N., Mills, G.B., *et al.* (2015) Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics*, **31**(6): 912.
- Kaelin, Jr, W. (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*, **5**(9): 689–98.
- Kaelin, Jr, W. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. *Genome Med*, **1**: 99.
- Kakiuchi, M., Nishizawa, T., Ueda, H., Gotoh, K., Tanaka, A., Hayashi, A., Yamamoto, S., Tatsuno, K., Katoh, H., Watanabe, Y., *et al.* (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet*, **46**(6): 583–587.
- Kamada, T. and Kawai, S. (1989) An algorithm for drawing general undirected graphs. *Information Processing Letters*, **31**(1): 7–15.
- Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., *et al.* (2013) Integrated genomic characterization of endometrial carcinoma. *Nature*, **497**(7447): 67–73.
- Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., *et al.* (2001) Functional annotation of a full-length mouse cDNA collection. *Nature*, **409**(6821): 685–690.
- Kelley, R. and Ideker, T. (2005) Systematic interpretation of genetic interactions using protein networks. *Nat Biotech*, **23**(5): 561–566.
- Kelly, S., Chen, A., Guilford, P., and Black, M. (2017a) Synthetic lethal interaction prediction of target pathways in E-cadherin deficient breast cancers. Submitted to *BMC Genomics*.
- Kelly, S.T. (2013) *Statistical Predictions of Synthetic Lethal Interactions in Cancer*. Dissertation, University of Otago.
- Kelly, S.T., Single, A.B., Telford, B.J., Beetham, H.G., Godwin, T.D., Chen, A., Black, M.A., and Guilford, P.J. (2017b) Towards HDGC chemoprevention: vulnerabilities

in E-cadherin-negative cells identified by genome-wide interrogation of isogenic cell lines and whole tumors. Submitted to *Cancer Prev Res.*

Kozlov, K.N., Gursky, V.V., Kulakovskiy, I.V., and Samsonova, M.G. (2015) Sequence-based model of gap gene regulation network. *BMC Genomics*, **15**(Suppl 12): S6.

Kranthi, S., Rao, S., and Manimaran, P. (2013) Identification of synthetic lethal pairs in biological systems through network information centrality. *Mol BioSyst*, **9**(8): 2163–2167.

Lander, E.S. (2011) Initial impact of the sequencing of the human genome. *Nature*, **470**(7333): 187–197.

Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**(6822): 860–921.

Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*, **10**(3): R25.

Latora, V. and Marchiori, M. (2001) Efficient behavior of small-world networks. *Phys Rev Lett*, **87**: 198701.

Laufer, C., Fischer, B., Billmann, M., Huber, W., and Boutros, M. (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. *Nat Methods*, **10**(5): 427–31.

Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014) voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*, **15**(2): R29.

Lawrence, M.S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S.B., Getz, G., Ally, A., Balasundaram, M., Birol, I., et al. (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **517**(7536): 576–582.

Le Meur, N. and Gentleman, R. (2008) Modeling synthetic lethality. *Genome Biol*, **9**(9): R135.

Le Meur, N., Jiang, Z., Liu, T., Mar, J., and Gentleman, R.C. (2014) Slgi: Synthetic lethal genetic interaction. r package version 1.26.0.

- Lee, A.Y., Perreault, R., Harel, S., Boulier, E.L., Suderman, M., Hallett, M., and Jenna, S. (2010a) Searching for signaling balance through the identification of genetic interactors of the rab guanine-nucleotide dissociation inhibitor gdi-1. *PLoS ONE*, **5**(5): e10624.
- Lee, I., Lehner, B., Vavouri, T., Shin, J., Fraser, A.G., and Marcotte, E.M. (2010b) Predicting genetic modifier loci using functional gene networks. *Genome Research*, **20**(8): 1143–1153.
- Lee, I. and Marcotte, E.M. (2009) Effects of functional bias on supervised learning of a gene network model. *Methods Mol Biol*, **541**: 463–75.
- Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, M.B. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell*, **149**(4): 780–94.
- Lehner, B., Crombie, C., Tischler, J., Fortunato, A., and Fraser, A.G. (2006) Systematic mapping of genetic interactions in *caenorhabditis elegans* identifies common modifiers of diverse signaling pathways. *Nat Genet*, **38**(8): 896–903.
- Li, X.J., Mishra, S.K., Wu, M., Zhang, F., and Zheng, J. (2014) Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. *Biomed Res Int*, **2014**: 196034.
- Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., Schmidt, L., Vocke, C.D., et al. (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, **374**(2): 135–145.
- Lokody, I. (2014) Computational modelling: A computational crystal ball. *Nature Reviews Cancer*, **14**(10): 649–649.
- Lord, C.J., Tutt, A.N., and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annu Rev Med*, **66**: 455–470.
- Lu, X., Kensche, P.R., Huynen, M.A., and Notebaart, R.A. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. *Nat Commun*, **4**: 2124.

- Lu, X., Megchelenbrink, W., Notebaart, R.A., and Huynen, M.A. (2015) Predicting human genetic interactions from cancer genome evolution. *PLoS One*, **10**(5): e0125795.
- Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinchshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., *et al.* (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. *Cell*, **116**(1): 121–137.
- Luo, J., Solimini, N.L., and Elledge, S.J. (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell*, **136**(5): 823–837.
- Machado, J., Olivera, C., Carvalh, R., Soares, P., Berx, G., Caldas, C., Sercuca, R., Carneiro, F., and Sorbrinho-Simoes, M. (2001) E-cadherin gene (*CDH1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*, **20**: 1525–1528.
- Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., Harris, L.N., Pinheiro, H.C., Troussard, A., Miron, P., *et al.* (2007) Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet*, **44**(11): 726–31.
- Mattison, J., van der Weyden, L., Hubbard, T., and Adams, D.J. (2009) Cancer gene discovery in mouse and man. *Biochim Biophys Acta*, **1796**(2): 140–161.
- Maxam, A.M. and Gilbert, W. (1977) A new method for sequencing DNA. *Proceedings of the National Academy of Science*, **74**(2): 560–564.
- McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O'Sullivan, J.M., and Salto-Tellez, M. (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **8**(7): e69604.
- McLachlan, J., George, A., and Banerjee, S. (2016) The current status of parp inhibitors in ovarian cancer. *Tumori*, **102**(5): 433–440.
- McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogianakis, G.M., Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., *et al.* (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **455**(7216): 1061–1068.

- Miles, D.W. (2001) Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. *Breast Cancer Res*, **3**(6): 380–384.
- Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*, **5**(7): 621–628.
- Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., *et al.* (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **487**(7407): 330–337.
- Neeley, E.S., Kornblau, S.M., Coombes, K.R., and Baggerly, K.A. (2009) Variable slope normalization of reverse phase protein arrays. *Bioinformatics*, **25**(11): 1384.
- Novomestky, F. (2012) *matrixcalc: Collection of functions for matrix calculations*. R package version 1.0-3.
- Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., Corso, G., Schouten, J., Fitzgerald, R., Vogelsang, H., *et al.* (2009) Germline *CDH1* deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **18**(9): 1545–1555.
- Oliveira, C., Seruca, R., Hoogerbrugge, N., Ligtenberg, M., and Carneiro, F. (2013) Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). *Eur J Hum Genet*, **21**(8).
- Pandey, G., Zhang, B., Chang, A.N., Myers, C.L., Zhu, J., Kumar, V., and Schadt, E.E. (2010) An integrative multi-network and multi-classifier approach to predict genetic interactions. *PLoS Comput Biol*, **6**(9).
- Parker, J., Mullins, M., Cheung, M., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **27**(8): 1160–1167.
- Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human disease in the postgenomic era. *Science*, **291**(5507): 1224–1229.
- Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., *et al.* (2016) Erratum: The somatic

mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. *Nat Commun*, **7**: 11908.

Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**(6797): 747–752.

Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordonez, G.R., Bignell, G.R., *et al.* (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*, **463**(7278): 191–196.

Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer*, **9**(4): 265–73.

Prahallaad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012) Unresponsiveness of colon cancer to *BRAF*(v600e) inhibition through feedback activation of egfr. *Nature*, **483**(7387): 100–3.

R Core Team (2016) *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. R version 3.3.2.

Ravnan, M.C. and Matalka, M.S. (2012) Vemurafenib in patients with *BRAF* v600e mutation-positive advanced melanoma. *Clin Ther*, **34**(7): 1474–86.

Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, **43**(7): e47.

Robin, J.D., Ludlow, A.T., LaRanger, R., Wright, W.E., and Shay, J.W. (2016) Comparison of DNA Quantification Methods for Next Generation Sequencing. *Sci Rep*, **6**: 24067.

Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*, **11**(3): R25.

Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S.R., Qu, H., Shales, M., Park, H.O., Hayles, J., *et al.* (2008) Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science*, **322**(5900): 405–10.

- Rung, J. and Brazma, A. (2013) Reuse of public genome-wide gene expression data. *Nat Rev Genet*, **14**(2): 89–99.
- Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Ison, J., Keays, M., et al. (2013) ArrayExpress update—trends in database growth and links to data analysis tools. *Nucleic Acids Res*, **41**(Database issue): D987–990.
- Ryan, C., Lord, C., and Ashworth, A. (2014) Daisy: Picking synthetic lethals from cancer genomes. *Cancer Cell*, **26**(3): 306–308.
- Sander, J.D. and Joung, J.K. (2014) Crispr-cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*, **32**(4): 347–55.
- Sanger, F. and Coulson, A. (1975) A rapid method for determining sequences in dna by primed synthesis with dna polymerase. *Journal of Molecular Biology*, **94**(3): 441 – 448.
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., et al. (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol*, **20**(5): 1260–1268.
- Semb, H. and Christofori, G. (1998) The tumor-suppressor function of E-cadherin. *Am J Hum Genet*, **63**(6): 1588–93.
- Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005) Rocr: visualizing classifier performance in r. *Bioinformatics*, **21**(20): 7881.
- Slurm development team (Slurm) (2017) Slurm workload manager. <https://slurm.schedmd.com/>. Accessed: 25/03/2017.
- Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*, **98**(19): 10869–10874.
- Stajich, J.E. and Lapp, H. (2006) Open source tools and toolkits for bioinformatics: significance, and where are we? *Brief Bioinformatics*, **7**(3): 287–296.

- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009) The cancer genome. *Nature*, **458**(7239): 719–724.
- Ström, C. and Helleday, T. (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (parp) inhibitors in cancer therapy. *Biomolecules*, **2**(4): 635–649.
- Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., *et al.* (2014) Reversible and adaptive resistance to *BRAF*(v600e) inhibition in melanoma. *Nature*, **508**(7494): 118–122.
- Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol*, **27**(2): 199–204.
- Telford, B.J., Chen, A., Beetham, H., Frick, J., Brew, T.P., Gould, C.M., Single, A., Godwin, T., Simpson, K.J., and Guilford, P. (2015) Synthetic lethal screens identify vulnerabilities in gpcr signalling and cytoskeletal organization in E-cadherin-deficient cells. *Mol Cancer Ther*, **14**(5): 1213–1223.
- The 1000 Genomes Project Consortium (1000 Genomes) (2010) A map of human genome variation from population-scale sequencing. *Nature*, **467**(7319): 1061–1073.
- The Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**(7418): 61–70.
- The Cancer Genome Atlas Research Network (TCGA) (2017a) The Cancer Genome Atlas Project. <https://cancergenome.nih.gov/>. Accessed: 26/03/2017.
- The Cancer Genome Atlas Research Network (TCGA) (2017b) The Cancer Genome Atlas Project Data Portal. <https://tcga-data.nci.nih.gov/>. Accessed: 06/02/2017 (via cBioPortal).
- The Cancer Society of New Zealand (Cancer Society of NZ) (2017) What is cancer? <https://otago-southland.cancernz.org.nz/en/cancer-information/other-links/what-is-cancer-3/>. Accessed: 22/03/2017.
- The Catalogue Of Somatic Mutations In Cancer (COSMIC) (2016) Cosmic: The catalogue of somatic mutations in cancer. <http://cancer.sanger.ac.uk/cosmic>. Release 79 (23/08/2016), Accessed: 05/02/2017.

The Comprehensive R Archive Network (CRAN) (2017) Cran. <https://cran.r-project.org/>. Accessed: 24/03/2017.

The ENCODE Project Consortium (ENCODE) (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science*, **306**(5696): 636–640.

The Internation Cancer Genome Consortium (ICGC) (2017) ICGC Data Portal. <https://dcc.icgc.org/>. Accessed: 06/02/2017.

The National Cancer Institute (NCI) (2015) The genetics of cancer. <https://www.cancer.gov/about-cancer/causes-prevention/genetics>. Published: 22/04/2015, Accessed: 22/03/2017.

The New Zealand eScience Infrastructure (NeSI) (2017) NeSI. <https://www.nesi.org.nz/>. Accessed: 25/03/2017.

The Pharmaceutical Management Agency (PHARMAC) (2016) Approval of multi-product funding proposal with roche.

Tierney, L., Rossini, A.J., Li, N., and Sevcikova, H. (2015) *snow: Simple Network of Workstations*. R package version 0.4-2.

Tiong, K.L., Chang, K.C., Yeh, K.T., Liu, T.Y., Wu, J.H., Hsieh, P.H., Lin, S.H., Lai, W.Y., Hsu, Y.C., Chen, J.Y., et al. (2014) Csnk1e/ctnnb1 are synthetic lethal to tp53 in colorectal cancer and are markers for prognosis. *Neoplasia*, **16**(5): 441–50.

Tischler, J., Lehner, B., and Fraser, A.G. (2008) Evolutionary plasticity of genetic interaction networks. *Nat Genet*, **40**(4): 390–391.

Tomasetti, C. and Vogelstein, B. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, **347**(6217): 78–81.

Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Page, N., Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., et al. (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science*, **294**(5550): 2364–8.

Tong, A.H., Lesage, G., Bader, G.D., Ding, H., Xu, H., Xin, X., Young, J., Berziz, G.F., Brost, R.L., Chang, M., et al. (2004) Global mapping of the yeast genetic interaction network. *Science*, **303**(5659): 808–13.

- Travers, J. and Milgram, S. (1969) An experimental study of the small world problem. *Sociometry*, **32**(4): 425–443.
- Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., et al. (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **21**(3): 430–46.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., et al. (2010) Oral poly(adribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 235–44.
- van der Meer, R., Song, H.Y., Park, S.H., Abdulkadir, S.A., and Roh, M. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. *Clinical Cancer Research*, **20**(12): 3211–3221.
- van Steen, K. (2012) Travelling the world of genegene interactions. *Briefings in Bioinformatics*, **13**(1): 1–19.
- van Steen, M. (2010) *Graph Theory and Complex Networks: An Introduction*. Maarten van Steen, VU Amsterdam.
- Vapnik, V.N. (1995) *The nature of statistical learning theory*. Springer-Verlag New York, Inc.
- Vargas, J.J., Gusella, G., Najfeld, V., Klotman, M., and Cara, A. (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. *Hum Gene Ther*, **15**: 361–372.
- Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S., Chandrashekhar, M., Buzina, A., Young, J.T., Kwan, J.H., Sayad, A., Mero, P., Lawo, S., et al. (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst Biol*, **9**: 696.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013) Cancer genome landscapes. *Science*, **339**(6127): 1546–1558.
- Vos, C.B., Cleton-Jansen, A.M., Berx, G., de Leeuw, W.J., ter Haar, N.T., van Roy, F., Cornelisse, C.J., Peterse, J.L., and van de Vijver, M.J. (1997) E-cadherin inactivation

in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer*, **76**(9): 1131–3.

Wang, K., Singh, D., Zeng, Z., Coleman, S.J., Huang, Y., Savich, G.L., He, X., Mieczkowski, P., Grimm, S.A., Perou, C.M., *et al.* (2010) MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. *Nucleic Acids Res*, **38**(18): e178.

Wang, K., Yuen, S.T., Xu, J., Lee, S.P., Yan, H.H., Shi, S.T., Siu, H.C., Deng, S., Chu, K.M., Law, S., *et al.* (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nat Genet*, **46**(6): 573–582.

Wang, X. and Simon, R. (2013) Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics*, **6**(1): 30.

Wappett, M. (2014) Bisep: Toolkit to identify candidate synthetic lethality. r package version 2.0.

Wappett, M., Dulak, A., Yang, Z.R., Al-Watban, A., Bradford, J.R., and Dry, J.R. (2016) Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. *BMC Genomics*, **17**: 65.

Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W.H.A., Lumley, T., Maechler, M., Magnusson, A., Moeller, S., Schwartz, M., *et al.* (2015) *gplots: Various R Programming Tools for Plotting Data*. R package version 2.17.0.

Watts, D.J. and Strogatz, S.H. (1998) Collective dynamics of 'small-world' networks. *Nature*, **393**(6684): 440–2.

Weinstein, I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis*, **21**(5): 857–864.

Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., *et al.* (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*, **507**(7492): 315–322.

Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Chang, K., *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*, **45**(10): 1113–1120.


- Wickham, H. and Chang, W. (2016) *devtools: Tools to Make Developing R Packages Easier*. R package version 1.12.0.
- Wickham, H., Danenberg, P., and Eugster, M. (2017) *roxygen2: In-Line Documentation for R*. R package version 6.0.1.
- Wong, S.L., Zhang, L.V., Tong, A.H.Y., Li, Z., Goldberg, D.S., King, O.D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., *et al.* (2004) Combining biological networks to predict genetic interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **101**(44): 15682–15687.
- World Health Organization (WHO) (2017) Fact sheet: Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Updated February 2017, Accessed: 22/03/2017.
- Wu, M., Li, X., Zhang, F., Li, X., Kwoh, C.K., and Zheng, J. (2014) In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer. *Cancer Inform*, **13**(Suppl 3): 71–80.
- Yu, H. (2002) Rmpi: Parallel statistical computing in r. *R News*, **2**(2): 10–14.
- Zhang, F., Wu, M., Li, X.J., Li, X.L., Kwoh, C.K., and Zheng, J. (2015) Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates. *J Bioinform Comput Biol*, **13**(3): 1541002.
- Zhang, J., Baran, J., Cros, A., Guberman, J.M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., *et al.* (2011) International cancer genome consortium data portal a one-stop shop for cancer genomics data. *Database: The Journal of Biological Databases and Curation*, **2011**: bar026.
- Zhong, W. and Sternberg, P.W. (2006) Genome-wide prediction of c. elegans genetic interactions. *Science*, **311**(5766): 1481–1484.
- Zweig, M.H. and Campbell, G. (1993) Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*, **39**(4): 561–577.


Appendix A

Sample Quality

A.1 Sample Correlation

Samples were excluded from expression analysis based on sample correlations and the clustering analysis presented below, as described in Section 2.2.2.





A.2 Replicate Samples in TCGA Breast

Replicate samples were picked where possible from the TCGA breast cancer gene expression data to examine for sample quality. Independent samples of the same tumour are expected to have very high Pearson's correlation between their expression profiles unless there were issues with sample collection or preparation and are thus an indicator of sample quality. The log-transformed raw read counts for replicate samples were examined in Figures A.3–A.5. These were examined before normalisation which would be expected to increase sample concordance.

Another consideration are the samples which were removed for quality concerns (in Section 2.2.2). While these were selected by unbiased hierarchical clustering (See Figure A.2), it is notable that many of the excluded (tumour) samples were performed in replicate despite relatively few replicate samples in the overall dataset. These samples correlate poorly with the rest of the dataset, in addition to with replicate samples.




Figure A.3: **Replicate excluded samples.** Both tumour samples of patient A2QH were excluded as they were poorly correlated with other samples, although they are highly similar to each other as shown by Pearson's correlation of log-raw counts.




Figure A.4: Replicate samples with all remaining. Patient A26J was sampled 3 times and compared pairwise. Pairs of samples were also compared for other patients with replicate samples. In all cases, replicate samples remaining in the dataset were highly concordant as shown by Pearson's correlation of log-raw counts.






Figure A.5: Replicate samples with some excluded. Patients A0DB, A13D, A13E, and A26E were each sampled 3 times and compared pairwise. Pairs of samples were also compared for other patients with replicate samples. In all cases, the replicate samples remaining in the dataset more were highly concordant (as shown by Pearson's correlation of log-log counts) than those excluded from the analysis.



(j) Remaining

(k) Compare with excluded

(l) Compare with excluded



(m) Compare with excluded

(n) Compare with excluded

Figure A.5: **Replicate samples with some excluded.** Patients A0DB, A13D, A13E, and A26E were each sampled 3 times and compared pairwise. Pairs of samples were also compared for other patients with replicate samples. In all cases, the replicate samples remaining in the dataset more were highly concordant (as shown by Pearson's correlation of log-raw counts) than those excluded from the analysis.

Appendix B

Software Used for Thesis

Table B.1: R Packages used during Thesis

Package	Repository	Laptop	Lab	Server	NeSI
base	base	3.3.2	3.3.2	3.3.1	3.3.0
abind	CRAN		1.4-5		1.4-3
acepack	CRAN		1.4.1		1.3-3.3
ade4	CRAN		1.7-5		
annaffy	Bioconductor		1.46.0		
AnnotationDbi	Bioconductor		1.36.0	1.36.0	1.34.4
apComplex	CRAN		2.40.0		
ape	CRAN		4		3.4
arm	CRAN		1.9-3		
assertthat	CRAN	0.1	0.1	0.1	0.1
backports	CRAN	1.0.5	1.0.4	1.0.5	1.0.2
base64	CRAN			2	2
base64enc	CRAN		0.1-3		0.1-3
beanplot	CRAN		1.2	1.2	1.2
BH	CRAN	1.60.0-2	1.62.0-1	1.62.0-1	1.60.0-2
Biobase	Bioconductor		2.34.0	2.34.0	2.32.0
BiocGenerics	Bioconductor		0.20.0	0.20.0	0.18.0
BiocInstaller	Bioconductor		1.24.0	1.20.3	1.22.3
BiocParallel	Bioconductor		1.8.1	1.8.1	
Biostrings	Bioconductor		2.42.1	2.42.0	
BiSEp	Bioconductor		2.0.1	2.0.1	2.0.1

bitops	CRAN	1.0-6	1.0-6	1.0-6	1.0-6
boot	base	1.3-18	1.3-18	1.3-18	1.3-18
brew	CRAN	1.0-6	1.0-6	1.0-6	1.0-6
broom	CRAN	0.4.1			
caTools	CRAN	1.17.1	1.17.1	1.17.1	1.17.1
cgdssr	CRAN		1.2.5		
checkmate	CRAN		1.8.2		1.7.4
chron	CRAN	2.3-47	2.3-48	2.3-50	2.3-47
class	base	7.3-14	7.3-14	7.3-14	7.3-14
cluster	base	2.0.5	2.0.5	2.0.5	2.0.4
coda	CRAN		0.19-1		0.18-1
codetools	base	0.2-15	0.2-15	0.2-15	0.2-14
colorRamps	CRAN		2.3		
colorspace	CRAN	1.2-6	1.3-2	1.3-2	1.2-6
commonmark	CRAN	1.1		1.2	
compiler	base	3.3.2	3.3.2	3.3.1	3.3.0
corpcor	CRAN		1.6.8	1.6.8	1.6.8
Cprob	CRAN		1.2.4		
crayon	CRAN	1.3.2	1.3.2	1.3.2	1.3.2
crop	CRAN		0.0-2	0.0-2	
curl	CRAN	1.2	2.3	2.3	0.9.7
d3Network	CRAN		0.5.2.1		
data.table	CRAN	1.9.6	1.10.0	1.10.1	1.9.6
data.tree	CRAN		0.7.0	0.7.0	
datasets	base	3.3.2	3.3.2	3.3.1	3.3.0
DBI	CRAN	0.5-1	0.5-1	0.5-1	0.5-1
dendextend	CRAN	1.4.0	1.4.0	1.4.0	
DEoptimR	CRAN	1.0-8	1.0-8	1.0-8	1.0-4
desc	CRAN	1.1.0		1.1.0	
devtools	CRAN	1.12.0	1.12.0	1.12.0	1.12.0
DiagrammeR	CRAN		0.9.0	0.9.0	
dichromat	CRAN	2.0-0	2.0-0	2.0-0	2.0-0
digest	CRAN	0.6.10	0.6.11	0.6.12	0.6.9
diptest	CRAN	0.75-7	0.75-7	0.75-7	
doParallel	CRAN	1.0.10	1.0.10	1.0.10	1.0.10

dplyr	CRAN	0.5.0	0.5.0	0.5.0	0.5.0
ellipse	CRAN		0.3-8	0.3-8	0.3-8
evaluate	CRAN		0.1	0.1	0.9
fdrtool	CRAN		1.2.15		
fields	CRAN		8.1		
flexmix	CRAN	2.3-13	2.3-13	2.3-13	
forcats	CRAN	0.2.0			
foreach	CRAN	1.4.3	1.4.3	1.4.3	1.4.3
foreign	base	0.8-67	0.8-67	0.8-67	0.8-66
formatR	CRAN		1.4	1.4	1.4
Formula	CRAN		1.2-1		1.2-1
fpc	CRAN	2.1-10	2.1-10	2.1-10	
futile.logger	CRAN		1.4.3	1.4.3	1.4.1
futile.options	CRAN		1.0.0	1.0.0	1.0.0
gdata	CRAN	2.17.0	2.17.0	2.17.0	2.17.0
geepack	CRAN		1.2-1		
GenomeInfoDb	Bioconductor		1.10.2	1.10.1	
GenomicAlignments	Bioconductor		1.10.0	1.10.0	
GenomicRanges	Bioconductor		1.26.2	1.26.1	
ggm	CRAN		2.3		
ggplot2	CRAN	2.1.0	2.2.1	2.2.1	2.1.0
git2r	CRAN	0.15.0	0.18.0	0.16.0	0.15.0
glasso	CRAN		1.8		
GO.db	Bioconductor		3.4.0	3.2.2	3.3.0
GOSemSim	Bioconductor		2.0.3	1.28.2	1.30.3
gplots	CRAN	3.0.1	3.0.1	3.0.1	3.0.1
graph	Bioconductor		1.52.0		
graphics	base	3.3.2	3.3.2	3.3.1	3.3.0
graphsim	GitHub TomKellyGenetics	0.1.0	0.1.0	0.1.0	0.1.0
grDevices	base	3.3.2	3.3.2	3.3.1	3.3.0
grid	base	3.3.2	3.3.2	3.3.1	3.3.0
gridBase	CRAN	0.4-7	0.4-7	0.4-7	0.4-7
gridExtra	CRAN	2.2.1	2.2.1	2.2.1	2.2.1
gridGraphics	CRAN		0.1-5		

gtable	CRAN	0.2.0	0.2.0	0.2.0	0.2.0
gtools	CRAN	3.5.0	3.5.0	3.5.0	3.5.0
haven	CRAN	1.0.0			
heatmap.2x	GitHub		0.0.0.9000	0.0.0.9000	0.0.0.9000
	TomKellyGenetics				0.0.0.9000
hgu133plus2.db	Bioconductor		3.2.3		
highr	CRAN		0.6	0.6	0.6
Hmisc	CRAN		4.0-2	4.0-2	3.17-4
hms	CRAN	0.2	0.3		
htmlTable	CRAN		1.8	1.9	
htmltools	CRAN	0.3.5	0.3.5	0.3.5	0.3.5
htmlwidgets	CRAN		0.8	0.8	
httpuv	CRAN	1.3.3		1.3.3	
httr	CRAN	1.2.1	1.2.1	1.2.1	1.1.0
huge	CRAN		1.2.7		
hunspell	CRAN		2.3		2
hypergraph	CRAN		1.46.0		
igraph	CRAN	1.0.1	1.0.1	1.0.1	1.0.1
igraph.extensions	GitHub				
	TomKellyGenetics	0.1.0.9001	0.1.0.9001	0.1.0.9001	0.1.0.9001
influenceR	CRAN		0.1.0	0.1.0	
info.centrality	GitHub				
	TomKellyGenetics	0.1.0	0.1.0	0.1.0	0.1.0
IRanges	Bioconductor		2.8.1	2.8.1	2.6.1
irlba	CRAN	2.1.1	2.1.2	2.1.2	2.0.0
iterators	CRAN	1.0.8	1.0.8	1.0.8	1.0.8
jpeg	CRAN		0.1-8		
jsonlite	CRAN	1.1	1.2	1.3	0.9.20
KEGG.db	Bioconductor		3.2.3		
kernlab	CRAN	0.9-25	0.9-25	0.9-25	
KernSmooth	base	2.23-15	2.23-15	2.23-15	2.23-15
knitr	CRAN		1.15.1	1.15.1	1.14
labeling	CRAN	0.3	0.3	0.3	0.3
lambda.r	CRAN		1.1.9	1.1.9	1.1.7
lattice	base	0.20-34	0.20-34	0.20-34	0.20-33

latticeExtra	CRAN		0.6-28		0.6-28
lava	CRAN		1.4.6		
lavaan	CRAN		0.5-22		
lazyeval	CRAN	0.2.0	0.2.0	0.2.0	0.2.0
les	CRAN		1.24.0		
lgtdl	CRAN		1.1.3		
limma	Bioconductor		3.30.7	3.30.3	
lme4	CRAN		1.1-12		1.1-12
lubridate	CRAN	1.6.0			
magrittr	CRAN	1.5	1.5	1.5	1.5
maps	CRAN		3.1.1		
markdown	CRAN		0.7.7	0.7.7	0.7.7
MASS	base	7.3-45	7.3-45	7.3-45	7.3-45
Matrix	base	1.2-7.1	1.2-7.1	1.2-8	1.2-6
matrixcalc	CRAN	1.0-3	1.0-3	1.0-3	1.0-3
mclust	CRAN	5.2	5.2.1	5.2.2	5.2
memoise	CRAN	1.0.0	1.0.0	1.0.0	1.0.0
methods	base	3.3.2	3.3.2	3.3.1	3.3.0
mgcv	base	1.8-16	1.8-16	1.8-17	1.8-12
mi	CRAN		1		
mime	CRAN	0.5	0.5	0.5	0.4
minqa	CRAN		1.2.4		1.2.4
mnormt	CRAN	1.5-5	1.5-5		1.5-4
modelr	CRAN	0.1.0			
modeltools	CRAN	0.2-21	0.2-21	0.2-21	
multtest	Bioconductor		2.30.0	2.30.0	
munsell	CRAN	0.4.3	0.4.3	0.4.3	0.4.3
mvtnorm	CRAN	1.0-5	1.0-5	1.0-6	1.0-5
network	CRAN		1.13.0		
nlme	base	3.1-128	3.1-128	3.1-131	3.1-128
nloptr	CRAN		1.0.4		1.0.4
NMF	CRAN	0.20.6	0.20.6	0.20.6	0.20.6
nnet	base	7.3-12	7.3-12	7.3-12	7.3-12
numDeriv	CRAN		2016.8-1		2014.2-1
openssl	CRAN	0.9.4	0.9.6	0.9.6	0.9.4

org.Hs.eg.db	Bioconductor		3.1.2		3.3.0
org.Sc.sgd.db	Bioconductor		3.4.0		
parallel	base	3.3.2	3.3.2	3.3.1	3.3.0
pathway.structure	GitHub	0.1.0	0.1.0	0.1.0	0.1.0
.permutation	TomKellyGenetics				
pbivnorm	CRAN		0.6.0		
PGSEA	Bioconductor		1.48.0		
pkgmaker	CRAN	0.22	0.22	0.22	0.22
PKI	CRAN		0.1-3		
plogr	CRAN		0.1-1	0.1-1	
plot.igraph	GitHub	0.0.0.9001	0.0.0.9001	0.0.0.9001	0.0.0.9001
	TomKellyGenetics				
plotrix	CRAN		3.6-4		
plyr	CRAN	1.8.4	1.8.4	1.8.4	1.8.3
png	CRAN		0.1-7		0.1-7
prabclus	CRAN	2.2-6	2.2-6	2.2-6	
praise	CRAN	1.0.0	1.0.0		1.0.0
pROC	CRAN		1.8	1.9.1	
prodlim	CRAN		1.5.7		
prof.tree	CRAN		0.1.0		
protools	CRAN		0.99-2		
progress	CRAN			1.1.2	
psych	CRAN	1.6.12	1.6.12		
purrr	CRAN	0.2.2	0.2.2	0.2.2	0.2.2
qgraph	CRAN		1.4.1		
quadprog	CRAN		1.5-5	1.5-5	1.5-5
R.methodsS3	CRAN		1.7.1		1.7.1
R.oo	CRAN		1.21.0		1.20.0
R.utils	CRAN		2.5.0		
R6	CRAN	2.1.3	2.2.0	2.2.0	2.1.3
RBGL	CRAN		1.50.0		
RColorBrewer	CRAN	1.1-2	1.1-2	1.1-2	1.1-2
Rcpp	CRAN	0.12.7	0.12.9	0.12.9	0.12.7
RcppArmadillo	CRAN			0.7.700.0.0	0.6.700.6.0
RcppEigen	CRAN		0.3.2.9.0		0.3.2.8.1

RCurl	CRAN		1.95-4.8	1.95-4.8	1.95-4.8
reactome.db	Bioconductor		1.52.1	1.52.1	
reactometree	GitHub		0.1		
	TomKellyGenetics				
readr	CRAN	1.0.0	1.0.0		
readxl	CRAN	0.1.1			
registry	CRAN	0.3	0.3	0.3	0.3
reshape2	CRAN	1.4.1	1.4.2	1.4.2	1.4.1
rgeff	CRAN		0.15.3	0.15.3	
rgl	CRAN			0.97.0	0.95.1441
Rgraphviz	CRAN		2.18.0		
rjson	CRAN		0.2.15		
RJSONIO	CRAN		1.3-0		
rmarkdown	CRAN		1.3	1.3	1
Rmpi	CRAN		0.6-6		0.6-5
rngtools	CRAN	1.2.4	1.2.4	1.2.4	1.2.4
robustbase	CRAN	0.92-7	0.92-7	0.92-7	0.92-5
ROCR	CRAN	1.0-7	1.0-7	1.0-7	1.0-7
Rook	CRAN		1.1-1	1.1-1	
roxygen2	CRAN	6.0.1	5.0.1	6.0.1	5.0.1
rpart	base	4.1-10	4.1-10	4.1-10	4.1-10
rprojroot	CRAN	1.2	1.1	1.2	
Rsamtools	Bioconductor		1.26.1	1.26.1	
rsconnect	CRAN		0.7		
RSQLite	CRAN		1.1-2	1.1-2	1.0.0
rstudioapi	CRAN	0.6	0.6	0.6	0.6
rvest	CRAN	0.3.2			
S4Vectors	Bioconductor		0.12.1	0.12.0	0.10.3
safe	Bioconductor		3.14.0	3.10.0	
scales	CRAN	0.4.0	0.4.1	0.4.1	0.4.0
selectr	CRAN	0.3-1			
sem	CRAN		3.1-8		
shiny	CRAN	0.14		1.0.0	
slipt	GitHub		0.1.0	0.1.0	0.1.0
	TomKellyGenetics				

sm	CRAN	2.2-5.4	2.2-5.4		
sna	CRAN		2.4		
snow	CRAN	0.4-1	0.4-2	0.4-2	0.3-13
sourcetools	CRAN	0.1.5		0.1.5	
SparseM	CRAN		1.74		1.7
spatial	base	7.3-11	7.3-11	7.3-11	7.3-11
splines	base	3.3.2	3.3.2	3.3.1	3.3.0
statnet.common	CRAN		3.3.0		
stats	base	3.3.2	3.3.2	3.3.1	3.3.0
stats4	base	3.3.2	3.3.2	3.3.1	3.3.0
stringi	CRAN	1.1.1	1.1.2	1.1.2	1.0-1
stringr	CRAN	1.1.0	1.1.0	1.2.0	1.0.0
Summarized Experiment	Bioconductor		1.4.0	1.4.0	
survival	base	2.39-4	2.40-1	2.40-1	2.39-4
tcltk	base	3.3.2	3.3.2	3.3.1	3.3.0
testthat	CRAN	1.0.2	1.0.2		1.0.2
tibble	CRAN	1.2	1.2	1.2	1.2
tidyverse	GitHub hadley	1.1.1			
timeline	CRAN		0.9		
tools	base	3.3.2	3.3.2	3.3.1	3.3.0
tpr	CRAN		0.3-1		
trimcluster	CRAN	0.1-2	0.1-2	0.1-2	
Unicode	CRAN	9.0.0-1	9.0.0-1	9.0.0-1	
utils	base	3.3.2	3.3.2	3.3.1	3.3.0
vioplot	CRAN		0.2		
vioplotx	GitHub TomKellyGenetics	0.0.0.9000	0.0.0.9000		
viridis	CRAN	0.3.4	0.3.4	0.3.4	
visNetwork	CRAN		1.0.3	1.0.3	
whisker	CRAN	0.3-2	0.3-2	0.3-2	0.3-2
withr	CRAN	1.0.2	1.0.2	1.0.2	1.0.2
XML	base	3.98-1.3	3.98-1.1	3.98-1.5	3.98-1.4

xml2	CRAN	1.1.1	1.1.1	1.0.0
xtable	CRAN	1.8-2	1.8-2	1.8-2
XVector	Bioconductor		0.14.0	0.14.0
yaml	CRAN		2.1.14	2.1.14
zlibbioc	CRAN		1.20.0	1.20.0
zoo	CRAN	1.7-13	1.7-14	1.7-13

Appendix C

Secondary Screen Data

A series of experimental genome-wide siRNA screens have been performed on synthetic lethal partners of *CDH1* (Telford *et al.*, 2015). The strongest candidates from a primary screen were subject to a further secondary screen for validation by independent replication with 4 gene knockdowns with different targeting siRNA. As shown in Table C.1, there is significant ($p = 7.49 \times 10^{-3}$ by Fisher’s exact test) association between SLIPT candidates and stronger validations of siRNA candidates. Since there were more SLIPT– genes among those not validated and more SLIPT+ genes among those validated with several siRNAs, this supports the use of SLIPT as a synthetic lethal discovery procedure which may augment such screening experiments.

Table C.1: Comparing SLIPT genes against Secondary siRNA Screen in breast cancer

		Secondary Screen					Total	
		0/4	1/4	2/4	3/4	4/4		
SLIPT+	Observed	70	46	31	8	2	157	
	Expected	85	44	10	4	2		
SLIPT–	Observed	190	90	31	10	4	325	
	Expected	175	91	42	12	4		
		Total	280	136	52	18	6	482

Similar analysis with mtSLIPT, comparing SLIPT against *CDH1* somatic mutation with siRNA validation results was not significant ($p = 7.02 \times 10^{-1}$ by Fisher’s exact test). However, as shown in Table C.2, the observed and expected values were in a direction consistent with that observed above for SLIPT against low *CDH1* expression.

It is not unexpected that this result does not have comparable statistical support due to the lower sample size for mutation data.

Table C.2: Comparing mtSLIPT genes against Secondary siRNA Screen in breast cancer

		Secondary Screen					Total
		0/4	1/4	2/4	3/4	4/4	
mtSLIPT+	Observed	54	35	17	4	6	111
	Expected	60	31	14	4	1	
mtSLIPT-	Observed	206	101	45	14	5	371
	Expected	200	105	48	14	4	
Total		269	143	63	19	6	482

This analysis was replicated on a (smaller) stomach cancer dataset but it was less conclusive ($p = 2.36 \times 10^{-1}$ by Fisher's exact test). As shown in Table C.3, fewer SLIPT candidates were validated than expected statistically. However, these results in stomach cancer may not be directly comparable to experiments in a breast cell line. Genes validated by 0 or 1 siRNA behave consistently with the results above.

Table C.3: Comparing SLIPT genes against Secondary siRNA Screen in stomach cancer

		Secondary Screen					Total
		0/4	1/4	2/4	3/4	4/4	
SLIPT+	Observed	67	47	13	4	1	132
	Expected	71	37	17	5	2	
SLIPT-	Observed	195	90	50	14	5	354
	Expected	190	100	46	13	4	
Total		262	137	63	19	6	486

Appendix D

Mutation Analysis in Breast Cancer

D.1 Synthetic Lethal Genes and Pathways

SLIPT expression analysis (described in Section 3.1) on TCGA breast cancer data ($n = 969$) found the following genes and pathways, described in sections 4.1 and 4.1.1.

Table D.1: Candidate synthetic lethal gene partners of *CDH1* from mtSLIPT

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>TFAP2B</i>	8	36.7	89.5	3.60×10^{-20}	8.37×10^{-17}
<i>ZNF423</i>	15	36.7	78.8	7.89×10^{-18}	1.22×10^{-14}
<i>CALCOCO1</i>	11	36.7	76.8	2.09×10^{-17}	2.59×10^{-14}
<i>RBM5</i>	13	36.7	75.7	3.65×10^{-17}	4.00×10^{-14}
<i>BTG2</i>	7	36.7	71.7	2.72×10^{-16}	1.81×10^{-13}
<i>RXRA</i>	6	36.7	70.5	5.00×10^{-16}	2.97×10^{-13}
<i>SLC27A1</i>	11	36.7	70.3	5.42×10^{-16}	2.97×10^{-13}
<i>MEF2D</i>	12	36.7	69.6	7.86×10^{-16}	3.95×10^{-13}
<i>NISCH</i>	12	36.7	69.6	7.86×10^{-16}	3.95×10^{-13}
<i>AVPR2</i>	9	36.7	69.2	9.36×10^{-16}	4.58×10^{-13}
<i>CRY2</i>	13	36.7	68.9	1.07×10^{-15}	4.98×10^{-13}
<i>RAPGEF3</i>	13	36.7	68.9	1.07×10^{-15}	4.98×10^{-13}
<i>NRIP2</i>	10	36.7	68.2	1.58×10^{-15}	7.18×10^{-13}
<i>DARC</i>	12	36.7	66.4	3.76×10^{-15}	1.54×10^{-12}
<i>SFRS5</i>	12	36.7	66.4	3.76×10^{-15}	1.54×10^{-12}
<i>NOSTRIN</i>	5	36.7	65.1	7.40×10^{-15}	2.70×10^{-12}
<i>KIF13B</i>	12	36.7	63.4	1.69×10^{-14}	5.16×10^{-12}
<i>TENC1</i>	10	36.7	62.5	2.67×10^{-14}	7.40×10^{-12}
<i>MFAP4</i>	12	36.7	60.5	7.17×10^{-14}	1.67×10^{-11}
<i>ELN</i>	13	36.7	59.7	1.07×10^{-13}	2.32×10^{-11}
<i>SGK223</i>	14	36.7	59	1.51×10^{-13}	3.05×10^{-11}
<i>KIF12</i>	11	36.7	58.8	1.74×10^{-13}	3.34×10^{-11}
<i>SELP</i>	11	36.7	58.8	1.74×10^{-13}	3.34×10^{-11}
<i>CIRBP</i>	9	36.7	58.7	1.83×10^{-13}	3.41×10^{-11}
<i>CTDSP1</i>	9	36.7	58.7	1.83×10^{-13}	3.41×10^{-11}

Strongest candidate SL partners for *CDH1* by mtSLIPT with observed and expected mutant samples with low expression of partner genes

Table D.2: Pathways for *CDH1* partners from mtSLIPT

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	60	2.0×10^{-128}
Peptide chain elongation	83	59	2.0×10^{-128}
Eukaryotic Translation Termination	83	58	2.3×10^{-125}
Viral mRNA Translation	81	57	2.5×10^{-124}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	59	8.6×10^{-124}
Nonsense-Mediated Decay	103	61	5.2×10^{-117}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	103	61	5.2×10^{-117}
Formation of a pool of free 40S subunits	93	58	1.6×10^{-116}
L13a-mediated translational silencing of Ceruloplasmin expression	103	59	1.3×10^{-111}
3' -UTR-mediated translational regulation	103	59	1.3×10^{-111}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	59	6.2×10^{-111}
SRP-dependent cotranslational protein targeting to membrane	104	58	2.9×10^{-108}
Eukaryotic Translation Initiation	111	59	3.0×10^{-106}
Cap-dependent Translation Initiation	111	59	3.0×10^{-106}
Influenza Viral RNA Transcription and Replication	108	57	5.1×10^{-103}
Influenza Infection	117	59	1.5×10^{-102}
Translation	141	64	3.7×10^{-101}
Influenza Life Cycle	112	57	1.4×10^{-100}
GPCR downstream signaling	472	116	1.0×10^{-80}
Hemostasis	422	105	1.4×10^{-78}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in mtSLIPT partners for *CDH1*

The genes and pathways identified in Tables D.1 and D.2 were derived from comparing the expression profiles of potential partners to the mutation status of *CDH1* (as shown in Figure 3.2). Thus the following analysis is only limited the samples for which TCGA provides both expression and somatic mutation data.

D.2 Synthetic Lethal Expression Profiles

Similar to the analysis of synthetic lethal partners against low *CDH1* expression in 4.1.2, the partners detected from *CDH1* mutation were also examined for their expression profiles and the pathway composition of gene clusters. Hierarchical clustering was performed on mtSLIPT partners for *CDH1* as showing in Figure D.1. Overrepresentation for Reactome pathways for each of the gene clusters identified is given in Table D.3.




Table D.3: Pathway composition for clusters of *CDH1* partners from mtSLIPT

Pathways Over-represented in Cluster 1	Pathway Size	Cluster Genes	p-value (FDR)
Olfactory Signaling Pathway	57	8	7.1×10^{-9}
Assembly of the primary cilium	149	14	8.0×10^{-9}
Sphingolipid metabolism	62	8	9.6×10^{-9}
Signaling by ERBB4	133	12	5.1×10^{-8}
PI3K Cascade	65	7	4.9×10^{-7}
Circadian Clock	33	5	4.9×10^{-7}
Nuclear signaling by ERBB4	34	5	4.9×10^{-7}
Intraflagellar transport	35	5	4.9×10^{-7}
PI3K events in ERBB4 signaling	87	8	4.9×10^{-7}
PIP3 activates AKT signaling	87	8	4.9×10^{-7}
PI3K events in ERBB2 signaling	87	8	4.9×10^{-7}
PI-3K cascade:FGFR1	87	8	4.9×10^{-7}
PI-3K cascade:FGFR2	87	8	4.9×10^{-7}
PI-3K cascade:FGFR3	87	8	4.9×10^{-7}
PI-3K cascade:FGFR4	87	8	4.9×10^{-7}
Deadenylation of mRNA	22	4	5.6×10^{-7}
PI3K/AKT activation	90	8	5.6×10^{-7}
Cargo trafficking to the periciliary membrane	38	5	5.6×10^{-7}
Signaling by Hedgehog	108	9	5.6×10^{-7}
Downstream signal transduction	143	11	5.6×10^{-7}


Pathways Over-represented in Cluster 2	Pathway Size	Cluster Genes	p-value (FDR)
G _{αs} signalling events	83	19	5.1×10^{-25}
Extracellular matrix organization	238	30	1.4×10^{-18}
Hemostasis	422	46	2.7×10^{-16}
Aquaporin-mediated transport	32	9	2.7×10^{-16}
Transcriptional regulation of white adipocyte differentiation	56	11	1.7×10^{-15}
Degradation of the extracellular matrix	102	15	1.7×10^{-15}
Integration of energy metabolism	84	13	8.8×10^{-15}
GPCR downstream signaling	472	48	2.8×10^{-14}
G _{αs} signalling events	15	6	5.0×10^{-14}
Molecules associated with elastic fibres	33	8	5.4×10^{-14}
Phase 1 - Functionalization of compounds	67	11	5.6×10^{-14}
Platelet activation, signaling and aggregation	179	20	5.6×10^{-14}
Vasopressin regulates renal water homeostasis via Aquaporins	24	7	6.1×10^{-14}
Elastic fibre formation	37	8	$.03 \times 10^{-13}$
Calmodulin induced events	27	7	3.3×10^{-13}
CaM pathway	27	7	3.3×10^{-13}
cGMP effects	18	6	3.6×10^{-13}
G _{αs} signalling events	167	18	6.3×10^{-13}
Ca-dependent events	29	7	8.2×10^{-13}
Binding and Uptake of Ligands by Scavenger Receptors	40	8	8.2×10^{-13}

Pathways Over-represented in Cluster 3	Pathway Size	Cluster Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	55	1.1×10^{-112}
Peptide chain elongation	83	54	1.3×10^{-112}
Viral mRNA Translation	81	53	1.6×10^{-111}
Eukaryotic Translation Termination	83	53	7.1×10^{-110}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	54	1.0×10^{-108}
Formation of a pool of free 40S subunits	93	53	4.1×10^{-102}
Nonsense-Mediated Decay	103	54	3.9×10^{-98}
Nonsense-Mediated Decay enhanced by the Exon Junction Complex	103	54	3.9×10^{-98}
L13a-mediated translational silencing of Ceruloplasmin expression	103	53	1.2×10^{-95}
3' -UTR-mediated translational regulation	103	53	1.2×10^{-95}
SRP-dependent cotranslational protein targeting to membrane	104	53	4.3×10^{-95}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	53	4.3×10^{-95}
Influenza Viral RNA Transcription and Replication	108	53	9.6×10^{-93}
Eukaryotic Translation Initiation	111	53	4.2×10^{-91}
Cap-dependent Translation Initiation	111	53	4.2×10^{-91}
Influenza Life Cycle	112	53	1.4×10^{-90}
Influenza Infection	117	53	6.2×10^{-88}
Translation	141	55	3×10^{-81}
Formation of the ternary complex, and subsequently, the 43S complex	47	23	2.3×10^{-48}
Translation initiation complex formation	54	23	9.1×10^{-45}

Pathways Over-represented in Cluster 4	Pathway Size	Cluster Genes	p-value (FDR)
ECM proteoglycans	66	10	2.9×10^{-11}
deactivation of the beta-catenin transactivating complex	38	7	5.1×10^{-10}
Arachidonic acid metabolism	41	7	1.1×10^{-9}
Gαq signalling events	149	14	4.0×10^{-9}
HS-GAG degradation	21	5	4.5×10^{-9}
Uptake and actions of bacterial toxins	22	5	6.1×10^{-9}
Gastrin-CREB signalling pathway via PKC and MAPK	170	15	6.1×10^{-9}
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription	64	8	6.1×10^{-9}
Non-integrin membrane-ECM interactions	53	7	1.5×10^{-8}
Syndecan interactions	25	5	1.5×10^{-8}
NOTCH1 Intracellular Domain Regulates Transcription	40	6	2.3×10^{-8}
Synthesis of Leukotrienes and Exoxins	15	4	3.2×10^{-8}
Signaling by NOTCH1	59	7	5.3×10^{-8}
Regulation of insulin secretion	44	6	6.0×10^{-8}
Metabolism of lipids and lipoproteins	471	37	8.2×10^{-8}
Signaling by NOTCH	80	8	1.2×10^{-7}
Platelet activation, signaling and aggregation	179	14	1.2×10^{-7}
Recruitment of mitotic centrosome proteins and complexes	64	7	1.2×10^{-7}
Centrosome maturation	64	7	1.2×10^{-7}
Biological oxidations	133	11	1.5×10^{-7}

D.3 Comparison to Primary Screen

The mutation synthetic lethal partners with *CDH1* were also compared to siRNA primary screen data (Telford *et al.*, 2015), as performed in Section 4.2.1. These are expected to be more concordant with the experimental results performed on a null mutant, however this is not the case at the gene level: less genes overlapped with experimental candidates in Figure D.2. This may be affected by lower sample size for mutations in TCGA data or lower frequency (expected value) of *CDH1* mutations compared to low expression.



Despite a lower sample size (and low number of predicted partners) for mutation analysis, the pathway composition (Tables D.2 and D.4) is similar to expression analysis, as described in Section 4.2.1.4. In particular, the resampling analysis (Section ??) supported many of the results of expression analysis (Section 4.2.1.4.1) with Tables D.5 and D.6 detecting many of the same or functionally-related pathways.

Table D.4: Pathway composition for *CDH1* partners from mtSLIPT and siRNA

Predicted only by SLIPT (2901 genes)	Pathway Size	Genes Identified	p-value (FDR)
Eukaryotic Translation Elongation	87	57	2.8×10^{-120}
Peptide chain elongation	84	56	3.1×10^{-120}
Eukaryotic Translation Termination	84	55	2.8×10^{-117}
Viral mRNA Translation	82	54	4.1×10^{-116}
Nonsense Mediated Decay independent of the Exon Junction Complex	89	55	3.7×10^{-113}
Formation of a pool of free 40S subunits	94	55	2.8×10^{-109}
Nonsense-Mediated Decay	104	57	8.4×10^{-108}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	104	57	8.4×10^{-108}
L13a-mediated translational silencing of Ceruloplasmin expression	104	56	3.4×10^{-105}
3' -UTR-mediated translational regulation	104	56	3.4×10^{-105}
GTP hydrolysis and joining of the 60S ribosomal subunit	105	56	1.4×10^{-104}
Eukaryotic Translation Initiation	112	56	2.8×10^{-100}
Cap-dependent Translation Initiation	112	56	2.8×10^{-100}
SRP-dependent cotranslational protein targeting to membrane	105	54	2.2×10^{-99}
Influenza Viral RNA Transcription and Replication	109	54	5.3×10^{-97}
Influenza Life Cycle	113	54	9.6×10^{-95}
Influenza Infection	118	55	1.7×10^{-94}
Translation	142	60	3.5×10^{-94}
Infectious disease	349	77	5.9×10^{-62}
Extracellular matrix organization	241	54	3.0×10^{-52}

Detected only by siRNA screen (1752 genes)	Pathway Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)	282	69	1.9×10^{-59}
GPCR ligand binding	363	78	2.7×10^{-54}
Peptide ligand-binding receptors	175	41	1.5×10^{-42}
$G_{\alpha i}$ signalling events	184	41	1.1×10^{-40}
Gastrin-CREB signalling pathway via PKC and MAPK	180	37	1.5×10^{-35}
$G_{\alpha q}$ signalling events	159	34	3.7×10^{-35}
DAP12 interactions	159	27	1.1×10^{-24}
VEGFA-VEGFR2 Pathway	91	19	1.0×10^{-23}
Downstream signal transduction	146	24	1.9×10^{-22}
Signaling by VEGF	99	19	2.6×10^{-22}
DAP12 signaling	149	24	4.2×10^{-22}
Organelle biogenesis and maintenance	264	34	4.3×10^{-20}
Downstream signaling of activated FGFR1	134	21	4.3×10^{-20}
Downstream signaling of activated FGFR2	134	21	4.3×10^{-20}
Downstream signaling of activated FGFR3	134	21	4.3×10^{-20}
Downstream signaling of activated FGFR4	134	21	4.3×10^{-20}
Signaling by ERBB2	146	22	5.3×10^{-20}
Signaling by FGFR	146	22	5.3×10^{-20}
Signaling by FGFR1	146	22	5.3×10^{-20}
Signaling by FGFR2	146	22	5.3×10^{-20}

Intersection of SLIPT and siRNA screen (450 genes)	Pathway Size	Genes Identified	p-value (FDR)
HS-GAG degradation	21	4	4.9×10^{-6}
Retinoid metabolism and transport	39	5	4.9×10^{-6}
Platelet activation, signaling and aggregation	186	13	4.9×10^{-6}
Signaling by NOTCH4	11	3	4.9×10^{-6}
$G_{\alpha s}$ signalling events	100	8	5.0×10^{-6}
Defective EXT2 causes exostoses 2	12	3	5.0×10^{-6}
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	12	3	5.0×10^{-6}
Class A/1 (Rhodopsin-like receptors)	289	18	2.2×10^{-5}
Signaling by PDGF	173	11	2.9×10^{-5}
Circadian Clock	34	4	2.9×10^{-5}
Signaling by ERBB4	139	9	4.3×10^{-5}
Role of LAT2/NTAL/LAB on calcium mobilization	99	7	4.4×10^{-5}
Peptide ligand-binding receptors	181	11	4.5×10^{-5}
Defective B4GALT7 causes EDS, progeroid type	19	3	4.5×10^{-5}
Defective B3GAT3 causes JDSSDHD	19	3	4.5×10^{-5}
Signaling by NOTCH	80	6	4.5×10^{-5}
$G_{\alpha q}$ signalling events	164	10	5.1×10^{-5}
Response to elevated platelet cytosolic Ca ²⁺	84	6	7.1×10^{-5}
Signaling by ERBB2	148	9	7.1×10^{-5}
Signaling by SCF-KIT	129	8	8.3×10^{-5}

D.3.1 Resampling Analysis

Table D.5: Pathways for *CDH1* partners from mtSLIPT

Reactome Pathway	Over-representation	Permutation
Eukaryotic Translation Elongation	3.2×10^{-128}	$< 7.035 \times 10^{-4}$
Peptide chain elongation	3.2×10^{-128}	$< 7.035 \times 10^{-4}$
Eukaryotic Translation Termination	3.7×10^{-125}	$< 7.035 \times 10^{-4}$
Viral mRNA Translation	4.1×10^{-124}	$< 7.035 \times 10^{-4}$
Nonsense Mediated Decay independent of the Exon Junction Complex	1.4×10^{-123}	$< 7.035 \times 10^{-4}$
Nonsense-Mediated Decay	8.4×10^{-117}	$< 7.035 \times 10^{-4}$
Nonsense Mediated Decay enhanced by the Exon Junction Complex	8.4×10^{-117}	$< 7.035 \times 10^{-4}$
Formation of a pool of free 40S subunits	2.6×10^{-116}	$< 7.035 \times 10^{-4}$
L13a-mediated translational silencing of Ceruloplasmin expression	2.0×10^{-111}	$< 7.035 \times 10^{-4}$
3' -UTR-mediated translational regulation	2.0×10^{-111}	$< 7.035 \times 10^{-4}$
GTP hydrolysis and joining of the 60S ribosomal subunit	9.9×10^{-111}	$< 7.035 \times 10^{-4}$
SRP-dependent cotranslational protein targeting to membrane	4.7×10^{-108}	$< 7.035 \times 10^{-4}$
Eukaryotic Translation Initiation	4.8×10^{-106}	$< 7.035 \times 10^{-4}$
Cap-dependent Translation Initiation	4.8×10^{-106}	$< 7.035 \times 10^{-4}$
Influenza Viral RNA Transcription and Replication	8.1×10^{-103}	$< 7.035 \times 10^{-4}$
Influenza Infection	2.4×10^{-102}	$< 7.035 \times 10^{-4}$
Translation	6.0×10^{-101}	$< 7.035 \times 10^{-4}$
Influenza Life Cycle	2.2×10^{-100}	$< 7.035 \times 10^{-4}$
Disease	2.1×10^{-90}	0.013347
GPCR downstream signaling	1.6×10^{-80}	0.095478
Hemostasis	2.1×10^{-78}	0.2671
Signaling by GPCR	1.2×10^{-73}	0.44939
<i>Extracellular matrix organization</i>	2.2×10^{-67}	0.054008
Metabolism of proteins	1.4×10^{-66}	0.9607
Signal Transduction	2.1×10^{-66}	0.48184
Developmental Biology	2.5×10^{-66}	0.54075
Innate Immune System	5.3×10^{-66}	0.9589
Infectious disease	9.6×10^{-66}	0.21075
Signalling by NGF	1.1×10^{-62}	0.43356
Immune System	2.8×10^{-62}	0.23052

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).



Table D.6: Pathways for *CDH1* partners from mtSLIPT and siRNA primary screen

Reactome Pathway	Over-representation	Permutation
Visual phototransduction	1.2×10^{-9}	0.86279
G_{αs} signalling events	2.9×10^{-7}	0.023066
Retinoid metabolism and transport	2.9×10^{-7}	0.299
Acylic chain remodelling of PS	1.1×10^{-5}	0.42584
Transcriptional regulation of white adipocyte differentiation	1.1×10^{-5}	0.53928
Chemokine receptors bind chemokines	1.1×10^{-5}	0.95259
<i>Signaling by NOTCH4</i>	1.2×10^{-5}	0.079229
Defective EXT2 causes exostoses 2	1.2×10^{-5}	0.22292
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	1.2×10^{-5}	0.22292
Platelet activation, signaling and aggregation	1.2×10^{-5}	0.48853
Serotonin receptors	1.4×10^{-5}	0.34596
Nicotinamide salvaging	1.4×10^{-5}	0.70881
Phase 1 - Functionalization of compounds	2×10^{-5}	0.31142
Amine ligand-binding receptors	2.5×10^{-5}	0.34934
Acylic chain remodelling of PE	3.8×10^{-5}	0.42615
Signaling by GPCR	3.8×10^{-5}	0.93888
Molecules associated with elastic fibres	3.9×10^{-5}	0.017982
DAP12 interactions	3.9×10^{-5}	0.71983
Beta defensins	3.9×10^{-5}	0.91458
Cytochrome P ₄₅₀ - arranged by substrate type	4.7×10^{-5}	0.83493
GPCR ligand binding	5.7×10^{-5}	0.95258
Acylic chain remodelling of PC	6.1×10^{-5}	0.42584
Response to elevated platelet cytosolic Ca ²⁺	6.4×10^{-5}	0.54046
Arachidonic acid metabolism	6.7×10^{-5}	0.026696
Defective B4GALT7 causes EDS, progeroid type	7.3×10^{-5}	0.24921
Defective B3GAT3 causes JDSSDHD	7.3×10^{-5}	0.24921
Hydrolysis of LPC	7.3×10^{-5}	0.80663
Elastic fibre formation	7.4×10^{-5}	0.0058768
HS-GAG degradation	9.4×10^{-5}	0.0083179
<i>Bile acid and bile salt metabolism</i>	9.4×10^{-5}	0.079905
Netrin-1 signaling	0.00011	0.92216
Integration of energy metabolism	0.00011	0.011152
Dectin-2 family	0.00012	0.10385
Platelet sensitization by LDL	0.00012	0.34596
DAP12 signaling	0.00012	0.62787
Defensins	0.00012	0.77542
GPCR downstream signaling	0.00012	0.79454
<i>Diseases associated with glycosaminoglycan metabolism</i>	0.00013	0.065927
<i>Diseases of glycosylation</i>	0.00013	0.065927
Signaling by Retinoic Acid	0.00013	0.22292
Signaling by Leptin	0.00013	0.34596
Signaling by SCF-KIT	0.00013	0.70881
Opioid Signalling	0.00013	0.96053
Signaling by NOTCH	0.00015	0.26884
Platelet homeostasis	0.00015	0.4878
Signaling by NOTCH1	0.00016	0.13043
Class B/2 (Secretin family receptors)	0.00016	0.13994
<i>Diseases of Immune System</i>	0.0002	0.0795
<i>Diseases associated with the TLR signaling cascade</i>	0.0002	0.0795
A tetrasaccharide linker sequence is required for GAG synthesis	0.0002	0.42615

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

D.4 Compare SLIPT genes

The mutation synthetic lethal partners with *CDH1* were also compared to siRNA primary screen data (Telford *et al.*, 2015), by correlation and siRNA viability as described in sections 4.2.1.1 and 4.2.1.2.






Figure D.5: Compare mtSLIPT and siRNA genes with siRNA viability. Genes detected as candidate synthetic lethal partners by mtSLIPT (in TCGA breast cancer) expression analysis against *CDH1* mutation and experimental screening (with siRNA) were compared against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. There were clear no differences in viability between genes detected by mtSLIPT and those not with the differences being primarily due to viability thresholds being used to detect synthetic lethality by Telford *et al.* (2015).

D.5 Metagene Analysis

Metagene analysis was also performed for synthetic lethal candidates for *CDH1* mutation. These are described and compared to expression analysis in Section 4.3.4.

Table D.7: Candidate synthetic lethal metagenes against *CDH1* from mtSLIPT


Pathway	ID	Observed	Expected	χ^2 value	p-value	p-value (FDR)
Neurotoxicity of clostridium toxins	168799	8	36.7	79.4	5.71×10^{-18}	3.14×10^{-15}
Aquaporin-mediated transport	445717	8	36.7	76.3	2.73×10^{-17}	9.01×10^{-15}
Toxicity of botulinum toxin type G (BoNT/G)	5250989	8	36.7	76.3	2.73×10^{-17}	9.01×10^{-15}
ABC-family proteins mediated transport	382556	10	36.7	68.2	1.58×10^{-15}	1.86×10^{-13}
G _{αz} signalling events	418597	10	36.7	59.9	9.97×10^{-14}	5.48×10^{-12}
Regulation of IGF transport and uptake by IGFBPs	381426	9	36.7	56.3	5.88×10^{-13}	2.11×10^{-11}
GP1b-IX-V activation signalling	430116	8	36.7	55.7	8.20×10^{-13}	2.76×10^{-11}
GABA receptor activation	977443	12	36.7	55.1	1.07×10^{-12}	3.26×10^{-11}
Vasopressin regulates renal water homeostasis via Aquaporins	432040	9	36.7	54.1	1.77×10^{-12}	4.88×10^{-11}
Toxicity of botulinum toxin type D (BoNT/D)	5250955	14	36.7	53.4	2.54×10^{-12}	6.64×10^{-11}
Toxicity of botulinum toxin type F (BoNT/F)	5250981	14	36.7	53.4	2.54×10^{-12}	6.64×10^{-11}
STAT6-mediated induction of chemokines	3249367	16	36.7	52.2	4.72×10^{-12}	1.13×10^{-10}
Toxicity of botulinum toxin type B (BoNT/B)	5250958	14	36.7	50.8	9.5×10^{-12}	1.98×10^{-10}
S6K1 signalling	165720	12	36.7	50.2	1.24×10^{-11}	2.5×10^{-10}
G _{αs} signalling events	418555	11	36.7	49.2	2.08×10^{-11}	3.85×10^{-10}
RHO GTPases activate CIT	5625900	14	36.7	48.2	3.34×10^{-11}	5.9×10^{-10}
NADE modulates death signalling	205025	15	36.7	47.4	5.00×10^{-11}	8.32×10^{-10}
Keratan sulfate degradation	2022857	10	36.7	46.6	7.5×10^{-11}	1.15×10^{-9}
Signaling by Retinoic Acid	5362517	10	36.7	46.6	7.5×10^{-11}	1.15×10^{-9}
Adenylate cyclase inhibitory pathway	170670	14	36.7	45.9	1.11×10^{-10}	1.59×10^{-9}
Inhibition of adenylate cyclase pathway	997269	14	36.7	45.9	1.11×10^{-10}	1.59×10^{-9}
Fatty acids	211935	6	36.7	45.7	1.21×10^{-10}	1.72×10^{-9}
Ionotropic activity of Kainate Receptors	451306	13	36.7	44.6	2.03×10^{-10}	2.58×10^{-9}
Activation of Ca-permeable Kainate Receptor	451308	13	36.7	44.6	2.03×10^{-10}	2.58×10^{-9}
RA biosynthesis pathway	5365859	13	36.7	44.6	2.03×10^{-10}	2.58×10^{-9}

Strongest candidate SL partners for *CDH1* by mtSLIPT with observed and expected mutant samples with low expression of partner metagenes


D.6 Mutation Variation

Mutations have different effects as shown by the following examples in cancer genes.


D.6.1 Mutation Frequency




(a) *PI3KCA*



(b) *PI3KR1*



(c) *CDH1*



(d) *TP53*

Figure D.6: **Somatic mutation locus.** Mutation frequency at each locus in TCGA breast cancer. *PIK3CA* shows clear recurrent E545K and H1047R oncogene mutations consistent with it being an oncogene. *PIK3R1* and *CDH1* are tumour suppressors with inactivating mutations distributed throughout the gene, whereas *TP53* exhibits both of these properties and a very high mutation frequency compared to other genes.

D.6.2 PI3K Mutation Expression




Figure D.7: **Somatic mutation against PIK3CA metagene.** Mutations in *PIK3CA*, *PIK3R1*, *CDH1*, and *TP53* were examined in TCGA breast cancer for their effect on the PIK3CA (Gatza *et al.*, 2014) pathway metagene. The tumour suppressors *CDH1* and *TP53* showed an increase and decrease in the metagene respectively, whereas *PIK3CA* and *PIK3R1* mutations weaker evidence of decrease in metagene levels.




Figure D.8: Somatic mutation against PI3K protein. Mutations in *PIK3CA*, *PIK3R1*, *CDH1*, and *TP53* were examined in TCGA breast cancer for their effect on the expression of the p110 α protein (encoded by *PIK3CA*). Protein levels were significantly elevated in samples with *PIK3CA* or *PIK3R1* mutations and lower in samples with *TP53* mutations.




Figure D.9: Somatic mutation against AKT protein. Mutations in *PIK3CA*, *PIK3R1*, *CDH1*, and *TP53* were examined in TCGA breast cancer for their effect on the expression of the AKT protein (a downstream target of *PIK3CA*). Protein levels were not significantly different in samples mutations in any of these cancer genes.

Appendix E

Metagene Expression Profiles




Figure E.1: **Pathway metagene expression profiles.** Expression profiles for metagene signatures from Gatz *et al.* (2014) in TCGA breast data, annotated for clinical factors and cancer gene mutations.




Figure E.2: Expression profiles for constituent genes of PI3K. Expression profiles for the genes contained in the PI3K gene signature from Gatza *et al.* (2011) in TCGA breast data, annotated for clinical factors and cancer gene mutations. Samples are separated by *CDH1* expression status and sorted by the metagene. In both cases, the majority of genes were consistent with the direction of the PI3K metagene, although considerable proportion were inversely correlated with the metagene. Normal samples had low PI3K metagene expression and *TP53* mutant samples had high PI3K expression. Although, oncogenic *PIK3CA* and tumour suppressor *PIK3R1* mutations across samples including those with low metagene response.






Figure E.3: Expression profiles for p53 related genes. Expression profiles the genes contained in the *TP53* gene signature from Gatza *et al.* (2011) in TCGA breast data, annotated for clinical factors and cancer gene mutations. Samples are separated by *CDH1* expression status and sorted by the metagene. In both cases, the majority of genes were consistent with the direction of the metagene, with few very exceptions. *TP53* mutant samples had low metagene expression, consistent with loss of tumour suppressor functions, and were less likely to have *CDH1* or *PIK3CA* mutations.





Appendix F

Stomach Expression Analysis

The following results are a replication of the TCGA results (in Chapter 4) with stomach cancer data, using synthetic lethality (SLIPT) against *CDH1* mutation.

F.1 Synthetic Lethal Genes and Pathways

Table F.1: Synthetic lethal gene partners of *CDH1* from SLIPT in stomach cancer

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>PRAF2</i>	17	50.4	121	3.54×10^{-25}	1.45×10^{-21}
<i>EMP3</i>	17	50.4	115	5.06×10^{-24}	1.48×10^{-20}
<i>PLEKHO1</i>	22	50.4	112	2.14×10^{-23}	4.75×10^{-20}
<i>SELM</i>	20	50.4	111	5.13×10^{-23}	8.09×10^{-20}
<i>GYPC</i>	20	50.4	110	5.77×10^{-23}	8.45×10^{-20}
<i>COX7A1</i>	18	50.4	109	1.15×10^{-22}	1.39×10^{-19}
<i>TNFSF12</i>	20	50.4	106	4.06×10^{-22}	4.38×10^{-19}
<i>SEPT4</i>	17	50.4	106	6.58×10^{-22}	5.91×10^{-19}
<i>LGALS1</i>	19	50.4	105	6.64×10^{-22}	5.91×10^{-19}
<i>RARRES2</i>	27	50.4	105	8.02×10^{-22}	6.85×10^{-19}
<i>VEGFB</i>	16	50.4	104	1.19×10^{-21}	9.74×10^{-19}
<i>PRR24</i>	22	50.4	102	2.96×10^{-21}	2.02×10^{-18}
<i>SYNC</i>	19	50.4	102	3.73×10^{-21}	2.39×10^{-18}
<i>MAGEH1</i>	17	50.4	100	9.52×10^{-21}	5.01×10^{-18}
<i>HSPB2</i>	23	50.4	99.6	1.19×10^{-20}	5.82×10^{-18}
<i>SMARCD3</i>	19	50.4	99	1.59×10^{-20}	7.57×10^{-18}
<i>CREM</i>	13	50.4	98.1	2.48×10^{-20}	1.13×10^{-17}
<i>GNG11</i>	20	50.4	97.3	3.68×10^{-20}	1.59×10^{-17}
<i>GNAI2</i>	17	50.4	96.4	5.75×10^{-20}	2.36×10^{-17}
<i>FUNDC2</i>	22	50.4	95.9	7.39×10^{-20}	2.91×10^{-17}
<i>CNRIP1</i>	21	50.4	95.3	1.0×10^{-19}	3.66×10^{-17}
<i>CALHM2</i>	22	50.4	93.1	2.94×10^{-19}	1.06×10^{-16}
<i>ARID5A</i>	18	50.4	92.7	3.47×10^{-19}	1.22×10^{-16}
<i>ST3GAL3</i>	27	50.4	92.2	4.49×10^{-19}	1.56×10^{-16}
<i>LOC339524</i>	21	50.4	92.1	4.8×10^{-19}	1.59×10^{-16}

SLIPT partners of *CDH1* with observed and expected mutant samples of both genes

Table F.2: Pathway composition for clusters of *CDH1* partners in stomach SLIPT

Pathways Over-represented in Cluster 1	Pathway Size	Cluster Genes	p-value (FDR)
Viral mRNA Translation	82	48	1.3×10^{-97}
Formation of a pool of free 40S subunits	94	51	1.3×10^{-97}
Eukaryotic Translation Elongation	87	49	4.8×10^{-97}
Peptide chain elongation	84	48	1.4×10^{-96}
Eukaryotic Translation Termination	84	48	1.4×10^{-96}
GTP hydrolysis and joining of the 60S ribosomal subunit	105	52	7.9×10^{-94}
Nonsense Mediated Decay independent of the Exon Junction Complex	89	48	3.1×10^{-93}
Li3a-mediated translational silencing of Ceruloplasmin expression	104	51	5.1×10^{-92}
3' UTR-mediated translational regulation	104	51	5.1×10^{-92}
SRP-dependent cotranslational protein targeting to membrane	105	51	1.7×10^{-91}
Eukaryotic Translation Initiation	112	52	3.3×10^{-90}
Cap-dependent Translation Initiation	112	52	3.3×10^{-90}
Translation	142	56	3.6×10^{-85}
Nonsense-Mediated Decay	104	48	1.2×10^{-84}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	104	48	1.2×10^{-84}
Influenza Viral RNA Transcription and Replication	109	48	4.1×10^{-82}
Influenza Life Cycle	113	48	3.4×10^{-80}
Influenza Infection	118	48	6.4×10^{-78}
Infections diseases	349	68	1.8×10^{-50}
Formation of the ternary complex, and subsequently, the 43S complex	48	21	3.7×10^{-43}

Pathways Over-represented in Cluster 2	Pathway Size	Cluster Genes	p-value (FDR)
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	65	12	1.3×10^{-15}
Phosphorylation of CD3 and TCR zeta chains	18	6	1.7×10^{-12}
Generation of second messenger molecules	29	7	2.7×10^{-12}
PD-1 signaling	21	6	7.4×10^{-12}
TCR signaling	62	9	4.3×10^{-11}
Translocation of ZAP-70 to Immunological synapse	16	5	1.1×10^{-10}
Interferon alpha/beta signaling	68	9	1.6×10^{-10}
Initial triggering of complement	17	5	1.6×10^{-10}
IKK complex recruitment mediated by RIP1	19	5	5.1×10^{-10}
TRIF-mediated programmed cell death	10	4	6.2×10^{-10}
Creation of C4 and C2 activators	11	4	1.3×10^{-9}
RHO GTPases Activate NADPH Oxidases	11	4	1.3×10^{-9}
Interferon Signaling	175	15	2.3×10^{-9}
Chemokine receptors bind chemokines	52	7	4.0×10^{-9}
Interferon gamma signaling	74	8	1.6×10^{-8}
TRAF6 mediated induction of TAK1 complex	15	4	1.6×10^{-8}
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon	16	4	2.7×10^{-8}
Downstream TCR signaling	45	6	3.5×10^{-8}
Ligand-dependent caspase activation	17	4	4.2×10^{-8}
Complement cascade	34	5	1.3×10^{-7}

Pathways Over-represented in Cluster 3	Pathway Size	Cluster Genes	p-value (FDR)
Uptake and actions of bacterial toxins	22	4	3.5×10^{-6}
Neurotoxicity of clostridium toxins	10	3	3.5×10^{-6}
Activation of PPARGC1A (PGC-1alpha) by phosphorylation	10	3	3.5×10^{-6}
SMAD2/SMAD3/SMAD4 heterotrimer regulates transcription	28	4	1.4×10^{-5}
Assembly of the primary cilium	149	10	2.5×10^{-5}
Serotonin Neurotransmitter Release Cycle	15	3	2.5×10^{-5}
Glycosaminoglycan metabolism	114	8	3.3×10^{-5}
Platelet homeostasis	54	5	3.3×10^{-5}
Norepinephrine Neurotransmitter Release Cycle	17	3	3.3×10^{-5}
Acetylcholine Neurotransmitter Release Cycle	17	3	3.3×10^{-5}
Gas signalling events	100	7	5.5×10^{-5}
GABA synthesis, release, reuptake and degradation	19	3	5.6×10^{-5}
deactivation of the beta-catenin transactivating complex	39	4	6.7×10^{-5}
Dopamine Neurotransmitter Release Cycle	20	3	6.7×10^{-5}
IRS-related events triggered by IGFIR	83	6	7.1×10^{-5}
Generic Transcription Pathway	186	11	7.1×10^{-5}
Termination of O-glycan biosynthesis	21	3	7.4×10^{-5}
Kinesins	22	3	8.5×10^{-5}
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	86	6	8.5×10^{-5}
IGF1R signaling cascade	86	6	8.5×10^{-5}

Pathways Over-represented in Cluster 4	Pathway Size	Cluster Genes	p-value (FDR)
Extracellular matrix organization	241	97	8.8×10^{-126}
Axon guidance	289	75	8.3×10^{-72}
Hemostasis	445	101	8.3×10^{-72}
Developmental Biology	432	95	3.0×10^{-67}
Response to elevated platelet cytosolic Ca ²⁺	84	37	5.8×10^{-67}
Platelet degranulation	79	36	5.8×10^{-67}
Degradation of the extracellular matrix	104	39	6.7×10^{-63}
Platelet activation, signaling and aggregation	186	52	6.6×10^{-62}
ECM proteoglycans	66	31	8.1×10^{-61}
Neuronal System	272	64	5.1×10^{-60}
Signaling by PDGF	173	47	9.7×10^{-57}
Integrin cell surface interactions	82	31	1.9×10^{-53}
Collagen biosynthesis and modifying enzymes	56	26	1.1×10^{-52}
Collagen formation	67	28	1.4×10^{-52}
Class A/1 (Rhodopsin-like receptors)	289	61	2.3×10^{-52}
GPCR ligand binding	373	73	2.8×10^{-52}
Elastic fibre formation	38	22	4.7×10^{-52}
Non-integrin membrane-ECM interactions	53	24	7.0×10^{-49}
Glycosaminoglycan metabolism	114	33	4.7×10^{-47}
Platelet homeostasis	54	23	1.0×10^{-45}

F.2 Comparison to Primary Screen

The synthetic lethal partners with *CDH1* expression in stomach cancers were also compared to siRNA primary screen data (Telford *et al.*, 2015), as performed in Section 4.2.1. These are expected to be more concordant with the experimental results performed on a null mutant, however this is not the case at the gene level: less genes overlapped with experimental candidates in Figure F.1. This may be affected by lower sample size for mutations in TCGA data or lower frequency (expected value) of *CDH1* mutations compared to low expression.




Figure F.1: **Comparison of SLIPT in stomach to siRNA.** Testing the overlap of gene candidates for E-cadherin synthetic lethal partners between computational (SLIPT) and experimental screening (siRNA) approaches. The χ^2 test suggests that the overlap is no more than would be expected by chance ($p = 0.281$).

Table F.3: Pathway composition for *CDH1* partners from SLIPT and siRNA screening

Predicted only by SLIPT (3392 genes)	Pathway	Size	Genes Identified	p-value (FDR)
Extracellular matrix organization		238	90	3.4×10^{-107}
Eukaryotic Translation Termination		79	46	7.6×10^{-91}
Viral mRNA Translation		77	45	1.2×10^{-89}
Eukaryotic Translation Elongation		82	46	5.8×10^{-89}
Peptide chain elongation		79	45	2.1×10^{-88}
Nonsense Mediated Decay independent of the Exon Junction Complex		84	46	9.4×10^{-88}
Formation of a pool of free 40S subunits		89	47	3.3×10^{-87}
GTP hydrolysis and joining of the 60S ribosomal subunit		100	48	3.2×10^{-83}
Axon guidance		284	84	3.9×10^{-82}
Developmental Biology		426	111	4.2×10^{-82}
L13a-mediated translational silencing of Ceruloplasmin expression		99	47	1.4×10^{-81}
3' -UTR-mediated translational regulation		99	47	1.4×10^{-81}
SRP-dependent cotranslational protein targeting to membrane		99	47	1.4×10^{-81}
Nonsense-Mediated Decay		99	47	1.4×10^{-81}
Nonsense Mediated Decay enhanced by the Exon Junction Complex		99	47	1.4×10^{-81}
Hemostasis		438	112	1.2×10^{-80}
Eukaryotic Translation Initiation		107	48	8.0×10^{-80}
Cap-dependent Translation Initiation		107	48	8.0×10^{-80}
Infectious disease		338	90	1.6×10^{-76}
Neuronal System		267	77	1.6×10^{-76}

Detected only by siRNA screen (1803 genes)	Pathway	Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)		282	62	8.1×10^{-50}
GPCR ligand binding		363	71	4.9×10^{-46}
Peptide ligand-binding receptors		175	38	7.9×10^{-38}
<i>Gαi</i> signalling events		184	37	1.1×10^{-34}
Gastrin-CREB signalling pathway via PKC and MAPK		180	35	1.4×10^{-32}
<i>Gαq</i> signalling events		159	32	4.8×10^{-32}
DAP12 interactions		159	29	1.4×10^{-27}
Downstream signal transduction		146	26	2.4×10^{-25}
DAP12 signaling		149	26	6.4×10^{-25}
VEGFA-VEGFR2 Pathway		91	19	8.1×10^{-24}
Signaling by PDGF		172	27	5.7×10^{-23}
Signaling by ERBB2		146	24	1.4×10^{-22}
Signaling by VEGF		99	19	2.0×10^{-22}
Visual phototransduction		85	17	1.3×10^{-21}
Downstream signaling of activated FGFR1		134	22	1.3×10^{-21}
Downstream signaling of activated FGFR2		134	22	1.3×10^{-21}
Downstream signaling of activated FGFR3		134	22	1.3×10^{-21}
Downstream signaling of activated FGFR4		134	22	1.3×10^{-21}
Signaling by FGFR		146	23	2.0×10^{-21}
Signaling by FGFR1		146	23	2.0×10^{-21}

Intersection of SLIPT and siRNA screen (547 genes)	Pathway	Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)		282	25	3.9×10^{-9}
Platelet activation, signaling and aggregation		182	17	3.9×10^{-9}
Response to elevated platelet cytosolic Ca ²⁺		82	9	5.5×10^{-8}
Platelet homeostasis		53	7	5.7×10^{-8}
Nucleotide-like (purinergic) receptors		16	4	1.8×10^{-7}
Platelet degranulation		77	8	2.8×10^{-7}
Peptide ligand-binding receptors		175	14	3.8×10^{-7}
Molecules associated with elastic fibres		34	5	7.1×10^{-7}
Amine ligand-binding receptors		35	5	8.6×10^{-7}
<i>Gαi</i> signalling events		184	14	9.8×10^{-7}
GPCR ligand binding		363	27	1.1×10^{-6}
Elastic fibre formation		38	5	1.5×10^{-6}
<i>Gαq</i> signalling events		159	12	1.9×10^{-6}
Serotonin receptors		12	3	3.8×10^{-6}
P2Y receptors		12	3	3.8×10^{-6}
Signal amplification		16	3	2.3×10^{-5}
Gastrin-CREB signalling pathway via PKC and MAPK		180	12	2.3×10^{-5}
Complement cascade		33	4	2.4×10^{-5}
Glycosaminoglycan metabolism		110	8	2.5×10^{-5}
Glycogen breakdown (glycogenolysis)		17	3	2.7×10^{-5}

F.2.1 Resampling Analysis

Table F.4: Pathways for *CDH1* partners from SLIPT in stomach cancer

Reactome Pathway	Over-representation	Permutation
<i>Extracellular matrix organization</i>	7.5×10^{-140}	0.070215
Hemostasis	1.8×10^{-121}	0.25804
Developmental Biology	9.2×10^{-107}	0.53032
Axon guidance	1.5×10^{-102}	0.6704
Eukaryotic Translation Termination	1.9×10^{-99}	$> 1.031 \times 10^{-5}$
GPCR ligand binding	3.8×10^{-99}	0.54914
Viral mRNA Translation	3.3×10^{-98}	$> 1.031 \times 10^{-5}$
Formation of a pool of free 40S subunits	3.3×10^{-98}	$> 1.031 \times 10^{-5}$
Eukaryotic Translation Elongation	1.6×10^{-97}	$> 1.031 \times 10^{-5}$
Peptide chain elongation	7.2×10^{-97}	$> 1.031 \times 10^{-5}$
Class A/1 (Rhodopsin-like receptors)	2.7×10^{-96}	0.58174
Nonsense Mediated Decay independent of the Exon Junction Complex	3×10^{-96}	$> 1.031 \times 10^{-5}$
Infectious disease	2.6×10^{-94}	0.25484
GTP hydrolysis and joining of the 60S ribosomal subunit	3.4×10^{-94}	$> 1.031 \times 10^{-5}$
L13a-mediated translational silencing of Ceruloplasmin expression	2.8×10^{-92}	$> 1.031 \times 10^{-5}$
3' -UTR-mediated translational regulation	2.8×10^{-92}	$> 1.031 \times 10^{-5}$
Neuronal System	8.4×10^{-92}	0.53433
SRP-dependent cotranslational protein targeting to membrane	9.5×10^{-92}	$> 1.031 \times 10^{-5}$
Eukaryotic Translation Initiation	2.0×10^{-90}	$> 1.031 \times 10^{-5}$
Cap-dependent Translation Initiation	2.0×10^{-90}	$> 1.031 \times 10^{-5}$
Nonsense-Mediated Decay	7.4×10^{-90}	$> 1.031 \times 10^{-5}$
Nonsense Mediated Decay enhanced by the Exon Junction Complex	7.4×10^{-90}	$> 1.031 \times 10^{-5}$
Adaptive Immune System	8.1×10^{-88}	0.14116
Translation	1.3×10^{-87}	$> 1.031 \times 10^{-5}$
Platelet activation, signaling and aggregation	1.3×10^{-86}	0.28959
Influenza Infection	1×10^{-82}	$> 1.031 \times 10^{-5}$
Influenza Viral RNA Transcription and Replication	2.4×10^{-82}	$> 1.031 \times 10^{-5}$
Influenza Life Cycle	2×10^{-80}	$> 1.031 \times 10^{-5}$
Response to elevated platelet cytosolic Ca ²⁺	4.9×10^{-78}	0.50817
Signalling by NGF	1.6×10^{-75}	0.38518
Rho GTPase cycle	5.1×10^{-75}	0.14864
Signaling by PDGF	7.4×10^{-74}	0.40493
<i>Signaling by Rho GTPases</i>	5.1×10^{-73}	0.077217
Glycosaminoglycan metabolism	1.4×10^{-68}	0.52984
Gαi signalling events	1.8×10^{-66}	0.9254
Metabolism of carbohydrates	1.1×10^{-65}	0.39501
Gαs signalling events	2.7×10^{-65}	0.0050293
Potassium Channels	2.7×10^{-65}	0.53359
Transmission across Chemical Synapses	1.8×10^{-64}	0.81833
ECM proteoglycans	3.4×10^{-64}	0.083482
Peptide ligand-binding receptors	4.8×10^{-64}	0.62817
Degradation of the extracellular matrix	1.1×10^{-63}	0.80879
Platelet homeostasis	5.3×10^{-63}	0.53134
NGF signalling via TRKA from the plasma membrane	6.1×10^{-63}	0.57117
Integration of energy metabolism	4.5×10^{-61}	0.10889
Collagen formation	5.4×10^{-61}	0.29896
Integrin cell surface interactions	7×10^{-59}	0.18167
Collagen biosynthesis and modifying enzymes	7×10^{-59}	0.30208
Neurotransmitter Receptor Binding And Downstream Transmission	8.7×10^{-57}	0.82522
In The Postsynaptic Cell		
Signaling by Wnt	8.7×10^{-57}	0.25468

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

Table F.5: Pathways for *CDH1* partners from SLIPT in stomach and siRNA screen

Reactome Pathway	Over-representation	Permutation
Platelet activation, signaling and aggregation	3.9×10^{-9}	0.49557
Class A/1 (Rhodopsin-like receptors)	3.9×10^{-9}	0.98432
Response to elevated platelet cytosolic Ca ²⁺	5.5×10^{-8}	0.54349
Platelet homeostasis	5.7×10^{-8}	0.45017
Nucleotide-like (purinergic) receptors	1.8×10^{-7}	0.36966
Peptide ligand-binding receptors	3.8×10^{-7}	0.91294
Molecules associated with elastic fibres	7.1×10^{-7}	0.0025868
Amine ligand-binding receptors	8.6×10^{-7}	0.43303
<i>Gαi</i> signalling events	9.8×10^{-7}	0.99626
GPCR ligand binding	1.1×10^{-6}	0.97733
Elastic fibre formation	1.5×10^{-6}	0.0025868
<i>Gαq</i> signalling events	1.9×10^{-6}	0.86089
P2Y receptors	3.8×10^{-6}	0.18795
Serotonin receptors	3.8×10^{-6}	0.37853
Signal amplification	2.3×10^{-5}	0.47856
Gastrin-CREB signalling pathway via PKC and MAPK	2.3×10^{-5}	0.98567
Complement cascade	2.4×10^{-5}	$> 3.4628 \times 10^{-6}$
Glycosaminoglycan metabolism	2.5×10^{-5}	0.38953
Glycogen breakdown (glycogenolysis)	2.7×10^{-5}	0.83772
Defective B4GALT7 causes EDS, progeroid type	4.9×10^{-5}	0.10792
Defective B3GAT3 causes JDSSDHD	4.9×10^{-5}	0.10792
Role of LAT2/NTAL/LAB on calcium mobilization	5.6×10^{-5}	0.35373
Cell surface interactions at the vascular wall	5.6×10^{-5}	0.47642
<i>Gαs</i> signalling events	6×10^{-5}	0.019858
Signaling by NOTCH	6×10^{-5}	0.19008
A tetrasaccharide linker sequence is required for GAG synthesis	0.00017	0.47642
Extracellular matrix organization	0.00018	0.0047308
Collagen formation	0.00018	0.19245
Effects of PIP2 hydrolysis	0.0002	0.37779
Syndecan interactions	0.0002	0.37779
Diseases associated with glycosaminoglycan metabolism	0.00023	0.01028
Diseases of glycosylation	0.00023	0.01028
<i>Chondroitin sulfate/dermatan sulfate metabolism</i>	0.00023	0.085541
Integrin alphaIIb beta3 signaling	0.00028	0.76936
Keratan sulfate biosynthesis	0.00034	0.68744
Rho GTPase cycle	0.00034	0.15675
Creation of C4 and C2 activators	0.00035	0.12275
Abacavir transport and metabolism	0.00035	0.12443
Amine compound SLC transporters	0.00037	0.69773
FCER1 mediated NF-κB activation	0.00037	0.69846
Fc epsilon receptor (FCER1) signaling	0.00056	0.43303
Defective EXT2 causes exostoses 2	0.00067	0.16053
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	0.00067	0.16053
<i>Collagen biosynthesis and modifying enzymes</i>	0.00071	0.052911
Keratan sulfate/keratin metabolism	0.00073	0.46533
G alpha (12/13) signalling events	0.00078	0.59164
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion	0.00084	0.038504
Signal attenuation	0.00084	0.37779
Eicosanoid ligand-binding receptors	0.0011	0.11117
SOS-mediated signalling	0.0011	0.25387

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italicics (FDR < 0.1).

F.3 Metagene Analysis

Metagene analysis was also performed for synthetic lethal candidates for *CDH1* expression in stomach cancer. These are described and compared to mutation analysis in Section G.4.

Table F.6: Candidate synthetic lethal metagenes against *CDH1* from SLIPT in stomach cancer

Pathway	ID	Observed	Expected	χ^2 value	p-value	p-value (FDR)
Cell-Cell communication	1500931	18	50.4	110	7.43×10^{-23}	1.53×10^{-20}
VEGFR2 mediated vascular permeability	5218920	19	50.4	109	1.36×10^{-22}	2.49×10^{-20}
Sema4D in semaphorin signaling	400685	20	50.4	104	1.62×10^{-21}	2.12×10^{-19}
Ion transport by P-type ATPases	936837	17	50.4	100	8.29×10^{-21}	8.06×10^{-19}
Sialic acid metabolism	4085001	19	50.4	95.3	9.95×10^{-20}	7.82×10^{-18}
Synthesis of pyrophosphates in the cytosol	1855167	26	50.4	94	1.86×10^{-19}	1.23×10^{-17}
Keratan sulfate/keratin metabolism	1638074	25	50.4	93.5	2.36×10^{-19}	1.44×10^{-17}
Ion channel transport	983712	19	50.4	92.8	3.37×10^{-19}	1.99×10^{-17}
Keratan sulfate biosynthesis	2022854	26	50.4	91.4	6.79×10^{-19}	3.62×10^{-17}
Arachidonic acid metabolism	2142753	22	50.4	90.6	9.81×10^{-19}	5.07×10^{-17}
RHO GTPases activate CIT	5625900	22	50.4	87	5.80×10^{-18}	2.66×10^{-16}
Stimuli-sensing channels	2672351	25	50.4	85.8	1.03×10^{-17}	4.58×10^{-16}
Synthesis of PI	1483226	19	50.4	85.6	1.15×10^{-17}	4.89×10^{-16}
G-protein activation	202040	19	50.4	85.3	1.34×10^{-17}	5.53×10^{-16}
NrCAM interactions	447038	22	50.4	84.3	2.1×10^{-17}	8.27×10^{-16}
Inwardly rectifying K^+ channels	1296065	24	50.4	83.5	3.19×10^{-17}	1.22×10^{-15}
Calcitonin-like ligand receptors	419812	20	50.4	82.2	6.07×10^{-17}	2.13×10^{-15}
Prostacyclin signalling through prostacyclin receptor	392851	24	50.4	81.8	7.27×10^{-17}	2.5×10^{-15}
Presynaptic function of Kainate receptors	500657	26	50.4	79.7	2.00×10^{-16}	6.34×10^{-15}
ADP signalling through P2Y purinoceptor 12	392170	23	50.4	79.2	2.57×10^{-16}	7.71×10^{-15}
regulation of FZD by ubiquitination	4641263	22	50.4	78.8	3.15×10^{-16}	9.3×10^{-15}
Toxicity of tetanus toxin (TeNT)	5250982	27	50.4	78.7	3.36×10^{-16}	9.75×10^{-15}
Gap junction degradation	190873	21	50.4	78.5	3.66×10^{-16}	1.04×10^{-14}
Nephrin interactions	373753	25	50.4	78.2	4.21×10^{-16}	1.14×10^{-14}
GABA synthesis, release, reuptake and degradation	888590	26	50.4	77	7.69×10^{-16}	1.95×10^{-14}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

Appendix G

Stomach Mutation Analysis

The following results are a replication of the TCGA results (in Appendix D) with stomach cancer data, using synthetic lethality (mtSLIPT) against *CDH1* mutation.

G.1 Synthetic Lethal Genes and Pathways

Table G.1: Synthetic lethal gene partners of *CDH1* from mtSLIPT in stomach cancer

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>OLFML1</i>	5	10.1	29.2	4.53×10^{-7}	0.0031
<i>NRIP2</i>	6	10.1	25.4	3.11×10^{-6}	0.00706
<i>VIM</i>	3	10.1	24.7	4.29×10^{-6}	0.00706
<i>TCF4</i>	5	10.1	24.7	4.33×10^{-6}	0.00706
<i>ZEB2</i>	5	10.1	24.7	4.33×10^{-6}	0.00706
<i>BCL2</i>	2	10.1	22	1.66×10^{-5}	0.0155
<i>SMARCA2</i>	2	10.1	22	1.66×10^{-5}	0.0155
<i>CCND2</i>	3	10.1	21.1	2.61×10^{-5}	0.0155
<i>MMP19</i>	3	10.1	21.1	2.61×10^{-5}	0.0155
<i>NEURL1B</i>	3	10.1	21.1	2.61×10^{-5}	0.0155
<i>IGFBP6</i>	6	10.1	21.1	2.65×10^{-5}	0.0155
<i>OGN</i>	6	10.1	21.1	2.65×10^{-5}	0.0155
<i>THY1</i>	6	10.2	21	2.7×10^{-5}	0.0155
<i>DZIP1</i>	4	10.1	20.6	3.29×10^{-5}	0.0155
<i>LOC650368</i>	4	10.1	20.6	3.29×10^{-5}	0.0155
<i>PCOLCE</i>	4	10.1	20.6	3.29×10^{-5}	0.0155
<i>PTGFR</i>	4	10.1	20.6	3.29×10^{-5}	0.0155
<i>RUNX1T1</i>	4	10.1	20.6	3.29×10^{-5}	0.0155
<i>CLEC2B</i>	5	10.1	20.6	3.3×10^{-5}	0.0155
<i>MSC</i>	5	10.1	20.6	3.3×10^{-5}	0.0155
<i>NISCH</i>	5	10.1	20.6	3.3×10^{-5}	0.0155
<i>TSPAN11</i>	5	10.1	20.6	3.3×10^{-5}	0.0155
<i>KCTD12</i>	2	10.1	19.1	7.19×10^{-5}	0.0246
<i>LRRK55</i>	2	10.1	19.1	7.19×10^{-5}	0.0246
<i>PCBP3</i>	2	10.1	19.1	7.19×10^{-5}	0.0246

mtSLIPT partners with observed and expected *CDH1* mutant samples with low expression

Table G.2: Pathways for *CDH1* partners from mtSLIPT in stomach cancer

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Extracellular matrix organization	241	20	9.6×10^{-9}
Elastic fibre formation	38	6	3.7×10^{-8}
Diseases associated with glycosaminoglycan metabolism	26	5	3.7×10^{-8}
Diseases of glycosylation	26	5	3.7×10^{-8}
Nitric oxide stimulates guanylate cyclase	24	4	3.1×10^{-6}
Molecules associated with elastic fibres	34	4	3.7×10^{-5}
Platelet homeostasis	54	5	3.7×10^{-5}
Initial triggering of complement	17	3	3.7×10^{-5}
Regulation of IGF transport and uptake by IGFBPs	17	3	3.7×10^{-5}
Collagen degradation	58	5	5.6×10^{-5}
Defective B4GALT7 causes EDS, progeroid type	19	3	5.6×10^{-5}
Defective B3GAT3 causes JDSSDHD	19	3	5.6×10^{-5}
Degradation of the extracellular matrix	104	7	8.0×10^{-5}
ECM proteoglycans	66	5	0.00017
A tetrasaccharide linker sequence is required for GAG synthesis	25	3	0.00025
RHO GTPases Activate WASPs and WAVEs	29	3	0.00059
Non-integrin membrane-ECM interactions	53	4	0.00065
Creation of C4 and C2 activators	11	2	0.00079
Dermatan sulfate biosynthesis	11	2	0.00079
Integrin cell surface interactions	82	5	0.00098

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in mtSLIPT partners for *CDH1*

G.2 Synthetic Lethal Expression Profiles

Similar to the analysis of synthetic lethal partners against low *CDH1* expression in F.1, the partners detected from *CDH1* mutation were also examined for their expression profiles and the pathway composition of gene clusters. Hierarchical clustering was performed on mtSLIPT partners for *CDH1* as showing in Figure G.1. Over-representation for Reactome pathways for each of the gene clusters identified is given in Table G.3.




Table G.3: Pathway composition for clusters of *CDH1* partners in stomach mtSLIPT

Pathways Over-represented in Cluster 1	Pathway Size	Cluster Genes	p-value (FDR)
CD28 dependent PI3K/Akt signaling	15	1	1
Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis	19	1	1
CD28 co-stimulation	26	1	1
Lipid digestion, mobilization, and transport	48	1	1
Costimulation by the CD28 family	51	1	1
Dectin-1 mediated noncanonical NF- κ B signaling	58	1	1
CLEC7A (Dectin-1) signaling	99	1	1
C-type lectin receptors (CLRs)	123	1	1
Adaptive Immune System	418	1	1
Metabolism of lipids and lipoproteins	494	1	1
Interleukin-6 signaling	10	0	1
Apoptosis	150	0	1
Hemostasis	445	0	1
Intrinsic Pathway for Apoptosis	36	0	1
Cleavage of Growing Transcript in the Termination Region	33	0	1
PKB-mediated events	28	0	1
PI3K Cascade	68	0	1
RAF/MAP kinase cascade	10	0	1
Global Genomic NER (GG-NER)	35	0	1
Repair synthesis for gap-filling by DNA polymerase in TC-NER	15	0	1

Pathways Over-represented in Cluster 2	Pathway Size	Cluster Genes	p-value (FDR)
Kinesins	22	1	1
O-linked glycosylation of mucins	49	1	1
O-linked glycosylation	59	1	1
MHC class II antigen presentation	85	1	1
Factors involved in megakaryocyte development and platelet production	120	1	1
Post-translational protein modification	303	1	1
Adaptive Immune System	418	1	1
Hemostasis	445	1	1
Interleukin-6 signaling	10	0	1
Apoptosis	150	0	1
Intrinsic Pathway for Apoptosis	36	0	1
Cleavage of Growing Transcript in the Termination Region	33	0	1
PKB-mediated events	28	0	1
PI3K Cascade	68	0	1
RAF/MAP kinase cascade	10	0	1
Global Genomic NER (GG-NER)	35	0	1
Repair synthesis for gap-filling by DNA polymerase in TC-NER	15	0	1
Gap-filling DNA repair synthesis and ligation in TC-NER	17	0	1
Formation of transcription-coupled NER (TC-NER) repair complex	29	0	1
Dual incision reaction in TC-NER	29	0	1

Pathways Over-represented in Cluster 3	Pathway Size	Cluster Genes	p-value (FDR)
Extracellular matrix organization	241	20	9.6×10^{-9}
Elastic fibre formation	38	6	3.7×10^{-8}
Diseases associated with glycosaminoglycan metabolism	26	5	3.7×10^{-8}
Diseases of glycosylation	26	5	3.7×10^{-8}
Molecules associated with elastic fibres	34	4	4.8×10^{-5}
Initial triggering of complement	17	3	4.8×10^{-5}
Regulation of IGF transport and uptake by IGFBPs	17	3	4.8×10^{-5}
Collagen degradation	58	5	6.7×10^{-5}
Defective B4GALT7 causes EDS, progeroid type	19	3	6.7×10^{-5}
Defective B3GAT3 causes JDSSDH	19	3	6.7×10^{-5}
Degradation of the extracellular matrix	104	7	9.5×10^{-5}
ECM proteoglycans	66	5	0.0002
A tetrasaccharide linker sequence is required for GAG synthesis	25	5	0.00029
Non-integrin membrane-ECM interactions	53	4	0.00079
Creation of C4 and C2 activators	11	2	0.00093
Dermatan sulfate biosynthesis	11	2	0.00093
Integrin cell surface interactions	82	5	0.0012
Keratan sulfate degradation	12	2	0.0012
Complement cascade	34	3	0.0013
CS/DS degradation	13	2	0.0015

Pathways Over-represented in Cluster 4	Pathway Size	Cluster Genes	p-value (FDR)
cGMP effects	18	2	0.11
Nitric oxide stimulates guanylate cyclase	24	2	0.19
Neurotoxicity of clostridium toxins	10	1	1
Platelet homeostasis	54	2	1
Eicosanoid ligand-binding receptors	14	1	1
Prolactin receptor signaling	15	1	1
Acyl chain remodelling of PI	15	1	1
Signaling by FGFR1 fusion mutants	15	1	1
PKA activation	16	1	1
PKA-mediated phosphorylation of CREB	17	1	1
Synthesis of glycosylphosphatidylinositol (GPI)	17	1	1
PKA activation in glucagon signalling	17	1	1
Butyrate Response Factor 1 (BRF1) destabilizes mRNA	17	1	1
Other semaphorin interactions	19	1	1
Acyl chain remodelling of PE	21	1	1
Signaling by Leptin	21	1	1
DARPP-32 events	22	1	1
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	22	1	1
Uptake and actions of bacterial toxins	22	1	1
Acyl chain remodelling of PC	23	1	1

G.3 Comparison to Primary Screen

The mutation synthetic lethal partners with *CDH1* were also compared to siRNA primary screen data (Telford *et al.*, 2015), as performed in Section 4.2.1. These are expected to be more concordant with the experimental results performed on a null mutant, however this is not the case at the gene level: less genes overlapped with experimental candidates in Figure G.2. This may be affected by lower sample size for mutations in TCGA data or lower frequency (expected value) of *CDH1* mutations compared to low expression.




Table G.4: Pathway composition for *CDH1* partners from mtSLIPT and siRNA

Predicted only by SLIPT (217 genes)	Pathway Size	Genes Identified	p-value (FDR)
Diseases associated with glycosaminoglycan metabolism	26	5	1.6×10^{-7}
Diseases of glycosylation	26	5	1.6×10^{-7}
Extracellular matrix organization	238	18	1.7×10^{-6}
Elastic fibre formation	38	5	4.6×10^{-6}
Initial triggering of complement	16	3	7.3×10^{-5}
Regulation of IGF transport and uptake by IGFBPs	17	3	8.9×10^{-5}
Defective B4GALT7 causes EDS, progeroid type	19	3	0.00013
Defective B3GAT3 causes JDSSDHD	19	3	0.00013
Collagen degradation	57	5	0.00013
ECM proteoglycans	65	5	0.00039
A tetrasaccharide linker sequence is required for GAG synthesis	24	3	0.00039
Nitric oxide stimulates guanylate cyclase	24	3	0.00039
RHO GTPases Activate WASPs and WAVEs	28	3	0.00094
Creation of C4 and C2 activators	10	2	0.00098
Non-integrin membrane-ECM interactions	52	4	0.0012
Dermatan sulfate biosynthesis	11	2	0.0013
Degradation of the extracellular matrix	101	6	0.0016
Keratan sulfate degradation	12	2	0.0016
Complement cascade	33	3	0.0018
Molecules associated with elastic fibres	34	3	0.002

Detected only by siRNA screen (2323 genes)	Pathway Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)	282	86	6.5×10^{-85}
GPCR ligand binding	363	97	9.2×10^{-79}
Peptide ligand-binding receptors	175	52	4.5×10^{-61}
G _{αi} signalling events	184	49	1.6×10^{-53}
G _{αq} signalling events	159	43	5.2×10^{-50}
Gastrin-CREB signalling pathway via PKC and MAPK	180	46	9.4×10^{-50}
DAP12 interactions	159	35	8.3×10^{-37}
Platelet activation, signaling and aggregation	182	37	2.3×10^{-35}
Hemostasis	438	71	3.3×10^{-35}
Downstream signal transduction	146	32	7.7×10^{-35}
Signaling by PDGF	172	35	2.1×10^{-34}
DAP12 signaling	149	32	2.7×10^{-34}
Signaling by ERBB2	146	31	2.5×10^{-33}
Signalling by NGF	266	44	5.3×10^{-31}
Downstream signaling of activated FGFR1	134	28	5.3×10^{-31}
Downstream signaling of activated FGFR2	134	28	5.3×10^{-31}
Downstream signaling of activated FGFR3	134	28	5.3×10^{-31}
Downstream signaling of activated FGFR4	134	28	5.3×10^{-31}
Signaling by FGFR	146	29	2.0×10^{-30}
Signaling by FGFR1	146	29	2.0×10^{-30}

Intersection of SLIPT and siRNA screen (23 genes)	Pathway Size	Genes Identified	p-value (FDR)
ADP signalling through P2Y purinoceptor 1	10	1	1
G-protein beta:gamma signalling	11	1	1
G-protein activation	12	1	1
Eicosanoid ligand-binding receptors	14	1	1
Platelet homeostasis	53	2	1
G _{αz} signalling events	15	1	1
Signal amplification	16	1	1
Activation of Kainate Receptors upon glutamate binding	17	1	1
Thrombin signalling through protease activated receptors (PARs)	17	1	1
Nitric oxide stimulates guanylate cyclase	24	1	1
Activation of G protein gated Potassium channels	25	1	1
G protein gated Potassium channels	25	1	1
Inhibition of voltage gated Ca ²⁺ channels via Gbeta/gamma subunits	25	1	1
Laminin interactions	29	1	1
Inwardly rectifying K ⁺ channels	31	1	1
Glucagon signaling in metabolic regulation	33	1	1
Molecules associated with elastic fibres	34	1	1
Ca ²⁺ pathway	36	1	1
Elastic fibre formation	38	1	1
GABA B receptor activation	38	1	1

G.3.1 Resampling Analysis

Table G.5: Pathways for *CDH1* partners from mtSLIPT in stomach cancer

Reactome Pathway	Over-representation	Permutation
<i>Extracellular matrix organization</i>	9.6×10^{-9}	0.057678
Elastic fibre formation	3.7×10^{-8}	0.033817
<i>Diseases associated with glycosaminoglycan metabolism</i>	3.7×10^{-8}	0.049336
<i>Diseases of glycosylation</i>	3.7×10^{-8}	0.049336
<i>Nitric oxide stimulates guanylate cyclase</i>	3.1×10^{-6}	0.037904
Initial triggering of complement	3.7×10^{-5}	0.020828
Molecules associated with elastic fibres	3.7×10^{-5}	0.027865
<i>Regulation of IGF transport and uptake by IGFBPs</i>	3.7×10^{-5}	0.069102
<i>Platelet homeostasis</i>	3.7×10^{-5}	0.097294
<i>Defective B4GALT7 causes EDS, progeroid type</i>	5.6×10^{-5}	0.081505
<i>Defective B3GAT3 causes JDSSDHD</i>	5.6×10^{-5}	0.081505
Collagen degradation	5.6×10^{-5}	0.1104
<i>Degradation of the extracellular matrix</i>	8×10^{-5}	0.43477
<i>ECM proteoglycans</i>	0.00017	0.06469
<i>A tetrasaccharide linker sequence is required for GAG synthesis</i>	0.00025	0.10536
<i>RHO GTPases Activate WASPs and WAVES</i>	0.00059	0.053929
<i>Non-integrin membrane-ECM interactions</i>	0.00065	0.10424
<i>Creation of C4 and C2 activators</i>	0.00079	0.05461
<i>Dermatan sulfate biosynthesis</i>	0.00079	0.21163
<i>Integrin cell surface interactions</i>	0.00098	0.092405
<i>Glucagon signaling in metabolic regulation</i>	0.00098	0.13425
<i>Keratan sulfate degradation</i>	0.00098	0.22137
Complement cascade	0.0011	0.01552
<i>CS/DS degradation</i>	0.0012	0.065012
<i>Eicosanoid ligand-binding receptors</i>	0.0016	0.066128
<i>Nuclear signaling by ERBB4</i>	0.0016	0.15511
<i>Collagen formation</i>	0.0026	0.13447
cGMP effects	0.0041	0.020195
<i>Voltage gated Potassium channels</i>	0.0041	0.068923
Chondroitin sulfate biosynthesis	0.0059	$> 1.5862 \times 10^{-5}$
<i>Chondroitin sulfate/dermatan sulfate metabolism</i>	0.0065	0.087745
<i>Heparan sulfate/heparin (HS-GAG) metabolism</i>	0.0071	0.085622
<i>Synthesis of substrates in N-glycan biosynthesis</i>	0.0085	0.09456
<i>Regulation of actin dynamics for phagocytic cup formation</i>	0.0085	0.096227
<i>CDO in myogenesis</i>	0.01	0.32599
<i>Myogenesis</i>	0.01	0.32599
<i>Syndecan interactions</i>	0.012	0.10975
<i>Activation of Matrix Metalloproteinases</i>	0.012	0.33499
<i>Glycosaminoglycan metabolism</i>	0.012	0.29716
<i>Collagen biosynthesis and modifying enzymes</i>	0.013	0.10774
<i>Keratan sulfate biosynthesis</i>	0.016	0.12644
<i>O-linked glycosylation</i>	0.016	0.65101
<i>Laminin interactions</i>	0.021	0.12766
<i>Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide) and transfer to a nascent protein</i>	0.027	0.065782
<i>Sialic acid metabolism</i>	0.027	0.13413
<i>Keratan sulfate/keratin metabolism</i>	0.029	0.15708
<i>Potassium Channels</i>	0.032	0.43477
<i>Fcgamma receptor (FCGR) dependent phagocytosis</i>	0.042	0.15851
<i>Ion transport by P-type ATPases</i>	0.048	0.66686
<i>Retinoid metabolism and transport</i>	0.051	0.058715

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR).

Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

Table G.6: Pathways for *CDH1* partners from mtSLIPT in stomach and siRNA screen

Reactome Pathway	Over-representation	Permutation
SLBP independent Processing of Histone Pre-mRNAs	1	$> 1.2349 \times 10^{-5}$
Mitochondrial protein import	1	$> 1.2349 \times 10^{-5}$
Voltage gated Potassium channels	1	$> 1.2349 \times 10^{-5}$
Tandem pore domain potassium channels	1	$> 1.2349 \times 10^{-5}$
L13a-mediated translational silencing of Ceruloplasmin expression	1	$> 1.2349 \times 10^{-5}$
Eukaryotic Translation Elongation	1	$> 1.2349 \times 10^{-5}$
Peptide chain elongation	1	$> 1.2349 \times 10^{-5}$
3' -UTR-mediated translational regulation	1	$> 1.2349 \times 10^{-5}$
Activation of Matrix Metalloproteinases	1	$> 1.2349 \times 10^{-5}$
HIV Infection	1	$> 1.2349 \times 10^{-5}$
Cell Cycle	1	$> 1.2349 \times 10^{-5}$
Influenza Infection	1	$> 1.2349 \times 10^{-5}$
Influenza Life Cycle	1	$> 1.2349 \times 10^{-5}$
Influenza Viral RNA Transcription and Replication	1	$> 1.2349 \times 10^{-5}$
Neurotoxicity of clostridium toxins	1	$> 1.2349 \times 10^{-5}$
p38MAPK events	1	$> 1.2349 \times 10^{-5}$
SCF-beta-TrCP mediated degradation of Emi1	1	$> 1.2349 \times 10^{-5}$
SRP-dependent cotranslational protein targeting to membrane	1	$> 1.2349 \times 10^{-5}$
Vpu mediated degradation of CD4	1	$> 1.2349 \times 10^{-5}$
Serotonin Neurotransmitter Release Cycle	1	$> 1.2349 \times 10^{-5}$
Acetylcholine Binding And Downstream Events	1	$> 1.2349 \times 10^{-5}$
Viral mRNA Translation	1	$> 1.2349 \times 10^{-5}$
Cobalamin (Cbl, vitamin B12) transport and metabolism	1	$> 1.2349 \times 10^{-5}$
ERK/MAPK targets	1	$> 1.2349 \times 10^{-5}$
Vitamin B5 (pantothenate) metabolism	1	$> 1.2349 \times 10^{-5}$
Signaling by BMP	1	$> 1.2349 \times 10^{-5}$
Synthesis of Leukotrienes (LT) and Eoxins (EX)	1	$> 1.2349 \times 10^{-5}$
Separation of Sister Chromatids	1	$> 1.2349 \times 10^{-5}$
Mitotic Metaphase and Anaphase	1	$> 1.2349 \times 10^{-5}$
TRP channels	1	$> 1.2349 \times 10^{-5}$
Defects in cobalamin (B12) metabolism	1	$> 1.2349 \times 10^{-5}$
Regulation by c-FLIP	1	$> 1.2349 \times 10^{-5}$
Attenuation phase	1	$> 1.2349 \times 10^{-5}$
Autodegradation of the E3 ubiquitin ligase COP1	1	$> 1.2349 \times 10^{-5}$
Apoptotic cleavage of cell adhesion proteins	1	$> 1.2349 \times 10^{-5}$
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	1	$> 1.2349 \times 10^{-5}$
PERK regulates gene expression	1	$> 1.2349 \times 10^{-5}$
Regulation of the Fanconi anemia pathway	1	$> 1.2349 \times 10^{-5}$
Passive transport by Aquaporins	1	$> 1.2349 \times 10^{-5}$
Lysosome Vesicle Biogenesis	1	$> 1.2349 \times 10^{-5}$
Zinc transporters	1	$> 1.2349 \times 10^{-5}$
Zinc influx into cells by the SLC39 gene family	1	$> 1.2349 \times 10^{-5}$
Asparagine N-linked glycosylation	1	$> 1.2349 \times 10^{-5}$
AUF1 (hnRNP D0) destabilizes mRNA	1	$> 1.2349 \times 10^{-5}$
Asymmetric localization of PCP proteins	1	$> 1.2349 \times 10^{-5}$
degradation of DVL	1	$> 1.2349 \times 10^{-5}$
CASP8 activity is inhibited	1	$> 1.2349 \times 10^{-5}$
Degradation of GLI1 by the proteasome	1	$> 1.2349 \times 10^{-5}$
BBSome-mediated cargo-targeting to cilium	1	$> 1.2349 \times 10^{-5}$
Regulation of necroptotic cell death	1	$> 1.2349 \times 10^{-5}$

G.4 Metagene Analysis

Metagene analysis was also performed for synthetic lethal candidates for *CDH1* mutation in stomach cancer. These are described and compared to expression analysis in Section F.3.

Table G.7: Candidate synthetic lethal metagenes against *CDH1* from mtSLIPT in stomach cancer

Pathway	ID	Observed	Expected	χ^2 value	p-value	p-value (FDR)
Prostacyclin signalling through prostacyclin receptor	392851	1	10.1	26.5	1.73×10^{-6}	0.00286
Cell surface interactions at the vascular wall	202733	3	10.1	21.1	2.61×10^{-5}	0.00642
The NLRP1 inflammasome	844455	3	10.1	21.1	2.61×10^{-5}	0.00642
Innate Immune System	168249	6	10.1	21.1	2.65×10^{-5}	0.00642
Keratan sulfate/keratin metabolism	1638074	4	10.1	20.6	3.29×10^{-5}	0.00642
Keratan sulfate biosynthesis	2022854	4	10.1	20.6	3.29×10^{-5}	0.00642
Signaling by SCF-KIT	1433557	5	10.1	20.6	3.30×10^{-5}	0.00642
VEGFA-VEGFR2 Pathway	4420097	5	10.1	20.6	3.30×10^{-5}	0.00642
p130Cas linkage to MAPK signaling for integrins	372708	2	10.1	19.1	7.19×10^{-5}	0.00651
cGMP effects	418457	8	10.1	19	7.46×10^{-5}	0.00651
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components	446388	8	10.1	19	7.46×10^{-5}	0.00651
Fcgamma receptor (FCGR) dependent phagocytosis	2029480	3	10.1	17.9	0.000127	0.00651
A third proteolytic cleavage releases NICD	157212	7	10.1	17.9	0.00013	0.00651
Signalling by NGF	166520	7	10.1	17.9	0.00013	0.00651
Signaling by VEGF	194138	7	10.1	17.9	0.00013	0.00651
Regulation of thyroid hormone activity	350864	7	10.1	17.9	0.00013	0.00651
Nitric oxide stimulates guanylate cyclase	392154	7	10.1	17.9	0.00013	0.00651
Platelet homeostasis	418346	7	10.1	17.9	0.00013	0.00651
PI3K events in ERBB4 signaling	1250342	4	10.1	17.3	0.000179	0.00651
PIP3 activates AKT signaling	1257604	4	10.1	17.3	0.000179	0.00651
GAB1 signalosome	180292	4	10.1	17.3	0.000179	0.00651
PI3K events in ERBB2 signaling	1963642	4	10.1	17.3	0.000179	0.00651
PI3K/AKT Signaling in Cancer	2219528	4	10.1	17.3	0.000179	0.00651
Rap1 signalling	392517	4	10.1	17.3	0.000179	0.00651
Lysosphingolipid and LPA receptors	419408	4	10.1	17.3	0.000179	0.00651

Strongest candidate SL partners for *CDH1* by mtSLIPT with observed and expected mutant samples with low expression of partner metagenes

Appendix H

Global Synthetic Lethality in Stomach Cancer




Figure H.1: **Synthetic lethal partners across query genes.** Global synthetic lethal pairs were examined across the genome in TCGA stomach expression data by applying SLIPT across query genes. The high number of predicted partners for *CDH1* was typical for a human gene and lower than many other genes.

H.1 Hub Genes

Table H.1: Query synthetic lethal genes with the most SLIPT partners

Gene	Direction	raw p-value	p-value (FDR)	SLIPT raw p-value	SLIPT (FDR)
<i>HEG1</i>	10719	16956	16724	9616	9532
<i>SYNE1</i>	10755	17210	16984	9749	9676
<i>A2M</i>	10743	16650	16378	9529	9433
<i>ANK2</i>	11008	16616	16355	9764	9653
<i>TTC28</i>	10757	16523	16248	9530	9429
<i>FAT4</i>	10451	16286	15978	9225	9115
<i>MRVI1</i>	10904	16967	16718	9775	9686
<i>PAPLN</i>	10483	16405	16104	9305	9193
<i>NFASC</i>	10773	16575	16307	9578	9475
<i>MACF1</i>	9697	16378	16058	8620	8540
<i>HMCN1</i>	10475	16101	15733	9156	9008
<i>MPDZ</i>	10878	16550	16299	9599	9491
<i>FLRT2</i>	10776	16760	16473	9590	9464
<i>SETBP1</i>	10869	16632	16349	9615	9489
<i>LAMA4</i>	10463	16447	16121	9273	9151
<i>IL1R1</i>	10611	16185	15803	9299	9174
<i>ABCA6</i>	10499	16573	16318	9260	9158
<i>LAMC1</i>	10238	15777	15392	8837	8691
<i>TNS1</i>	10920	17038	16806	9836	9751
<i>AMOTL1</i>	10612	16458	16178	9367	9250

Genes with the most candidate SL partners SLIPT in TCGA stomach expression data with the number of partner genes predicted by direction criteria and χ^2 testing separately and combined as a SLIPT analysis. Where specified, the p-values for the χ^2 test were adjusted for multiple tests (FDR).

H.2 Hub Pathways

Table H.2: Pathways for genes with the most SLIPT partners

Pathways Over-represented	Pathway Size	SL Genes	p-value	p-value (FDR)
Molecules associated with elastic fibres	34	10	4.6×10^{-21}	2.7×10^{-18}
Extracellular matrix organization	241	29	5.3×10^{-21}	2.7×10^{-18}
Smooth Muscle Contraction	29	9	5.6×10^{-20}	1.6×10^{-17}
Elastic fibre formation	38	10	6×10^{-20}	1.6×10^{-17}
Nitric oxide stimulates guanylate cyclase	24	8	6.9×10^{-19}	1.4×10^{-16}
Muscle contraction	64	12	8.3×10^{-19}	1.4×10^{-16}
Platelet homeostasis	54	11	1.3×10^{-18}	1.9×10^{-16}
cGMP effects	18	6	3.3×10^{-15}	4.3×10^{-13}
Laminin interactions	30	7	1.3×10^{-14}	1.6×10^{-12}
Axon guidance	289	25	5×10^{-13}	5.2×10^{-11}
Signaling by BMP	23	5	3.7×10^{-11}	3.2×10^{-9}
RHO GTPases activate PAKs	23	5	3.7×10^{-11}	3.2×10^{-9}
Non-integrin membrane-ECM interactions	53	7	7.2×10^{-11}	5.8×10^{-9}
Rho GTPase cycle	120	11	1.2×10^{-10}	8.7×10^{-9}
Degradation of the extracellular matrix	104	10	1.3×10^{-10}	8.8×10^{-9}
Netrin-1 signaling	42	6	2.5×10^{-10}	1.6×10^{-8}
Developmental Biology	432	32	8.3×10^{-10}	5×10^{-8}
L1CAM interactions	80	8	8.7×10^{-10}	5×10^{-8}
Semaphorin interactions	64	7	1.1×10^{-9}	6.1×10^{-8}
Cell-extracellular matrix interactions	18	4	1.3×10^{-9}	6.6×10^{-8}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in the top 500 “hub” genes with the most candidate synthetic lethal partners by SLIPT analysis of TCGA stomach expression data

Appendix I

Replication in cell line encyclopaedia

Table I.1: Candidate synthetic lethal gene partners of *CDH1* from SLIPT in CCLE

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>ZEB1</i>	24	115	555	7.84×10^{-119}	3.62×10^{-116}
<i>RP11-620J15.3</i>	17	115	471	1.54×10^{-100}	3.68×10^{-98}
<i>AP1S2</i>	20	115	462	1.38×10^{-98}	3.07×10^{-96}
<i>VIM</i>	24	115	424	1.73×10^{-90}	3.06×10^{-88}
<i>CCDC88A</i>	24	115	418	3.94×10^{-89}	6.86×10^{-87}
<i>RECK</i>	28	115	416	8.23×10^{-89}	1.42×10^{-86}
<i>AP1M1</i>	16	115	414	2.42×10^{-88}	4.06×10^{-86}
<i>ZEB2</i>	23	115	396	2.32×10^{-84}	3.4×10^{-82}
<i>WIPF1</i>	25	115	390	4.9×10^{-83}	6.74×10^{-81}
<i>SLC35B4</i>	29	115	386	3.2×10^{-82}	4.38×10^{-80}
<i>SACS</i>	28	115	373	2.13×10^{-79}	2.7×10^{-77}
<i>ST3GAL2</i>	25	115	351	9.7×10^{-75}	1.08×10^{-72}
<i>ATP8B2</i>	38	115	341	1.53×10^{-72}	1.61×10^{-70}
<i>IFFO1</i>	39	115	332	1.66×10^{-70}	1.65×10^{-68}
<i>EMP3</i>	38	115	329	5.04×10^{-70}	4.95×10^{-68}
<i>LEPRE1</i>	40	115	325	5.4×10^{-69}	5.22×10^{-67}
<i>STARD9</i>	39	115	311	4.52×10^{-66}	3.96×10^{-64}
<i>DENND5A</i>	48	115	304	1.89×10^{-64}	1.59×10^{-62}
<i>SYT11</i>	38	115	300	1.21×10^{-63}	9.89×10^{-62}
<i>EID2B</i>	38	115	299	1.99×10^{-63}	1.61×10^{-61}
<i>NXPE3</i>	35	115	294	1.71×10^{-62}	1.35×10^{-60}
<i>STX2</i>	49	115	293	3.83×10^{-62}	3×10^{-60}
<i>ARHGEF6</i>	43	115	289	2.2×10^{-61}	1.71×10^{-59}
<i>KATNAL1</i>	50	115	283	4.45×10^{-60}	3.38×10^{-58}
<i>ANXA6</i>	37	115	282	8.92×10^{-60}	6.67×10^{-58}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

Table I.2: Candidate synthetic lethal gene partners of *CDH1* from SLIPT in breast CCLE

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>MIR155HG</i>	1	6.78	31.5	2.41×10^{-6}	0.00371
<i>ENPP2</i>	1	6.78	30.7	3.47×10^{-6}	0.00383
<i>DCLK2</i>	3	6.78	28.3	1.08×10^{-5}	0.0071
<i>PID1</i>	1	6.78	27.8	1.34×10^{-5}	0.00791
<i>SCFD2</i>	5	6.78	27.7	1.42×10^{-5}	0.00791
<i>FAT4</i>	4	6.78	27.3	1.69×10^{-5}	0.00865
<i>ILK</i>	1	6.78	26.9	2.04×10^{-5}	0.00884
<i>RWDD1</i>	0	6.78	26.8	2.15×10^{-5}	0.00884
<i>RIC8A</i>	2	6.78	26.8	2.2×10^{-5}	0.00884
<i>F2RL2</i>	1	6.78	26.6	2.34×10^{-5}	0.00901
<i>SDCBP</i>	5	6.78	25.9	3.26×10^{-5}	0.0108
<i>PPM1F</i>	4	6.78	25.8	3.41×10^{-5}	0.0108
<i>IKBIP</i>	5	6.78	25.8	3.49×10^{-5}	0.0108
<i>SPRED1</i>	3	6.78	25.5	3.97×10^{-5}	0.0108
<i>RNH1</i>	1	6.78	25.4	4.22×10^{-5}	0.0108
<i>SYDE1</i>	3	6.78	25.4	4.22×10^{-5}	0.0108
<i>LINC00968</i>	1	6.78	25.2	4.63×10^{-5}	0.0109
<i>ARHGEF10</i>	5	6.78	24.5	6.22×10^{-5}	0.0116
<i>P4HA1</i>	0	6.78	24.5	6.34×10^{-5}	0.0116
<i>AZI2</i>	2	6.78	24.5	6.34×10^{-5}	0.0116
<i>TNFAIP6</i>	2	6.78	24.5	6.34×10^{-5}	0.0116
<i>CD200</i>	4	6.78	24.5	6.37×10^{-5}	0.0116
<i>SMPD1</i>	1	6.78	24.4	6.67×10^{-5}	0.0116
<i>ATP6V1G2</i>	3	6.78	24.2	7.33×10^{-5}	0.0123
<i>FGF2</i>	4	6.78	24.1	7.49×10^{-5}	0.0123

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

Table I.3: Candidate synthetic lethal gene partners of *CDH1* from SLIPT in stomach CCLE

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>ZEB1</i>	1	4.45	36	2.84×10^{-7}	0.00175
<i>WDR47</i>	0	4.45	26.7	2.3×10^{-5}	0.013
<i>KANK2</i>	1	4.45	25.1	4.81×10^{-5}	0.0222
<i>LEPRE1</i>	0	4.45	24.5	6.26×10^{-5}	0.0228
<i>KATNAL1</i>	0	4.45	24.3	6.88×10^{-5}	0.0231
<i>TET1</i>	0	4.45	23.9	8.23×10^{-5}	0.0249
<i>AP1S2</i>	1	4.45	23.1	0.00012	0.0273
<i>CDKN2C</i>	1	4.45	22.8	0.000136	0.0292
<i>ARMC4</i>	1	4.45	22.4	0.000164	0.0315
<i>CSTF3</i>	1	4.45	22.4	0.000166	0.0315
<i>FAM216A</i>	1	4.45	22.4	0.000166	0.0315
<i>ANKRD32</i>	1	4.45	22.4	0.000166	0.0315
<i>WDR35</i>	1	4.45	22.4	0.000169	0.0315
<i>ECI2</i>	0	4.45	21.7	0.000232	0.0378
<i>SAMD8</i>	0	4.45	21.7	0.000232	0.0378
<i>CHST12</i>	0	4.45	21.7	0.000232	0.0378
<i>RPL23AP32</i>	0	4.45	21.7	0.000232	0.0378
<i>STARD9</i>	1	4.45	21.7	0.000232	0.0378
<i>MCM8</i>	0	4.45	21.5	0.000255	0.0379

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

Table I.4: Pathways for *CDH1* partners from SLIPT in stomach CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Nef mediated downregulation of MHC class I complex cell surface expression	10	1	1
Unwinding of DNA	11	1	1
Processing of Intronless Pre-mRNAs	13	1	1
E2F mediated regulation of DNA replication	20	1	1
Chondroitin sulfate biosynthesis	20	1	1
Post-Elongation Processing of Intronless pre-mRNA	21	1	1
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	21	1	1
Processing of Capped Intronless Pre-mRNA	21	1	1
Post-Elongation Processing of Intron-Containing pre-mRNA	23	1	1
Activation of the pre-replicative complex	23	1	1
mRNA 3'-end processing	23	1	1
Golgi Associated Vesicle Biogenesis	24	1	1
Lysosome Vesicle Biogenesis	25	1	1
Oncogene Induced Senescence	27	1	1
The role of Nef in HIV-1 replication and disease pathogenesis	28	1	1
Cyclin D associated events in G1	29	1	1
G1 Phase	29	1	1
Cleavage of Growing Transcript in the Termination Region	31	1	1
Activation of ATR in response to replication stress	31	1	1
DNA strand elongation	31	1	1

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*


Table I.5: Pathways for *CDH1* partners from SLIPT in breast and stomach CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Collagen formation	66	8	1.1×10^{-7}
Glycosaminoglycan metabolism	111	11	1.1×10^{-7}
Extracellular matrix organization	236	20	1.1×10^{-7}
Collagen biosynthesis and modifying enzymes	55	7	1.7×10^{-7}
Keratan sulfate biosynthesis	28	5	2.2×10^{-7}
Keratan sulfate/keratin metabolism	32	5	7.5×10^{-7}
ECM proteoglycans	65	7	1.1×10^{-6}
Non-integrin membrane-ECM interactions	52	6	2.0×10^{-6}
Cell junction organization	71	7	3.0×10^{-6}
Assembly of collagen fibrils and other multimeric structures	39	5	3.6×10^{-6}
Post-chaperonin tubulin folding pathway	14	3	1.7×10^{-5}
Adherens junctions interactions	29	4	1.7×10^{-5}
Cell-Cell communication	118	9	1.7×10^{-5}
Sialic acid metabolism	31	4	2.5×10^{-5}
Synthesis and interconversion of nucleotide di- and triphosphates	16	3	3.1×10^{-5}
Transport to the Golgi and subsequent modification	34	4	4.8×10^{-5}
Asparagine N-linked glycosylation	113	8	7.8×10^{-5}
Elastic fibre formation	37	4	8.5×10^{-5}
L1CAM interactions	77	6	9.5×10^{-5}
Signal transduction by L1	20	3	9.5×10^{-5}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

Appendix J

Synthetic Lethal Genes in Pathways






Figure J.2: Synthetic Lethality in the PI3K/AKT Pathway. The Reactome PI3K/AKT Pathway pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.3: Synthetic Lethality in the PI3K/AKT Pathway in Cancer. The Reactome PI3K/AKT Pathway in Cancer pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.4: Synthetic Lethality in the Elastic Fibre Formation Pathway. The Reactome Elastic Fibre Formation Pathway pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.5: Synthetic Lethality in the Fibrin Clot Formation. The Reactome Fibrin Clot Formation pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.6: Synthetic Lethality in the Extracellular Matrix. The Reactome Extracellular Matrix pathway with synthetic lethal candidates detected, coloured as shown in the Legend.

Synthetic Lethality in G alpha (i) signalling

- exprSLIPT
- siRNA
- exprSLIPT+siRNA
- other





Figure J.7: Synthetic Lethality in the GPCRs. The Reactome GPCRs pathway with synthetic lethal candidates detected, coloured as shown in the Legend.






Figure J.9: Synthetic Lethality in the Translation Elongation. The Reactome Translation Elongation pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.10: **Synthetic Lethality in the Nonsense-mediated Decay.** The Reactome Nonsense-mediated Decay pathway with synthetic lethal candidates detected, coloured as shown in the Legend.




Figure J.11: **Synthetic Lethality in the 3' UTR.** The Reactome 3' UTR pathway with synthetic lethal candidates detected, coloured as shown in the Legend.





Figure J.12: Synthetic Lethality in the 3' UTR. The Reactome 3' UTR pathway with synthetic lethal candidates detected, coloured as shown in the Legend.

Appendix K

Pathway Connectivity for Mutation SLIPT






Figure K.2: Synthetic Lethality and Centrality. Synthetic Lethality and Information Centrality (log-scale).




Figure K.3: Synthetic Lethality and PageRank. Synthetic Lethality and PageRank.

Appendix L

Pathway Structure for Mutation SLIPT

pathway	Graph:		States:		Observed:					Permutation p-value:	
	nodes	edges	mtSL	siRNA	up	down	up-down	up/down	up abs	down abs	
PI3K Cascade	138	1495	42	25	131	123	8	1.0650406504065	0.4473	0.5466	
PI3K/AKT Signaling in Cancer	275	12882	56	44	478	440	38	1.08636363636364	0.4163	0.581	
G _{αi}	292	22003	57	58	543	866	-323	0.6270207852194	0.9507	0.0488	
GPCR downstream	1270	142071	218	160	7632	6500	1132	1.17415384615385	0.1707	0.8291	
Elastic fibre formation	42	175	16	7	6	7	-1	0.857142857142857	0.5512	0.3681	
Extracellular matrix	299	3677	81	29	313	347	-34	0.902017291066282	0.5762	0.4215	
Formation of Fibrin	52	243	11	5	8	19	-11	0.421052631578947	0.7993	0.18	
Nonsense-Mediated Decay	103	102	56	2	0	0	0	NaN	0.197	0.1373	
3' -UTR-mediated translational regulation	107	2860	56	1	52	1	51	52	0.121	0.8751	
Eukaryotic Translation Elongation	92	3746	57	0	0	0	0	NaN	0.4952	0.4892	

Appendix M

Information Centrality for Gene Essentiality

Network structure is another useful strategy to analyse gene function and this has been used to investigate network properties of a network constructed from of Reactome pathways imported with the paxtoolsr R package (Demir et al. 2010). Most notably, information centrality which has been proposed as a measure of gene essentiality was calculated as performed by Kranthi et al. (2013) using the efficiency and shortest path between each pair of nodes in the network before and after a node of interest is removed to test the importance of a node to network connectivity. Reactome contains substrates and cofactors in addition to genes or proteins, supporting the idea of centrality as a measure of essentiality, a number nodes with the highest centrality were essential nutrients including Mg^{2+} , Ca^{2+} , Zn^{2+} , and Fe^{3+} .